{
  "@context": "https://schema.org",
  "@type": "DataCatalogItem",
  "name": "Interface 2F9Q_3",
  "description": "Protein-protein interaction interface between chains A and D",
  "identifier": "2F9Q_3",
  "mainEntity": {
    "@context": "https://schema.org",
    "@type": "Protein",
    "@id": "#protein_2F9Q",
    "dct:conformsTo": "https://bioschemas.org/profiles/Protein/0.11-RELEASE",
    "identifier": "2F9Q",
    "name": "Protein 2F9Q",
    "description": "Protein structure with PDB ID: 2F9Q. Part of the ELIXIR 3D-BioInfo benchmark dataset. This protein participates in interface 2F9Q_3 as a homodimer.",
    "url": "https://www.rcsb.org/structure/2F9Q",
    "taxonomicRange": {
      "@type": "DefinedTerm",
      "name": "Homo sapiens",
      "inDefinedTermSet": "https://www.ncbi.nlm.nih.gov/taxonomy",
      "description": "Organism taxonomy information from PDB metadata",
      "termCode": "9606",
      "url": "https://www.ncbi.nlm.nih.gov/Taxonomy/Browser/wwwtax.cgi?id=9606",
      "identifier": "taxonomy:9606"
    },
    "alternateName": [
      "PDB 2F9Q",
      "Protein ID 2F9Q"
    ],
    "hasRepresentation": [
      {
        "@type": "PropertyValue",
        "name": "PDB Structure",
        "value": "https://raw.githubusercontent.com/biofold/ppi-benchmark-fair/main/data/benchmark_pdb_format/2f9q_3.pdb.gz",
        "description": "Compressed PDB format structure file"
      },
      {
        "@type": "PropertyValue",
        "name": "mmCIF Structure",
        "value": "https://raw.githubusercontent.com/biofold/ppi-benchmark-fair/main/data/benchmark_mmcif_format/2f9q_3.cif.gz",
        "description": "Compressed mmCIF format structure file"
      },
      {
        "@type": "PropertyValue",
        "name": "PDB ID",
        "value": "2F9Q",
        "description": "RCSB PDB identifier"
      }
    ],
    "additionalProperty": [
      {
        "@type": "PropertyValue",
        "name": "PDB_ID",
        "value": "2F9Q",
        "description": "Protein Data Bank identifier (4 letters)"
      },
      {
        "@type": "PropertyValue",
        "name": "AssociatedInterface",
        "value": "2F9Q_3",
        "description": "Interface this protein participates in"
      },
      {
        "@type": "PropertyValue",
        "name": "InterfaceSource",
        "value": "ProtCID",
        "description": "Source of interface ID: ProtCID"
      },
      {
        "@type": "PropertyValue",
        "name": "InterfaceChains",
        "value": "A-D",
        "description": "Chains involved in the interface"
      },
      {
        "@type": "PropertyValue",
        "name": "InterfaceClassification",
        "value": "Non-physiological",
        "description": "Classification of the associated interface"
      },
      {
        "@type": "PropertyValue",
        "name": "LabelInterfaceChains",
        "value": "A-B",
        "description": "Chains involved in the assembly interface"
      },
      {
        "@type": "PropertyValue",
        "name": "Gene",
        "value": "CYP2D6",
        "description": "Gene name associated with the protein"
      },
      {
        "@type": "PropertyValue",
        "name": "Superfamily",
        "value": "1.10.630.10",
        "description": "Protein superfamily classification"
      },
      {
        "@type": "PropertyValue",
        "name": "Pfam",
        "value": "PF00067",
        "description": "Pfam domain classification"
      },
      {
        "@type": "PropertyValue",
        "name": "PDBStructureMetadata",
        "description": "Structural metadata from RCSB Protein Data Bank",
        "value": "{\"pdb_id\": \"2F9Q\", \"structure_metadata\": {\"pdb_id\": \"2F9Q\", \"resolution\": 3.002, \"deposition_date\": \"2005-12-06T00:00:00+0000\", \"release_date\": \"2005-12-20T00:00:00+0000\", \"experimental_method\": null, \"source_organism\": [\"Homo sapiens\"], \"citation\": {\"title\": \"Crystal Structure of Human Cytochrome P450 2D6\", \"doi\": \"10.1074/jbc.M511232200\", \"authors\": [\"Rowland, P.\", \"Blaney, F.E.\", \"Smyth, M.G.\", \"Jones, J.J.\", \"Leydon, V.R.\", \"Oxbrow, A.K.\", \"Lewis, C.J.\", \"Tennant, M.G.\", \"Modi, S.\", \"Eggleston, D.S.\", \"Chenery, R.J.\", \"Bridges, A.M.\"]}, \"entity_count\": 4, \"r_factor\": null, \"space_group\": null, \"unit_cell\": {\"a\": 145.066, \"b\": 155.495, \"c\": 95.801, \"alpha\": 90.0, \"beta\": 90.0, \"gamma\": 90.0}, \"found_in_api\": true, \"obsolete\": false, \"replaced_by\": null, \"sequences\": {\"A\": \"MAKKTSSKGKLPPGPLPLPGLGNLLHVDFQNTPYCFDQLRRRFGDVFSLQLAWTPVVVLNGLAAVREALVTHGEDTADRPPVPITQILGFGPRSQGVFLARYGPAWREQRRFSVSTLRNLGLGKKSLEQWVTEEAACLCAAFANHSGRPFRPNGLLDKAVSNVIASLTCGRRFEYDDPRFLRLLDLAQEGLKEESGFLREVLNAVPVDRHIPALAGKVLRFQKAFLTQLDELLTEHRMTWDPAQPPRDLTEAFLAEMEKAKGNPESSFNDENLRIVVADLFSAGMVTTSTTLAWGLLLMILHPDVQRRVQQEIDDVIGQVRRPEMGDQAHMPYTTAVIHEVQRFGDIVPLGMTHMTSRDIEVQGFRIPKGTTLITNLSSVLKDEAVWEKPFRFHPEHFLDAQGHFVKPEAFLPFSAGRRACLGEPLARMELFLFFTSLLQHFSFSVPTGQPRPSHHGVFAFLVSPSPYELCAVPRHHHH\", \"B\": \"MAKKTSSKGKLPPGPLPLPGLGNLLHVDFQNTPYCFDQLRRRFGDVFSLQLAWTPVVVLNGLAAVREALVTHGEDTADRPPVPITQILGFGPRSQGVFLARYGPAWREQRRFSVSTLRNLGLGKKSLEQWVTEEAACLCAAFANHSGRPFRPNGLLDKAVSNVIASLTCGRRFEYDDPRFLRLLDLAQEGLKEESGFLREVLNAVPVDRHIPALAGKVLRFQKAFLTQLDELLTEHRMTWDPAQPPRDLTEAFLAEMEKAKGNPESSFNDENLRIVVADLFSAGMVTTSTTLAWGLLLMILHPDVQRRVQQEIDDVIGQVRRPEMGDQAHMPYTTAVIHEVQRFGDIVPLGMTHMTSRDIEVQGFRIPKGTTLITNLSSVLKDEAVWEKPFRFHPEHFLDAQGHFVKPEAFLPFSAGRRACLGEPLARMELFLFFTSLLQHFSFSVPTGQPRPSHHGVFAFLVSPSPYELCAVPRHHHH\", \"C\": \"MAKKTSSKGKLPPGPLPLPGLGNLLHVDFQNTPYCFDQLRRRFGDVFSLQLAWTPVVVLNGLAAVREALVTHGEDTADRPPVPITQILGFGPRSQGVFLARYGPAWREQRRFSVSTLRNLGLGKKSLEQWVTEEAACLCAAFANHSGRPFRPNGLLDKAVSNVIASLTCGRRFEYDDPRFLRLLDLAQEGLKEESGFLREVLNAVPVDRHIPALAGKVLRFQKAFLTQLDELLTEHRMTWDPAQPPRDLTEAFLAEMEKAKGNPESSFNDENLRIVVADLFSAGMVTTSTTLAWGLLLMILHPDVQRRVQQEIDDVIGQVRRPEMGDQAHMPYTTAVIHEVQRFGDIVPLGMTHMTSRDIEVQGFRIPKGTTLITNLSSVLKDEAVWEKPFRFHPEHFLDAQGHFVKPEAFLPFSAGRRACLGEPLARMELFLFFTSLLQHFSFSVPTGQPRPSHHGVFAFLVSPSPYELCAVPRHHHH\", \"D\": \"MAKKTSSKGKLPPGPLPLPGLGNLLHVDFQNTPYCFDQLRRRFGDVFSLQLAWTPVVVLNGLAAVREALVTHGEDTADRPPVPITQILGFGPRSQGVFLARYGPAWREQRRFSVSTLRNLGLGKKSLEQWVTEEAACLCAAFANHSGRPFRPNGLLDKAVSNVIASLTCGRRFEYDDPRFLRLLDLAQEGLKEESGFLREVLNAVPVDRHIPALAGKVLRFQKAFLTQLDELLTEHRMTWDPAQPPRDLTEAFLAEMEKAKGNPESSFNDENLRIVVADLFSAGMVTTSTTLAWGLLLMILHPDVQRRVQQEIDDVIGQVRRPEMGDQAHMPYTTAVIHEVQRFGDIVPLGMTHMTSRDIEVQGFRIPKGTTLITNLSSVLKDEAVWEKPFRFHPEHFLDAQGHFVKPEAFLPFSAGRRACLGEPLARMELFLFFTSLLQHFSFSVPTGQPRPSHHGVFAFLVSPSPYELCAVPRHHHH\"}, \"chain_info\": {\"A\": {\"entity_id\": \"1\", \"organism\": \"Homo sapiens\", \"sequence_length\": 479, \"polymer_type\": \"polypeptide(L)\", \"gene_name\": null}, \"B\": {\"entity_id\": \"1\", \"organism\": \"Homo sapiens\", \"sequence_length\": 479, \"polymer_type\": \"polypeptide(L)\", \"gene_name\": null}, \"C\": {\"entity_id\": \"1\", \"organism\": \"Homo sapiens\", \"sequence_length\": 479, \"polymer_type\": \"polypeptide(L)\", \"gene_name\": null}, \"D\": {\"entity_id\": \"1\", \"organism\": \"Homo sapiens\", \"sequence_length\": 479, \"polymer_type\": \"polypeptide(L)\", \"gene_name\": null}}, \"entity_info\": {\"1\": {\"entity_id\": \"1\", \"sequence\": \"MAKKTSSKGKLPPGPLPLPGLGNLLHVDFQNTPYCFDQLRRRFGDVFSLQLAWTPVVVLNGLAAVREALVTHGEDTADRPPVPITQILGFGPRSQGVFLARYGPAWREQRRFSVSTLRNLGLGKKSLEQWVTEEAACLCAAFANHSGRPFRPNGLLDKAVSNVIASLTCGRRFEYDDPRFLRLLDLAQEGLKEESGFLREVLNAVPVDRHIPALAGKVLRFQKAFLTQLDELLTEHRMTWDPAQPPRDLTEAFLAEMEKAKGNPESSFNDENLRIVVADLFSAGMVTTSTTLAWGLLLMILHPDVQRRVQQEIDDVIGQVRRPEMGDQAHMPYTTAVIHEVQRFGDIVPLGMTHMTSRDIEVQGFRIPKGTTLITNLSSVLKDEAVWEKPFRFHPEHFLDAQGHFVKPEAFLPFSAGRRACLGEPLARMELFLFFTSLLQHFSFSVPTGQPRPSHHGVFAFLVSPSPYELCAVPRHHHH\", \"organism\": \"Homo sapiens\", \"taxonomy_id\": 9606, \"chain_ids\": [\"A\", \"B\", \"C\", \"D\"], \"polymer_type\": \"polypeptide(L)\", \"sequence_length\": 479, \"gene_name\": null, \"uniprot_ids\": [\"P10635\"]}}, \"is_homomer\": true, \"sequence_clusters\": [{\"sequence\": \"MAKKTSSKGKLPPGPLPLPGLGNLLHVDFQNTPYCFDQLRRRFGDVFSLQLAWTPVVVLNGLAAVREALVTHGEDTADRPPVPITQILGFGPRSQGVFLARYGPAWREQRRFSVSTLRNLGLGKKSLEQWVTEEAACLCAAFANHSGRPFRPNGLLDKAVSNVIASLTCGRRFEYDDPRFLRLLDLAQEGLKEESGFLREVLNAVPVDRHIPALAGKVLRFQKAFLTQLDELLTEHRMTWDPAQPPRDLTEAFLAEMEKAKGNPESSFNDENLRIVVADLFSAGMVTTSTTLAWGLLLMILHPDVQRRVQQEIDDVIGQVRRPEMGDQAHMPYTTAVIHEVQRFGDIVPLGMTHMTSRDIEVQGFRIPKGTTLITNLSSVLKDEAVWEKPFRFHPEHFLDAQGHFVKPEAFLPFSAGRRACLGEPLARMELFLFFTSLLQHFSFSVPTGQPRPSHHGVFAFLVSPSPYELCAVPRHHHH\", \"entities\": [\"1\"], \"chain_count\": 4}], \"chain_ids\": [], \"entity_ids\": [\"1\", \"2\", \"3\", \"4\"], \"polymer_composition\": \"homomeric protein\", \"homomer_type\": \"monomer\", \"homomer_chains\": 4, \"chain_count\": 4, \"unique_sequences\": 1, \"avg_sequence_length\": 479.0, \"min_sequence_length\": 479, \"max_sequence_length\": 479}, \"entity_metadata\": {\"1\": {\"entity_poly\": {\"nstd_linkage\": \"no\", \"nstd_monomer\": \"no\", \"pdbx_seq_one_letter_code\": \"MAKKTSSKGKLPPGPLPLPGLGNLLHVDFQNTPYCFDQLRRRFGDVFSLQLAWTPVVVLNGLAAVREALVTHGEDTADRPPVPITQILGFGPRSQGVFLARYGPAWREQRRFSVSTLRNLGLGKKSLEQWVTEEAACLCAAFANHSGRPFRPNGLLDKAVSNVIASLTCGRRFEYDDPRFLRLLDLAQEGLKEESGFLREVLNAVPVDRHIPALAGKVLRFQKAFLTQLDELLTEHRMTWDPAQPPRDLTEAFLAEMEKAKGNPESSFNDENLRIVVADLFSAGMVTTSTTLAWGLLLMILHPDVQRRVQQEIDDVIGQVRRPEMGDQAHMPYTTAVIHEVQRFGDIVPLGMTHMTSRDIEVQGFRIPKGTTLITNLSSVLKDEAVWEKPFRFHPEHFLDAQGHFVKPEAFLPFSAGRRACLGEPLARMELFLFFTSLLQHFSFSVPTGQPRPSHHGVFAFLVSPSPYELCAVPRHHHH\", \"pdbx_seq_one_letter_code_can\": \"MAKKTSSKGKLPPGPLPLPGLGNLLHVDFQNTPYCFDQLRRRFGDVFSLQLAWTPVVVLNGLAAVREALVTHGEDTADRPPVPITQILGFGPRSQGVFLARYGPAWREQRRFSVSTLRNLGLGKKSLEQWVTEEAACLCAAFANHSGRPFRPNGLLDKAVSNVIASLTCGRRFEYDDPRFLRLLDLAQEGLKEESGFLREVLNAVPVDRHIPALAGKVLRFQKAFLTQLDELLTEHRMTWDPAQPPRDLTEAFLAEMEKAKGNPESSFNDENLRIVVADLFSAGMVTTSTTLAWGLLLMILHPDVQRRVQQEIDDVIGQVRRPEMGDQAHMPYTTAVIHEVQRFGDIVPLGMTHMTSRDIEVQGFRIPKGTTLITNLSSVLKDEAVWEKPFRFHPEHFLDAQGHFVKPEAFLPFSAGRRACLGEPLARMELFLFFTSLLQHFSFSVPTGQPRPSHHGVFAFLVSPSPYELCAVPRHHHH\", \"pdbx_strand_id\": \"A,B,C,D\", \"rcsb_artifact_monomer_count\": 2, \"rcsb_conflict_count\": 0, \"rcsb_deletion_count\": 0, \"rcsb_entity_polymer_type\": \"Protein\", \"rcsb_insertion_count\": 0, \"rcsb_mutation_count\": 2, \"rcsb_non_std_monomer_count\": 0, \"rcsb_sample_sequence_length\": 479, \"type\": \"polypeptide(L)\"}, \"entity_src_gen\": [{\"gene_src_common_name\": \"human\", \"gene_src_genus\": \"Homo\", \"host_org_genus\": \"Escherichia\", \"pdbx_alt_source_flag\": \"sample\", \"pdbx_gene_src_gene\": \"CYP2D6\", \"pdbx_gene_src_ncbi_taxonomy_id\": \"9606\", \"pdbx_gene_src_scientific_name\": \"Homo sapiens\", \"pdbx_host_org_ncbi_taxonomy_id\": \"562\", \"pdbx_host_org_scientific_name\": \"Escherichia coli\", \"pdbx_src_id\": 1}], \"rcsb_cluster_flexibility\": {\"avg_rmsd\": 1.028, \"label\": \"Low\", \"link\": \"http://pdbflex.org/cluster.html#!/5tftA/31171/2f9qA\", \"max_rmsd\": 2.404, \"provenance_code\": \"PDBFlex\"}, \"rcsb_cluster_membership\": [{\"cluster_id\": 339694, \"identity\": 100}, {\"cluster_id\": 5773, \"identity\": 95}, {\"cluster_id\": 5548, \"identity\": 90}, {\"cluster_id\": 6444, \"identity\": 70}, {\"cluster_id\": 4285, \"identity\": 50}, {\"cluster_id\": 311, \"identity\": 30}], \"rcsb_entity_host_organism\": [{\"ncbi_common_names\": [\"Bacillus coli\", \"Bacterium coli\", \"Bacterium coli commune\", \"E. coli\", \"Enterococcus coli\", \"Escherichia/Shigella coli\"], \"ncbi_parent_scientific_name\": \"Bacteria\", \"ncbi_scientific_name\": \"Escherichia coli\", \"ncbi_taxonomy_id\": 562, \"pdbx_src_id\": 1, \"provenance_source\": \"Primary Data\", \"scientific_name\": \"Escherichia coli\", \"taxonomy_lineage\": [{\"depth\": 1, \"id\": \"131567\", \"name\": \"cellular organisms\"}, {\"depth\": 1, \"id\": \"131567\", \"name\": \"biota\"}, {\"depth\": 2, \"id\": \"2\", \"name\": \"Bacteria\"}, {\"depth\": 2, \"id\": \"2\", \"name\": \"Bacteria (ex Cavalier-Smith 1987)\"}, {\"depth\": 2, \"id\": \"2\", \"name\": \"Bacteria Woese et al. 2024\"}, {\"depth\": 2, \"id\": \"2\", \"name\": \"Bacteriobiota\"}, {\"depth\": 2, \"id\": \"2\", \"name\": \"bacteria\"}, {\"depth\": 2, \"id\": \"2\", \"name\": \"eubacteria\"}, {\"depth\": 3, \"id\": \"3379134\", \"name\": \"Pseudomonadati\"}, {\"depth\": 4, \"id\": \"1224\", \"name\": \"Pseudomonadota\"}, {\"depth\": 4, \"id\": \"1224\", \"name\": \"\\\"Alphaproteobacteriota\\\" Whitman et al. 2018\"}, {\"depth\": 4, \"id\": \"1224\", \"name\": \"Alphaproteobacteriota\"}, {\"depth\": 4, \"id\": \"1224\", \"name\": \"Proteobacteria\"}, {\"depth\": 4, \"id\": \"1224\", \"name\": \"Proteobacteriota\"}, {\"depth\": 4, \"id\": \"1224\", \"name\": \"proteobacteria\"}, {\"depth\": 4, \"id\": \"1224\", \"name\": \"purple photosynthetic bacteria and relatives\"}, {\"depth\": 5, \"id\": \"1236\", \"name\": \"Gammaproteobacteria\"}, {\"depth\": 5, \"id\": \"1236\", \"name\": \"Proteobacteria gamma subdivision\"}, {\"depth\": 5, \"id\": \"1236\", \"name\": \"Pseudomonadia\"}, {\"depth\": 5, \"id\": \"1236\", \"name\": \"Purple bacteria, gamma subdivision\"}, {\"depth\": 5, \"id\": \"1236\", \"name\": \"g-proteobacteria\"}, {\"depth\": 5, \"id\": \"1236\", \"name\": \"gamma proteobacteria\"}, {\"depth\": 5, \"id\": \"1236\", \"name\": \"gamma subdivision\"}, {\"depth\": 5, \"id\": \"1236\", \"name\": \"gamma subgroup\"}, {\"depth\": 6, \"id\": \"91347\", \"name\": \"Enterobacterales\"}, {\"depth\": 6, \"id\": \"91347\", \"name\": \"Enterobacteriaceae and related endosymbionts\"}, {\"depth\": 6, \"id\": \"91347\", \"name\": \"Enterobacteriaceae group\"}, {\"depth\": 6, \"id\": \"91347\", \"name\": \"Enterobacteriales\"}, {\"depth\": 7, \"id\": \"543\", \"name\": \"Enterobacteriaceae\"}, {\"depth\": 7, \"id\": \"543\", \"name\": \"Enterobacteraceae\"}, {\"depth\": 7, \"id\": \"543\", \"name\": \"enterobacteria\"}, {\"depth\": 8, \"id\": \"561\", \"name\": \"Escherichia\"}, {\"depth\": 9, \"id\": \"562\", \"name\": \"Escherichia coli\"}, {\"depth\": 9, \"id\": \"562\", \"name\": \"Bacillus coli\"}, {\"depth\": 9, \"id\": \"562\", \"name\": \"Bacterium coli\"}, {\"depth\": 9, \"id\": \"562\", \"name\": \"Bacterium coli commune\"}, {\"depth\": 9, \"id\": \"562\", \"name\": \"E. coli\"}, {\"depth\": 9, \"id\": \"562\", \"name\": \"Enterococcus coli\"}, {\"depth\": 9, \"id\": \"562\", \"name\": \"Escherichia/Shigella coli\"}]}], \"rcsb_entity_source_organism\": [{\"common_name\": \"human\", \"ncbi_common_names\": [\"human\"], \"ncbi_parent_scientific_name\": \"Eukaryota\", \"ncbi_scientific_name\": \"Homo sapiens\", \"ncbi_taxonomy_id\": 9606, \"pdbx_src_id\": 1, \"provenance_source\": \"Primary Data\", \"scientific_name\": \"Homo sapiens\", \"source_type\": \"genetically engineered\", \"taxonomy_lineage\": [{\"depth\": 1, \"id\": \"131567\", \"name\": \"cellular organisms\"}, {\"depth\": 1, \"id\": \"131567\", \"name\": \"biota\"}, {\"depth\": 2, \"id\": \"2759\", \"name\": \"Eukaryota\"}, {\"depth\": 2, \"id\": \"2759\", \"name\": \"Eucarya\"}, {\"depth\": 2, \"id\": \"2759\", \"name\": \"Eucaryotae\"}, {\"depth\": 2, \"id\": \"2759\", \"name\": \"Eukarya\"}, {\"depth\": 2, \"id\": \"2759\", \"name\": \"Eukaryotae\"}, {\"depth\": 2, \"id\": \"2759\", \"name\": \"eukaryotes\"}, {\"depth\": 3, \"id\": \"33154\", \"name\": \"Opisthokonta\"}, {\"depth\": 3, \"id\": \"33154\", \"name\": \"Fungi/Metazoa group\"}, {\"depth\": 3, \"id\": \"33154\", \"name\": \"opisthokonts\"}, {\"depth\": 4, \"id\": \"33208\", \"name\": \"Metazoa\"}, {\"depth\": 4, \"id\": \"33208\", \"name\": \"Animalia\"}, {\"depth\": 4, \"id\": \"33208\", \"name\": \"animals\"}, {\"depth\": 4, \"id\": \"33208\", \"name\": \"metazoans\"}, {\"depth\": 4, \"id\": \"33208\", \"name\": \"multicellular animals\"}, {\"depth\": 5, \"id\": \"6072\", \"name\": \"Eumetazoa\"}, {\"depth\": 6, \"id\": \"33213\", \"name\": \"Bilateria\"}, {\"depth\": 7, \"id\": \"33511\", \"name\": \"Deuterostomia\"}, {\"depth\": 7, \"id\": \"33511\", \"name\": \"deuterostomes\"}, {\"depth\": 8, \"id\": \"7711\", \"name\": \"Chordata\"}, {\"depth\": 8, \"id\": \"7711\", \"name\": \"chordates\"}, {\"depth\": 9, \"id\": \"89593\", \"name\": \"Craniata\"}, {\"depth\": 10, \"id\": \"7742\", \"name\": \"Vertebrata\"}, {\"depth\": 10, \"id\": \"7742\", \"name\": \"vertebrates\"}, {\"depth\": 11, \"id\": \"7776\", \"name\": \"Gnathostomata\"}, {\"depth\": 11, \"id\": \"7776\", \"name\": \"jawed vertebrates\"}, {\"depth\": 12, \"id\": \"117570\", \"name\": \"Teleostomi\"}, {\"depth\": 13, \"id\": \"117571\", \"name\": \"Euteleostomi\"}, {\"depth\": 13, \"id\": \"117571\", \"name\": \"bony vertebrates\"}, {\"depth\": 14, \"id\": \"8287\", \"name\": \"Sarcopterygii\"}, {\"depth\": 15, \"id\": \"1338369\", \"name\": \"Dipnotetrapodomorpha\"}, {\"depth\": 16, \"id\": \"32523\", \"name\": \"Tetrapoda\"}, {\"depth\": 16, \"id\": \"32523\", \"name\": \"tetrapods\"}, {\"depth\": 17, \"id\": \"32524\", \"name\": \"Amniota\"}, {\"depth\": 17, \"id\": \"32524\", \"name\": \"amniotes\"}, {\"depth\": 18, \"id\": \"40674\", \"name\": \"Mammalia\"}, {\"depth\": 18, \"id\": \"40674\", \"name\": \"mammals\"}, {\"depth\": 19, \"id\": \"32525\", \"name\": \"Theria\"}, {\"depth\": 20, \"id\": \"9347\", \"name\": \"Eutheria\"}, {\"depth\": 20, \"id\": \"9347\", \"name\": \"Placentalia\"}, {\"depth\": 20, \"id\": \"9347\", \"name\": \"eutherian mammals\"}, {\"depth\": 20, \"id\": \"9347\", \"name\": \"placental mammals\"}, {\"depth\": 20, \"id\": \"9347\", \"name\": \"placentals\"}, {\"depth\": 21, \"id\": \"1437010\", \"name\": \"Boreoeutheria\"}, {\"depth\": 21, \"id\": \"1437010\", \"name\": \"Boreotheria\"}, {\"depth\": 22, \"id\": \"314146\", \"name\": \"Euarchontoglires\"}, {\"depth\": 23, \"id\": \"9443\", \"name\": \"Primates\"}, {\"depth\": 23, \"id\": \"9443\", \"name\": \"Primata\"}, {\"depth\": 23, \"id\": \"9443\", \"name\": \"primate\"}, {\"depth\": 23, \"id\": \"9443\", \"name\": \"primates\"}, {\"depth\": 24, \"id\": \"376913\", \"name\": \"Haplorrhini\"}, {\"depth\": 25, \"id\": \"314293\", \"name\": \"Simiiformes\"}, {\"depth\": 25, \"id\": \"314293\", \"name\": \"Anthropoidea\"}, {\"depth\": 26, \"id\": \"9526\", \"name\": \"Catarrhini\"}, {\"depth\": 27, \"id\": \"314295\", \"name\": \"Hominoidea\"}, {\"depth\": 27, \"id\": \"314295\", \"name\": \"ape\"}, {\"depth\": 27, \"id\": \"314295\", \"name\": \"apes\"}, {\"depth\": 28, \"id\": \"9604\", \"name\": \"Hominidae\"}, {\"depth\": 28, \"id\": \"9604\", \"name\": \"Pongidae\"}, {\"depth\": 28, \"id\": \"9604\", \"name\": \"great apes\"}, {\"depth\": 29, \"id\": \"207598\", \"name\": \"Homininae\"}, {\"depth\": 29, \"id\": \"207598\", \"name\": \"Homo/Pan/Gorilla group\"}, {\"depth\": 30, \"id\": \"9605\", \"name\": \"Homo\"}, {\"depth\": 30, \"id\": \"9605\", \"name\": \"humans\"}, {\"depth\": 31, \"id\": \"9606\", \"name\": \"Homo sapiens\"}, {\"depth\": 31, \"id\": \"9606\", \"name\": \"human\"}], \"rcsb_gene_name\": [{\"provenance_source\": \"Primary Data\", \"value\": \"CYP2D6\"}]}], \"rcsb_genomic_lineage\": [{\"depth\": 0, \"id\": \"9606\", \"name\": \"Homo sapiens\"}, {\"depth\": 1, \"id\": \"9606:22\", \"name\": \"Chromosome 22\"}, {\"depth\": 2, \"id\": \"9606:22:cytochrome_p450_family_2_subfamily_d_member_6\", \"name\": \"cytochrome P450 family 2 subfamily D member 6\"}], \"rcsb_polymer_entity\": {\"formula_weight\": 53.809, \"pdbx_description\": \"Cytochrome P450 2D6\", \"pdbx_ec\": \"1.14.14.1\", \"pdbx_number_of_molecules\": 4, \"rcsb_multiple_source_flag\": \"N\", \"rcsb_source_part_count\": 1, \"rcsb_source_taxonomy_count\": 1, \"src_method\": \"man\", \"rcsb_ec_lineage\": [{\"depth\": 1, \"id\": \"1\", \"name\": \"Oxidoreductases\"}, {\"depth\": 2, \"id\": \"1.14\", \"name\": \"Acting on paired donors, with incorporation or reduction of molecular oxygen\"}, {\"depth\": 3, \"id\": \"1.14.14\", \"name\": \"With reduced flavin or flavoprotein as one donor, and incorporation of one atom of oxygen into the other donor\"}, {\"depth\": 4, \"id\": \"1.14.14.1\", \"name\": \"unspecific monooxygenase\"}, {\"depth\": 1, \"id\": \"1\", \"name\": \"Oxidoreductases\"}, {\"depth\": 2, \"id\": \"1.14\", \"name\": \"Acting on paired donors, with incorporation or reduction of molecular oxygen\"}, {\"depth\": 3, \"id\": \"1.14.14\", \"name\": \"With reduced flavin or flavoprotein as one donor, and incorporation of one atom of oxygen into the other donor\"}], \"rcsb_macromolecular_names_combined\": [{\"name\": \"Cytochrome P450 2D6\", \"provenance_code\": \"ECO:0000304\", \"provenance_source\": \"PDB Preferred Name\"}, {\"name\": \"CYPIID6\", \"provenance_code\": \"ECO:0000303\", \"provenance_source\": \"PDB Synonym\"}], \"rcsb_enzyme_class_combined\": [{\"depth\": 4, \"ec\": \"1.14.14.1\", \"provenance_source\": \"PDB Primary Data\"}, {\"depth\": 3, \"ec\": \"1.14.14\", \"provenance_source\": \"UniProt\"}], \"rcsb_polymer_name_combined\": {\"names\": [\"Cytochrome P450 2D6\"], \"provenance_source\": \"UniProt Name\"}}, \"rcsb_polymer_entity_align\": [{\"provenance_source\": \"SIFTS\", \"reference_database_accession\": \"P10635\", \"reference_database_name\": \"UniProt\", \"aligned_regions\": [{\"entity_beg_seq_id\": 12, \"length\": 464, \"ref_beg_seq_id\": 34}]}], \"rcsb_polymer_entity_annotation\": [{\"annotation_id\": \"PF00067\", \"assignment_version\": \"34.0\", \"name\": \"Cytochrome P450 (p450)\", \"provenance_source\": \"Pfam\", \"type\": \"Pfam\"}, {\"annotation_id\": \"Transmembrane.Bitopic proteins.Cytochrome P450.Cytochrome P450\", \"name\": \"Cytochrome P450\", \"provenance_source\": \"PDB\", \"type\": \"OPM\", \"annotation_lineage\": [{\"depth\": 1, \"id\": \"Transmembrane.Bitopic proteins\", \"name\": \"Bitopic proteins\"}, {\"depth\": 3, \"id\": \"Transmembrane.Bitopic proteins.Cytochrome P450.Cytochrome P450\", \"name\": \"Cytochrome P450\"}, {\"depth\": 2, \"id\": \"Transmembrane.Bitopic proteins.Cytochrome P450\", \"name\": \"Cytochrome P450\"}, {\"depth\": 0, \"id\": \"Transmembrane\", \"name\": \"Transmembrane\"}]}, {\"annotation_id\": \"GO:0005739\", \"name\": \"mitochondrion\", \"provenance_source\": \"UNIPROT\", \"type\": \"GO\", \"annotation_lineage\": [{\"id\": \"GO:0043227\", \"name\": \"membrane-bounded organelle\"}, {\"id\": \"GO:0043229\", \"name\": \"intracellular organelle\"}, {\"id\": \"GO:0110165\", \"name\": \"cellular anatomical structure\"}, {\"id\": \"GO:0005575\", \"name\": \"cellular_component\"}, {\"id\": \"GO:0005622\", \"name\": \"intracellular anatomical structure\"}, {\"id\": \"GO:0005739\", \"name\": \"mitochondrion\"}, {\"id\": \"GO:0043226\", \"name\": \"organelle\"}, {\"id\": \"GO:0005737\", \"name\": \"cytoplasm\"}, {\"id\": \"GO:0043231\", \"name\": \"intracellular membrane-bounded organelle\"}]}, {\"annotation_id\": \"GO:0016491\", \"name\": \"oxidoreductase activity\", \"provenance_source\": \"UNIPROT\", \"type\": \"GO\", \"annotation_lineage\": [{\"id\": \"GO:0016491\", \"name\": \"oxidoreductase activity\"}, {\"id\": \"GO:0003824\", \"name\": \"catalytic activity\"}, {\"id\": \"GO:0003674\", \"name\": \"molecular_function\"}]}, {\"annotation_id\": \"IPR002401\", \"name\": \"Cytochrome P450, E-class, group I\", \"provenance_source\": \"UNIPROT\", \"type\": \"InterPro\", \"annotation_lineage\": [{\"depth\": 3, \"id\": \"IPR002401\", \"name\": \"Cytochrome P450, E-class, group I\"}, {\"depth\": 1, \"id\": \"IPR050121\", \"name\": \"Cytochrome P450 monooxygenase\"}, {\"depth\": 2, \"id\": \"IPR001128\", \"name\": \"Cytochrome P450\"}]}, {\"annotation_id\": \"GO:0070989\", \"name\": \"oxidative demethylation\", \"provenance_source\": \"UNIPROT\", \"type\": \"GO\", \"annotation_lineage\": [{\"id\": \"GO:0070989\", \"name\": \"oxidative demethylation\"}, {\"id\": \"GO:0008150\", \"name\": \"biological_process\"}, {\"id\": \"GO:0070988\", \"name\": \"demethylation\"}, {\"id\": \"GO:0008152\", \"name\": \"metabolic process\"}, {\"id\": \"GO:0009987\", \"name\": \"cellular process\"}]}, {\"annotation_id\": \"GO:0062187\", \"name\": \"anandamide 8,9 epoxidase activity\", \"provenance_source\": \"UNIPROT\", \"type\": \"GO\", \"annotation_lineage\": [{\"id\": \"GO:0016491\", \"name\": \"oxidoreductase activity\"}, {\"id\": \"GO:0004497\", \"name\": \"monooxygenase activity\"}, {\"id\": \"GO:0062187\", \"name\": \"anandamide 8,9 epoxidase activity\"}, {\"id\": \"GO:0016705\", \"name\": \"oxidoreductase activity, acting on paired donors, with incorporation or reduction of molecular oxygen\"}, {\"id\": \"GO:0016709\", \"name\": \"oxidoreductase activity, acting on paired donors, with incorporation or reduction of molecular oxygen, NAD(P)H as one donor, and incorporation of one atom of oxygen\"}, {\"id\": \"GO:0003824\", \"name\": \"catalytic activity\"}, {\"id\": \"GO:0003674\", \"name\": \"molecular_function\"}, {\"id\": \"GO:0062186\", \"name\": \"anandamide epoxidase activity\"}]}, {\"annotation_id\": \"GO:0009822\", \"name\": \"alkaloid catabolic process\", \"provenance_source\": \"UNIPROT\", \"type\": \"GO\", \"annotation_lineage\": [{\"id\": \"GO:0009056\", \"name\": \"catabolic process\"}, {\"id\": \"GO:0009822\", \"name\": \"alkaloid catabolic process\"}, {\"id\": \"GO:0008150\", \"name\": \"biological_process\"}, {\"id\": \"GO:0008152\", \"name\": \"metabolic process\"}, {\"id\": \"GO:0009987\", \"name\": \"cellular process\"}, {\"id\": \"GO:0009820\", \"name\": \"alkaloid metabolic process\"}]}, {\"annotation_id\": \"GO:0009804\", \"name\": \"coumarin metabolic process\", \"provenance_source\": \"UNIPROT\", \"type\": \"GO\", \"annotation_lineage\": [{\"id\": \"GO:0009698\", \"name\": \"phenylpropanoid metabolic process\"}, {\"id\": \"GO:0009804\", \"name\": \"coumarin metabolic process\"}, {\"id\": \"GO:0008150\", \"name\": \"biological_process\"}, {\"id\": \"GO:0008152\", \"name\": \"metabolic process\"}, {\"id\": \"GO:0009987\", \"name\": \"cellular process\"}, {\"id\": \"GO:0019748\", \"name\": \"secondary metabolic process\"}]}, {\"annotation_id\": \"GO:0008210\", \"name\": \"estrogen metabolic process\", \"provenance_source\": \"UNIPROT\", \"type\": \"GO\", \"annotation_lineage\": [{\"id\": \"GO:0008210\", \"name\": \"estrogen metabolic process\"}, {\"id\": \"GO:0010817\", \"name\": \"regulation of hormone levels\"}, {\"id\": \"GO:0008202\", \"name\": \"steroid metabolic process\"}, {\"id\": \"GO:0065007\", \"name\": \"biological regulation\"}, {\"id\": \"GO:0008150\", \"name\": \"biological_process\"}, {\"id\": \"GO:0044238\", \"name\": \"primary metabolic process\"}, {\"id\": \"GO:0008152\", \"name\": \"metabolic process\"}, {\"id\": \"GO:0009987\", \"name\": \"cellular process\"}, {\"id\": \"GO:0065008\", \"name\": \"regulation of biological quality\"}, {\"id\": \"GO:0042445\", \"name\": \"hormone metabolic process\"}, {\"id\": \"GO:0006629\", \"name\": \"lipid metabolic process\"}]}, {\"annotation_id\": \"GO:0004497\", \"name\": \"monooxygenase activity\", \"provenance_source\": \"UNIPROT\", \"type\": \"GO\", \"annotation_lineage\": [{\"id\": \"GO:0004497\", \"name\": \"monooxygenase activity\"}, {\"id\": \"GO:0016491\", \"name\": \"oxidoreductase activity\"}, {\"id\": \"GO:0003824\", \"name\": \"catalytic activity\"}, {\"id\": \"GO:0003674\", \"name\": \"molecular_function\"}]}, {\"annotation_id\": \"IPR017972\", \"name\": \"Cytochrome P450, conserved site\", \"provenance_source\": \"UNIPROT\", \"type\": \"InterPro\", \"annotation_lineage\": [{\"id\": \"IPR017972\", \"name\": \"Cytochrome P450, conserved site\"}]}, {\"annotation_id\": \"GO:0043231\", \"name\": \"intracellular membrane-bounded organelle\", \"provenance_source\": \"UNIPROT\", \"type\": \"GO\", \"annotation_lineage\": [{\"id\": \"GO:0043227\", \"name\": \"membrane-bounded organelle\"}, {\"id\": \"GO:0043229\", \"name\": \"intracellular organelle\"}, {\"id\": \"GO:0110165\", \"name\": \"cellular anatomical structure\"}, {\"id\": \"GO:0005575\", \"name\": \"cellular_component\"}, {\"id\": \"GO:0005622\", \"name\": \"intracellular anatomical structure\"}, {\"id\": \"GO:0043226\", \"name\": \"organelle\"}, {\"id\": \"GO:0043231\", \"name\": \"intracellular membrane-bounded organelle\"}]}, {\"annotation_id\": \"GO:0005737\", \"name\": \"cytoplasm\", \"provenance_source\": \"UNIPROT\", \"type\": \"GO\", \"annotation_lineage\": [{\"id\": \"GO:0110165\", \"name\": \"cellular anatomical structure\"}, {\"id\": \"GO:0005575\", \"name\": \"cellular_component\"}, {\"id\": \"GO:0005622\", \"name\": \"intracellular anatomical structure\"}, {\"id\": \"GO:0005737\", \"name\": \"cytoplasm\"}]}, {\"annotation_id\": \"GO:0008203\", \"name\": \"cholesterol metabolic process\", \"provenance_source\": \"UNIPROT\", \"type\": \"GO\", \"annotation_lineage\": [{\"id\": \"GO:1902652\", \"name\": \"secondary alcohol metabolic process\"}, {\"id\": \"GO:0016125\", \"name\": \"sterol metabolic process\"}, {\"id\": \"GO:0008202\", \"name\": \"steroid metabolic process\"}, {\"id\": \"GO:0008203\", \"name\": \"cholesterol metabolic process\"}, {\"id\": \"GO:0008150\", \"name\": \"biological_process\"}, {\"id\": \"GO:0006066\", \"name\": \"alcohol metabolic process\"}, {\"id\": \"GO:0044281\", \"name\": \"small molecule metabolic process\"}, {\"id\": \"GO:0008152\", \"name\": \"metabolic process\"}, {\"id\": \"GO:0009987\", \"name\": \"cellular process\"}, {\"id\": \"GO:0044238\", \"name\": \"primary metabolic process\"}, {\"id\": \"GO:0006629\", \"name\": \"lipid metabolic process\"}]}, {\"annotation_id\": \"GO:0005789\", \"name\": \"endoplasmic reticulum membrane\", \"provenance_source\": \"UNIPROT\", \"type\": \"GO\", \"annotation_lineage\": [{\"id\": \"GO:0043227\", \"name\": \"membrane-bounded organelle\"}, {\"id\": \"GO:0005575\", \"name\": \"cellular_component\"}, {\"id\": \"GO:0005622\", \"name\": \"intracellular anatomical structure\"}, {\"id\": \"GO:0031984\", \"name\": \"organelle subcompartment\"}, {\"id\": \"GO:0016020\", \"name\": \"membrane\"}, {\"id\": \"GO:0043231\", \"name\": \"intracellular membrane-bounded organelle\"}, {\"id\": \"GO:0012505\", \"name\": \"endomembrane system\"}, {\"id\": \"GO:0098827\", \"name\": \"endoplasmic reticulum subcompartment\"}, {\"id\": \"GO:0043229\", \"name\": \"intracellular organelle\"}, {\"id\": \"GO:0110165\", \"name\": \"cellular anatomical structure\"}, {\"id\": \"GO:0043226\", \"name\": \"organelle\"}, {\"id\": \"GO:0042175\", \"name\": \"nuclear outer membrane-endoplasmic reticulum membrane network\"}, {\"id\": \"GO:0005783\", \"name\": \"endoplasmic reticulum\"}, {\"id\": \"GO:0005737\", \"name\": \"cytoplasm\"}, {\"id\": \"GO:0031090\", \"name\": \"organelle membrane\"}, {\"id\": \"GO:0005789\", \"name\": \"endoplasmic reticulum membrane\"}]}, {\"annotation_id\": \"GO:0062188\", \"name\": \"anandamide 11,12 epoxidase activity\", \"provenance_source\": \"UNIPROT\", \"type\": \"GO\", \"annotation_lineage\": [{\"id\": \"GO:0016491\", \"name\": \"oxidoreductase activity\"}, {\"id\": \"GO:0004497\", \"name\": \"monooxygenase activity\"}, {\"id\": \"GO:0016705\", \"name\": \"oxidoreductase activity, acting on paired donors, with incorporation or reduction of molecular oxygen\"}, {\"id\": \"GO:0016709\", \"name\": \"oxidoreductase activity, acting on paired donors, with incorporation or reduction of molecular oxygen, NAD(P)H as one donor, and incorporation of one atom of oxygen\"}, {\"id\": \"GO:0003824\", \"name\": \"catalytic activity\"}, {\"id\": \"GO:0003674\", \"name\": \"molecular_function\"}, {\"id\": \"GO:0062188\", \"name\": \"anandamide 11,12 epoxidase activity\"}, {\"id\": \"GO:0062186\", \"name\": \"anandamide epoxidase activity\"}]}, {\"annotation_id\": \"GO:0008202\", \"name\": \"steroid metabolic process\", \"provenance_source\": \"UNIPROT\", \"type\": \"GO\", \"annotation_lineage\": [{\"id\": \"GO:0008202\", \"name\": \"steroid metabolic process\"}, {\"id\": \"GO:0008150\", \"name\": \"biological_process\"}, {\"id\": \"GO:0044238\", \"name\": \"primary metabolic process\"}, {\"id\": \"GO:0008152\", \"name\": \"metabolic process\"}, {\"id\": \"GO:0009987\", \"name\": \"cellular process\"}, {\"id\": \"GO:0006629\", \"name\": \"lipid metabolic process\"}]}, {\"annotation_id\": \"GO:0062189\", \"name\": \"anandamide 14,15 epoxidase activity\", \"provenance_source\": \"UNIPROT\", \"type\": \"GO\", \"annotation_lineage\": [{\"id\": \"GO:0016491\", \"name\": \"oxidoreductase activity\"}, {\"id\": \"GO:0004497\", \"name\": \"monooxygenase activity\"}, {\"id\": \"GO:0062189\", \"name\": \"anandamide 14,15 epoxidase activity\"}, {\"id\": \"GO:0016705\", \"name\": \"oxidoreductase activity, acting on paired donors, with incorporation or reduction of molecular oxygen\"}, {\"id\": \"GO:0016709\", \"name\": \"oxidoreductase activity, acting on paired donors, with incorporation or reduction of molecular oxygen, NAD(P)H as one donor, and incorporation of one atom of oxygen\"}, {\"id\": \"GO:0003824\", \"name\": \"catalytic activity\"}, {\"id\": \"GO:0003674\", \"name\": \"molecular_function\"}, {\"id\": \"GO:0062186\", \"name\": \"anandamide epoxidase activity\"}]}, {\"annotation_id\": \"GO:0009820\", \"name\": \"alkaloid metabolic process\", \"provenance_source\": \"UNIPROT\", \"type\": \"GO\", \"annotation_lineage\": [{\"id\": \"GO:0008150\", \"name\": \"biological_process\"}, {\"id\": \"GO:0009820\", \"name\": \"alkaloid metabolic process\"}, {\"id\": \"GO:0008152\", \"name\": \"metabolic process\"}, {\"id\": \"GO:0009987\", \"name\": \"cellular process\"}]}, {\"annotation_id\": \"GO:0006805\", \"name\": \"xenobiotic metabolic process\", \"provenance_source\": \"UNIPROT\", \"type\": \"GO\", \"annotation_lineage\": [{\"id\": \"GO:0051716\", \"name\": \"cellular response to stimulus\"}, {\"id\": \"GO:0070887\", \"name\": \"cellular response to chemical stimulus\"}, {\"id\": \"GO:0050896\", \"name\": \"response to stimulus\"}, {\"id\": \"GO:0042221\", \"name\": \"response to chemical\"}, {\"id\": \"GO:0071466\", \"name\": \"cellular response to xenobiotic stimulus\"}, {\"id\": \"GO:0008150\", \"name\": \"biological_process\"}, {\"id\": \"GO:0008152\", \"name\": \"metabolic process\"}, {\"id\": \"GO:0009987\", \"name\": \"cellular process\"}, {\"id\": \"GO:0006805\", \"name\": \"xenobiotic metabolic process\"}, {\"id\": \"GO:0009410\", \"name\": \"response to xenobiotic stimulus\"}]}, {\"annotation_id\": \"GO:0042178\", \"name\": \"xenobiotic catabolic process\", \"provenance_source\": \"UNIPROT\", \"type\": \"GO\", \"annotation_lineage\": [{\"id\": \"GO:0051716\", \"name\": \"cellular response to stimulus\"}, {\"id\": \"GO:0009056\", \"name\": \"catabolic process\"}, {\"id\": \"GO:0050896\", \"name\": \"response to stimulus\"}, {\"id\": \"GO:0071466\", \"name\": \"cellular response to xenobiotic stimulus\"}, {\"id\": \"GO:0042178\", \"name\": \"xenobiotic catabolic process\"}, {\"id\": \"GO:0006805\", \"name\": \"xenobiotic metabolic process\"}, {\"id\": \"GO:0009410\", \"name\": \"response to xenobiotic stimulus\"}, {\"id\": \"GO:0070887\", \"name\": \"cellular response to chemical stimulus\"}, {\"id\": \"GO:0042221\", \"name\": \"response to chemical\"}, {\"id\": \"GO:0008150\", \"name\": \"biological_process\"}, {\"id\": \"GO:0008152\", \"name\": \"metabolic process\"}, {\"id\": \"GO:0009987\", \"name\": \"cellular process\"}]}, {\"annotation_id\": \"IPR008069\", \"name\": \"Cytochrome P450, E-class, group I, CYP2D-like\", \"provenance_source\": \"UNIPROT\", \"type\": \"InterPro\", \"annotation_lineage\": [{\"depth\": 4, \"id\": \"IPR008069\", \"name\": \"Cytochrome P450, E-class, group I, CYP2D-like\"}, {\"depth\": 3, \"id\": \"IPR002401\", \"name\": \"Cytochrome P450, E-class, group I\"}, {\"depth\": 1, \"id\": \"IPR050121\", \"name\": \"Cytochrome P450 monooxygenase\"}, {\"depth\": 2, \"id\": \"IPR001128\", \"name\": \"Cytochrome P450\"}]}, {\"annotation_id\": \"GO:0020037\", \"name\": \"heme binding\", \"provenance_source\": \"UNIPROT\", \"type\": \"GO\", \"annotation_lineage\": [{\"id\": \"GO:0005488\", \"name\": \"binding\"}, {\"id\": \"GO:0046906\", \"name\": \"tetrapyrrole binding\"}, {\"id\": \"GO:0020037\", \"name\": \"heme binding\"}, {\"id\": \"GO:0003674\", \"name\": \"molecular_function\"}]}, {\"annotation_id\": \"GO:0019369\", \"name\": \"arachidonate metabolic process\", \"provenance_source\": \"UNIPROT\", \"type\": \"GO\", \"annotation_lineage\": [{\"id\": \"GO:0006690\", \"name\": \"icosanoid metabolic process\"}, {\"id\": \"GO:0006631\", \"name\": \"fatty acid metabolic process\"}, {\"id\": \"GO:0001676\", \"name\": \"long-chain fatty acid metabolic process\"}, {\"id\": \"GO:0033559\", \"name\": \"unsaturated fatty acid metabolic process\"}, {\"id\": \"GO:0043436\", \"name\": \"oxoacid metabolic process\"}, {\"id\": \"GO:0019369\", \"name\": \"arachidonate metabolic process\"}, {\"id\": \"GO:0019752\", \"name\": \"carboxylic acid metabolic process\"}, {\"id\": \"GO:0044238\", \"name\": \"primary metabolic process\"}, {\"id\": \"GO:0006082\", \"name\": \"organic acid metabolic process\"}, {\"id\": \"GO:0008150\", \"name\": \"biological_process\"}, {\"id\": \"GO:0120254\", \"name\": \"olefinic compound metabolic process\"}, {\"id\": \"GO:0008152\", \"name\": \"metabolic process\"}, {\"id\": \"GO:0009987\", \"name\": \"cellular process\"}, {\"id\": \"GO:0044281\", \"name\": \"small molecule metabolic process\"}, {\"id\": \"GO:0032787\", \"name\": \"monocarboxylic acid metabolic process\"}, {\"id\": \"GO:0006629\", \"name\": \"lipid metabolic process\"}]}, {\"annotation_id\": \"GO:0005506\", \"name\": \"iron ion binding\", \"provenance_source\": \"UNIPROT\", \"type\": \"GO\", \"annotation_lineage\": [{\"id\": \"GO:0043169\", \"name\": \"cation binding\"}, {\"id\": \"GO:0046914\", \"name\": \"transition metal ion binding\"}, {\"id\": \"GO:0005506\", \"name\": \"iron ion binding\"}, {\"id\": \"GO:0043167\", \"name\": \"ion binding\"}, {\"id\": \"GO:0005488\", \"name\": \"binding\"}, {\"id\": \"GO:0003674\", \"name\": \"molecular_function\"}, {\"id\": \"GO:0046872\", \"name\": \"metal ion binding\"}, {\"id\": \"GO:0036094\", \"name\": \"small molecule binding\"}]}, {\"annotation_id\": \"GO:0090350\", \"name\": \"negative regulation of organofluorine metabolic process\", \"provenance_source\": \"UNIPROT\", \"type\": \"GO\", \"annotation_lineage\": [{\"id\": \"GO:0050789\", \"name\": \"regulation of biological process\"}, {\"id\": \"GO:0050794\", \"name\": \"regulation of cellular process\"}, {\"id\": \"GO:0009892\", \"name\": \"negative regulation of metabolic process\"}, {\"id\": \"GO:0065007\", \"name\": \"biological regulation\"}, {\"id\": \"GO:0048519\", \"name\": \"negative regulation of biological process\"}, {\"id\": \"GO:0090350\", \"name\": \"negative regulation of organofluorine metabolic process\"}, {\"id\": \"GO:0090347\", \"name\": \"regulation of organohalogen metabolic process\"}, {\"id\": \"GO:0090345\", \"name\": \"organohalogen metabolic process\"}, {\"id\": \"GO:0090346\", \"name\": \"organofluorine metabolic process\"}, {\"id\": \"GO:0048523\", \"name\": \"negative regulation of cellular process\"}, {\"id\": \"GO:0008150\", \"name\": \"biological_process\"}, {\"id\": \"GO:0008152\", \"name\": \"metabolic process\"}, {\"id\": \"GO:0009987\", \"name\": \"cellular process\"}, {\"id\": \"GO:0019222\", \"name\": \"regulation of metabolic process\"}]}, {\"annotation_id\": \"IPR050182\", \"name\": \"Cytochrome P450 family 2\", \"provenance_source\": \"UNIPROT\", \"type\": \"InterPro\", \"annotation_lineage\": [{\"id\": \"IPR050182\", \"name\": \"Cytochrome P450 family 2\"}]}, {\"annotation_id\": \"IPR001128\", \"name\": \"Cytochrome P450\", \"provenance_source\": \"UNIPROT\", \"type\": \"InterPro\", \"annotation_lineage\": [{\"depth\": 1, \"id\": \"IPR050121\", \"name\": \"Cytochrome P450 monooxygenase\"}, {\"depth\": 2, \"id\": \"IPR001128\", \"name\": \"Cytochrome P450\"}]}, {\"annotation_id\": \"GO:0042759\", \"name\": \"long-chain fatty acid biosynthetic process\", \"provenance_source\": \"UNIPROT\", \"type\": \"GO\", \"annotation_lineage\": [{\"id\": \"GO:0006631\", \"name\": \"fatty acid metabolic process\"}, {\"id\": \"GO:0001676\", \"name\": \"long-chain fatty acid metabolic process\"}, {\"id\": \"GO:0072330\", \"name\": \"monocarboxylic acid biosynthetic process\"}, {\"id\": \"GO:0043436\", \"name\": \"oxoacid metabolic process\"}, {\"id\": \"GO:0044283\", \"name\": \"small molecule biosynthetic process\"}, {\"id\": \"GO:0042759\", \"name\": \"long-chain fatty acid biosynthetic process\"}, {\"id\": \"GO:0019752\", \"name\": \"carboxylic acid metabolic process\"}, {\"id\": \"GO:0008610\", \"name\": \"lipid biosynthetic process\"}, {\"id\": \"GO:0044238\", \"name\": \"primary metabolic process\"}, {\"id\": \"GO:0006082\", \"name\": \"organic acid metabolic process\"}, {\"id\": \"GO:0016053\", \"name\": \"organic acid biosynthetic process\"}, {\"id\": \"GO:0006633\", \"name\": \"fatty acid biosynthetic process\"}, {\"id\": \"GO:0046394\", \"name\": \"carboxylic acid biosynthetic process\"}, {\"id\": \"GO:0009058\", \"name\": \"biosynthetic process\"}, {\"id\": \"GO:0008150\", \"name\": \"biological_process\"}, {\"id\": \"GO:0008152\", \"name\": \"metabolic process\"}, {\"id\": \"GO:0009987\", \"name\": \"cellular process\"}, {\"id\": \"GO:0044281\", \"name\": \"small molecule metabolic process\"}, {\"id\": \"GO:0032787\", \"name\": \"monocarboxylic acid metabolic process\"}, {\"id\": \"GO:0006629\", \"name\": \"lipid metabolic process\"}]}, {\"annotation_id\": \"GO:0033076\", \"name\": \"isoquinoline alkaloid metabolic process\", \"provenance_source\": \"UNIPROT\", \"type\": \"GO\", \"annotation_lineage\": [{\"id\": \"GO:0008150\", \"name\": \"biological_process\"}, {\"id\": \"GO:0009820\", \"name\": \"alkaloid metabolic process\"}, {\"id\": \"GO:0008152\", \"name\": \"metabolic process\"}, {\"id\": \"GO:0009987\", \"name\": \"cellular process\"}, {\"id\": \"GO:0033076\", \"name\": \"isoquinoline alkaloid metabolic process\"}]}, {\"annotation_id\": \"GO:0016098\", \"name\": \"monoterpenoid metabolic process\", \"provenance_source\": \"UNIPROT\", \"type\": \"GO\", \"annotation_lineage\": [{\"id\": \"GO:0016098\", \"name\": \"monoterpenoid metabolic process\"}, {\"id\": \"GO:0008150\", \"name\": \"biological_process\"}, {\"id\": \"GO:0044238\", \"name\": \"primary metabolic process\"}, {\"id\": \"GO:0008152\", \"name\": \"metabolic process\"}, {\"id\": \"GO:0009987\", \"name\": \"cellular process\"}, {\"id\": \"GO:0006721\", \"name\": \"terpenoid metabolic process\"}, {\"id\": \"GO:0006720\", \"name\": \"isoprenoid metabolic process\"}, {\"id\": \"GO:0006629\", \"name\": \"lipid metabolic process\"}]}, {\"annotation_id\": \"GO:0005783\", \"name\": \"endoplasmic reticulum\", \"provenance_source\": \"UNIPROT\", \"type\": \"GO\", \"annotation_lineage\": [{\"id\": \"GO:0043227\", \"name\": \"membrane-bounded organelle\"}, {\"id\": \"GO:0043229\", \"name\": \"intracellular organelle\"}, {\"id\": \"GO:0110165\", \"name\": \"cellular anatomical structure\"}, {\"id\": \"GO:0005575\", \"name\": \"cellular_component\"}, {\"id\": \"GO:0005622\", \"name\": \"intracellular anatomical structure\"}, {\"id\": \"GO:0043226\", \"name\": \"organelle\"}, {\"id\": \"GO:0005783\", \"name\": \"endoplasmic reticulum\"}, {\"id\": \"GO:0005737\", \"name\": \"cytoplasm\"}, {\"id\": \"GO:0043231\", \"name\": \"intracellular membrane-bounded organelle\"}, {\"id\": \"GO:0012505\", \"name\": \"endomembrane system\"}]}, {\"annotation_id\": \"GO:0016712\", \"name\": \"oxidoreductase activity, acting on paired donors, with incorporation or reduction of molecular oxygen, reduced flavin or flavoprotein as one donor, and incorporation of one atom of oxygen\", \"provenance_source\": \"UNIPROT\", \"type\": \"GO\", \"annotation_lineage\": [{\"id\": \"GO:0016491\", \"name\": \"oxidoreductase activity\"}, {\"id\": \"GO:0004497\", \"name\": \"monooxygenase activity\"}, {\"id\": \"GO:0016705\", \"name\": \"oxidoreductase activity, acting on paired donors, with incorporation or reduction of molecular oxygen\"}, {\"id\": \"GO:0003824\", \"name\": \"catalytic activity\"}, {\"id\": \"GO:0003674\", \"name\": \"molecular_function\"}, {\"id\": \"GO:0016712\", \"name\": \"oxidoreductase activity, acting on paired donors, with incorporation or reduction of molecular oxygen, reduced flavin or flavoprotein as one donor, and incorporation of one atom of oxygen\"}]}, {\"annotation_id\": \"GO:0042572\", \"name\": \"retinol metabolic process\", \"provenance_source\": \"UNIPROT\", \"type\": \"GO\", \"annotation_lineage\": [{\"id\": \"GO:0016101\", \"name\": \"diterpenoid metabolic process\"}, {\"id\": \"GO:0010817\", \"name\": \"regulation of hormone levels\"}, {\"id\": \"GO:0065007\", \"name\": \"biological regulation\"}, {\"id\": \"GO:0044238\", \"name\": \"primary metabolic process\"}, {\"id\": \"GO:0006066\", \"name\": \"alcohol metabolic process\"}, {\"id\": \"GO:0042445\", \"name\": \"hormone metabolic process\"}, {\"id\": \"GO:0001523\", \"name\": \"retinoid metabolic process\"}, {\"id\": \"GO:0008150\", \"name\": \"biological_process\"}, {\"id\": \"GO:0120254\", \"name\": \"olefinic compound metabolic process\"}, {\"id\": \"GO:0008152\", \"name\": \"metabolic process\"}, {\"id\": \"GO:0009987\", \"name\": \"cellular process\"}, {\"id\": \"GO:0044281\", \"name\": \"small molecule metabolic process\"}, {\"id\": \"GO:0065008\", \"name\": \"regulation of biological quality\"}, {\"id\": \"GO:0042572\", \"name\": \"retinol metabolic process\"}, {\"id\": \"GO:0006721\", \"name\": \"terpenoid metabolic process\"}, {\"id\": \"GO:0006720\", \"name\": \"isoprenoid metabolic process\"}, {\"id\": \"GO:0006629\", \"name\": \"lipid metabolic process\"}, {\"id\": \"GO:0034308\", \"name\": \"primary alcohol metabolic process\"}]}, {\"annotation_id\": \"IPR036396\", \"name\": \"Cytochrome P450 superfamily\", \"provenance_source\": \"UNIPROT\", \"type\": \"InterPro\", \"annotation_lineage\": [{\"id\": \"IPR036396\", \"name\": \"Cytochrome P450 superfamily\"}]}], \"rcsb_polymer_entity_container_identifiers\": {\"asym_ids\": [\"A\", \"B\", \"C\", \"D\"], \"auth_asym_ids\": [\"A\", \"B\", \"C\", \"D\"], \"chem_comp_monomers\": [\"ALA\", \"ARG\", \"ASN\", \"ASP\", \"CYS\", \"GLN\", \"GLU\", \"GLY\", \"HIS\", \"ILE\", \"LEU\", \"LYS\", \"MET\", \"PHE\", \"PRO\", \"SER\", \"THR\", \"TRP\", \"TYR\", \"VAL\"], \"entity_id\": \"1\", \"entry_id\": \"2F9Q\", \"rcsb_id\": \"2F9Q_1\", \"uniprot_ids\": [\"P10635\"], \"reference_sequence_identifiers\": [{\"database_accession\": \"P10635\", \"database_name\": \"UniProt\", \"entity_sequence_coverage\": 0.9686847599164927, \"provenance_source\": \"SIFTS\", \"reference_sequence_coverage\": 0.9336016096579477}]}, \"rcsb_polymer_entity_feature\": [{\"assignment_version\": \"34.0\", \"feature_id\": \"PF00067\", \"name\": \"Cytochrome P450 (p450)\", \"provenance_source\": \"Pfam\", \"type\": \"Pfam\", \"feature_positions\": [{\"beg_seq_id\": 12, \"end_seq_id\": 472}]}, {\"assignment_version\": \"V1.0\", \"feature_id\": \"monomer_feature_1\", \"name\": \"engineered mutation\", \"provenance_source\": \"PDB\", \"type\": \"mutation\", \"feature_positions\": [{\"beg_seq_id\": 208}]}, {\"assignment_version\": \"V1.0\", \"feature_id\": \"monomer_feature_2\", \"name\": \"engineered mutation\", \"provenance_source\": \"PDB\", \"type\": \"mutation\", \"feature_positions\": [{\"beg_seq_id\": 209}]}, {\"assignment_version\": \"V1.0\", \"feature_id\": \"range_feature_1\", \"name\": \"cloning artifact\", \"provenance_source\": \"PDB\", \"type\": \"artifact\", \"feature_positions\": [{\"beg_seq_id\": 2, \"end_seq_id\": 11}]}, {\"assignment_version\": \"V1.0\", \"feature_id\": \"range_feature_2\", \"name\": \"expression tag\", \"provenance_source\": \"PDB\", \"type\": \"artifact\", \"feature_positions\": [{\"beg_seq_id\": 476, \"end_seq_id\": 479}]}, {\"name\": \"Hydropathy values\", \"provenance_source\": \"biojava-7.2.4\", \"type\": \"hydropathy\", \"feature_positions\": [{\"beg_seq_id\": 5, \"values\": [-1.19, -1.83, -1.61, -1.36, -1.1, -1.07, -1.16, -0.64, -0.39, 0.08, 0.33, -0.13, 0.47, 0.6, 0.26, 0.86, 0.86, 0.68, 0.72, 0.51, 0.87, 0.06, -0.29, 0.02, -0.58, -1.14, -0.51, -0.67, -0.67, -1.37, -0.56, -0.67, -1.09, -1.41, -0.96, -1.28, -1.98, -1.12, -0.42, -0.93, -0.01, 0.1, 1.02, 0.91, 0.86, 1.17, 0.52, 0.68, 1.23, 1.28, 2.09, 1.28, 1.03, 1.56, 1.83, 2.21, 2.21, 1.24, 0.39, 0.17, 0.98, 1.49, 0.99, 0.43, 0.19, -0.67, -0.56, -0.24, -0.24, -1.06, -2.02, -2.12, -1.94, -1.43, -1.22, -0.33, -0.33, -0.92, -0.03, 0.89, 1.02, 1.51, 1.0, 1.0, 0.0, -0.01, -0.01, -0.56, -0.51, -0.16, -0.04, 0.2, -0.12, 0.23, 0.28, 0.49, 0.73, 0.17, -0.64, -1.46, -2.04, -2.04, -2.4, -2.04, -1.96, -1.69, -1.68, -1.26, -0.44, -0.56, -0.44, 0.48, 0.12, 0.63, 0.12, -0.22, -0.58, -1.09, -0.17, -0.17, -0.98, -1.03, -0.99, -1.02, -0.98, -0.93, -0.64, -0.87, -0.2, 0.61, 0.99, 0.72, 1.0, 1.7, 2.29, 1.7, 1.14, 0.78, 0.31, -0.47, -0.84, -0.73, -1.54, -1.92, -1.92, -1.61, -1.1, -0.63, -0.52, -0.78, -0.89, 0.08, 0.17, 0.17, 0.68, 0.76, 0.53, 0.83, 1.69, 1.41, 1.22, 1.27, 1.16, 0.19, 0.0, -0.59, -0.64, -1.46, -1.77, -2.22, -2.68, -1.87, -0.94, -1.76, -0.94, -0.38, -0.38, 0.43, 0.81, 0.92, 0.22, -0.24, 0.68, -0.18, -0.99, -0.99, -1.5, -1.74, -1.04, -0.23, -0.69, -1.5, -0.6, 0.21, 0.21, 0.5, 1.01, 0.52, 0.57, 0.68, 0.57, -0.26, -0.18, 0.03, 0.03, -0.01, 0.37, -0.14, -0.19, 0.78, 1.56, 0.56, 1.04, 0.46, -0.4, -0.4, -0.04, 0.81, 0.27, -0.54, 0.38, -0.32, -0.32, 0.53, 0.76, 0.37, -0.44, -0.72, -0.83, -1.04, -0.73, -0.44, -1.26, -1.86, -1.58, -1.58, -1.4, -1.08, -1.79, -2.1, -1.58, -1.27, -1.48, -1.48, -0.78, -0.18, 0.2, 0.31, 0.91, 0.1, -0.26, 0.33, -0.3, -0.66, -1.47, -1.84, -1.84, -2.14, -1.84, -1.1, -1.69, -1.64, -1.99, -1.99, -1.39, -1.5, -0.91, -0.36, -0.2, 0.39, 0.39, 1.2, 1.9, 1.39, 2.09, 1.54, 1.29, 1.29, 1.01, 1.32, 0.81, 0.42, 0.43, 0.66, 0.9, 0.59, 0.08, 0.58, 1.08, 1.59, 1.88, 2.46, 2.46, 1.9, 1.82, 1.48, 1.52, 0.71, -0.21, -0.92, -0.96, -1.77, -1.8, -2.01, -1.12, -1.98, -1.98, -1.01, -0.01, -0.52, -0.52, 0.33, 0.22, -0.78, -0.57, -0.57, -0.82, -1.37, -1.71, -1.71, -1.98, -1.83, -1.12, -1.12, -0.88, -1.17, -1.2, -0.61, 0.24, 0.54, 0.54, -0.06, 0.59, 0.34, -0.08, 0.31, 0.07, -0.79, -0.79, 0.03, 0.24, 0.2, 0.54, 1.26, 0.87, 0.56, 1.16, 0.58, 0.02, -0.3, -1.11, -0.57, -1.17, -0.62, -0.66, -0.91, -0.52, -0.93, 0.07, 0.28, -0.66, -0.31, -0.86, -0.54, -0.08, 0.11, 0.53, -0.36, 0.24, 0.59, 0.54, 1.09, 1.59, 0.73, -0.16, -0.47, 0.12, 0.17, 0.16, -0.14, -1.04, -1.64, -0.9, -1.01, -0.31, -0.87, -1.51, -1.8, -1.77, -1.02, -0.42, -1.12, -0.42, -1.12, -0.81, -0.99, -0.29, 0.53, -0.21, -0.81, -0.81, -0.81, -0.11, 0.36, 0.53, 0.53, -0.02, 0.61, 0.74, 0.63, -0.07, -0.18, -0.32, 0.28, -0.08, -0.38, -0.76, -0.29, 0.41, 0.41, 0.42, -0.24, -0.24, 0.11, 0.92, 1.41, 1.3, 1.02, 1.43, 1.64, 2.46, 1.64, 0.98, 0.87, 0.47, 0.47, 0.46, 1.01, 0.41, -0.09, 0.26, 0.22, -0.27, -0.68, -1.17, -1.17, -1.99, -2.17, -2.13, -1.62, -0.92, -0.54, 0.27, 0.87, 1.42, 1.69, 1.87, 1.82, 1.18, 0.72, 0.13, 0.24, 0.1, -0.17, 0.39, 0.39, -0.02, -0.2, -0.41, -0.38, -1.16]}]}, {\"name\": \"Disordered regions\", \"provenance_source\": \"IUPred2(short)\", \"type\": \"disorder\", \"feature_positions\": [{\"beg_seq_id\": 1, \"values\": [0.96, 0.96, 0.95, 0.93, 0.92, 0.84, 0.83, 0.73, 0.71, 0.68, 0.58, 0.6, 0.63, 0.55, 0.48, 0.47, 0.39, 0.39, 0.29, 0.31, 0.31, 0.37, 0.37, 0.26, 0.19, 0.1, 0.15, 0.14, 0.12, 0.1, 0.09, 0.13, 0.07, 0.06, 0.1, 0.09, 0.05, 0.07, 0.04, 0.07, 0.04, 0.03, 0.01, 0.01, 0.03, 0.03, 0.04, 0.02, 0.01, 0.02, 0.02, 0.01, 0.01, 0.02, 0.01, 0.01, 0.02, 0.04, 0.02, 0.03, 0.03, 0.05, 0.06, 0.12, 0.13, 0.12, 0.13, 0.2, 0.27, 0.38, 0.41, 0.33, 0.44, 0.39, 0.43, 0.52, 0.46, 0.37, 0.41, 0.41, 0.49, 0.52, 0.51, 0.51, 0.51, 0.5, 0.44, 0.41, 0.33, 0.31, 0.28, 0.18, 0.25, 0.25, 0.3, 0.21, 0.2, 0.27, 0.34, 0.32, 0.39, 0.3, 0.27, 0.21, 0.2, 0.19, 0.13, 0.17, 0.22, 0.2, 0.23, 0.15, 0.22, 0.21, 0.18, 0.21, 0.22, 0.22, 0.23, 0.16, 0.12, 0.12, 0.19, 0.19, 0.22, 0.2, 0.12, 0.13, 0.08, 0.07, 0.09, 0.05, 0.07, 0.07, 0.06, 0.06, 0.06, 0.1, 0.11, 0.06, 0.09, 0.15, 0.14, 0.13, 0.09, 0.07, 0.09, 0.15, 0.17, 0.19, 0.22, 0.24, 0.27, 0.22, 0.2, 0.21, 0.14, 0.15, 0.1, 0.09, 0.15, 0.15, 0.07, 0.08, 0.05, 0.08, 0.13, 0.15, 0.14, 0.1, 0.09, 0.09, 0.05, 0.05, 0.09, 0.06, 0.05, 0.09, 0.09, 0.13, 0.08, 0.08, 0.1, 0.16, 0.16, 0.23, 0.15, 0.09, 0.06, 0.08, 0.09, 0.08, 0.09, 0.12, 0.12, 0.14, 0.15, 0.18, 0.16, 0.16, 0.09, 0.17, 0.15, 0.09, 0.07, 0.08, 0.07, 0.08, 0.09, 0.09, 0.05, 0.08, 0.14, 0.12, 0.09, 0.1, 0.07, 0.13, 0.08, 0.09, 0.09, 0.1, 0.05, 0.06, 0.12, 0.13, 0.12, 0.1, 0.15, 0.16, 0.17, 0.28, 0.25, 0.26, 0.32, 0.43, 0.5, 0.51, 0.44, 0.52, 0.53, 0.5, 0.52, 0.53, 0.52, 0.52, 0.49, 0.51, 0.54, 0.52, 0.59, 0.59, 0.56, 0.61, 0.61, 0.58, 0.54, 0.48, 0.47, 0.53, 0.55, 0.53, 0.47, 0.52, 0.49, 0.43, 0.35, 0.34, 0.33, 0.26, 0.19, 0.2, 0.17, 0.17, 0.12, 0.07, 0.07, 0.07, 0.12, 0.12, 0.11, 0.05, 0.04, 0.04, 0.04, 0.04, 0.04, 0.03, 0.03, 0.02, 0.01, 0.03, 0.04, 0.05, 0.03, 0.04, 0.05, 0.05, 0.04, 0.04, 0.04, 0.04, 0.05, 0.06, 0.12, 0.08, 0.09, 0.15, 0.24, 0.21, 0.29, 0.37, 0.41, 0.38, 0.34, 0.42, 0.43, 0.44, 0.41, 0.49, 0.45, 0.48, 0.39, 0.47, 0.47, 0.43, 0.44, 0.46, 0.46, 0.47, 0.47, 0.49, 0.5, 0.38, 0.38, 0.42, 0.35, 0.28, 0.31, 0.25, 0.25, 0.24, 0.21, 0.29, 0.25, 0.25, 0.27, 0.33, 0.4, 0.32, 0.31, 0.31, 0.31, 0.31, 0.31, 0.3, 0.21, 0.3, 0.35, 0.32, 0.4, 0.4, 0.36, 0.3, 0.3, 0.33, 0.26, 0.25, 0.25, 0.18, 0.19, 0.18, 0.24, 0.25, 0.22, 0.23, 0.16, 0.23, 0.2, 0.23, 0.15, 0.15, 0.09, 0.13, 0.21, 0.22, 0.21, 0.2, 0.13, 0.14, 0.17, 0.26, 0.27, 0.25, 0.17, 0.13, 0.18, 0.29, 0.29, 0.26, 0.15, 0.15, 0.18, 0.16, 0.16, 0.12, 0.11, 0.11, 0.17, 0.21, 0.13, 0.09, 0.08, 0.08, 0.11, 0.1, 0.13, 0.13, 0.08, 0.08, 0.06, 0.07, 0.07, 0.03, 0.04, 0.04, 0.04, 0.02, 0.01, 0.02, 0.02, 0.02, 0.03, 0.02, 0.01, 0.01, 0.01, 0.02, 0.02, 0.03, 0.03, 0.05, 0.1, 0.15, 0.21, 0.31, 0.31, 0.24, 0.23, 0.3, 0.2, 0.15, 0.18, 0.18, 0.3, 0.31, 0.4, 0.3, 0.31, 0.25, 0.15, 0.13, 0.1, 0.09, 0.1, 0.1, 0.11, 0.1, 0.14, 0.27, 0.32, 0.46, 0.56, 0.66, 0.69, 0.71, 0.75, 0.77, 0.88]}]}, {\"name\": \"Disordered binding sites\", \"provenance_source\": \"Anchor2\", \"type\": \"disorder_binding\", \"feature_positions\": [{\"beg_seq_id\": 1, \"values\": [0.44, 0.44, 0.43, 0.43, 0.43, 0.43, 0.43, 0.43, 0.43, 0.43, 0.43, 0.43, 0.43, 0.42, 0.42, 0.42, 0.42, 0.42, 0.42, 0.41, 0.41, 0.4, 0.4, 0.4, 0.39, 0.39, 0.38, 0.38, 0.38, 0.38, 0.38, 0.38, 0.39, 0.39, 0.4, 0.41, 0.42, 0.43, 0.43, 0.42, 0.41, 0.41, 0.4, 0.4, 0.39, 0.4, 0.4, 0.41, 0.42, 0.43, 0.42, 0.4, 0.39, 0.37, 0.34, 0.32, 0.3, 0.29, 0.28, 0.27, 0.27, 0.26, 0.26, 0.26, 0.26, 0.27, 0.28, 0.29, 0.3, 0.31, 0.32, 0.32, 0.33, 0.33, 0.34, 0.34, 0.34, 0.34, 0.34, 0.34, 0.34, 0.34, 0.34, 0.34, 0.34, 0.34, 0.34, 0.35, 0.36, 0.37, 0.37, 0.38, 0.38, 0.38, 0.39, 0.41, 0.42, 0.43, 0.43, 0.43, 0.42, 0.43, 0.43, 0.42, 0.42, 0.41, 0.42, 0.43, 0.42, 0.42, 0.43, 0.43, 0.43, 0.42, 0.41, 0.4, 0.38, 0.37, 0.36, 0.36, 0.35, 0.35, 0.33, 0.33, 0.32, 0.31, 0.3, 0.3, 0.29, 0.28, 0.26, 0.25, 0.23, 0.22, 0.22, 0.21, 0.21, 0.21, 0.21, 0.22, 0.23, 0.24, 0.24, 0.24, 0.25, 0.26, 0.27, 0.28, 0.29, 0.3, 0.3, 0.3, 0.3, 0.31, 0.32, 0.32, 0.32, 0.31, 0.3, 0.29, 0.27, 0.26, 0.25, 0.24, 0.23, 0.22, 0.21, 0.21, 0.2, 0.2, 0.21, 0.22, 0.23, 0.24, 0.25, 0.26, 0.28, 0.29, 0.3, 0.31, 0.32, 0.32, 0.31, 0.3, 0.29, 0.28, 0.27, 0.26, 0.24, 0.24, 0.23, 0.22, 0.22, 0.22, 0.22, 0.22, 0.23, 0.24, 0.24, 0.24, 0.25, 0.26, 0.27, 0.28, 0.29, 0.31, 0.32, 0.32, 0.33, 0.35, 0.36, 0.37, 0.37, 0.38, 0.38, 0.39, 0.39, 0.4, 0.42, 0.43, 0.42, 0.4, 0.38, 0.36, 0.34, 0.33, 0.33, 0.32, 0.32, 0.32, 0.32, 0.32, 0.33, 0.34, 0.36, 0.37, 0.38, 0.38, 0.39, 0.39, 0.4, 0.4, 0.4, 0.41, 0.4, 0.4, 0.4, 0.4, 0.4, 0.4, 0.4, 0.4, 0.4, 0.4, 0.41, 0.41, 0.42, 0.42, 0.43, 0.43, 0.43, 0.43, 0.43, 0.43, 0.43, 0.43, 0.43, 0.43, 0.43, 0.43, 0.42, 0.41, 0.4, 0.4, 0.38, 0.37, 0.35, 0.34, 0.33, 0.32, 0.31, 0.31, 0.32, 0.32, 0.32, 0.33, 0.34, 0.34, 0.34, 0.34, 0.34, 0.33, 0.32, 0.31, 0.3, 0.29, 0.29, 0.29, 0.3, 0.32, 0.34, 0.37, 0.4, 0.43, 0.41, 0.38, 0.36, 0.34, 0.33, 0.32, 0.31, 0.31, 0.31, 0.32, 0.33, 0.34, 0.35, 0.36, 0.37, 0.38, 0.4, 0.41, 0.42, 0.43, 0.43, 0.43, 0.42, 0.42, 0.42, 0.41, 0.41, 0.42, 0.42, 0.42, 0.42, 0.42, 0.42, 0.41, 0.41, 0.41, 0.41, 0.4, 0.39, 0.38, 0.37, 0.37, 0.36, 0.36, 0.36, 0.36, 0.36, 0.35, 0.36, 0.36, 0.37, 0.37, 0.38, 0.38, 0.39, 0.39, 0.4, 0.4, 0.41, 0.41, 0.42, 0.43, 0.43, 0.42, 0.41, 0.4, 0.39, 0.38, 0.37, 0.36, 0.35, 0.34, 0.34, 0.34, 0.34, 0.34, 0.35, 0.35, 0.35, 0.35, 0.36, 0.37, 0.37, 0.37, 0.36, 0.36, 0.35, 0.33, 0.33, 0.32, 0.3, 0.28, 0.26, 0.24, 0.23, 0.22, 0.21, 0.2, 0.2, 0.19, 0.18, 0.17, 0.18, 0.18, 0.19, 0.19, 0.2, 0.2, 0.21, 0.21, 0.22, 0.24, 0.25, 0.24, 0.25, 0.25, 0.25, 0.25, 0.25, 0.25, 0.24, 0.24, 0.23, 0.23, 0.23, 0.22, 0.21, 0.2, 0.2, 0.19, 0.19, 0.18, 0.18, 0.17, 0.17, 0.17, 0.16, 0.16, 0.16, 0.16, 0.16, 0.17, 0.18, 0.19, 0.19, 0.2, 0.2, 0.21, 0.21, 0.21, 0.22, 0.22, 0.21, 0.2, 0.18, 0.17, 0.16, 0.16, 0.14, 0.14, 0.13, 0.13, 0.13, 0.13, 0.14, 0.15, 0.17, 0.19, 0.21, 0.23, 0.25, 0.26, 0.27, 0.29, 0.31]}]}], \"rcsb_polymer_entity_feature_summary\": [{\"count\": 1, \"coverage\": 0.96242, \"type\": \"Pfam\"}, {\"count\": 2, \"coverage\": 0.00418, \"type\": \"mutation\"}, {\"count\": 2, \"coverage\": 0.02923, \"maximum_length\": 10, \"minimum_length\": 4, \"type\": \"artifact\"}], \"rcsb_polymer_entity_group_membership\": [{\"aggregation_method\": \"sequence_identity\", \"group_id\": \"6444_70\", \"similarity_cutoff\": 70.0, \"aligned_regions\": [{\"entity_beg_seq_id\": 1, \"length\": 479, \"ref_beg_seq_id\": 26}]}, {\"aggregation_method\": \"sequence_identity\", \"group_id\": \"4285_50\", \"similarity_cutoff\": 50.0, \"aligned_regions\": [{\"entity_beg_seq_id\": 1, \"length\": 306, \"ref_beg_seq_id\": 26}, {\"entity_beg_seq_id\": 307, \"length\": 173, \"ref_beg_seq_id\": 350}]}, {\"aggregation_method\": \"sequence_identity\", \"group_id\": \"311_30\", \"similarity_cutoff\": 30.0, \"aligned_regions\": [{\"entity_beg_seq_id\": 1, \"length\": 29, \"ref_beg_seq_id\": 120}, {\"entity_beg_seq_id\": 30, \"length\": 1, \"ref_beg_seq_id\": 168}, {\"entity_beg_seq_id\": 31, \"length\": 14, \"ref_beg_seq_id\": 173}, {\"entity_beg_seq_id\": 45, \"length\": 9, \"ref_beg_seq_id\": 190}, {\"entity_beg_seq_id\": 54, \"length\": 28, \"ref_beg_seq_id\": 200}, {\"entity_beg_seq_id\": 82, \"length\": 3, \"ref_beg_seq_id\": 229}, {\"entity_beg_seq_id\": 85, \"length\": 43, \"ref_beg_seq_id\": 261}, {\"entity_beg_seq_id\": 128, \"length\": 17, \"ref_beg_seq_id\": 311}, {\"entity_beg_seq_id\": 145, \"length\": 31, \"ref_beg_seq_id\": 340}, {\"entity_beg_seq_id\": 176, \"length\": 3, \"ref_beg_seq_id\": 372}, {\"entity_beg_seq_id\": 179, \"length\": 17, \"ref_beg_seq_id\": 377}, {\"entity_beg_seq_id\": 196, \"length\": 8, \"ref_beg_seq_id\": 395}, {\"entity_beg_seq_id\": 204, \"length\": 3, \"ref_beg_seq_id\": 406}, {\"entity_beg_seq_id\": 207, \"length\": 2, \"ref_beg_seq_id\": 412}, {\"entity_beg_seq_id\": 209, \"length\": 1, \"ref_beg_seq_id\": 446}, {\"entity_beg_seq_id\": 210, \"length\": 4, \"ref_beg_seq_id\": 448}, {\"entity_beg_seq_id\": 214, \"length\": 2, \"ref_beg_seq_id\": 457}, {\"entity_beg_seq_id\": 216, \"length\": 8, \"ref_beg_seq_id\": 466}, {\"entity_beg_seq_id\": 224, \"length\": 15, \"ref_beg_seq_id\": 475}, {\"entity_beg_seq_id\": 239, \"length\": 7, \"ref_beg_seq_id\": 493}, {\"entity_beg_seq_id\": 246, \"length\": 2, \"ref_beg_seq_id\": 503}, {\"entity_beg_seq_id\": 248, \"length\": 12, \"ref_beg_seq_id\": 506}, {\"entity_beg_seq_id\": 260, \"length\": 1, \"ref_beg_seq_id\": 520}, {\"entity_beg_seq_id\": 261, \"length\": 3, \"ref_beg_seq_id\": 522}, {\"entity_beg_seq_id\": 264, \"length\": 3, \"ref_beg_seq_id\": 528}, {\"entity_beg_seq_id\": 267, \"length\": 12, \"ref_beg_seq_id\": 536}, {\"entity_beg_seq_id\": 279, \"length\": 10, \"ref_beg_seq_id\": 549}, {\"entity_beg_seq_id\": 289, \"length\": 18, \"ref_beg_seq_id\": 560}, {\"entity_beg_seq_id\": 307, \"length\": 4, \"ref_beg_seq_id\": 596}, {\"entity_beg_seq_id\": 311, \"length\": 7, \"ref_beg_seq_id\": 601}, {\"entity_beg_seq_id\": 318, \"length\": 3, \"ref_beg_seq_id\": 611}, {\"entity_beg_seq_id\": 321, \"length\": 6, \"ref_beg_seq_id\": 617}, {\"entity_beg_seq_id\": 327, \"length\": 34, \"ref_beg_seq_id\": 624}, {\"entity_beg_seq_id\": 361, \"length\": 45, \"ref_beg_seq_id\": 659}, {\"entity_beg_seq_id\": 406, \"length\": 11, \"ref_beg_seq_id\": 707}, {\"entity_beg_seq_id\": 417, \"length\": 30, \"ref_beg_seq_id\": 727}, {\"entity_beg_seq_id\": 447, \"length\": 11, \"ref_beg_seq_id\": 758}, {\"entity_beg_seq_id\": 458, \"length\": 3, \"ref_beg_seq_id\": 771}, {\"entity_beg_seq_id\": 461, \"length\": 11, \"ref_beg_seq_id\": 775}, {\"entity_beg_seq_id\": 472, \"length\": 3, \"ref_beg_seq_id\": 787}, {\"entity_beg_seq_id\": 475, \"length\": 5, \"ref_beg_seq_id\": 791}]}, {\"aggregation_method\": \"matching_uniprot_accession\", \"group_id\": \"P10635\", \"aligned_regions\": [{\"entity_beg_seq_id\": 12, \"length\": 464, \"ref_beg_seq_id\": 34}]}, {\"aggregation_method\": \"sequence_identity\", \"group_id\": \"5773_95\", \"similarity_cutoff\": 95.0, \"aligned_regions\": [{\"entity_beg_seq_id\": 1, \"length\": 479, \"ref_beg_seq_id\": 23}]}, {\"aggregation_method\": \"sequence_identity\", \"group_id\": \"339694_100\", \"similarity_cutoff\": 100.0, \"aligned_regions\": [{\"entity_beg_seq_id\": 1, \"length\": 479, \"ref_beg_seq_id\": 1}]}, {\"aggregation_method\": \"sequence_identity\", \"group_id\": \"5548_90\", \"similarity_cutoff\": 90.0, \"aligned_regions\": [{\"entity_beg_seq_id\": 1, \"length\": 479, \"ref_beg_seq_id\": 23}]}], \"rcsb_polymer_entity_name_com\": [{\"name\": \"CYPIID6; P450-DB1; Debrisoquine 4-hydroxylase\"}], \"rcsb_polymer_entity_name_sys\": [{\"name\": \"E.C.1.14.14.1\"}], \"rcsb_related_target_references\": [{\"related_resource_name\": \"ChEMBL\", \"related_resource_version\": \"36\", \"related_target_id\": \"CHEMBL4523986\", \"target_taxonomy_id\": 9606, \"aligned_target\": [{\"entity_beg_seq_id\": 1, \"length\": 474, \"target_beg_seq_id\": 23}]}, {\"related_resource_name\": \"ChEMBL\", \"related_resource_version\": \"36\", \"related_target_id\": \"CHEMBL289\", \"target_taxonomy_id\": 9606, \"aligned_target\": [{\"entity_beg_seq_id\": 1, \"length\": 474, \"target_beg_seq_id\": 23}]}, {\"related_resource_name\": \"DrugBank\", \"related_resource_version\": \"5.1\", \"related_target_id\": \"P10635\", \"target_taxonomy_id\": 9606, \"aligned_target\": [{\"entity_beg_seq_id\": 1, \"length\": 474, \"target_beg_seq_id\": 23}]}, {\"related_resource_name\": \"Pharos\", \"related_resource_version\": \"6.13.4\", \"related_target_id\": \"58\", \"target_taxonomy_id\": 9606, \"aligned_target\": [{\"entity_beg_seq_id\": 1, \"length\": 474, \"target_beg_seq_id\": 23}]}], \"rcsb_target_cofactors\": [{\"cofactor_name\": \"Peginterferon alfa-2b\", \"cofactor_resource_id\": \"DB00022\", \"mechanism_of_action\": \"Peginterferon alfa-2b is derived from recombinant human interferon's alfa-2b moeity [FDA Label]. It binds to and activates human type 1 interferon receptors causing them to dimerize. This activates the JAK/STAT pathway. Activation of the JAK/STAT pathway increases expression of multiple genes in multiple tissues involved in the innate antiviral response. Peginterferon alfa-2b may also acitvate the nuclear factor \\u03baB pathway.\", \"neighbor_flag\": \"N\", \"resource_name\": \"DrugBank\", \"resource_version\": \"5.1\", \"target_resource_id\": \"P10635\"}, {\"cofactor_in_ch_ikey\": \"PMATZTZNYRCHOR-CGLBZJNRSA-N\", \"cofactor_smiles\": \"CC[C@@H]1NC(=O)[C@H]([C@H](O)[C@H](C)C\\\\C=C\\\\C)N(C)C(=O)[C@H](C(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)N(C)C(=O)[C@@H](NC(=O)[C@H](CC(C)C)N(C)C(=O)CN(C)C1=O)C(C)C\", \"cofactor_name\": \"Cyclosporine\", \"cofactor_resource_id\": \"DB00091\", \"mechanism_of_action\": \"Cyclosporine is a calcineurin inhibitor that inhibits T cell activation.[A174049,A174088,A189411] Its binding to the receptor cyclophilin-1 inside cells produces a complex known as cyclosporine-cyclophilin. This complex subsequently inhibits calcineurin, which in turn stops the dephosphorylation as well as the activation of the nuclear factor of activated T cells (NF-AT) that normally cause inflammatory reactions.  NF-AT is a transcription factor that promotes the production of cytokines such as IL-2, IL-4, interferon-gamma and TNF-alpha, all of which are involved in the inflammatory process. Specifically, the inhibition of IL-2, which is necessary for T cell activation or proliferation, is believed to be responsible for cyclosporine's  immunosuppressive actions.[A174049,A189408] In addition to the above, the inhibition of NF-AT leads to lower levels of other factors associated with T helper cell function and thymocyte development.[A174049]\", \"neighbor_flag\": \"N\", \"pubmed_ids\": [17202802], \"resource_name\": \"DrugBank\", \"resource_version\": \"5.1\", \"target_resource_id\": \"P10635\"}, {\"cofactor_in_ch_ikey\": \"MJVAVZPDRWSRRC-UHFFFAOYSA-N\", \"cofactor_smiles\": \"CC1=CC(=O)C2=CC=CC=C2C1=O\", \"cofactor_chem_comp_id\": \"VK3\", \"cofactor_name\": \"Menadione\", \"cofactor_resource_id\": \"DB00170\", \"mechanism_of_action\": \"Menadione (vitamin K3) is involved as a cofactor in the posttranslational gamma-carboxylation of glutamic acid residues of certain proteins in the body. These proteins include the vitamin K-dependent coagulation factors II (prothrombin), VII (proconvertin), IX (Christmas factor), X (Stuart factor), protein C, protein S, protein Zv and a growth-arrest-specific factor (Gas6). In contrast to the other vitamin K-dependent proteins in the blood coagulation cascade, protein C and protein S serve anticoagulant roles. The two vitamin K-dependent proteins found in bone are osteocalcin, also known as bone G1a (gamma-carboxyglutamate) protein or BGP, and the matrix G1a protein or MGP. Gamma-carboxylation is catalyzed by the vitamin K-dependent gamma-carboxylases. The reduced form of vitamin K, vitamin K hydroquinone, is the actual cofactor for the gamma-carboxylases. Proteins containing gamma-carboxyglutamate are called G1a proteins.\", \"neighbor_flag\": \"N\", \"pubmed_ids\": [26212258], \"resource_name\": \"DrugBank\", \"resource_version\": \"5.1\", \"target_resource_id\": \"P10635\"}, {\"cofactor_in_ch_ikey\": \"CJOFXWAVKWHTFT-XSFVSMFZSA-N\", \"cofactor_smiles\": \"COCCCC\\\\C(=N/OCCN)C1=CC=C(C=C1)C(F)(F)F\", \"cofactor_chem_comp_id\": \"FVX\", \"cofactor_name\": \"Fluvoxamine\", \"cofactor_resource_id\": \"DB00176\", \"mechanism_of_action\": \"The exact mechanism of action of fluvoxamine has not been fully determined, but appears to be linked to its inhibition of CNS neuronal uptake of serotonin [FDA Label, A249, A250]. Fluvoxamine blocks the reuptake of serotonin at the serotonin reuptake pump of the neuronal membrane, enhancing the actions of serotonin on 5HT<sub>1A</sub> autoreceptors [FDA Label, A249, A250]. Studies have also demonstrated that fluvoxamine has virtually no affinity for \\u03b1<sub>1</sub>- or \\u03b1<sub>2</sub>-adrenergic, \\u03b2-adrenergic, muscarinic, dopamine D<sub>2</sub>, histamine H<sub>1</sub>, GABA-benzodiazepine, opiate, 5-HT<sub>1</sub>, or 5-HT<sub>2</sub> receptors, despite having an affinity for binding to \\u03c31 receptors [A250].\", \"neighbor_flag\": \"N\", \"pubmed_ids\": [8968657, 10774624, 9617978], \"resource_name\": \"DrugBank\", \"resource_version\": \"5.1\", \"target_resource_id\": \"P10635\"}, {\"cofactor_in_ch_ikey\": \"KWTSXDURSIMDCE-UHFFFAOYSA-N\", \"cofactor_smiles\": \"CC(N)CC1=CC=CC=C1\", \"cofactor_name\": \"Amphetamine\", \"cofactor_resource_id\": \"DB00182\", \"mechanism_of_action\": \"It is important to consider that amphetamine has a very similar structure to the catecholamine neurotransmitters mainly on the presence of a long planar conformation, the presence of an aromatic ring and nitrogen in the aryl side chain. Amphetamine, as well as other catecholamines, is taken into presynaptic nerve terminals by the association with two sodium ions and one chloride ion. The complex of the amphetamine with the ions is actively transported by monoamine reuptake transporters. As amphetamine acts competitively with the endogenous monoamines, the greater the number of amphetamines the more internalized amphetamine will be found.[A18540]\\r\\n\\r\\nOnce inside the presynaptic terminal, amphetamine displaces other monoamines to be stored by VMAT2 which produces the pumping of the neurotransmitters into the synapse by a process called retro-transport.[A174211] This process of release of neurotransmitters is approximately fourfold more potent in the d-isomer for the release of dopamine.[A174214]\\r\\n\\r\\nThe mechanism of action of amphetamine is complemented by the inhibition of the reuptake and of monoamine oxidase which acts synergistically to produce a significant increase the monoamine concentration.[A18540] This activity is not done as an inhibitor per se but more as a competitive substrate and thus, amphetamine is known to be a weak dopamine reuptake inhibitor, moderate noradrenaline reuptake inhibitor and very weak serotonin reuptake inhibitor. From this specific action, the l-isomer is known to be significantly less potent.[A174214]\\r\\n\\r\\nLastly, amphetamine is known to be an inhibitor of the mitochondrial-bound enzyme MAO which is the catalytic enzyme in charge of degrading all the excess of neurotransmitters. This mechanism of action is often overpassed as amphetamine is a weak MAO inhibitor but this mechanism cannot be dismissed.[A18540]\", \"neighbor_flag\": \"N\", \"pubmed_ids\": [9264312, 10456690], \"resource_name\": \"DrugBank\", \"resource_version\": \"5.1\", \"target_resource_id\": \"P10635\"}, {\"cofactor_in_ch_ikey\": \"SNICXCGAKADSCV-JTQLQIEISA-N\", \"cofactor_smiles\": \"CN1CCC[C@H]1C1=CN=CC=C1\", \"cofactor_chem_comp_id\": \"NCT\", \"cofactor_name\": \"Nicotine\", \"cofactor_resource_id\": \"DB00184\", \"mechanism_of_action\": \"Nicotine is a stimulant drug that acts as an agonist at nicotinic acetylcholine receptors. These are ionotropic receptors composed up of five homomeric or heteromeric subunits. In the brain, nicotine binds to nicotinic acetylcholine receptors on dopaminergic neurons in the cortico-limbic pathways. This causes the channel to open and allow conductance of multiple cations including sodium, calcium, and potassium. This leads to depolarization, which activates voltage-gated calcium channels and allows more calcium to enter the axon terminal. Calcium stimulates vesicle trafficking towards the plasma membrane and the release of dopamine into the synapse. Dopamine binding to its receptors is responsible the euphoric and addictive properties of nicotine.\\r\\nNicotine also binds to nicotinic acetylcholine receptors on the chromaffin cells in the adrenal medulla. Binding opens the ion channel allowing influx of sodium, causing depolarization of the cell, which activates voltage-gated calcium channels. Calcium triggers the release of epinephrine from intracellular vesicles into the bloodstream, which causes vasoconstriction, increased blood pressure, increased heart rate, and increased blood sugar.\", \"neighbor_flag\": \"N\", \"pubmed_ids\": [10350185, 8807663, 26287939], \"resource_name\": \"DrugBank\", \"resource_version\": \"5.1\", \"target_resource_id\": \"P10635\"}, {\"cofactor_in_ch_ikey\": \"WUTYZMFRCNBCHQ-LHIURRSHSA-N\", \"cofactor_smiles\": \"CC1O[C@@]2(CS1)CN1CCC2CC1\", \"cofactor_name\": \"Cevimeline\", \"cofactor_resource_id\": \"DB00185\", \"mechanism_of_action\": \"Muscarinic agonists such as cevimeline bind and activate the muscarinic M1 and M3 receptors. The M1 receptors are common in secretory glands (exocrine glands such as salivary and sweat glands), and their activation results in an increase in secretion from the secretory glands. The M3 receptors are found on smooth muscles and in many glands which help to stimulate secretion in salivary glands, and their activation generally results in smooth muscle contraction and increased glandular secretions. Therefore, as saliva excretion is increased, the symptoms of dry mouth are relieved.\", \"neighbor_flag\": \"N\", \"pubmed_ids\": [11725960, 12608011], \"resource_name\": \"DrugBank\", \"resource_version\": \"5.1\", \"target_resource_id\": \"P10635\"}, {\"cofactor_in_ch_ikey\": \"AQNDDEOPVVGCPG-UHFFFAOYSA-N\", \"cofactor_smiles\": \"COC(=O)CCC1=CC=C(OCC(O)CNC(C)C)C=C1\", \"cofactor_name\": \"Esmolol\", \"cofactor_resource_id\": \"DB00187\", \"mechanism_of_action\": \"Similar to other beta-blockers, esmolol blocks the agonistic effect of the sympathetic neurotransmitters by competing for receptor binding sites. Because it predominantly blocks the beta-1 receptors in cardiac tissue, it is said to be cardioselective. In general, so-called cardioselective beta-blockers are relatively cardioselective; at lower doses they block beta-1 receptors only but begin to block beta-2 receptors as the dose increases. At therapeutic dosages, esmolol does not have intrinsic sympathomimetic activity (ISA) or membrane-stabilizing (quinidine-like) activity. Antiarrhythmic activity is due to blockade of adrenergic stimulation of cardiac pacemaker potentials. In the Vaughan Williams classification of antiarrhythmics, beta-blockers are considered to be class II agents.\", \"neighbor_flag\": \"N\", \"pubmed_ids\": [17125412, 14732961, 27836712], \"resource_name\": \"DrugBank\", \"resource_version\": \"5.1\", \"target_resource_id\": \"P10635\"}, {\"cofactor_in_ch_ikey\": \"GXJABQQUPOEUTA-RDJZCZTQSA-N\", \"cofactor_smiles\": \"CC(C)C[C@H](NC(=O)[C@H](CC1=CC=CC=C1)NC(=O)C1=CN=CC=N1)B(O)O\", \"cofactor_chem_comp_id\": \"BO2\", \"cofactor_name\": \"Bortezomib\", \"cofactor_resource_id\": \"DB00188\", \"mechanism_of_action\": \"The ubiquitin-proteasome pathway is a homeostatic proteolytic pathway for intracellular protein degradation: proteins marked with a poly-ubiquitin chain are degraded to small peptides and free ubiquitin by the proteasome, which is a large multimeric protease.[A18508] Aberrant proteasome-dependent proteolysis, as seen in some malignancies, can lead to uncontrolled cell division, leading to tumorigenesis, cancer growth, and spread.[A18508, A204083] \\r\\n\\r\\nBortezomib is a reversible inhibitor of the 26S proteasome, which is made up of a 20S core complexed with a 19S regulatory complex. Individual \\u03b2-subunits allow specific catalytic action of the 20S core.[A18509, A204083] In mammalian cells, bortezomib is a potent inhibitor of the proteasome\\u2019s chymotryptic-like activity, which is attributed to the \\u03b25-subunit of the 20S core particle.[A18509] Bortezomib binds to the active site of the threonine hydroxyl group in the \\u03b25-subunit.[A204083] A probing study showed bortezomib also binding to and inhibiting the \\u03b21-subunit, which mediates the caspase-like activity of the proteasome, and \\u03b21i-subunit, which is an altered subunit that is expressed to form immunoproteasomes in response to cell stress or inflammation.[A18509] By inhibiting the proteasome-mediated degradation of key proteins that promote cell apoptosis,[A18508] bortezomib induces a cell cycle arrest during the G2-M phase.[L14180] It is believed that multiple mechanisms, other than proteasome inhibition, may be involved in the anticancer activity of bortezomib.[A204083] The anticancer activity of bortezomib was largely associated with suppression of the NF-\\u03baB signalling pathway, resulting in the downregulation of anti-apoptotic target genes and expression of anti-apoptic proteins. This may be explained by bortezomib preventing uncontrolled degradation of I\\u03baB, which is an inhibitory protein of NF-\\u03baB. NOXA, which is a pro-apoptotic factor, induced by bortezomib selectively in cancer cells; thus, it is suggested to be another key mechanism of bortezomib.[A204083]\", \"neighbor_flag\": \"N\", \"pubmed_ids\": [19515014, 16103134, 15764713], \"resource_name\": \"DrugBank\", \"resource_version\": \"5.1\", \"target_resource_id\": \"P10635\"}, {\"cofactor_in_ch_ikey\": \"TVYLLZQTGLZFBW-UHFFFAOYSA-N\", \"cofactor_smiles\": \"COC1=CC=CC(=C1)C1(O)CCCCC1CN(C)C\", \"cofactor_name\": \"Tramadol\", \"cofactor_resource_id\": \"DB00193\", \"mechanism_of_action\": \"Tramadol is a centrally acting \\u03bc-opioid receptor agonist and SNRI (serotonin/norepinephrine reuptake-inhibitor) that is structurally related to [codeine] and [morphine]. Tramadol binds weakly to \\u03ba- and \\u03b4-opioid receptors and to the \\u03bc-opioid receptor with 6000-fold less affinity than morphine.[A182300]\\r\\n\\r\\nTramadol exists as a racemic mixture consisting of two pharmacologically active enantiomers that both contribute to its analgesic property through different mechanisms: (+)-tramadol and its primary metabolite (+)-O-desmethyl-tramadol (M1) are agonists of the \\u03bc opioid receptor while (+)-tramadol inhibits serotonin reuptake and (-)-tramadol inhibits norepinephrine reuptake. These pathways are complementary and synergistic, improving tramadol's ability to modulate the perception of and response to pain.[A4269] \\r\\n\\r\\nIn animal models, M1 is up to 6 times more potent than tramadol in producing analgesia and 200 times more potent in \\u03bc-opioid binding.[L9257] \\r\\n\\r\\nTramadol has also been shown to affect a number of pain modulators including alpha2-adrenoreceptors, neurokinin 1 receptors, the voltage-gated sodium channel type II alpha subunit[A183728], transient receptor potential cation channel subfamily V member 1 (TRPV1 - also known as the capsaicin receptor)[A183734], muscarinic receptors (M1 and M3), N-methyl-D-aspartate receptor (also known as the NMDA receptor or glutamate receptor)[A17158], Adenosine A1 receptors[A183761], and nicotinic acetylcholine receptor.[A17159] \\r\\n\\r\\nIn addition to the above neuronal targets, tramadol has a number of effects on inflammatory and immune mediators involved in the pain response. This includes inhibitory effects on cytokines, prostaglandin E2 (PGE2), nuclear factor-\\u03baB, and glial cells as well as a change in the polarization state of M1 macrophages.[A182300]\", \"neighbor_flag\": \"N\", \"pubmed_ids\": [15509185], \"resource_name\": \"DrugBank\", \"resource_version\": \"5.1\", \"target_resource_id\": \"P10635\"}, {\"cofactor_in_ch_ikey\": \"NWIUTZDMDHAVTP-UHFFFAOYSA-N\", \"cofactor_smiles\": \"CC(C)NCC(O)COC1=CC=C(CCOCC2CC2)C=C1\", \"cofactor_name\": \"Betaxolol\", \"cofactor_resource_id\": \"DB00195\", \"mechanism_of_action\": \"Betaxolol selectively blocks catecholamine stimulation of beta(1)-adrenergic receptors in the heart and vascular smooth muscle. This results in a reduction of heart rate, cardiac output, systolic and diastolic blood pressure, and possibly reflex orthostatic hypotension. Betaxolol can also competitively block beta(2)-adrenergic responses in the bronchial and vascular smooth muscles, causing bronchospasm.\", \"neighbor_flag\": \"N\", \"pubmed_ids\": [17635183, 25341854], \"resource_name\": \"DrugBank\", \"resource_version\": \"5.1\", \"target_resource_id\": \"P10635\"}, {\"cofactor_in_ch_ikey\": \"RYYVLZVUVIJVGH-UHFFFAOYSA-N\", \"cofactor_smiles\": \"CN1C=NC2=C1C(=O)N(C)C(=O)N2C\", \"cofactor_chem_comp_id\": \"CFF\", \"cofactor_name\": \"Caffeine\", \"cofactor_resource_id\": \"DB00201\", \"mechanism_of_action\": \"The mechanism of action of caffeine is complex, as it impacts several body systems, which are listed below. The effects as they relate to various body systems are described as follows:\\r\\n\\r\\n**General and cellular actions**\\r\\n\\r\\nCaffeine exerts several actions on cells, but the clinical relevance is poorly understood. One probable mechanism is the inhibition of nucleotide phosphodiesterase enzymes, adenosine receptors, regulation of calcium handling in cells, and participates in adenosine receptor antagonism.[A187721,L9857] Phosphodiesterase enzymes regulate cell function via actions on second messengers cAMP and cGMP.[A187724] This causes lipolysis through activation of hormone-sensitive lipases, releasing fatty acids and glycerol.[T722]\\r\\n\\r\\n**Respiratory**\\r\\n\\r\\nThe exact mechanism of action of caffeine in treating apnea related to prematurity is unknown, however, there are several proposed mechanisms, including respiratory center stimulation in the central nervous system, a reduced threshold to hypercapnia with increased response, and increased consumption of oxygen, among others.[L9851] The blocking of the adenosine receptors enhances respiratory drive via an increase in brain medullary response to carbon dioxide, stimulating ventilation and respiratory drive, while increasing contractility of the diaphragm.[T716]\\r\\n\\r\\n**Central nervous system**\\r\\n\\r\\nCaffeine demonstrates antagonism of all 4 adenosine receptor subtypes (A1, A2a, A2b, A3) in the central nervous system.[T716,L9851] Caffeine's effects on alertness and combatting drowsiness are specifically related to the antagonism of the A2a receptor.[T716]\\r\\n\\r\\n**Renal system**\\r\\n\\r\\nCaffeine has diuretic effects due to is stimulatory effects on renal blood flow, increase in glomerular filtration, and increase in sodium excretion.[T716]\\r\\n\\r\\n**Cardiovascular system**\\r\\n\\r\\nAdenosine receptor antagonism at the A1 receptor by caffeine stimulates inotropic effects in the heart. Blocking of adenosine receptors promotes catecholamine release, leading to stimulatory effects occurring in the heart and the rest of the body.  In the blood vessels, caffeine exerts direct antagonism of adenosine receptors, causing vasodilation. It stimulates the endothelial cells in the blood vessel wall to release nitric oxide, potentiating blood vessel relaxation. Catecholamine release, however, antagonizes this and exerts inotropic and chronotropic effects on the heart, ultimately leading to vasoconstriction. Finally, caffeine is shown to raise systolic blood pressure measurements by 5 to 10 mmHg when it is not taken regularly, versus no effect in those who consume it regularly.[T716] The vasoconstricting effects of caffeine are beneficial in migraines and other types of headache, which are normally caused by vasodilation in the brain.[A187709,L9872]\", \"neighbor_flag\": \"N\", \"pubmed_ids\": [8857078, 9617978], \"resource_name\": \"DrugBank\", \"resource_version\": \"5.1\", \"target_resource_id\": \"P10635\"}, {\"cofactor_in_ch_ikey\": \"BNRNXUUZRGQAQC-UHFFFAOYSA-N\", \"cofactor_smiles\": \"CCCC1=NN(C)C2=C1N=C(NC2=O)C1=CC(=CC=C1OCC)S(=O)(=O)N1CCN(C)CC1\", \"cofactor_chem_comp_id\": \"VIA\", \"cofactor_name\": \"Sildenafil\", \"cofactor_resource_id\": \"DB00203\", \"mechanism_of_action\": \"Sildenafil is an oral therapy for erectile dysfunction [A175582, F3853, F3856, F3886, L5611]. In the natural setting, i.e. with sexual stimulation, it restores impaired erectile function by increasing blood flow to the penis [A175582, F3853, F3856, F3886, L5611].\\r\\n\\r\\nThe physiological mechanism responsible for the erection of the penis involves the release of nitric oxide (NO) in the corpus cavernosum during sexual stimulation [A175582, F3853, F3856, F3886, L5611]. Nitric oxide then activates the enzyme guanylate cyclase, which results in increased levels of cyclic guanosine monophosphate (cGMP), producing smooth muscle relaxation in the corpus cavernosum and allowing inflow of blood [A175582, F3853, F3856, F3886, L5611].\\r\\n\\r\\nSildenafil is a potent and selective inhibitor of cGMP specific phosphodiesterase type 5 (PDE5) in the corpus cavernosum, where PDE5 is responsible for degradation of cGMP [A175582, F3853, F3856, F3886, L5611]. Sildenafil has a peripheral site of action on erections [A175582, F3853, F3856, F3886, L5611]. Sildenafil has no direct relaxant effect on isolated human corpus cavernosum but potently enhances the relaxant effect of NO on this tissue [A175582, F3853, F3856, F3886, L5611]. When the NO/cGMP pathway is activated, as occurs with sexual stimulation, inhibition of PDE5 by sildenafil results in increased corpus cavernosum levels of cGMP [A175582, F3853, F3856, F3886, L5611]. Therefore sexual stimulation is required in order for sildenafil to produce its intended beneficial pharmacological effects [A175582, F3853, F3856, F3886, L5611].\\r\\n\\r\\nMoreover, apart from the presence of PDE5 in the corpus cavernosum of the penis, PDE5 is also present in the pulmonary vasculature [A175579, F3850, F3859, F3883, L5614]. Sildenafil, therefore, increases cGMP within pulmonary vascular smooth muscle cells resulting in relaxation [A175579, F3850, F3859, F3883, L5614]. In patients with pulmonary arterial hypertension, this can lead to vasodilation of the pulmonary vascular bed and, to a lesser degree, vasodilatation in the systemic circulation [A175579, F3850, F3859, F3883, L5614].\", \"neighbor_flag\": \"N\", \"pubmed_ids\": [19515014, 10725306], \"resource_name\": \"DrugBank\", \"resource_version\": \"5.1\", \"target_resource_id\": \"P10635\"}, {\"cofactor_in_ch_ikey\": \"PHWBOXQYWZNQIN-UHFFFAOYSA-N\", \"cofactor_smiles\": \"ClC1=CC=CC=C1CN1CCC2=C(C1)C=CS2\", \"cofactor_chem_comp_id\": \"TIC\", \"cofactor_name\": \"Ticlopidine\", \"cofactor_resource_id\": \"DB00208\", \"mechanism_of_action\": \"The active metabolite of ticlopidine prevents binding of adenosine diphosphate (ADP) to its platelet receptor, impairing the ADP-mediated activation of the glycoprotein GPIIb/IIIa complex. It is proposed that the inhibition involves a defect in the mobilization from the storage sites of the platelet granules to the outer membrane. No direct interference occurs with the GPIIb/IIIa receptor. As the glycoprotein GPIIb/IIIa complex is the major receptor for fibrinogen, its impaired activation prevents fibrinogen binding to platelets and inhibits platelet aggregation. By blocking the amplification of platelet activation by released ADP, platelet aggregation induced by agonists other than ADP is also inhibited by the active metabolite of ticlopidine.\", \"neighbor_flag\": \"N\", \"pubmed_ids\": [19515014, 10759690, 28496987], \"resource_name\": \"DrugBank\", \"resource_version\": \"5.1\", \"target_resource_id\": \"P10635\"}, {\"cofactor_in_ch_ikey\": \"OYYDSUSKLWTMMQ-JKHIJQBDSA-N\", \"cofactor_smiles\": \"[H][C@]12CC[C@]([H])(C[C@@H](C1)OC(=O)C(O)(C1=CC=CC=C1)C1=CC=CC=C1)[N+]21CCCC1\", \"cofactor_name\": \"Trospium\", \"cofactor_resource_id\": \"DB00209\", \"mechanism_of_action\": \"Trospium antagonizes the effect of acetylcholine on muscarinic receptors in cholinergically innervated organs. Its parasympatholytic action reduces the tonus of smooth muscle in the bladder.\", \"neighbor_flag\": \"N\", \"pubmed_ids\": [10628907], \"resource_name\": \"DrugBank\", \"resource_version\": \"5.1\", \"target_resource_id\": \"P10635\"}, {\"cofactor_in_ch_ikey\": \"PTKSEFOSCHHMPD-UHFFFAOYSA-N\", \"cofactor_smiles\": \"COC1=CC(C(O)CNC(=O)CN)=C(OC)C=C1\", \"cofactor_name\": \"Midodrine\", \"cofactor_resource_id\": \"DB00211\", \"mechanism_of_action\": \"Midodrine undergoes metabolism to form its pharmacologically active metabolite, desglymidodrine. Desglymidodrine acts as an agonist at the alpha<sub>1</sub>-adrenergic receptors expressed in the arteriolar and venous vasculature. Activation of alpha<sub>1</sub>-adrenergic receptor signaling pathways lead to an increase in the vascular tone and elevation of blood pressure. Desglymidodrine is reported to have negligible effect on the cardiac beta-adrenergic receptors.\", \"neighbor_flag\": \"N\", \"pubmed_ids\": [16670408], \"resource_name\": \"DrugBank\", \"resource_version\": \"5.1\", \"target_resource_id\": \"P10635\"}, {\"cofactor_in_ch_ikey\": \"WSEQXVZVJXJVFP-UHFFFAOYSA-N\", \"cofactor_smiles\": \"CN(C)CCCC1(OCC2=C1C=CC(=C2)C#N)C1=CC=C(F)C=C1\", \"cofactor_name\": \"Citalopram\", \"cofactor_resource_id\": \"DB00215\", \"mechanism_of_action\": \"The mechanism of action of citalopram is unclear but is presumed to be related to potentiation of serotonergic activity in the central nervous system (CNS) resulting from its inhibition of CNS neuronal reuptake of serotonin (5-HT), potentially through the inhibition of the serotonin transporter (solute carrier family 6 member 4, _SLC6A4_).[L47941,A37688] \\r\\n\\r\\nCitalopram binds with significantly less affinity to histamine, acetylcholine, and norepinephrine receptors than tricyclic antidepressant drugs. Particularly, citalopram has no or very low affinity for 5-HT<sub>1A</sub>, 5-HT<sub>2A</sub>, dopamine D<sub>1</sub> and D<sub>2</sub>, \\u03b1<sub>1</sub>-, \\u03b1<sub>2</sub>-, and \\u03b2-adrenergic, histamine H<sub>1</sub>, gamma aminobutyric acid (GABA), muscarinic cholinergic, and benzodiazepine receptors.[L47941]\", \"neighbor_flag\": \"N\", \"pubmed_ids\": [8968657], \"resource_name\": \"DrugBank\", \"resource_version\": \"5.1\", \"target_resource_id\": \"P10635\"}, {\"cofactor_in_ch_ikey\": \"PWVXXGRKLHYWKM-LJQANCHMSA-N\", \"cofactor_smiles\": \"CN1CCC[C@@H]1CC1=CNC2=C1C=C(CCS(=O)(=O)C1=CC=CC=C1)C=C2\", \"cofactor_name\": \"Eletriptan\", \"cofactor_resource_id\": \"DB00216\", \"mechanism_of_action\": \"Eletriptan binds with high affinity to 5-HT1B, 5-HT1D and 5-HT1F receptors, has modest affinity for 5-HT1A, 5-HT1E, 5-HT2B and 5-HT7 receptors, and little or no affinity for 5-HT2A, 5-HT2C, 5-HT3, 5-HT4, 5-HT5A and 5-HT6 receptors. In contrast, eletriptan displays insignificant pharmacological activity at adrenergic alpha1, alpha2, or beta; dopaminergic D1 or D2; muscarinic; or opioid receptors. While the full mechanism of action of 5-HT receptor agonists in relieving migrains is not fully elucidated, it is proposed that the activation of 5-HT1 receptors located on intracranial blood vessels leads to vasoconstriction that correlates with the relief of migraine headaches. It is also proposed that the activation of 5-HT1 receptors on sensory nerve endings in the trigeminal system leads to the inhibition of release of pro-inflammatory neuropeptides. \", \"neighbor_flag\": \"N\", \"pubmed_ids\": [12814962, 29497279], \"resource_name\": \"DrugBank\", \"resource_version\": \"5.1\", \"target_resource_id\": \"P10635\"}, {\"cofactor_in_ch_ikey\": \"QAGYKUNXZHXKMR-HKWSIXNMSA-N\", \"cofactor_smiles\": \"[H][C@@]12CCCC[C@]1([H])CN(C[C@@H](O)[C@H](CSC1=CC=CC=C1)NC(=O)C1=C(C)C(O)=CC=C1)[C@@H](C2)C(=O)NC(C)(C)C\", \"cofactor_chem_comp_id\": \"1UN\", \"cofactor_name\": \"Nelfinavir\", \"cofactor_resource_id\": \"DB00220\", \"mechanism_of_action\": \"HIV viral protease is an important enzyme for HIV maturation and pathogenicity since HIV produces its structural and key proteins in the form of a polyprotein that needs to be cleaved by a protease.[A246853] HIV protease is synthesized as part of the Gag-pol polyprotein, where Gag encodes for the capsid and matrix protein to form the outer protein shell, and Pol encodes for the reverse transcriptase and integrase protein to synthesize and incorporate its genome into host cells.[A246853, A246858] The Gag-pol polyprotein undergoes proteolytic cleavage by HIV protease to produce 66 molecular species which will assume conformational changes to become fully active.[A246853] Inhibition of protease, therefore, prevents HIV virion from fully maturing and becoming infective.[A246853]\\r\\n\\r\\nNelfinavir is a competitive inhibitor of the HIV protease by reversibly binding to the active site of the enzyme, preventing it from interacting with its substrate to produce mature and infectious viral particles.[L36485, L41608]\\r\\n\\r\\n\", \"neighbor_flag\": \"N\", \"pubmed_ids\": [9758674, 9660842], \"resource_name\": \"DrugBank\", \"resource_version\": \"5.1\", \"target_resource_id\": \"P10635\"}, {\"cofactor_in_ch_ikey\": \"CBVCZFGXHXORBI-PXQQMZJSSA-N\", \"cofactor_smiles\": \"CC(C)(C)NC(=O)[C@@H]1CN(CC2=CN=CC=C2)CCN1C[C@@H](O)C[C@@H](CC1=CC=CC=C1)C(=O)N[C@@H]1[C@H](O)CC2=CC=CC=C12\", \"cofactor_chem_comp_id\": \"MK1\", \"cofactor_name\": \"Indinavir\", \"cofactor_resource_id\": \"DB00224\", \"mechanism_of_action\": \"Indinavir inhibits the HIV viral protease enzyme which prevents cleavage of the gag-pol polyprotein, resulting in noninfectious, immature viral particles.\", \"neighbor_flag\": \"N\", \"pubmed_ids\": [9758674], \"resource_name\": \"DrugBank\", \"resource_version\": \"5.1\", \"target_resource_id\": \"P10635\"}, {\"cofactor_in_ch_ikey\": \"CBQGYUDMJHNJBX-RTBURBONSA-N\", \"cofactor_smiles\": \"[H][C@@]1(CNCCO1)[C@H](OC1=CC=CC=C1OCC)C1=CC=CC=C1\", \"cofactor_chem_comp_id\": \"41X\", \"cofactor_name\": \"Reboxetine\", \"cofactor_resource_id\": \"DB00234\", \"mechanism_of_action\": \"Reboxetine is a selective inhibitor of noradrenaline reuptake. It inhibits noradrenaline reuptake <i>in vitro</i> to a similar extent to the tricyclic antidepressant desmethylimipramine. Reboxetine does not affect dopamine or serotonin reuptake and it has low <i>in vivo</i> and <i>in vitro</i> affinity for adrenergic, cholinergic, histaminergic, dopaminergic and serotonergic receptors.\", \"neighbor_flag\": \"N\", \"pubmed_ids\": [10534319, 17256449], \"resource_name\": \"DrugBank\", \"resource_version\": \"5.1\", \"target_resource_id\": \"P10635\"}, {\"cofactor_in_ch_ikey\": \"NQDJXKOVJZTUJA-UHFFFAOYSA-N\", \"cofactor_smiles\": \"CC1=C2NC(=O)C3=C(N=CC=C3)N(C3CC3)C2=NC=C1\", \"cofactor_chem_comp_id\": \"NVP\", \"cofactor_name\": \"Nevirapine\", \"cofactor_resource_id\": \"DB00238\", \"mechanism_of_action\": \"Nevirapine binds directly to reverse transcriptase (RT) and blocks the RNA-dependent and DNA-dependent DNA polymerase activities by causing a disruption of the enzyme's catalytic site. The activity of nevirapine does not compete with template or nucleoside triphosphates.\", \"neighbor_flag\": \"N\", \"pubmed_ids\": [11225565, 22354160, 19364830], \"resource_name\": \"DrugBank\", \"resource_version\": \"5.1\", \"target_resource_id\": \"P10635\"}, {\"cofactor_in_ch_ikey\": \"XKLMZUWKNUAPSZ-UHFFFAOYSA-N\", \"cofactor_smiles\": \"COC1=CC=CC=C1OCC(O)CN1CCN(CC(=O)NC2=C(C)C=CC=C2C)CC1\", \"cofactor_name\": \"Ranolazine\", \"cofactor_resource_id\": \"DB00243\", \"mechanism_of_action\": \"Myocardial ischemia exerts effects on adenosine triphosphate flux, leading to a decrease in the energy available for contraction and relaxation of the heart muscle. Electrolyte balance of sodium and potassium is necessary for maintaining normal cardiac contraction and relaxation. Disruption of adequate sodium and potassium electrolyte balance leads to excessively high concentrations of sodium and calcium, which likely interferes with oxygen supply to the heart muscle. This imbalance eventually leads to angina symptoms of chest pain or pressure, nausea, and dizziness, among others.[A189234,L10965]\\r\\n\\r\\nThe mechanism of action for ranolazine is not fully understood.  At therapeutic concentrations, it can inhibit the cardiac late sodium\\r\\n205 current (INa), which may affect the electrolyte balance in the myocardium, relieving angina symptoms. The clinical significance this inhibition in the treatment of angina symptoms is not yet confirmed.[L3580]\\r\\n\\r\\nRanolazine inhibits sodium and potassium ion channel currents.[A174898]  It has been shown to  exert weak activity on L-type calcium channels making it a weak direct vasodilator and exerts minimal direct effects on atrioventricular nodal conduction.[A174913] Some additional mechanisms have been elucidated. Ranolazine exerts antagonistic activity towards the alpha 1 and beta 1 adrenergic receptors and inhibition of fatty acid oxidation.[A174898,A189252]\", \"neighbor_flag\": \"N\", \"pubmed_ids\": [26979079, 25028555], \"resource_name\": \"DrugBank\", \"resource_version\": \"5.1\", \"target_resource_id\": \"P10635\"}, {\"cofactor_in_ch_ikey\": \"CXOFVDLJLONNDW-UHFFFAOYSA-N\", \"cofactor_smiles\": \"O=C1NC(=O)C(N1)(C1=CC=CC=C1)C1=CC=CC=C1\", \"cofactor_name\": \"Phenytoin\", \"cofactor_resource_id\": \"DB00252\", \"mechanism_of_action\": \"Although phenytoin first appeared in the literature in 1946, it has taken decades for the mechanism of action to be more specifically elucidated.[A188826] Although several scientists were convinced that phenytoin altered sodium permeability, it wasn\\u2019t until the 1980\\u2019s that this phenomenon was linked to voltage-gated sodium channels.[A188826] \\r\\n\\r\\nPhenytoin is often described as a non-specific sodium channel blocker and targets almost all voltage-gated sodium channel subtypes.[A188826] More specifically, phenytoin prevents seizures by inhibiting the positive feedback loop that results in neuronal propagation of high frequency action potentials.[A188772,A189219,A189273]\\r\\n\", \"neighbor_flag\": \"N\", \"pubmed_ids\": [22569204], \"resource_name\": \"DrugBank\", \"resource_version\": \"5.1\", \"target_resource_id\": \"P10635\"}, {\"cofactor_in_ch_ikey\": \"VNFPBHJOKIVQEB-UHFFFAOYSA-N\", \"cofactor_smiles\": \"ClC1=CC=CC=C1C(N1C=CN=C1)(C1=CC=CC=C1)C1=CC=CC=C1\", \"cofactor_chem_comp_id\": \"CL6\", \"cofactor_name\": \"Clotrimazole\", \"cofactor_resource_id\": \"DB00257\", \"mechanism_of_action\": \"Clotrimazole acts primarily by damaging the permeability barrier in the cell membrane of fungi. Clotrimazole causes inhibition of ergosterol biosynthesis, an essential constituent of fungal cell membranes. If ergosterol synthesis is either completely or partially inhibited, the cell is no longer able to construct an intact and functional cell membrane [F3088],[F3100]. Because ergosterol directly promotes the growth of fungal cells in a hormone\\u2010like fashion, rapid onset of the above events leads to dose-dependent inhibition of fungal growth [A174094].\\r\\n\\r\\nThough decreased ergosterol, due to the inhibition of lanosterol 14-demethylase (also known as _CYP51_) [A174094] is accepted to be primarily responsible for the antimycotic properties of clotrimazole, this drug also shows other pharmacological effects. These include the inhibition of sarcoplasmic reticulum Ca2+\\u2010ATPase,  depletion of intracellular calcium, and blocking of calcium\\u2010dependent potassium channels and voltage\\u2010dependent calcium channels [A174094]. The action of clotrimazole on these targets accounts for other effects of this drug that are separate from its antimycotic activities [A174094].\", \"neighbor_flag\": \"N\", \"pubmed_ids\": [11854151], \"resource_name\": \"DrugBank\", \"resource_version\": \"5.1\", \"target_resource_id\": \"P10635\"}, {\"cofactor_in_ch_ikey\": \"IUBSYMUCCVWXPE-UHFFFAOYSA-N\", \"cofactor_smiles\": \"COCCC1=CC=C(OCC(O)CNC(C)C)C=C1\", \"cofactor_name\": \"Metoprolol\", \"cofactor_resource_id\": \"DB00264\", \"mechanism_of_action\": \"Metoprolol is a beta-1-adrenergic receptor inhibitor specific to cardiac cells with negligible effect on beta-2 receptors. This inhibition decreases cardiac output by producing negative chronotropic and inotropic effects without presenting activity towards membrane stabilization nor intrinsic sympathomimetics.[A175141]\", \"neighbor_flag\": \"N\", \"pubmed_ids\": [9681670, 11038161, 30248178], \"resource_name\": \"DrugBank\", \"resource_version\": \"5.1\", \"target_resource_id\": \"P10635\"}, {\"cofactor_in_ch_ikey\": \"ZFXYFBGIUFBOJW-UHFFFAOYSA-N\", \"cofactor_smiles\": \"CN1C2=C(NC=N2)C(=O)N(C)C1=O\", \"cofactor_chem_comp_id\": \"TEP\", \"cofactor_name\": \"Theophylline\", \"cofactor_resource_id\": \"DB00277\", \"mechanism_of_action\": \"Theophylline relaxes the smooth muscle of the bronchial airways and pulmonary blood vessels and reduces airway responsiveness to histamine, methacholine, adenosine, and allergen. Theophylline competitively inhibits type III and type IV phosphodiesterase (PDE), the enzyme responsible for breaking down cyclic AMP in smooth muscle cells, possibly resulting in bronchodilation. Theophylline also binds to the adenosine A2B receptor and blocks adenosine mediated bronchoconstriction. In inflammatory states, theophylline activates histone deacetylase to prevent transcription of inflammatory genes that require the acetylation of histones for transcription to begin.\", \"neighbor_flag\": \"N\", \"pubmed_ids\": [7619675, 7632164, 11996015], \"resource_name\": \"DrugBank\", \"resource_version\": \"5.1\", \"target_resource_id\": \"P10635\"}, {\"cofactor_in_ch_ikey\": \"NNJVILVZKWQKPM-UHFFFAOYSA-N\", \"cofactor_smiles\": \"CCN(CC)CC(=O)NC1=C(C)C=CC=C1C\", \"cofactor_chem_comp_id\": \"LQZ\", \"cofactor_name\": \"Lidocaine\", \"cofactor_resource_id\": \"DB00281\", \"mechanism_of_action\": \"Lidocaine is a local anesthetic of the amide type [F4349, L5930, L5948]. It is used to provide local anesthesia by nerve blockade at various sites in the body [F4349, L5930, L5948]. It does so by stabilizing the neuronal membrane by inhibiting the ionic fluxes required for the initiation and conduction of impulses, thereby effecting local anesthetic action [F4349, L5930, L5948]. In particular, the lidocaine agent acts on sodium ion channels located on the internal surface of nerve cell membranes [F4349, L5930, L5948]. At these channels, neutral uncharged lidocaine molecules diffuse through neural sheaths into the axoplasm where they are subsequently ionized by joining with hydrogen ions [F4349, L5930, L5948]. The resultant lidocaine cations are then capable of reversibly binding the sodium channels from the inside, keeping them locked in an open state that prevents nerve depolarization [F4349, L5930, L5948]. As a result, with sufficient blockage, the membrane of the postsynaptic neuron will ultimately not depolarize and will thus fail to transmit an action potential [F4349, L5930, L5948]. This facilitates an anesthetic effect by not merely preventing pain signals from propagating to the brain but by aborting their generation in the first place [F4349, L5930, L5948].\\r\\n\\r\\nIn addition to blocking conduction in nerve axons in the peripheral nervous system, lidocaine has important effects on the central nervous system and cardiovascular system [F4349, L5930, L5948]. After absorption, lidocaine may cause stimulation of the CNS followed by depression and in the cardiovascular system, it acts primarily on the myocardium where it may produce decreases in electrical excitability, conduction rate, and force of contraction [F4349, L5930, L5948].\", \"neighbor_flag\": \"N\", \"pubmed_ids\": [8565792, 10901707], \"resource_name\": \"DrugBank\", \"resource_version\": \"5.1\", \"target_resource_id\": \"P10635\"}, {\"cofactor_in_ch_ikey\": \"YNNUSGIPVFPVBX-NHCUHLMSSA-N\", \"cofactor_smiles\": \"CN1CCC[C@@H]1CCO[C@](C)(C1=CC=CC=C1)C1=CC=C(Cl)C=C1\", \"cofactor_name\": \"Clemastine\", \"cofactor_resource_id\": \"DB00283\", \"mechanism_of_action\": \"Clemastine is a selective histamine H1 antagonist and binds to the histamine H1 receptor. This blocks the action of endogenous histamine, which subsequently leads to temporary relief of the negative symptoms brought on by histamine.\", \"neighbor_flag\": \"N\", \"resource_name\": \"DrugBank\", \"resource_version\": \"5.1\", \"target_resource_id\": \"P10635\"}, {\"cofactor_in_ch_ikey\": \"PNVNVHUZROJLTJ-UHFFFAOYSA-N\", \"cofactor_smiles\": \"COC1=CC=C(C=C1)C(CN(C)C)C1(O)CCCCC1\", \"cofactor_name\": \"Venlafaxine\", \"cofactor_resource_id\": \"DB00285\", \"mechanism_of_action\": \"The exact mechanism of action of venlafaxine in the treatment of various psychiatric conditions has not been fully elucidated; however, it is understood that venlafaxine and its active metabolite O-desmethylvenlafaxine (ODV) potently and selectively inhibits the reuptake of both serotonin and norepinephrine at the presynaptic terminal.[A27600,A252065,L43030] This results in increased levels of neurotransmitters available at the synapse that can stimulate postsynaptic receptors.[A252075] It is suggested that venlafaxine has a 30-fold selectivity for serotonin compared to norepinephrine: venlafaxine initially inhibits serotonin reuptake at low doses, and with higher doses, it inhibits norepinephrine reuptake in addition to serotonin.[A252065,A252070] Venlafaxine and ODV are also weak inhibitors of dopamine reuptake.[L43030]\", \"neighbor_flag\": \"N\", \"pubmed_ids\": [10192828, 30485867], \"resource_name\": \"DrugBank\", \"resource_version\": \"5.1\", \"target_resource_id\": \"P10635\"}, {\"cofactor_in_ch_ikey\": \"VHGCDTVCOLNTBX-QGZVFWFLSA-N\", \"cofactor_smiles\": \"CNCC[C@@H](OC1=CC=CC=C1C)C1=CC=CC=C1\", \"cofactor_chem_comp_id\": \"A1LX4\", \"cofactor_name\": \"Atomoxetine\", \"cofactor_resource_id\": \"DB00289\", \"mechanism_of_action\": \"Atomoxetine is known to be a potent and selective inhibitor of the norepinephrine transporter (NET),[A175723] which prevents cellular reuptake of norepinephrine throughout the brain, which is thought to improve the symptoms of ADHD. More recently, positron emission tomography (PET) imaging studies in rhesus monkeys have shown that atomoxetine also binds to the serotonin transporter (SERT),[A178111] and blocks the N-methyl-d-aspartate (NMDA) receptor,[A18263] indicating a role for the glutamatergic system in the pathophysiology of ADHD. \", \"neighbor_flag\": \"N\", \"pubmed_ids\": [16142049, 19445548, 14610241, 26859445], \"resource_name\": \"DrugBank\", \"resource_version\": \"5.1\", \"target_resource_id\": \"P10635\"}, {\"cofactor_in_ch_ikey\": \"LEBVLXFERQHONN-UHFFFAOYSA-N\", \"cofactor_smiles\": \"CCCCN1CCCCC1C(=O)NC1=C(C)C=CC=C1C\", \"cofactor_name\": \"Bupivacaine\", \"cofactor_resource_id\": \"DB00297\", \"mechanism_of_action\": \"Like [lidocaine], bupivacaine is an amide local anesthetic that provides local anesthesia through blockade of nerve impulse generation and conduction.[L30533 ] These impulses, also known as action potentials, critically depend on membrane depolarization produced by the influx of sodium ions into the neuron through voltage-gated sodium channels.[L41310] Bupivacaine crosses the neuronal membrane and exerts its anesthetic action through blockade of these channels at the intracellular portion of their pore-forming transmembrane segments.[A246170] The block is use-dependent, where repetitive or prolonged depolarization increases sodium channel blockade.[A4530, A246170] Without sodium ions passing through the channel\\u2019s pore, bupivacaine stabilizes the membrane at rest and therefore prevents neurotransmission.\\r\\n\\r\\n\\r\\nIn general, the progression of anesthesia is related to the diameter, myelination and conduction velocity of affected nerve fibers.[L30533] Clinically, the order of loss of nerve function is as follows: (1) pain, (2) temperature, (3) touch, (4) proprioception, and (5) skeletal muscle tone.[L30533] \\r\\n\\r\\nWhile it is well-established that the main action of bupivacaine is through sodium channel block, additional analgesic effects of bupivacaine are thought to potentially be due to its binding to the prostaglandin E2 receptors, subtype EP1 (PGE2EP1), which inhibits the production of prostaglandins, thereby reducing fever, inflammation, and hyperalgesia.[A246170, A246175] \", \"neighbor_flag\": \"N\", \"pubmed_ids\": [10725304], \"resource_name\": \"DrugBank\", \"resource_version\": \"5.1\", \"target_resource_id\": \"P10635\"}, {\"cofactor_in_ch_ikey\": \"RZVAJINKPMORJF-UHFFFAOYSA-N\", \"cofactor_smiles\": \"CC(=O)NC1=CC=C(O)C=C1\", \"cofactor_chem_comp_id\": \"TYL\", \"cofactor_name\": \"Acetaminophen\", \"cofactor_resource_id\": \"DB00316\", \"mechanism_of_action\": \"According to its FDA labeling, acetaminophen's exact mechanism of action has not been fully established[Label] - despite this, it is often categorized alongside NSAIDs (nonsteroidal anti-inflammatory drugs) due to its ability to inhibit the cyclooxygenase (COX) pathways.[T518] It is thought to exert central actions which ultimately lead to the alleviation of pain symptoms.[T518]\\r\\n\\r\\nOne theory is that acetaminophen increases the pain threshold by inhibiting two isoforms of cyclooxygenase, COX-1 and COX-2, which are involved in prostaglandin (PG) synthesis. Prostaglandins are responsible for eliciting pain sensations.[A176366] Acetaminophen does not inhibit cyclooxygenase in peripheral tissues and, therefore, has no peripheral anti-inflammatory effects. Though acetylsalicylic acid (aspirin) is an irreversible inhibitor of COX and directly blocks the active site of this enzyme, studies have shown that acetaminophen (paracetamol) blocks COX indirectly.[F4133] Studies also suggest that acetaminophen selectively blocks a variant type of the COX enzyme that is unique from the known variants COX-1 and COX-2.[A468] This enzyme has been referred to as _COX-3_. The antipyretic actions of acetaminophen are likely attributed to direct action on heat-regulating centers in the brain, resulting in peripheral vasodilation, sweating, and loss of body heat.[F4133] The exact mechanism of action of this drug is not fully understood at this time, but future research may contribute to deeper knowledge.[F4133] \", \"neighbor_flag\": \"N\", \"pubmed_ids\": [11095574, 28872689], \"resource_name\": \"DrugBank\", \"resource_version\": \"5.1\", \"target_resource_id\": \"P10635\"}, {\"cofactor_in_ch_ikey\": \"XGALLCVXEZPNRQ-UHFFFAOYSA-N\", \"cofactor_smiles\": \"COC1=C(OCCCN2CCOCC2)C=C2C(NC3=CC(Cl)=C(F)C=C3)=NC=NC2=C1\", \"cofactor_chem_comp_id\": \"IRE\", \"cofactor_name\": \"Gefitinib\", \"cofactor_resource_id\": \"DB00317\", \"mechanism_of_action\": \"Gefitinib is an inhibitor of the epidermal growth factor receptor (EGFR) tyrosine kinase that binds to the adenosine triphosphate (ATP)-binding site of the enzyme. EGFR is often shown to be overexpressed in certain human carcinoma cells, such as lung and breast cancer cells. Overexpression leads to enhanced activation of the anti-apoptotic Ras signal transduction cascades, subsequently resulting in increased survival of cancer cells and uncontrolled cell proliferation. Gefitinib is the first selective inhibitor of the EGFR tyrosine kinase which is also referred to as Her1 or ErbB-1. By inhibiting EGFR tyrosine kinase, the downstream signaling cascades are also inhibited, resulting in inhibited malignant cell proliferation. \", \"neighbor_flag\": \"N\", \"pubmed_ids\": [16719544, 16176119, 23207012, 23664723], \"resource_name\": \"DrugBank\", \"resource_version\": \"5.1\", \"target_resource_id\": \"P10635\"}, {\"cofactor_in_ch_ikey\": \"OROGSEYTTFOCAN-DNJOTXNNSA-N\", \"cofactor_smiles\": \"[H][C@]12C=C[C@H](O)[C@@H]3OC4=C5C(C[C@H]1N(C)CC[C@@]235)=CC=C4OC\", \"cofactor_name\": \"Codeine\", \"cofactor_resource_id\": \"DB00318\", \"mechanism_of_action\": \"Although the exact mechanism of action of codeine is still unknown, it is generally thought to be mediated through the agonism of opioid receptors, particularly the mu-opioid receptors.[A175096] Morphine was previously postulated to contribute to the analgesic effect of codeine due to the O-demethylation of codeine to morphine by CYP2D6. Particularly, CYP2D6 poor metabolizer did not experience the analgesic effect of codeine.[A473,A261461] However, this is unlikely to be the main mechanism of action of codeine as only 5% of codeine is metabolized to morphine.[A473] Other hypotheses also postulate that codeine-6-glucuronide, the main metabolite of codeine, mediates the analgesic effect of codeine as it not only has an affinity to the mu receptors as codeine but also can be metabolized to morphine-6-glucuronide, which was observed to be more potent than morphine.[A474] \\r\\n\\r\\nBinding to the mu receptors by codeine activates the G-proteins G\\u03b1<sub>i</sub>, causing a decrease in intracellular cAMP and Ca<sup>2+</sup> level.[A179533,A261466] This causes hyperpolarization of nociceptive neurons, thus imparing the transmission of pain signals.[A179533,A261466]\\r\\n\\r\\n\", \"neighbor_flag\": \"N\", \"pubmed_ids\": [19817501, 9143866], \"resource_name\": \"DrugBank\", \"resource_version\": \"5.1\", \"target_resource_id\": \"P10635\"}, {\"cofactor_in_ch_ikey\": \"KRMDCWKBEZIMAB-UHFFFAOYSA-N\", \"cofactor_smiles\": \"CN(C)CCC=C1C2=CC=CC=C2CCC2=CC=CC=C12\", \"cofactor_chem_comp_id\": \"TP0\", \"cofactor_name\": \"Amitriptyline\", \"cofactor_resource_id\": \"DB00321\", \"mechanism_of_action\": \"The mechanism of action of this drug is not fully elucidated. It is suggested that amitriptyline inhibits the membrane pump mechanism responsible for the re-uptake of transmitter amines, such as norepinephrine and serotonin, thereby increasing their concentration at the synaptic clefts of the brain [FDA label], [A174673].   These amines are important in regulating mood.  The monoamine hypothesis in depression, one of the oldest hypotheses, postulates that deficiencies of serotonin (5-HT) and/or norepinephrine (NE) neurotransmission in the brain lead to depressive effects [A174670].   This drug counteracts these mechanisms, and this may be the mechanism of amitriptyline in improving depressive symptoms.\\r\\n\\r\\nWhether its analgesic effects are related to its mood-altering activities or attributable to a different, less obvious pharmacological action (or a combination of both) is unknown [A174661].\", \"neighbor_flag\": \"N\", \"pubmed_ids\": [8968657, 18359012, 9131945, 11259560, 9143866], \"resource_name\": \"DrugBank\", \"resource_version\": \"5.1\", \"target_resource_id\": \"P10635\"}, {\"cofactor_in_ch_ikey\": \"AEUTYOVWOVBAKS-UWVGGRQHSA-N\", \"cofactor_smiles\": \"CC[C@@H](CO)NCCN[C@@H](CC)CO\", \"cofactor_chem_comp_id\": \"95E\", \"cofactor_name\": \"Ethambutol\", \"cofactor_resource_id\": \"DB00330\", \"mechanism_of_action\": \"Ethambutol diffuses into _Mycobacterium_ cells.[L31663] Once inside the cell, ethambutol inhibits the arabinosyltransferases (embA, embB, and embC), preventing formation of the cell wall components arabinogalactan and lipoarabinomannan, and preventing cell division.[A228973,A4616,A229043,A228968] Decreased concentrations of arabinogalactan in the cell wall reduces the number of binding sites for mycolic acid, leading to the accumulation of mycolic acid, trehalose monomycolate, and trehalose dimycolate.[A229028,A4616] Lipoarabinomannan is a component of a cell surface molecule involved in the interaction with host cells.[A4616] Reduced levels of lipoarabinomannan may interfere with mycobacterial interaction with host cells.[A4616]\", \"neighbor_flag\": \"N\", \"pubmed_ids\": [24910189], \"resource_name\": \"DrugBank\", \"resource_version\": \"5.1\", \"target_resource_id\": \"P10635\"}, {\"cofactor_in_ch_ikey\": \"USSIQXCVUWKGNF-UHFFFAOYSA-N\", \"cofactor_smiles\": \"CCC(=O)C(CC(C)N(C)C)(C1=CC=CC=C1)C1=CC=CC=C1\", \"cofactor_name\": \"Methadone\", \"cofactor_resource_id\": \"DB00333\", \"mechanism_of_action\": \"Methadone is a synthetic opioid analgesic with full agonist activity at the \\u00b5-opioid receptor. While agonism of the \\u00b5-opioid receptor is the primary mechanism of action for the treatment of pain, methadone also acts as an agonist of \\u03ba- and \\u03c3-opioid receptors within the central and peripheral nervous systems. Interestingly, methadone differs from [morphine] (which is considered the gold standard reference opioid) in its antagonism of the N-methyl-D-aspartate (NMDA) receptor and its strong inhibition of serotonin and norepinephrine uptake, which likely also contributes to its antinociceptive activity.[A497] \\r\\n\\r\\nMethadone is administered as a 50:50 racemic mixture of (R)- and (S)-stereoisomers, with (R)-methadone demonstrating ~10-fold higher affinity and potency for the \\u00b5-opioid receptor than the (S) stereoisomer.[A497] The analgesic activity of the racemate is almost entirely due to the (R)-isomer, while the (S)-isomer lacks significant respiratory depressant activity but does have antitussive effects.\\r\\n\\r\\nWhile methadone shares similar effects and risks of other opioids such as [morphine], [hydromorphone], [oxycodone], and [fentanyl] it has a number of unique pharmacokinetic and pharmacodynamic properties that distinguish it from them and make it a useful agent for the treatment of opioid addiction. For example, methadone abstinence syndrome, although qualitatively similar to that of morphine, differs in that the onset is slower, the course is more prolonged, and the symptoms are less severe.\", \"neighbor_flag\": \"N\", \"pubmed_ids\": [8448065, 22092298, 22369095, 30205091, 9143866], \"resource_name\": \"DrugBank\", \"resource_version\": \"5.1\", \"target_resource_id\": \"P10635\"}, {\"cofactor_in_ch_ikey\": \"KVWDHTXUZHCGIO-UHFFFAOYSA-N\", \"cofactor_smiles\": \"CN1CCN(CC1)C1=NC2=CC=CC=C2NC2=C1C=C(C)S2\", \"cofactor_name\": \"Olanzapine\", \"cofactor_resource_id\": \"DB00334\", \"mechanism_of_action\": \"The activity of olanzapine is achieved by the antagonism of multiple neuronal receptors including the dopamine receptor D1, D2, D3 and D4 in the brain, the serotonin receptors 5HT2A, 5HT2C, 5HT3 and 5HT6, the alpha-1 adrenergic receptor, the histamine receptor H1 and multiple muscarinic receptors.[A176993, A176999]\\r\\n\\r\\nAs abovementioned, olanzapine presents a wide profile of targets, however, its antagonistic effect towards the dopamine D2 receptor in the mesolimbic pathway is key as it blocks dopamine from having a potential action at the post-synaptic receptor. The binding of olanzapine to the dopamine D2 receptors is easily dissociable and hence, it allows for a certain degree of dopamine neurotransmission.[A177014]\\r\\n\\r\\nOn the other hand, olanzapine acts in the serotonin 5HT2A receptors in the frontal cortex in a similar manner than the reported on dopamine D2 receptors. This determined effect allows for a decrease in adverse effects.[A177014]\", \"neighbor_flag\": \"N\", \"pubmed_ids\": [10511917, 30422498, 11704898], \"resource_name\": \"DrugBank\", \"resource_version\": \"5.1\", \"target_resource_id\": \"P10635\"}, {\"cofactor_in_ch_ikey\": \"METKIMKYRPQLGS-UHFFFAOYSA-N\", \"cofactor_smiles\": \"CC(C)NCC(O)COC1=CC=C(CC(N)=O)C=C1\", \"cofactor_name\": \"Atenolol\", \"cofactor_resource_id\": \"DB00335\", \"mechanism_of_action\": \"Atenolol is a cardioselective beta-blocker, called such because it selectively binds to the \\u03b21-adrenergic receptor as an antagonist up to a reported 26 fold more than \\u03b22 receptors.[A178372] Selective activity at the \\u03b21 receptor produces cardioselectivity due to the higher population of this receptor in cardiac tissue. Some binding to \\u03b22 and possibly \\u03b23 receptors can still occur at therapeutic dosages but the effects mediated by antagonizing these are significantly reduced from those of non-selective agents. \\u03b21 and \\u03b22 receptors are G<sub>s</sub> coupled therefore antagonism of their activation reduces activity of adenylyl cyclase and its downstream signalling via cyclic adenosime monophosphate and protein kinase A (PKA). \\r\\n\\r\\nIn cardiomyocytes PKA is thought to mediate activation of L-type calcium channels and ryanodine receptors through their phosphorylation.[A178396] L-type calcium channels can then provide an initial rise in intracellular calcium and trigger the ryanodine receptors to release calcium stored in the sarcoplasmic reticulum (SR) and increased contractility. PKA also plays a role in the cessation of contraction by phosphorylating phospholamban which in turn increases the affinity of SR Ca<sup>2+</sup> ATPase to increase reuptake of calcium into the SR. It also phophorylates troponin I to reduce affinity of the protein for calcium. Both of these events lead to a reduction in contraction which, when coupled with the initial increase in contraction, allows for faster cycling and consequently higher heart rate with increased contractility. L-type calcium channels are also a major contributor to cardiac depolarization and their activation can increase frequency of action potentials and possibly the incidence of ectopic potentials.[A178405] \\r\\n\\r\\nSimilar inihibitory events occur in the bronchial smooth muscle to mediate relaxation including phosphorylation of myosin light-chain kinase, reducing its affinity for calcium.[A178408] PKA also inhibits the excitatory G<sub>q</sub> coupled pathway by phosphorylating the inositol trisphosphate receptor and phospholipase C resulting in inhibition of intracellular calcium release. Antagonism of this activity by beta-blocker agents like atenolol can thus cause increased bronchoconstriction.\\r\\n\", \"neighbor_flag\": \"N\", \"pubmed_ids\": [17125412, 14732961], \"resource_name\": \"DrugBank\", \"resource_version\": \"5.1\", \"target_resource_id\": \"P10635\"}, {\"cofactor_in_ch_ikey\": \"SUBDBMMJDZJVOS-UHFFFAOYSA-N\", \"cofactor_smiles\": \"COC1=CC2=C(C=C1)N=C(N2)S(=O)CC1=NC=C(C)C(OC)=C1C\", \"cofactor_name\": \"Omeprazole\", \"cofactor_resource_id\": \"DB00338\", \"mechanism_of_action\": \"Hydrochloric acid (HCl) secretion into the gastric lumen is a process regulated mainly by the H(+)/K(+)-ATPase of the proton pump [A175180], expressed in high quantities by the parietal cells of the stomach. ATPase is an enzyme on the parietal cell membrane that facilitates hydrogen and potassium exchange through the cell, which normally results in the extrusion of potassium and formation of HCl (gastric acid) [A174295].\\r\\n\\r\\nOmeprazole is a member of a class of antisecretory compounds, the substituted _benzimidazoles_, that stop gastric acid secretion by selective inhibition of the _H+/K+ ATPase_ enzyme system. Proton-pump inhibitors such as omeprazole bind covalently to cysteine residues via disulfide bridges on the alpha subunit of the _H+/K+ ATPase_ pump, inhibiting gastric acid secretion for up to 36 hours [A175192].  This antisecretory effect is dose-related and leads to the inhibition of both basal and stimulated acid secretion, regardless of the stimulus [FDA label].  \\r\\n\\r\\n**Mechanism of H. pylori eradication**\\r\\n\\r\\nPeptic ulcer disease (PUD) is frequently associated with _Helicobacter pylori_ bacterial infection (NSAIDs) [A175195]. The treatment of H. pylori infection may include the addition of omeprazole or other proton pump inhibitors as part of the treatment regimen [FDA label], [A175198]. \\r\\n_H. pylori_ replicates most effectively at a neutral pH [A175213]. Acid inhibition in H. pylori eradication therapy, including proton-pump inhibitors such as omeprazole, raises gastric pH, discouraging the growth of H.pylori [A175198]. It is generally believed that proton pump inhibitors inhibit the _urease_ enzyme, which increases the pathogenesis of H. pylori in gastric-acid related conditions [A175216].   \", \"neighbor_flag\": \"N\", \"pubmed_ids\": [11334262, 15258107], \"resource_name\": \"DrugBank\", \"resource_version\": \"5.1\", \"target_resource_id\": \"P10635\"}, {\"cofactor_in_ch_ikey\": \"GUGOEEXESWIERI-UHFFFAOYSA-N\", \"cofactor_smiles\": \"CC(C)(C)C1=CC=C(C=C1)C(O)CCCN1CCC(CC1)C(O)(C1=CC=CC=C1)C1=CC=CC=C1\", \"cofactor_name\": \"Terfenadine\", \"cofactor_resource_id\": \"DB00342\", \"mechanism_of_action\": \"Terfenadine competes with histamine for binding at H1-receptor sites in the GI tract, uterus, large blood vessels, and bronchial muscle. This reversible binding of terfenadine to H1-receptors suppresses the formation of edema, flare, and pruritus resulting from histaminic activity. As the drug does not readily cross the blood-brain barrier, CNS depression is minimal.\", \"neighbor_flag\": \"N\", \"pubmed_ids\": [9485522, 12662125, 12365197, 9733666], \"resource_name\": \"DrugBank\", \"resource_version\": \"5.1\", \"target_resource_id\": \"P10635\"}, {\"cofactor_in_ch_ikey\": \"HSUGRBWQSSZJOP-RTWAWAEBSA-N\", \"cofactor_smiles\": \"COC1=CC=C(C=C1)[C@@H]1SC2=C(C=CC=C2)N(CCN(C)C)C(=O)[C@@H]1OC(C)=O\", \"cofactor_chem_comp_id\": \"C9F\", \"cofactor_name\": \"Diltiazem\", \"cofactor_resource_id\": \"DB00343\", \"mechanism_of_action\": \"Excitation of cardiac muscle involves the activation of a slow calcium inward current that is induced by L-type slow calcium channels, which are voltage-sensitive, ion-selective channels[A178444] associated with a high activation threshold and slow inactivation profile.[T28] L-type calcium channels are the main current responsible for the late phase of the pacemaker potential.[A178492] Acting as the main Ca2+ source for contraction in smooth and cardiac muscle, activation of L-type calcium channels allows the influx of calcium ions into the muscles upon depolarization and excitation of the channel.[A178444] It is proposed that this cation influx may also trigger the release of additional calcium ions from intracellular storage sites.[A178444] Diltiazem is a slow calcium channel blocker that binds to the extracellular site of the alpha-1C subunit of the channel, which is thought to be the S5-6 linker region of the transmembrane domain IV and/or S6 segment of domain III.[A178492]  Diltiazem can get access to this binding site from either the intracellular or extracellular side, but it requires a voltage-induced conformational changes in the membrane.[A178492] Diltiazem inhibits the influx of extracellular calcium across the myocardial and vascular smooth muscle cell membranes.[L10556] In isolated human atrial and ventricular myocardium, diltiazem suppressed tension over the range of membrane potentials associated with calcium channel activity but had little effect on the tension-voltage relations at more positive potentials.[A178453] This effect is thought to be mediated by the voltage-dependent block of the L-type calcium channels and inhibition of calcium ion release from the ER stores, without altering the sodium-calcium coupled transport or calcium sensitivity of myofilaments.[A178453] Through inhibition of inward calcium current, diltiazem exerts a direct ionotropic and energy sparing effect on the myocardium.[A178444] Diltiazem fslows atrioventricular nodal conduction, which is due to its ability to impede slow channel function.[A178444]\\r\\n\\r\\nReduced intracellular calcium concentrations equate to increased smooth muscle relaxation resulting in arterial vasodilation and therefore, decreased blood pressure.[L6289] The decrease in intracellular calcium inhibits the contractile processes of the myocardial smooth muscle cells, causing dilation of the coronary and systemic arteries, increased oxygen delivery to the myocardial tissue, decreased total peripheral resistance, decreased systemic blood pressure, and decreased afterload.[L6289,L10556] Through its actions on reducing calcium levels in cardiac and vascular smooth muscles, diltiazem causes a reduction in the contractile processes of the myocardial smooth muscle cells and vasodilation of the coronary and systemic arteries, including epicardial and subendocardial. This subsequently leads to increased oxygen delivery to the myocardial tissue, improved cardiac output due to increased stroke volume, decreased total peripheral resistance, decreased systemic blood pressure and heart rate, and decreased afterload.[L6289,L10556] Diltiazem lowers myocardial oxygen demand through a reduction in heart rate, blood pressure, and cardiac contractility; this leads to a therapeutic effect in improving exercise tolerance in chronic stable angina.[A178432,L6289] \", \"neighbor_flag\": \"N\", \"pubmed_ids\": [11744603, 12235455, 11151747], \"resource_name\": \"DrugBank\", \"resource_version\": \"5.1\", \"target_resource_id\": \"P10635\"}, {\"cofactor_in_ch_ikey\": \"CXOXHMZGEKVPMT-UHFFFAOYSA-N\", \"cofactor_smiles\": \"CN1C2=C(C=C(Cl)C=C2)N(C2=CC=CC=C2)C(=O)CC1=O\", \"cofactor_name\": \"Clobazam\", \"cofactor_resource_id\": \"DB00349\", \"mechanism_of_action\": \"The exact mechanism of action for clobazam, a 1,5-benzodiazepine, is not fully understood but is thought to involve the potentiation of GABAergic neurotransmission resulting from binding at the benzodiazepine site of the GABA<sub>A</sub> receptor.[L44888] Specifically, clobazam binds to the interface of the \\u03b1<sub>2</sub> and \\u03b3<sub>2</sub>-subunit of the GABA<sub>A</sub> receptor.[A256868] It has a great affinity for the \\u03b1<sub>2</sub> subunit than the \\u03b1<sub>1</sub> subunit compared to other 1,4\\u2010benzodiazepines.[A256938]Binding of clobazam to the GABA<sub>A</sub> receptor causes chloride channels to open, resulting in an influx of chloride and thus hyperpolarization of neurons.[A256868]\", \"neighbor_flag\": \"N\", \"pubmed_ids\": [29517622, 22422635, 26224203], \"resource_name\": \"DrugBank\", \"resource_version\": \"5.1\", \"target_resource_id\": \"P10635\"}, {\"cofactor_in_ch_ikey\": \"TZFWDZFKRBELIQ-UHFFFAOYSA-N\", \"cofactor_smiles\": \"ClC1=CC2=C(OC(=O)N2)C=C1\", \"cofactor_chem_comp_id\": \"CLW\", \"cofactor_name\": \"Chlorzoxazone\", \"cofactor_resource_id\": \"DB00356\", \"mechanism_of_action\": \"Chlorzoxazone inhibits degranulation of mast cells, subsequently preventing the release of histamine and slow-reacting substance of anaphylaxis (SRS-A), mediators of type I allergic reactions. Chlorzoxazone also may reduce the release of inflammatory leukotrienes. Chlorzoxazone may act by inhibiting calcium and potassium influx which would lead to neuronal inhibition and muscle relaxation. Data available from animal experiments as well as human study indicate that chlorzoxazone acts primarily at the level of the spinal cord and subcortical areas of the brain where it inhibits multisynaptic reflex arcs involved in producing and maintaining skeletal muscle spasm\", \"neighbor_flag\": \"N\", \"pubmed_ids\": [10534312, 9141232], \"resource_name\": \"DrugBank\", \"resource_version\": \"5.1\", \"target_resource_id\": \"P10635\"}, {\"cofactor_in_ch_ikey\": \"GBABOYUKABKIAF-IELIFDKJSA-N\", \"cofactor_smiles\": \"[H][C@@]12N(C)C3=CC(OC)=C(C=C3[C@@]11CCN3CC=C[C@](CC)([C@@]13[H])[C@@]([H])(OC(C)=O)[C@]2(O)C(=O)OC)[C@]1(C[C@@]2([H])CN(CC(CC)=C2)CC2=C1NC1=CC=CC=C21)C(=O)OC\", \"cofactor_name\": \"Vinorelbine\", \"cofactor_resource_id\": \"DB00361\", \"mechanism_of_action\": \"Vinca alkaloids are structurally similar compounds composed of two multi-ringed units, _vindoline_, and _catharanthine_. _Vinorelbine tartrate_ is a vinca alkaloid in which the catharanthine component is the target of structural modification [L2005], [L2006].\\r\\n\\r\\nThis structural modification contributes to unique pharmacologic properties.The antitumor activity of vinorelbine tartrate is believed to be owed to the inhibition of mitosis at metaphase via its interaction with tubulin [L1998].\\r\\n\\r\\nVinorelbine is a mitotic spindle poison that interferes with chromosomal segregation during mitosis, also known as cell division. It pauses cells at the _G2/M_ phases, when present at concentrations close to the half maximal inhibitory concentration (IC50). Microtubules, which are derived from polymers of tubulin, are the main target of vinorelbine. \\r\\n\\r\\nThe chemical modification used to produce vinorelbine allows for the opening of the eight-member catharanthine ring with the formation of both a covalent and reversible bond with tubulin [L2007].\\r\\n\\r\\nThe relative contribution of different microtubule-associated proteins in the production of tubulin vary between neural tissue and proliferating cells and this has important functional implications. The ability of vinorelbine to bind specifically to mitotic rather than other microtubules has been shown and may suggest that neurotoxicity is less likely to be a problem than with the molecular mechanism of action [L2007]. \\r\\n\\r\\nAs with other anti-microtubule agents, vinorelbine is known to contribute apoptosis in malignant cells. The exact mechanisms by which this process occurs are complex and many details are yet to be elucidated. The disarray of the microtubule structure has a number of effects, including the induction of tumor suppressor gene _p53_ and activation/inactivation of a number of protein kinases involved in essential signaling pathways, including _p21 WAF1/CIP1_ and _Ras/Raf_, _PKC/PKA_. These molecular changes lead to phosphorylation and consequently inactivation of the apoptosis inhibitor _Bcl2_. This, in turn, results in a decrease in the formation of heterodimers between _Bcl2_ and the pro-apoptotic gene _BAX_, stimulating the sequence of cell apoptosis [L2007].\\r\\n\\r\\nVinorelbine tartrate also possibly interferes with amino acid, cyclic AMP and glutathione metabolism, calmodulin-dependent Ca++-transport ATPase activity, cellular respiration, and nucleic acid and lipid biosynthesis [L1998].\\r\\n\", \"neighbor_flag\": \"N\", \"pubmed_ids\": [8258200], \"resource_name\": \"DrugBank\", \"resource_version\": \"5.1\", \"target_resource_id\": \"P10635\"}, {\"cofactor_in_ch_ikey\": \"QZUDBNBUXVUHMW-UHFFFAOYSA-N\", \"cofactor_smiles\": \"CN1CCN(CC1)C1=NC2=CC(Cl)=CC=C2NC2=CC=CC=C12\", \"cofactor_chem_comp_id\": \"VBU\", \"cofactor_name\": \"Clozapine\", \"cofactor_resource_id\": \"DB00363\", \"mechanism_of_action\": \"The mechanism of action of clozapine is unknown. However, it has been proposed that the therapeutic efficacy of clozapine in schizophrenia is mediated through antagonism of the dopamine type 2 (D<sub>2</sub>) and the serotonin type 2A (5-HT<sub>2A</sub>) receptors. Clozapine also acts as an antagonist at adrenergic, cholinergic, histaminergic, and other dopaminergic and serotonergic receptors.[L905] \\r\\n\\r\\nClozapine demonstrated binding affinity to the following receptors: histamine H1 (Ki 1.1 nM), adrenergic \\u03b11A (Ki 1.6 nM), serotonin 5-HT6 (Ki 4 nM), serotonin 5-HT2A (Ki 5.4 nM), muscarinic M1 (Ki 6.2 nM), serotonin 5-HT7 (Ki 6.3 nM), serotonin 5-HT2C (Ki 9.4 nM), dopamine D4 (Ki 24 nM), adrenergic \\u03b12A (Ki 90 nM), serotonin 5-HT3 (Ki 95 nM), serotonin 5-HT1A (Ki 120 nM), dopamine D2 (Ki 160 nM), dopamine D1 (Ki 270 nM), dopamine D5 (Ki 454 nM), and dopamine D3 (Ki 555 nM).[L905] \\r\\n\\r\\nClozapine acts as an antagonist at other receptors, but with lower potency. Antagonism at receptors other than dopamine and 5HT<sub>2</sub> with similar receptor affinities may explain some of the other therapeutic and side effects of clozapine. Clozapine's antagonism of muscarinic M1-5 receptors may explain its anticholinergic effects.[A256553] Clozapine's antagonism of histamine H1 receptors may explain the somnolence observed with this drug.[A256558] Clozapine's antagonism of adrenergic \\u03b11 receptors may explain the orthostatic hypotension observed with this drug.[A256563]\", \"neighbor_flag\": \"N\", \"pubmed_ids\": [17504220, 12670127, 1545398], \"resource_name\": \"DrugBank\", \"resource_version\": \"5.1\", \"target_resource_id\": \"P10635\"}, {\"cofactor_in_ch_ikey\": \"RONZAEMNMFQXRA-UHFFFAOYSA-N\", \"cofactor_smiles\": \"CN1CCN2C(C1)C1=CC=CC=C1CC1=C2N=CC=C1\", \"cofactor_name\": \"Mirtazapine\", \"cofactor_resource_id\": \"DB00370\", \"mechanism_of_action\": \"**Summary**\\r\\n\\r\\nThe mechanism of action of mirtazapine is not fully understood[FDA label] but may be explained by its effects on central adrenergic and serotonergic activity. This drug exhibits a fast onset of action, a high level of response, a manageable side-effect profile, and dual noradrenergic and serotonergic effects that are unique from the effects of other antidepressants.[A177811]\\r\\n\\r\\n**Effects on various receptors**\\r\\n\\r\\nIt has been shown that both noradrenergic and serotonergic activity increase following mirtazapine administration. The results of these studies demonstrate mirtazapine exerts antagonist activity at presynaptic \\u03b12-adrenergic inhibitory autoreceptors and heteroreceptors in the central nervous system. This is thought to lead to enhanced noradrenergic and serotonergic activity [FDA label], which are known to improve the symptoms of depression and form the basis of antidepressant therapy.[A178198, A178201]\\r\\n\\r\\nMirtazapine is a strong antagonist of serotonin 5-HT2 and 5-HT3 receptors. It has not been found to bind significantly to the serotonin 5-HT1A and 5-HT1B receptors [FDA label] but indirectly increases 5-HT1A transmission.[A4709]  \\r\\n\\r\\nIn addition to the above effects, mirtazapine is a peripheral \\u03b11-adrenergic antagonist. This action may explain episodes of orthostatic hypotension that have been reported after mirtazapine use.[FDA label] Mirtazapine is a potent histamine (H1) receptor antagonist, which may contribute to its powerful sedating effects.[FDA label] The pain-relieving effects of mirtazapine may be explained by its effects on opioid receptors.[A13073,A177868]\", \"neighbor_flag\": \"N\", \"pubmed_ids\": [11607047, 10997935, 15538128], \"resource_name\": \"DrugBank\", \"resource_version\": \"5.1\", \"target_resource_id\": \"P10635\"}, {\"cofactor_in_ch_ikey\": \"BLJRIMJGRPQVNF-JTQLQIEISA-N\", \"cofactor_smiles\": \"[H][C@](O)(CNC(C)(C)C)COC1=NSN=C1N1CCOCC1\", \"cofactor_chem_comp_id\": \"TIM\", \"cofactor_name\": \"Timolol\", \"cofactor_resource_id\": \"DB00373\", \"mechanism_of_action\": \"Timolol competes with adrenergic neurotransmitters for binding to beta(1)-adrenergic receptors in the heart and the beta(2)-receptors in the vascular and bronchial smooth muscle. This leads to diminished actions of catecholamines, which normally bind to adrenergic receptors and exert sympathetic effects leading to an increase in blood pressure and heart rate.[A179521] Beta(1)-receptor blockade by timolol leads to a decrease in both heart rate and cardiac output during rest and exercise, and a decrease in both systolic and diastolic blood pressure.[A179524,A179527] In addition to this, a reduction in reflex orthostatic hypotension may also occur. The blockade of beta(2) receptors by timolol in the blood vessels leads to a decrease in peripheral vascular resistance, reducing blood pressure.[L6724,L6727,L6733]\\r\\n\\r\\nThe exact mechanism by which timolol reduces ocular pressure is unknown at this time, however, it likely decreases the secretion of aqueous humor in the eye.[L6730] According to one study, the reduction of aqueous humor secretion may occur through the decreased blood supply to the ciliary body resulting from interference with the active transport system or interference with prostaglandin biosynthesis.[A179515]\", \"neighbor_flag\": \"N\", \"pubmed_ids\": [27534869, 17431033], \"resource_name\": \"DrugBank\", \"resource_version\": \"5.1\", \"target_resource_id\": \"P10635\"}, {\"cofactor_in_ch_ikey\": \"CPZBLNMUGSZIPR-NVXWUHKLSA-N\", \"cofactor_smiles\": \"[H][C@]12CCCC3=C1C(=CC=C3)C(=O)N(C2)[C@@H]1CN2CCC1CC2\", \"cofactor_chem_comp_id\": \"O7B\", \"cofactor_name\": \"Palonosetron\", \"cofactor_resource_id\": \"DB00377\", \"mechanism_of_action\": \"Palonosetron is a selective serotonin 5-HT<sub>3</sub> receptor antagonist. The antiemetic activity of the drug is brought about through the inhibition of 5-HT<sub>3</sub> receptors present both centrally (medullary chemoreceptor zone) and peripherally (GI tract). This inhibition of 5-HT<sub>3</sub> receptors in turn inhibits the visceral afferent stimulation of the vomiting center, likely indirectly at the level of the area postrema, as well as through direct inhibition of serotonin activity within the area postrema and the chemoreceptor trigger zone. Alternative mechanisms appear to be primarily responsible for delayed nausea and vomiting induced by emetogenic chemotherapy, since similar temporal relationships between between serotonin and emesis beyond the first day after a dose have not been established, and 5-HT<sub>3</sub> receptor antagonists generally have not appeared to be effective alone in preventing or ameliorating delayed effects. It has been hypothesized that palonosetron's potency and long plasma half-life may contribute to its observed efficacy in preventing delayed nausea and vomiting caused by moderately emetogenic cancer chemotherapy.\", \"neighbor_flag\": \"N\", \"pubmed_ids\": [15378559, 15102873, 16192915], \"resource_name\": \"DrugBank\", \"resource_version\": \"5.1\", \"target_resource_id\": \"P10635\"}, {\"cofactor_in_ch_ikey\": \"VLPIATFUUWWMKC-UHFFFAOYSA-N\", \"cofactor_smiles\": \"CC(N)COC1=C(C)C=CC=C1C\", \"cofactor_name\": \"Mexiletine\", \"cofactor_resource_id\": \"DB00379\", \"mechanism_of_action\": \"Mexiletine, like lidocaine, inhibits the inward sodium current required for the initiation and conduction of impulses, thus reducing the rate of rise of the action potential, Phase 0. It achieves this reduced sodium current by inhibiting sodium channels. Mexiletine decreases the effective refractory period (ERP) in Purkinje fibers in the heart. The decrease in ERP is of lesser magnitude than the decrease in action potential duration (APD), which results in an increase in the ERP/APD ratio. It does not significantly affect resting membrane potential or sinus node automaticity, left ventricular function, systolic arterial blood pressure, atrioventricular (AV) conduction velocity, or QRS or QT intervals\", \"neighbor_flag\": \"N\", \"pubmed_ids\": [9690950, 12937870, 11453897], \"resource_name\": \"DrugBank\", \"resource_version\": \"5.1\", \"target_resource_id\": \"P10635\"}, {\"cofactor_in_ch_ikey\": \"HTIQEAQVCYTUBX-UHFFFAOYSA-N\", \"cofactor_smiles\": \"CCOC(=O)C1=C(COCCN)NC(C)=C(C1C1=CC=CC=C1Cl)C(=O)OC\", \"cofactor_name\": \"Amlodipine\", \"cofactor_resource_id\": \"DB00381\", \"mechanism_of_action\": \"**Mechanism of action on blood pressure**\\r\\n\\r\\nAmlodipine is considered a peripheral arterial vasodilator that exerts its action directly on vascular smooth muscle to lead to a reduction in peripheral vascular resistance, causing a decrease in blood pressure. Amlodipine is a dihydropyridine calcium antagonist (calcium ion antagonist or slow-channel blocker) that inhibits the influx of calcium ions into both vascular smooth muscle and cardiac muscle. Experimental studies imply that amlodipine binds to both _dihydropyridine_ and _nondihydropyridine_ binding sites, located on cell membranes. The contraction of cardiac muscle and vascular smooth muscle are dependent on the movement of extracellular calcium ions into these cells by specific ion channels. Amlodipine blocks calcium ion influx across cell membranes with selectivity. A stronger effect of amlodipine is exerted on vascular smooth muscle cells than on cardiac muscle cells [FDA label]. Direct actions of amlodipine on vascular smooth muscle result in reduced blood pressure [F3757]. \\r\\n\\r\\n**Mechanism of action in angina**\\r\\n\\r\\nThe exact mechanism by which amlodipine relieves the symptoms of angina have not been fully elucidated to this date, however, the mechanism of action is likely twofold:\\r\\n\\r\\nAmlodipine has a dilating effect on peripheral arterioles, reducing the total peripheral resistance (afterload) against which the cardiac muscle functions. Since the heart rate remains stable during amlodipine administration, the reduced work of the heart reduces both myocardial energy use and oxygen requirements [F3757].\\r\\n\\r\\nDilatation of the main coronary arteries and coronary arterioles, both in healthy and ischemic areas, is another possible mechanism of amlodipine reduction of blood pressure. The dilatation causes an increase in myocardial oxygen delivery in patients experiencing coronary artery spasm (Prinzmetal's or variant angina) and reduces coronary vasoconstriction caused by smoking [F3757].\", \"neighbor_flag\": \"N\", \"pubmed_ids\": [30102628, 10640508], \"resource_name\": \"DrugBank\", \"resource_version\": \"5.1\", \"target_resource_id\": \"P10635\"}, {\"cofactor_in_ch_ikey\": \"RJKFOVLPORLFTN-LEKSSAKUSA-N\", \"cofactor_smiles\": \"[H][C@@]12CC[C@H](C(C)=O)[C@@]1(C)CC[C@@]1([H])[C@@]2([H])CCC2=CC(=O)CC[C@]12C\", \"cofactor_chem_comp_id\": \"STR\", \"cofactor_name\": \"Progesterone\", \"cofactor_resource_id\": \"DB00396\", \"mechanism_of_action\": \"Progesterone binds and activates its nuclear receptor, _PR_, which plays an important part in the signaling of stimuli that maintain the endometrium during its preparation for pregnancy.\\r\\n\\r\\nProgesterone receptor (PR) is a member of the nuclear/steroid hormone receptor (SHR) family of ligand-dependent transcription factors that is expressed primarily in female reproductive tissue as well as the central nervous system. As a result of its binding its associated steroid hormone, progesterone, the progesterone receptor (PR) modulates the expression of genes that regulate the development, differentiation, and proliferation of target tissues [A175666]. In humans, PR is found to be highly expressed in the stromal (connective tissue) cells during the secretory phase and during pregnancy [A175651]. \\r\\n\\r\\nProgesterone may prevent pregnancy by changing the consistency of cervical mucus to be unfavorable for sperm penetration, and by inhibiting follicle-stimulating hormone (FSH), which normally causes ovulation.  With perfect use, the first-year failure rate for progestin-only oral contraceptives is approximately 0.5%. The typical failure rate, however, is estimated to be approximately 5%, due to late or missed pills [F3904].\", \"neighbor_flag\": \"N\", \"pubmed_ids\": [15469888, 18310890, 24611668], \"resource_name\": \"DrugBank\", \"resource_version\": \"5.1\", \"target_resource_id\": \"P10635\"}, {\"cofactor_in_ch_ikey\": \"MLDQJTXFUGDVEO-UHFFFAOYSA-N\", \"cofactor_smiles\": \"CNC(=O)C1=NC=CC(OC2=CC=C(NC(=O)NC3=CC(=C(Cl)C=C3)C(F)(F)F)C=C2)=C1\", \"cofactor_chem_comp_id\": \"BAX\", \"cofactor_name\": \"Sorafenib\", \"cofactor_resource_id\": \"DB00398\", \"mechanism_of_action\": \"Kinases are involved in tumour cell signalling, proliferation, angiogenesis, and apoptosis.[A14794,L9341] Sorafenib inhibits multiple intracellular serine/threonine kinases in the Ras/mitogen-activated protein kinase (MAPK) signal transduction pathway. Intracellular Raf serine/threonine kinase isoforms inhibited by sorafenib include Raf-1 (or C-Raf), wild-type B-Raf, and mutant B-Raf. Sorafenib inhibits cell surface tyrosine kinase receptors such as KIT, FMS-like tyrosine kinase 3 (FLT-3), RET, RET/PTC, vascular endothelial growth factor receptor-1 (VEGFR-1), VEGFR-2, VEGFR-3, and platelet-derived growth factor receptor-\\u03b2 (PDGFR-\\u03b2).[A255852,A255857,A14794,L9341] \\r\\n\\r\\nSorafenib is thought to exhibit a dual mechanism of action: it blocks tumour proliferation and growth by inhibiting the RAF/MEK/extracellular signal-regulated kinase (ERK) pathway on tumour cells, and reduces tumour angiogenesis by inhibiting VEGFR and PDGFR signalling in tumour vasculature.[A255852,A10489]\", \"neighbor_flag\": \"N\", \"pubmed_ids\": [21350850], \"resource_name\": \"DrugBank\", \"resource_version\": \"5.1\", \"target_resource_id\": \"P10635\"}, {\"cofactor_in_ch_ikey\": \"GUJRSXAPGDDABA-NSHDSACASA-N\", \"cofactor_smiles\": \"CCN1CCC[C@H]1CNC(=O)C1=C(OC)C=CC(Br)=C1OC\", \"cofactor_name\": \"Remoxipride\", \"cofactor_resource_id\": \"DB00409\", \"mechanism_of_action\": \"Remoxipride is an atypical antipsychotic dopamine D<sub>2</sub> antagonist.[A215422] Chronic use upregulates the expression of D<sub>2</sub> receptors, while downregulating the expression of D<sub>1</sub> and D<sub>5</sub> receptors in the prefrontal cortex.[A215422] This activity may be related to the antipsychotic activity of remoxipride.[A215422] Remoxipride displays weaker binding to D<sub>2</sub> dopaminergic receptors that dopamine.[A12818] This weaker binding is thought to account for the reduced incidence of Parkinsonism.[A12818] Remoxipride also increases expression of the protein _Fos_ in the nucleus accumbens but not the dorsolateral striatum, which may be responsible for a reduced incidence of extrapyramidal symptoms.[A215422]\", \"neighbor_flag\": \"N\", \"pubmed_ids\": [10050706, 8329289], \"resource_name\": \"DrugBank\", \"resource_version\": \"5.1\", \"target_resource_id\": \"P10635\"}, {\"cofactor_in_ch_ikey\": \"YASAKCUCGLMORW-UHFFFAOYSA-N\", \"cofactor_smiles\": \"CN(CCOC1=CC=C(CC2SC(=O)NC2=O)C=C1)C1=CC=CC=N1\", \"cofactor_chem_comp_id\": \"BRL\", \"cofactor_name\": \"Rosiglitazone\", \"cofactor_resource_id\": \"DB00412\", \"mechanism_of_action\": \"Rosiglitazone acts as a highly selective and potent agonist at peroxisome proliferator activated receptors (PPAR) in target tissues for insulin action such as adipose tissue, skeletal muscle, and liver. Activation of PPAR-gamma receptors regulates the transcription of insulin-responsive genes involved in the control of glucose production, transport, and utilization. In this way, rosiglitazone enhances tissue sensitivity to insulin.\", \"neighbor_flag\": \"N\", \"pubmed_ids\": [12642470], \"resource_name\": \"DrugBank\", \"resource_version\": \"5.1\", \"target_resource_id\": \"P10635\"}, {\"cofactor_in_ch_ikey\": \"ZGUGWUXLJSTTMA-UHFFFAOYSA-N\", \"cofactor_smiles\": \"CN(C)CCCN1C2=CC=CC=C2SC2=CC=CC=C12\", \"cofactor_chem_comp_id\": \"P2Z\", \"cofactor_name\": \"Promazine\", \"cofactor_resource_id\": \"DB00420\", \"mechanism_of_action\": \"Promazine is an antagonist at types 1, 2, and 4 dopamine receptors, 5-HT receptor types 2A and 2C, muscarinic receptors 1 through 5, alpha(1)-receptors, and histamine H1-receptors. Promazine's antipsychotic effect is due to antagonism at dopamine and serotonin type 2 receptors, with greater activity at serotonin 5-HT2 receptors than at dopamine type-2 receptors. This may explain the lack of extrapyramidal effects. Promazine does not appear to block dopamine within the tubero-infundibular tract, explaining the lower incidence of hyperprolactinemia than with typical antipsychotic agents or risperidone. Antagonism at muscarinic receptors, H1-receptors, and alpha(1)-receptors also occurs with promazine.\", \"neighbor_flag\": \"N\", \"pubmed_ids\": [12721102], \"resource_name\": \"DrugBank\", \"resource_version\": \"5.1\", \"target_resource_id\": \"P10635\"}, {\"cofactor_in_ch_ikey\": \"ZAFYATHCZYHLPB-UHFFFAOYSA-N\", \"cofactor_smiles\": \"CN(C)C(=O)CC1=C(N=C2C=CC(C)=CN12)C1=CC=C(C)C=C1\", \"cofactor_chem_comp_id\": \"R5R\", \"cofactor_name\": \"Zolpidem\", \"cofactor_resource_id\": \"DB00425\", \"mechanism_of_action\": \"\\r\\nZolpidem, the active moiety of zolpidem tartrate, is a hypnotic substance with a chemical structure that is not related to the structure benzodiazepines, barbiturates, pyrrolopyrazines, pyrazolopyrimidines or other drugs exerting hypnotic effects. It interacts with a _GABA-BZ_ receptor complex and shares various pharmacological properties with the _benzodiazepine_ class of drugs [FDA label].\\r\\n\\r\\nSubunit binding of the _GABAA_ receptor chloride channel macromolecular complex is thought to lead to the sedative, anticonvulsant, anxiolytic, and myorelaxant drug effects of zolpidem. The main regulatory site of the GABAA receptor complex can be found on its _alpha (\\u03b1) subunit_ and is called the _benzodiazepine_ (BZ) or _omega (\\u03c9)_ receptor. At least three different subtypes of the (\\u03c9) receptor have been identified to this date [FDA label].\\r\\n\\r\\nIn contrast to benzodiazepine drugs, which are found to modulate all benzodiazepine receptor subtypes in a non-selective fashion, zolpidem binds the (BZ1) receptor specifically with a potent affinity for the alpha 1/alpha 5 subunits (in vitro) [FDA label].   More recent studies suggest that zolpidem binds primarily to the alpha 1, 2, and 3 subunits of the GABA receptor [A173896], [A10523], [A175567], and not the alpha 5 subunit. \\r\\n\\r\\nThe (_BZ1_) receptor is found primarily on the Lamina IV of the brain sensorimotor cortical regions, substantia nigra (pars reticulata), cerebellum molecular layer, olfactory bulb, ventral thalamic complex, pons, inferior colliculus, and globus pallidus. Specific and selective binding of zolpidem on the (BZ1) receptor is not considered absolute, however, this binding could potentially explain the relative lack of myorelaxant and anticonvulsant activity in animal studies in addition to the preservation of deep sleep (stages 3 and 4) in human studies of zolpidem at hypnotic doses [FDA label]. \", \"neighbor_flag\": \"N\", \"pubmed_ids\": [30178440, 8591727], \"resource_name\": \"DrugBank\", \"resource_version\": \"5.1\", \"target_resource_id\": \"P10635\"}, {\"cofactor_in_ch_ikey\": \"WIKYUJGCLQQFNW-UHFFFAOYSA-N\", \"cofactor_smiles\": \"CN1CCN(CCCN2C3=CC=CC=C3SC3=C2C=C(Cl)C=C3)CC1\", \"cofactor_chem_comp_id\": \"P77\", \"cofactor_name\": \"Prochlorperazine\", \"cofactor_resource_id\": \"DB00433\", \"mechanism_of_action\": \"The mechanism of action of prochlorperazine has not been fully determined, but may be primarily related to its anti-dopaminergic effects. Prochlorperazine blocks the D2 dopamine receptors in the brain, which are somatodendritic autoreceptors. Inhibition of D2 receptor signaling results in the blockade of postsynaptic dopamine receptors in the mesolimbic system [L6643] and an increased dopamine turnover. Nausea and vomiting are proposed to arise from peripheral or central stimulation of  serotonin type 3 (5-HT3) and dopamine type 2 receptors, the predominant receptors expressed at the chemoreceptor trigger zone (CTZ).[A179194,L6643] Prochlorperazine exerts antiemetic effects and was shown to inhibit apomorphine-induced vomiting by blocking D2 dopamine receptors in the CTZ.[A179179]. \", \"neighbor_flag\": \"N\", \"pubmed_ids\": [15025745], \"resource_name\": \"DrugBank\", \"resource_version\": \"5.1\", \"target_resource_id\": \"P10635\"}, {\"cofactor_in_ch_ikey\": \"SEERZIQQUAZTOL-ANMDKAQQSA-N\", \"cofactor_smiles\": \"COCC1=C(C2=CC=C(F)C=C2)C(\\\\C=C\\\\[C@@H](O)C[C@@H](O)CC(O)=O)=C(C(C)C)N=C1C(C)C\", \"cofactor_chem_comp_id\": \"116\", \"cofactor_name\": \"Cerivastatin\", \"cofactor_resource_id\": \"DB00439\", \"mechanism_of_action\": \"Cerivastatin competitively inhibits hydroxymethylglutaryl-coenzyme A (HMG-CoA) reductase, the hepatic enzyme responsible for converting HMG-CoA to mevalonate. As mevalonate is a precursor of sterols such as cholesterol, this results in a decrease in cholesterol in hepatic cells, upregulation of LDL-receptors, and an increase in hepatic uptake of LDL-cholesterol from the circulation.\", \"neighbor_flag\": \"N\", \"pubmed_ids\": [11523064], \"resource_name\": \"DrugBank\", \"resource_version\": \"5.1\", \"target_resource_id\": \"P10635\"}, {\"cofactor_in_ch_ikey\": \"MJIHNNLFOKEZEW-UHFFFAOYSA-N\", \"cofactor_smiles\": \"CC1=C(OCC(F)(F)F)C=CN=C1CS(=O)C1=NC2=CC=CC=C2N1\", \"cofactor_name\": \"Lansoprazole\", \"cofactor_resource_id\": \"DB00448\", \"mechanism_of_action\": \"As a PPI, lansoprazole is a prodrug and requires protonation via an acidic environment to become activated. [A174244]  Once protonated, lansoprazole is able to react with cysteine residues, specifically Cys813 and Cys321, on parietal H+,K+-ATPase resulting in stable disulfides.[A174244][A177077]  PPI's in general are able to provide prolonged inhibition of acid secretion due to their ability to bind covalently to their targets.[A174244]   \", \"neighbor_flag\": \"N\", \"pubmed_ids\": [9224780], \"resource_name\": \"DrugBank\", \"resource_version\": \"5.1\", \"target_resource_id\": \"P10635\"}, {\"cofactor_in_ch_ikey\": \"XADCESSVHJOZHK-UHFFFAOYSA-N\", \"cofactor_smiles\": \"CCOC(=O)C1(CCN(C)CC1)C1=CC=CC=C1\", \"cofactor_name\": \"Meperidine\", \"cofactor_resource_id\": \"DB00454\", \"mechanism_of_action\": \"Meperidine is primarily a kappa-opiate receptor agonist and also has local anesthetic effects. Meperidine has more affinity for the kappa-receptor than morphine. Opiate receptors are coupled with G-protein receptors and function as both positive and negative regulators of synaptic transmission via G-proteins that activate effector proteins. Binding of the opiate stimulates the exchange of GTP for GDP on the G-protein complex. As the effector system is adenylate cyclase and cAMP located at the inner surface of the plasma membrane, opioids decrease intracellular cAMP by inhibiting adenylate cyclase. Subsequently, the release of nociceptive neurotransmitters such as substance P, GABA, dopamine, acetylcholine and noradrenaline is inhibited. Opioids also inhibit the release of vasopressin, somatostatin, insulin and glucagon. Opioids close N-type voltage-operated calcium channels (OP2-receptor agonist) and open calcium-dependent inwardly rectifying potassium channels (OP3 and OP1 receptor agonist). This results in hyperpolarization and reduced neuronal excitability.\", \"neighbor_flag\": \"N\", \"pubmed_ids\": [15319333], \"resource_name\": \"DrugBank\", \"resource_version\": \"5.1\", \"target_resource_id\": \"P10635\"}, {\"cofactor_in_ch_ikey\": \"JCCNYMKQOSZNPW-UHFFFAOYSA-N\", \"cofactor_smiles\": \"CCOC(=O)N1CCC(CC1)=C1C2=C(CCC3=C1N=CC=C3)C=C(Cl)C=C2\", \"cofactor_name\": \"Loratadine\", \"cofactor_resource_id\": \"DB00455\", \"mechanism_of_action\": \"Histamine release is a key mediator in allergic rhinitis and urticaria.[A185312][A176441][A175060] As a result, loratadine exerts it's effect by targeting H1 histamine receptors.\\r\\n\\r\\nLoratadine binds to H1 histamine receptors found on the surface of epithelial cells, endothelial cells, eosinophils, neutrophils, airway cells, and vascular smooth muscle cells among others.[A176441] H1 histamine receptors fall under the wider umbrella of G-protein coupled receptors, and exist in a state of equilibrium between the active and inactive forms.[A176441][A175060] Histamine binding to the H1-receptor facilitates cross linking between transmembrane domains III and V, stabilizing the active form of the receptor.[A176441][A175060] On the other hand, antihistamines bind to a different site on the H1 receptor favouring the inactive form.[A176441][A175060]\\r\\n\\r\\nHence, loratadine can more accurately be classified as an \\\"inverse agonist\\\" as opposed to a \\\"histamine antagonist\\\", and can prevent or reduce the severity of histamine mediated symptoms.[A176441][A175060][L8486]    \", \"neighbor_flag\": \"N\", \"pubmed_ids\": [11502723, 8615885, 15932952], \"resource_name\": \"DrugBank\", \"resource_version\": \"5.1\", \"target_resource_id\": \"P10635\"}, {\"cofactor_in_ch_ikey\": \"BCGWQEUPMDMJNV-UHFFFAOYSA-N\", \"cofactor_smiles\": \"CN(C)CCCN1C2=CC=CC=C2CCC2=CC=CC=C12\", \"cofactor_chem_comp_id\": \"IXX\", \"cofactor_name\": \"Imipramine\", \"cofactor_resource_id\": \"DB00458\", \"mechanism_of_action\": \"Imipramine works by inhibiting the neuronal reuptake of the neurotransmitters norepinephrine and serotonin [A6584,T116]. It binds the sodium-dependent serotonin transporter and sodium-dependent norepinephrine transporter reducing the reuptake of norepinephrine and serotonin by neurons. Depression has been linked to a lack of stimulation of the post-synaptic neuron by norepinephrine and serotonin [A31933]. Slowing the reuptake of these neurotransmitters increases their concentration in the synaptic cleft, producing knock-on effects in protein kinase signalling which is thought to contribute to changes in neurotransmission and brain physiology which relieves symptoms of depression [A31939]. \", \"neighbor_flag\": \"N\", \"pubmed_ids\": [9190854, 15687478, 8565792], \"resource_name\": \"DrugBank\", \"resource_version\": \"5.1\", \"target_resource_id\": \"P10635\"}, {\"cofactor_in_ch_ikey\": \"LOUPRKONTZGTKE-WZBLMQSHSA-N\", \"cofactor_smiles\": \"[H][C@]1(C[C@@H]2CC[N@]1C[C@@H]2C=C)[C@H](O)C1=CC=NC2=CC=C(OC)C=C12\", \"cofactor_chem_comp_id\": \"QI9\", \"cofactor_name\": \"Quinine\", \"cofactor_resource_id\": \"DB00468\", \"mechanism_of_action\": \"The theorized mechanism of action for quinine and related anti-malarial drugs is that these drugs are toxic to the malaria parasite. Specifically, the drugs interfere with the parasite's ability to break down and digest hemoglobin. Consequently, the parasite starves and/or builds up toxic levels of partially degraded hemoglobin in itself. \", \"neighbor_flag\": \"Y\", \"pubmed_ids\": [9431830, 12703961], \"resource_name\": \"DrugBank\", \"resource_version\": \"5.1\", \"target_resource_id\": \"P10635\"}, {\"cofactor_in_ch_ikey\": \"CYQFCXCEBYINGO-IAGOWNOFSA-N\", \"cofactor_smiles\": \"[H][C@@]12C=C(C)CC[C@@]1([H])C(C)(C)OC1=C2C(O)=CC(CCCCC)=C1\", \"cofactor_chem_comp_id\": \"TCI\", \"cofactor_name\": \"Dronabinol\", \"cofactor_resource_id\": \"DB00470\", \"mechanism_of_action\": \"Dronabinol is a synthetic form of delta-9-tetrahydrocannabinol (\\u0394\\u2079-THC), the primary psychoactive component of cannabis (marijuana). THC demonstrates its effects through weak partial agonist activity at Cannabinoid-1 (CB1R) and Cannabinoid-2 (CB2R) receptors, which results in the well-known effects of smoking cannabis such as increased appetite, reduced pain, and changes in emotional and cognitive processes.\", \"neighbor_flag\": \"N\", \"pubmed_ids\": [34493602, 30583596, 24160757, 31433338], \"resource_name\": \"DrugBank\", \"resource_version\": \"5.1\", \"target_resource_id\": \"P10635\"}, {\"cofactor_in_ch_ikey\": \"RTHCYVBBDHJXIQ-UHFFFAOYSA-N\", \"cofactor_smiles\": \"CNCCC(OC1=CC=C(C=C1)C(F)(F)F)C1=CC=CC=C1\", \"cofactor_name\": \"Fluoxetine\", \"cofactor_resource_id\": \"DB00472\", \"mechanism_of_action\": \"The monoaminergic hypothesis of depression emerged in 1965 and linked depression with dysfunction of neurotransmitters such as noradrenaline and serotonin.[L7721] Indeed, low levels of serotonin have been observed in the cerebrospinal fluid of patients diagnosed with depression.[A181793] As a result of this hypothesis, drugs that modulate levels of serotonin such as fluoxetine were developed.[L7721]\\r\\n\\r\\nFluoxetine is a selective serotonin reuptake inhibitor (SSRI) and as the name suggests, it exerts it's therapeutic effect by inhibiting the presynaptic reuptake of the neurotransmitter serotonin.[A181673] As a result, levels of 5-hydroxytryptamine (5-HT) are increased in various parts of the brain.[L7721] Further, fluoxetine has high affinity for 5-HT transporters, weak affinity for noradrenaline transporters and no affinity for dopamine transporters indicating that it is 5-HT selective.[L7721]\\r\\n\\r\\nFluoxetine interacts to a degree with the 5-HT<sub>2C</sub> receptor and it has been suggested that through this mechanism, it is able to increase noradrenaline and dopamine levels in the prefrontal cortex.[L7721]\", \"neighbor_flag\": \"N\", \"pubmed_ids\": [10997938], \"resource_name\": \"DrugBank\", \"resource_version\": \"5.1\", \"target_resource_id\": \"P10635\"}, {\"cofactor_in_ch_ikey\": \"ZEUITGRIYCTCEM-KRWDZBQOSA-N\", \"cofactor_smiles\": \"CNCC[C@H](OC1=CC=CC2=CC=CC=C12)C1=CC=CS1\", \"cofactor_chem_comp_id\": \"29E\", \"cofactor_name\": \"Duloxetine\", \"cofactor_resource_id\": \"DB00476\", \"mechanism_of_action\": \"Duloxetine is a potent inhibitor of neuronal serotonin and norepinephrine reuptake and a less potent inhibitor of dopamine reuptake.[A178714] Duloxetine has no significant affinity for dopaminergic, adrenergic, cholinergic, histaminergic, opioid, glutamate, and GABA receptors.\\r\\n\\r\\nAction on the external urinary sphincter is mediated via duloxetine's CNS effects. Increased serotonin and norepinephrine concentrations in Onuf's nucleus leads to increased activation of 5-HT<sub>2</sub>, 5-HT<sub>3</sub>, and \\u03b1<sub>1</sub> adrenergic receptors.[A178663,A178666] 5-HT<sub>2</sub> and \\u03b1<sub>1</sub> are both G<sub>q</sub> coupled and their activation increases the activity of the inositol trisphosphate/phospholipase C (IP<sub>3</sub>/PLC) pathway.[T116] This pathway leads to release of intracellular calcium stores, increasing intracellular calcium concentrations, and facilitating neuronal excitability. 5-HT<sub>3</sub> functions as a ligand-gated sodium channel which allows sodium to flow into the neuron when activated. Increased flow of sodium into the neuron contributes to depolarization and activation of voltage gated channels involved in action potential generation. The combined action of these three receptors contributes to increased excitability of the pudendal motor nerve in response to glutamate.\\r\\n\\r\\nAlso related to duloxetine's action at the spinal cord is its modulation of pain. Increasing the concentration of serotonin and norepinephrine in the dorsal horn of the spinal cord increases descending inhibition of pain through activation of 5-HT<sub>1A</sub>, 5-HT<sub>1B</sub>, 5-HT<sub>1D</sub>, 5-HT<sub>2</sub>, 5-HT<sub>3</sub>, \\u03b1<sub>1</sub>-adrenergic, and \\u03b1<sub>2</sub>-adrenergic receptors.[A178705] 5-HT<sub>2</sub>, 5-HT<sub>3</sub>, and \\u03b1<sub>1</sub>-adrenergic mediate neuronal activation as described above. The activated neuron in this case is the GABAergic inhibitory interneuron which synapses onto the nociceptive projection neuron to inhibit the transmission of painful stimuli to the brain. The 5-HT<sub>1</sub> and \\u03b1<sub>2</sub> receptors are G<sub>i</sub>/G<sub>o</sub> coupled and their activation leads to increased potassium current through inward rectifier channels and decreased adenylyl cyclase/protein kinase A signaling which contributes to neuronal inhibition.[A178705,T116] These inhibitory receptors are present on the projection neuron itself as well as the dorsal root ganglion which precedes it and serves to directly suppress the transmission of painful stimuli.\\r\\n\\r\\nThe mechanisms involved in duloxetine's benefits in depression and anxiety have not been fully elucidated. Dysfunctional serotonin and norepinephrine signaling are thought to be involved and increases in the availability of these neurotransmitters at the synaptic cleft thought to mediate a therapeutic effect.[A178666] It is postulated that the involvement of serotonin and norepinephrine in area responsible for emotional modulation such as the limbic system contributes to the effects in mood disorders specifically but this has yet to be confirmed.\\r\\n\\r\\nDuloxetine's hypertensive effect is related to its intended pharmacological effect. Increased availability of norepinephrine leads to activation of adrenergic receptors on the vascular endothelium. Since the action of \\u03b1<sub>1</sub> receptors predominates, vasoconstriction results as the G<sub>q</sub> coupled receptor mediates calcium release from the sarcoplasmic reticulum to facilitate smooth muscle contraction.[T116]\", \"neighbor_flag\": \"N\", \"pubmed_ids\": [21366359, 19057238, 17121211, 19480470], \"resource_name\": \"DrugBank\", \"resource_version\": \"5.1\", \"target_resource_id\": \"P10635\"}, {\"cofactor_in_ch_ikey\": \"ZPEIMTDSQAKGNT-UHFFFAOYSA-N\", \"cofactor_smiles\": \"CN(C)CCCN1C2=CC=CC=C2SC2=C1C=C(Cl)C=C2\", \"cofactor_chem_comp_id\": \"Z80\", \"cofactor_name\": \"Chlorpromazine\", \"cofactor_resource_id\": \"DB00477\", \"mechanism_of_action\": \"Chlorpromazine acts as an antagonist (blocking agent) on different postsysnaptic receptors -on dopaminergic-receptors (subtypes D1, D2, D3 and D4 - different antipsychotic properties on productive and unproductive symptoms), on serotonergic-receptors (5-HT1 and 5-HT2, with anxiolytic, antidepressive and antiaggressive properties as well as an attenuation of extrapypramidal side-effects, but also leading to weight gain, fall in blood pressure, sedation and ejaculation difficulties), on histaminergic-receptors (H1-receptors, sedation, antiemesis, vertigo, fall in blood pressure and weight gain), alpha1/alpha2-receptors (antisympathomimetic properties, lowering of blood pressure, reflex tachycardia, vertigo, sedation, hypersalivation and incontinence as well as sexual dysfunction, but may also attenuate pseudoparkinsonism - controversial) and finally on muscarinic (cholinergic) M1/M2-receptors (causing anticholinergic symptoms like dry mouth, blurred vision, obstipation, difficulty/inability to urinate, sinus tachycardia, ECG-changes and loss of memory, but the anticholinergic action may attenuate extrapyramidal side-effects).\\r\\nAdditionally, Chlorpromazine is a weak presynaptic inhibitor of Dopamine reuptake, which may lead to (mild) antidepressive and antiparkinsonian effects. This action could also account for psychomotor agitation and amplification of psychosis (very rarely noted in clinical use).\", \"neighbor_flag\": \"N\", \"pubmed_ids\": [16910628, 10688273, 10901285], \"resource_name\": \"DrugBank\", \"resource_version\": \"5.1\", \"target_resource_id\": \"P10635\"}, {\"cofactor_in_ch_ikey\": \"RZEKVGVHFLEQIL-UHFFFAOYSA-N\", \"cofactor_smiles\": \"CC1=CC=C(C=C1)C1=CC(=NN1C1=CC=C(C=C1)S(N)(=O)=O)C(F)(F)F\", \"cofactor_chem_comp_id\": \"CEL\", \"cofactor_name\": \"Celecoxib\", \"cofactor_resource_id\": \"DB00482\", \"mechanism_of_action\": \"Unlike most NSAIDs, which inhibit both types of cyclooxygenases (COX-1 and COX-2), celecoxib is a selective noncompetitive inhibitor of cyclooxygenase-2 (COX-2) enzyme. COX-2 is expressed heavily in inflamed tissues where it is induced by inflammatory mediators.[L7646] The inhibition of this enzyme reduces the synthesis of metabolites that include prostaglandin E2 (PGE2), prostacyclin (PGI2), thromboxane (TXA2), prostaglandin D2 (PGD2), and prostaglandin F2 (PGF2). Resultant inhibition of these mediators leads to the alleviation of pain and inflammation.[A34124,L7646] \\r\\n\\r\\nBy inhibiting prostaglandin synthesis, non-steroidal anti-inflammatory drugs (NSAIDs) cause mucosal damage, ulceration and ulcer complication throughout the gastrointestinal tract.[L7646] Celecoxib poses less of an ulceration risk than other NSAIDS, owing to its decreased effect on gastric mucosal prostaglandin synthesis when compared to placebo.[A34152] \\r\\n\\r\\nCelecoxib exerts anticancer effects by binding to the cadherin-11 (CDH11)protein,  which is thought to be involved in the progression of tumors, and inhibiting the 3-phosphoinositide-dependent kinase-1 (PDK-1) signaling mechanism.[T647,A11861] In addition, celecoxib has been found to inhibit carbonic anhydrase enzymes 2 and 3, further enhancing its anticancer effects.[A28426,A20066]\\r\\n\\r\\nAs mentioned in the pharmacodynamics section of this drug entry, celecoxib may cause an increased risk of thrombotic events. The risk of thrombosis resulting from COX-2 inhibition is caused by the vasoconstricting actions of thromboxane A2, leading to enhanced platelet aggregation, which is uncontrolled when the actions of prostacyclin, a platelet aggregation inhibitor, are suppressed through the inhibition of COX-2.[L7622]\", \"neighbor_flag\": \"N\", \"pubmed_ids\": [12891223, 30219715, 22336956, 16003301], \"resource_name\": \"DrugBank\", \"resource_version\": \"5.1\", \"target_resource_id\": \"P10635\"}, {\"cofactor_in_ch_ikey\": \"ZBMZVLHSJCTVON-UHFFFAOYSA-N\", \"cofactor_smiles\": \"CC(C)NCC(O)C1=CC=C(NS(C)(=O)=O)C=C1\", \"cofactor_name\": \"Sotalol\", \"cofactor_resource_id\": \"DB00489\", \"mechanism_of_action\": \"Sotalol inhibits beta-1 adrenoceptors in the myocardium as well as rapid potassium channels to slow repolarization, lengthen the QT interval, and slow and shorten conduction of action potentials through the atria.[A178522,A178540,A178561,A34177] The action of sotalol on beta adrenergic receptors lengthens the sinus node cycle, conduction time through the atrioventricular node, refractory period, and duration of action potentials.[A178579]\", \"neighbor_flag\": \"N\", \"pubmed_ids\": [27836712, 14732961, 17125412], \"resource_name\": \"DrugBank\", \"resource_version\": \"5.1\", \"target_resource_id\": \"P10635\"}, {\"cofactor_in_ch_ikey\": \"QWCRAEMEVRGPNT-UHFFFAOYSA-N\", \"cofactor_smiles\": \"O=C1CC2(CCCC2)CC(=O)N1CCCCN1CCN(CC1)C1=NC=CC=N1\", \"cofactor_chem_comp_id\": \"YLX\", \"cofactor_name\": \"Buspirone\", \"cofactor_resource_id\": \"DB00490\", \"mechanism_of_action\": \"The therapeutic action of buspirone in generalized anxiety disorders is thought to be mainly derived from its interaction with two major 5-HT<sub>1A</sub> receptor subtypes that are involved in the brain's anxiety and fear circuitry to enhance the serotonergic activity in these brain areas.[L7375] Buspirone acts as a full agonist at presynaptic 5-HT<sub>1A</sub> receptors, or 5-HT<sub>1A</sub> autoreceptors, expressed at dorsal raphe while acting as a partial agonist at the postsynaptic 5-HT<sub>1A</sub> receptors expressed on hippocampus and cortex.[A182315,A182420] 5-HT<sub>1A</sub> receptors function as inhibitory autoreceptors by being expressed on the soma or dendrites of serotonergic neurons or mediate postsynaptic actions of 5-HT by being highly expressed on the corticolimbic circuits.[T28] They are inhibitory G-protein coupled receptors that couple to Gi/Go proteins. When activated, presynaptic 5-HT<sub>1A</sub> autoreceptors causes neuron hyperpolarization and reduces the firing rate of the serotonergic neuron, thereby decreasing extracellular 5-HT levels in the neuron's projection areas. Activated postsynaptic 5-HT<sub>1A</sub> receptors promote hyperpolarization to released 5-HT on pyramidal neurons.[A182420] \\r\\n\\r\\nThe anxiolytic action of buspirone is mainly thought to arise from the interaction at presynaptic 5-HT<sub>1A</sub> autoreceptors. Acting as a potent agonist in these receptors, buspirone initially causes activation of these autoreceptors and inhibition of 5-HT release. It is proposed that buspirone induces desensitization of somatodendritic autoreceptors over time, which may explain the delayed onset of action of the drug. Desensitization of the autoreceptors ultimately results in heightened excitation of serotonergic neurons and enhanced 5-HT release.[T28] Buspirone also displays a weak affinity for serotonin 5HT2 receptors and acts as a weak antagonist on dopamine D2 autoreceptors,[L7375] although there is not much evidence that the action at these receptors contribute to the anxiolytic effect of buspirone.[A182312] It acts as an antagonist at presynaptic dopamine D3 and D4 receptors and may bind to alpha-1 adrenergic receptors as a partial agonist.[A181751]\", \"neighbor_flag\": \"N\", \"pubmed_ids\": [15640381, 15185539], \"resource_name\": \"DrugBank\", \"resource_version\": \"5.1\", \"target_resource_id\": \"P10635\"}, {\"cofactor_in_ch_ikey\": \"JRURYQJSLYLRLN-BJMVGYQFSA-N\", \"cofactor_smiles\": \"CCN(CC)C(=O)C(=C\\\\C1=CC(=C(O)C(O)=C1)[N+]([O-])=O)\\\\C#N\", \"cofactor_chem_comp_id\": \"PD9\", \"cofactor_name\": \"Entacapone\", \"cofactor_resource_id\": \"DB00494\", \"mechanism_of_action\": \"The mechanism of action of entacapone is believed to be through its ability to inhibit COMT in peripheral tissues, altering the plasma pharmacokinetics of levodopa. When entacapone is given in conjunction with levodopa and an aromatic amino acid decarboxylase inhibitor, such as carbidopa, plasma levels of levodopa are greater and more sustained than after administration of levodopa and an aromatic amino acid decarboxylase inhibitor alone. It is believed that at a given frequency of levodopa administration, these more sustained plasma levels of levodopa result in more constant dopaminergic stimulation in the brain, leading to a greater reduction in the manifestations of parkinsonian syndrome.\", \"neighbor_flag\": \"N\", \"resource_name\": \"DrugBank\", \"resource_version\": \"5.1\", \"target_resource_id\": \"P10635\"}, {\"cofactor_in_ch_ikey\": \"HXGBXQDTNZMWGS-RUZDIDTESA-N\", \"cofactor_smiles\": \"NC(=O)C([C@@H]1CCN(CCC2=CC3=C(OCC3)C=C2)C1)(C1=CC=CC=C1)C1=CC=CC=C1\", \"cofactor_chem_comp_id\": \"A1CIW\", \"cofactor_name\": \"Darifenacin\", \"cofactor_resource_id\": \"DB00496\", \"mechanism_of_action\": \"Darifenacin selectively antagonizes the muscarinic M3 receptor. M3 receptors are involved in contraction of human bladder and gastrointestinal smooth muscle, saliva production, and iris sphincter function.\", \"neighbor_flag\": \"N\", \"pubmed_ids\": [16584282], \"resource_name\": \"DrugBank\", \"resource_version\": \"5.1\", \"target_resource_id\": \"P10635\"}, {\"cofactor_in_ch_ikey\": \"BRUQQQPBMZOVGD-XFKAJCMBSA-N\", \"cofactor_smiles\": \"COC1=C2O[C@H]3C(=O)CC[C@@]4(O)[C@H]5CC(C=C1)=C2[C@@]34CCN5C\", \"cofactor_chem_comp_id\": \"OOX\", \"cofactor_name\": \"Oxycodone\", \"cofactor_resource_id\": \"DB00497\", \"mechanism_of_action\": \"The full mechanism of oxycodone is not known.[Label] Under conditions of inflammation or hyperalgesia, opioid receptors in the heart, lungs, liver, gastrointestinal tract, and reproductive system are upregulated and transported to nerve terminals.[A178696] Oxycodone and its active metabolites, noroxycodone, oxymorphone, and noroxymorphone are opioid agonists.[A178639] These compounds passively diffuse across the blood brain barrier or may be actively transported across by an unknown mechanism.[A178696] Oxycodone and its active metabolites can selectively bind to the mu opioid receptor, but also the kappa and delta opioid receptors in the central nervous system and periphery, and induce a G protein coupled receptor signalling pathway.[A178696] Activation of mu opioid receptors inhibits N-type voltage operated calcium channels, inhibiting responses to pain.[A178735]\", \"neighbor_flag\": \"N\", \"pubmed_ids\": [15039299, 26227254, 23555934], \"resource_name\": \"DrugBank\", \"resource_version\": \"5.1\", \"target_resource_id\": \"P10635\"}, {\"cofactor_in_ch_ikey\": \"AQIXAKUUQRKLND-UHFFFAOYSA-N\", \"cofactor_smiles\": \"CN\\\\C(NCCSCC1=C(C)NC=N1)=N\\\\C#N\", \"cofactor_chem_comp_id\": \"SD9\", \"cofactor_name\": \"Cimetidine\", \"cofactor_resource_id\": \"DB00501\", \"mechanism_of_action\": \"Cimetidine binds to an H<sub>2</sub>-receptor located on the basolateral membrane of the gastric parietal cell, blocking histamine effects. This competitive inhibition results in reduced gastric acid secretion and a reduction in gastric volume and acidity.\", \"neighbor_flag\": \"N\", \"pubmed_ids\": [10223772, 8063004, 10664926, 11334262, 31334975], \"resource_name\": \"DrugBank\", \"resource_version\": \"5.1\", \"target_resource_id\": \"P10635\"}, {\"cofactor_in_ch_ikey\": \"LNEPOXFFQSENCJ-UHFFFAOYSA-N\", \"cofactor_smiles\": \"OC1(CCN(CCCC(=O)C2=CC=C(F)C=C2)CC1)C1=CC=C(Cl)C=C1\", \"cofactor_chem_comp_id\": \"GMJ\", \"cofactor_name\": \"Haloperidol\", \"cofactor_resource_id\": \"DB00502\", \"mechanism_of_action\": \"While haloperidol has demonstrated pharmacologic activity at a number of receptors in the brain, it exerts its antipsychotic effect through its strong antagonism of the dopamine receptor (mainly D2), particularly within the mesolimbic and mesocortical systems of the brain. Schizophrenia is theorized to be caused by a hyperdopaminergic state within the limbic system of the brain.[A34360] Dopamine-antagonizing medications such as haloperidol, therefore, are thought to improve psychotic symptoms by halting this over-production of dopamine. The optimal clinical efficacy of antipsychotics is associated with the blockade of approximately 60 % - 80 % of D2 receptors in the brain.[A34360]\\r\\n\\r\\nWhile the exact mechanism is not entirely understood, haloperidol is known to inhibit the effects of dopamine and increase its turnover. Traditional antipsychotics, such as haloperidol, bind more tightly than dopamine itself to the dopamine D2 receptor, with dissociation constants that are lower than that for dopamine.[A4962] It is believed that haloperidol competitively blocks post-synaptic dopamine (D2) receptors in the brain, eliminating dopamine neurotransmission and leading to the relief of delusions and hallucinations that are commonly associated with psychosis. It acts primarily on the D2-receptors and has some effect on 5-HT2 and \\u03b11-receptors, with negligible effects on dopamine  D1-receptors. The drug also exerts some blockade of \\u03b1-adrenergic receptors of the autonomic system.[L2022]\\r\\n\\r\\nAntagonistic activity regulated through dopamine D2 receptors in the chemoreceptive trigger zone (CTZ) of the brain renders its antiemetic activity. Of the three D2-like receptors, only the D2 receptor is blocked by antipsychotic drugs in direct relation to their clinical antipsychotic abilities. \\r\\n\\r\\nClinical brain-imaging findings show that haloperidol remains tightly bound to D2 dopamine receptors in humans undergoing 2 positron emission tomography (PET) scans with a 24h pause in between scans.[A4962] A common adverse effect of this drug is the development of extrapyramidal symptoms (EPS), due to this tight binding of haloperidol to the dopamine D2 receptor.\\r\\n\\r\\nDue to the risk of unpleasant and sometimes lifelong extrapyramidal symptoms, newer antipsychotic medications than haloperidol have been discovered and formulated. Rapid dissociation of drugs from dopamine D2 receptors is a plausible explanation for the improved EPS profile of atypical antipsychotics such as [DB00734]. This is also consistent with the theory of a lower affinity for D2 receptors for these drugs.  As mentioned above, haloperidol binds tightly to the dopamine receptor, potentiating the risk of extrapyramidal symptoms,[A4962] and therefore should only been used when necessary.\", \"neighbor_flag\": \"N\", \"pubmed_ids\": [16910628, 10688273, 10628896], \"resource_name\": \"DrugBank\", \"resource_version\": \"5.1\", \"target_resource_id\": \"P10635\"}, {\"cofactor_in_ch_ikey\": \"NCDNCNXCDXHOMX-XGKFQTDJSA-N\", \"cofactor_smiles\": \"CC(C)[C@H](NC(=O)N(C)CC1=CSC(=N1)C(C)C)C(=O)N[C@H](C[C@H](O)[C@H](CC1=CC=CC=C1)NC(=O)OCC1=CN=CS1)CC1=CC=CC=C1\", \"cofactor_chem_comp_id\": \"RIT\", \"cofactor_name\": \"Ritonavir\", \"cofactor_resource_id\": \"DB00503\", \"mechanism_of_action\": \"Ritonavic inhibits the HIV viral proteinase enzyme that normally cleaves the structural and replicative proteins that arise from major HIV genes, such as *gag* and *pol*. *Gag* encodes proteins involved in the core and the nucleocapsid, while *pol* encodes the the HIV reverse transcriptase, ribonuclease H, integrase, and protease [A19647]. The *pol*-encoded proteins are initially translated in the form of a larger precursoe polypeptide, *gag-pol*, and needs to be cleaved by HIV protease to form other complement proteins [A19647]. Ritonavir prevents the cleavage of the *gag-pol* polyprotein, which results in noninfectious, immature viral particles. Ritonavir is a potent inhibitor of cytochrome P450 CYP3A4 isoenzyme present both in the intestinal tract and liver [A19647]. It is a type II ligand that perfectly fits into the CYP3A4 active site cavity and irreversibly binds to the heme iron via the thiazole nitrogen, which decreases the redox potential of the protein and precludes its reduction with the redox partner, cytochrome P450 reductase [A19648]. Ritonavir may also play a role in limiting cellular transport and efflux of other protease inhibitors via the P-glycoprotein and MRP efflux channels [A19647].\", \"neighbor_flag\": \"N\", \"pubmed_ids\": [9549640, 8960344, 18183034], \"resource_name\": \"DrugBank\", \"resource_version\": \"5.1\", \"target_resource_id\": \"P10635\"}, {\"cofactor_in_ch_ikey\": \"MKXZASYAUGDDCJ-NJAFHUGGSA-N\", \"cofactor_smiles\": \"[H][C@]12CCCC[C@]11CCN(C)[C@H]2CC2=C1C=C(OC)C=C2\", \"cofactor_chem_comp_id\": \"4NQ\", \"cofactor_name\": \"Dextromethorphan\", \"cofactor_resource_id\": \"DB00514\", \"mechanism_of_action\": \"Dextromethorphan is a low-affinity uncompetitive NMDA antagonist and sigma-1 receptor agonist.[L14363] It is also an antagonist of \\u03b13/\\u03b24 nicotinic receptors.[A10589] However, the mechanism by which dextromethorphan's receptor agonism and antagonism translate to a clinical effect is not well understood.[A215397]\", \"neighbor_flag\": \"N\", \"pubmed_ids\": [19817501, 12401364, 11602530, 9690700, 12433797], \"resource_name\": \"DrugBank\", \"resource_version\": \"5.1\", \"target_resource_id\": \"P10635\"}, {\"cofactor_in_ch_ikey\": \"LWAFSWPYPHEXKX-UHFFFAOYSA-N\", \"cofactor_smiles\": \"CC(C)(C)NCC(O)COC1=CC=CC2=C1CCC(=O)N2\", \"cofactor_name\": \"Carteolol\", \"cofactor_resource_id\": \"DB00521\", \"mechanism_of_action\": \"The primary mechanism of the ocular hypotensive action of carteolol in reducing intraocular pressure is most likely a decrease in aqueous humor production. This process is initiated by the non-selective beta1 and beta2 adrenergic receptor blockade.\", \"neighbor_flag\": \"N\", \"pubmed_ids\": [9342584, 9681669], \"resource_name\": \"DrugBank\", \"resource_version\": \"5.1\", \"target_resource_id\": \"P10635\"}, {\"cofactor_in_ch_ikey\": \"ZDXUKAKRHYTAKV-UHFFFAOYSA-N\", \"cofactor_smiles\": \"COC(=O)C1=C(C)NC(C)=C(C1C1=CC(=CC=C1)[N+]([O-])=O)C(=O)OC(C)(C)CN(C)CCC(C1=CC=CC=C1)C1=CC=CC=C1\", \"cofactor_name\": \"Lercanidipine\", \"cofactor_resource_id\": \"DB00528\", \"mechanism_of_action\": \"By deforming the channel, inhibiting ion-control gating mechanisms, and/or interfering with the release of calcium from the sarcoplasmic reticulum, Lercanidipine inhibits the influx of extracellular calcium across the myocardial and vascular smooth muscle cell membranes The decrease in intracellular calcium inhibits the contractile processes of the myocardial smooth muscle cells, causing dilation of the coronary and systemic arteries, increased oxygen delivery to the myocardial tissue, decreased total peripheral resistance, decreased systemic blood pressure, and decreased afterload.\", \"neighbor_flag\": \"N\", \"pubmed_ids\": [11996015], \"resource_name\": \"DrugBank\", \"resource_version\": \"5.1\", \"target_resource_id\": \"P10635\"}, {\"cofactor_in_ch_ikey\": \"AAKJLRGGTJKAMG-UHFFFAOYSA-N\", \"cofactor_smiles\": \"COCCOC1=CC2=C(C=C1OCCOC)C(NC1=CC(=CC=C1)C#C)=NC=N2\", \"cofactor_chem_comp_id\": \"AQ4\", \"cofactor_name\": \"Erlotinib\", \"cofactor_resource_id\": \"DB00530\", \"mechanism_of_action\": \"The mechanism of clinical antitumor action of erlotinib is not fully characterized. Erlotinib inhibits the intracellular phosphorylation of tyrosine kinase associated with the epidermal growth factor receptor (EGFR). Specificity of inhibition with regard to other tyrosine kinase receptors has not been fully characterized. EGFR is expressed on the cell surface of normal cells and cancer cells.\", \"neighbor_flag\": \"N\", \"pubmed_ids\": [19733976, 17575239], \"resource_name\": \"DrugBank\", \"resource_version\": \"5.1\", \"target_resource_id\": \"P10635\"}, {\"cofactor_in_ch_ikey\": \"GMHKMTDVRCWUDX-UHFFFAOYSA-N\", \"cofactor_smiles\": \"CCC1(NC(=O)N(C)C1=O)C1=CC=CC=C1\", \"cofactor_name\": \"Mephenytoin\", \"cofactor_resource_id\": \"DB00532\", \"mechanism_of_action\": \"The mechanism of action of mephenytoin is not definitely known, but extensive research strongly suggests that its main mechanism is to block frequency-, use- and voltage-dependent neuronal sodium channels, and therefore limit repetitive firing of action potentials.\", \"neighbor_flag\": \"N\", \"pubmed_ids\": [9190854], \"resource_name\": \"DrugBank\", \"resource_version\": \"5.1\", \"target_resource_id\": \"P10635\"}, {\"cofactor_in_ch_ikey\": \"PHVGLTMQBUFIQQ-UHFFFAOYSA-N\", \"cofactor_smiles\": \"CNCCC=C1C2=CC=CC=C2CCC2=CC=CC=C12\", \"cofactor_chem_comp_id\": \"21B\", \"cofactor_name\": \"Nortriptyline\", \"cofactor_resource_id\": \"DB00540\", \"mechanism_of_action\": \"Though prescribing information does not identify a specific mechanism of action for nortriptyline[L11878], is believed that nortriptyline either inhibits the reuptake of the neurotransmitter serotonin at the neuronal membrane or acts at the level of the beta-adrenergic receptors. It displays a more selective reuptake inhibition for noradrenaline, which may explain increased symptom improvement after nortriptyline therapy.[T28] Tricyclic antidepressants do not inhibit monoamine oxidase nor do they affect dopamine reuptake.[L11878] As with other tricyclics, nortriptyline displays affinity for other receptors including mACh receptors, histamine receptors, 5-HT receptors, in addition to other receptors.[A18198,A4909,T28] \", \"neighbor_flag\": \"N\", \"pubmed_ids\": [18359012, 19515014, 10354960, 9193876, 28296334], \"resource_name\": \"DrugBank\", \"resource_version\": \"5.1\", \"target_resource_id\": \"P10635\"}, {\"cofactor_in_ch_ikey\": \"QWGDMFLQWFTERH-UHFFFAOYSA-N\", \"cofactor_smiles\": \"ClC1=CC2=C(OC3=CC=CC=C3N=C2N2CCNCC2)C=C1\", \"cofactor_name\": \"Amoxapine\", \"cofactor_resource_id\": \"DB00543\", \"mechanism_of_action\": \"Amoxapine acts by decreasing the reuptake of norepinephrine and serotonin (5-HT).\", \"neighbor_flag\": \"N\", \"pubmed_ids\": [19746353, 24294487, 23218233], \"resource_name\": \"DrugBank\", \"resource_version\": \"5.1\", \"target_resource_id\": \"P10635\"}, {\"cofactor_in_ch_ikey\": \"YEEZWCHGZNKEEK-UHFFFAOYSA-N\", \"cofactor_smiles\": \"COC1=CC(=CC=C1CC1=CN(C)C2=C1C=C(NC(=O)OC1CCCC1)C=C2)C(=O)NS(=O)(=O)C1=CC=CC=C1C\", \"cofactor_chem_comp_id\": \"ZLK\", \"cofactor_name\": \"Zafirlukast\", \"cofactor_resource_id\": \"DB00549\", \"mechanism_of_action\": \"Zafirlukast is a selective and competitive receptor antagonist of leukotriene D4 and E4 (LTD<sub>4</sub> and LTE4), components of slow-reacting substance of anaphylaxis (SRSA). Cysteinyl leukotriene production and receptor occupation have been correlated with the pathophysiology of asthma, including airway edema, smooth muscle constriction, and altered cellular activity associated with the inflammatory process, which contribute to the signs and symptoms of asthma.\", \"neighbor_flag\": \"N\", \"pubmed_ids\": [10870095], \"resource_name\": \"DrugBank\", \"resource_version\": \"5.1\", \"target_resource_id\": \"P10635\"}, {\"cofactor_in_ch_ikey\": \"ZQDWXGKKHFNSQK-UHFFFAOYSA-N\", \"cofactor_smiles\": \"OCCOCCN1CCN(CC1)C(C1=CC=CC=C1)C1=CC=C(Cl)C=C1\", \"cofactor_name\": \"Hydroxyzine\", \"cofactor_resource_id\": \"DB00557\", \"mechanism_of_action\": \"The H<sub>1</sub> histamine receptor is responsible for mediating hypersensitivity and allergic reactions. Exposure to an allergen results in degranulation of mast cells and basophils, which then release histamine and other inflammatory mediators. Histamine binds to, and activates, H<sub>1</sub> receptors, which results in the further release of pro-inflammatory cytokines, such as interleukins, from basophils and mast cells. These downstream effects of histamine binding are responsible for a wide variety of allergic symptoms, such as pruritus, rhinorrhea, and watery eyes.[A1495]\\r\\n\\r\\nHydroxyzine is a potent inverse agonist of histamine H<sub>1</sub>-receptors[A1257] - inverse agonists are agents that are considered to have a \\\"negative efficacy\\\", so rather than simply blocking activity at a receptor they actively dampen its activity.[T707] Inverse agonism at these receptors is responsible for hydroxyzine's efficacy in the treatment of histaminic edema, flare, and pruritus.\\r\\n\\r\\nHydroxyzine is not a cortical depressant, so its sedative properties likely occur at the subcortical level of the CNS.[L9677] These sedative properties allow activity as an anxiolytic. Antiemetic efficacy is likely secondary to activity at off-targets.[A189753]\", \"neighbor_flag\": \"N\", \"pubmed_ids\": [9616188], \"resource_name\": \"DrugBank\", \"resource_version\": \"5.1\", \"target_resource_id\": \"P10635\"}, {\"cofactor_in_ch_ikey\": \"DERZBLKQOCDDDZ-JLHYYAGUSA-N\", \"cofactor_smiles\": \"C(\\\\C=C\\\\C1=CC=CC=C1)N1CCN(CC1)C(C1=CC=CC=C1)C1=CC=CC=C1\", \"cofactor_chem_comp_id\": \"N90\", \"cofactor_name\": \"Cinnarizine\", \"cofactor_resource_id\": \"DB00568\", \"mechanism_of_action\": \"Cinnarizine inhibits contractions of vascular smooth muscle cells by blocking L-type and T-type voltage gated calcium channels. Cinnarizine has also been implicated in binding to dopamine D2 receptors, histamine H1 receptors, and muscarinic acetylcholine receptors. \", \"neighbor_flag\": \"N\", \"pubmed_ids\": [19515014, 8323546], \"resource_name\": \"DrugBank\", \"resource_version\": \"5.1\", \"target_resource_id\": \"P10635\"}, {\"cofactor_in_ch_ikey\": \"JXLYSJRDGCGARV-CFWMRBGOSA-N\", \"cofactor_smiles\": \"[H][C@@]12N(C)C3=CC(OC)=C(C=C3[C@@]11CCN3CC=C[C@@](CC)([C@@H](OC(C)=O)[C@]2(O)C(=O)OC)[C@@]13[H])[C@]1(C[C@@]2([H])CN(C[C@](O)(CC)C2)CCC2=C1NC1=C2C=CC=C1)C(=O)OC\", \"cofactor_chem_comp_id\": \"VLB\", \"cofactor_name\": \"Vinblastine\", \"cofactor_resource_id\": \"DB00570\", \"mechanism_of_action\": \"The antitumor activity of vinblastine is thought to be due primarily to inhibition of mitosis at metaphase through its interaction with tubulin. Vinblastine binds to the microtubular proteins of the mitotic spindle, leading to crystallization of the microtubule and mitotic arrest or cell death.\", \"neighbor_flag\": \"N\", \"pubmed_ids\": [8258200], \"resource_name\": \"DrugBank\", \"resource_version\": \"5.1\", \"target_resource_id\": \"P10635\"}, {\"cofactor_in_ch_ikey\": \"AQHHHDLHHXJYJD-UHFFFAOYSA-N\", \"cofactor_smiles\": \"CC(C)NCC(O)COC1=CC=CC2=C1C=CC=C2\", \"cofactor_name\": \"Propranolol\", \"cofactor_resource_id\": \"DB00571\", \"mechanism_of_action\": \"Propranolol is a nonselective \\u03b2-adrenergic receptor antagonist.[A179902] Blocking of these receptors leads to vasoconstriction, inhibition of angiogenic factors like vascular endothelial growth factor (VEGF) and basic growth factor of fibroblasts (bFGF), induction of apoptosis of endothelial cells, as well as down regulation of the renin-angiotensin-aldosterone system.[A179902]\", \"neighbor_flag\": \"N\", \"pubmed_ids\": [7640150, 11996013, 7895609, 7946944], \"resource_name\": \"DrugBank\", \"resource_version\": \"5.1\", \"target_resource_id\": \"P10635\"}, {\"cofactor_in_ch_ikey\": \"DBGIVFWFUFKIQN-UHFFFAOYSA-N\", \"cofactor_smiles\": \"CCNC(C)CC1=CC=CC(=C1)C(F)(F)F\", \"cofactor_name\": \"Fenfluramine\", \"cofactor_resource_id\": \"DB00574\", \"mechanism_of_action\": \"Dravet syndrome is a complex pediatric encephalopathy characterized by recurrent pharmacoresistant seizures of variable type, delayed development, and in many cases, impairment in speech, language, gait, and other neurocognitive functions.[A214694, A214709, A214712, A214715] Despite substantial variation in presentation and severity, roughly 80% of patients with Dravet syndrome have mutations in the _SCN1A_ gene, which encodes the alpha subunit of a voltage-gated sodium channel (Na<sub>v</sub>1.1).[A214685, A214688, A214691, A214700, A214709, A214715] This channel is predominantly localized in inhibitory GABAergic interneurons as well as in excitatory pyramidal neurons; it is thought that dysfunction of neurotransmission regulation results in the seizures and other corresponding symptoms of Dravet syndrome.[A214700, A214709]\\r\\n\\r\\nVarious _in vitro_ and _in vivo_ studies have demonstrated that fenfluramine is capable of acting as an agonist of multiple serotonin receptors including 5-HT<sub>1A</sub>, 5-HT<sub>1D</sub>, 5-HT<sub>2A</sub>, 5-HT<sub>2B</sub>, and 5-HT<sub>2C</sub>, as well as a \\u03c31 receptor antagonist.[A214682, A214685, A214688, A28641, A214691, A214694, A214697, A214700, L14522] This is at least partly because fenfluramine, as well as its active metabolite norfenfluramine, can act on sodium-dependent serotonin transporters (SERTs) to reverse transport direction and thereby increase extracellular serotonin levels.[A214802, A214807] However, work in animal models of Dravet syndrome suggest that only the modulation of 5-HT<sub>1D</sub>, 5-HT<sub>2C</sub>, \\u03c31, and possibly 5-HT<sub>2A</sub> receptors of fenfluramine result in the anti-epileptiform activity.[A214688, A214691, A214700] Interestingly, 5-HT<sub>2B</sub> receptor agonism, which had previously been associated with cardiac valvulopathy,[A214718, A11906] is not anticipated to have any therapeutic value in Dravet syndrome.[A214700]\\r\\n\\r\\nAlthough the exact mechanism by which stimulation/inhibition of various receptors leads to the observed therapeutic benefit is unclear, it is hypothesized to be two-fold. Stimulation of 5-HT<sub>1D</sub> and 5-HT<sub>2C</sub> may result in increased GABAergic neurotransmission, while \\u03c31 receptor antagonism may help to modulate responses to _N_-methyl-D-aspartate (NMDA).[A214700] \", \"neighbor_flag\": \"N\", \"pubmed_ids\": [9825834, 9690701], \"resource_name\": \"DrugBank\", \"resource_version\": \"5.1\", \"target_resource_id\": \"P10635\"}, {\"cofactor_in_ch_ikey\": \"GJSURZIOUXUGAL-UHFFFAOYSA-N\", \"cofactor_smiles\": \"ClC1=CC=CC(Cl)=C1NC1=NCCN1\", \"cofactor_chem_comp_id\": \"CLU\", \"cofactor_name\": \"Clonidine\", \"cofactor_resource_id\": \"DB00575\", \"mechanism_of_action\": \"Clonidine is primarily an alpha-2 adrenoceptor agonist which causes central hypotensive and anti-arrhythmogenic effects.[A180559] The alpha-2 adrenoceptor is coupled to the G-proteins G<sub>o</sub> and G<sub>i</sub>.[A180559] G<sub>i</sub> inhibits adenylyl cyclase and activates opening of a potassium channel that causes hyperpolarization.[A180559] Clonidine binding to the alpha-2 adrenoceptor causes structural changes in the alpha subunit of the G-protein, reducing its affinity for GDP.[A180559] Magnesium catalyzes the replacement of GDP with GTP.[A180559] The alpha subunit dissociates from the other subunits and associates with an effector.[A180559]\\r\\n\\r\\nThe stimulation of alpha-2 adrenoceptors in the locus coeruleus may be responsible for the hypnotic effects of clonidine as this region of the brain helps regulate wakefulness.[A180559] Clonidine can also decrease transmission of pain signals at the spine.[A180559] Finally clonidine can affect regulators of blood pressure in the ventromedial and rostral-ventrolateral areas of the medulla.[A180559]\", \"neighbor_flag\": \"N\", \"pubmed_ids\": [20570945], \"resource_name\": \"DrugBank\", \"resource_version\": \"5.1\", \"target_resource_id\": \"P10635\"}, {\"cofactor_in_ch_ikey\": \"RUZYUOTYCVRMRZ-UHFFFAOYSA-N\", \"cofactor_smiles\": \"COC1=C(OC)C=C2C(N)=NC(=NC2=C1)N1CCN(CC1)C(=O)C1COC2=CC=CC=C2O1\", \"cofactor_name\": \"Doxazosin\", \"cofactor_resource_id\": \"DB00590\", \"mechanism_of_action\": \"Doxazosin selectively inhibits the postsynaptic alpha-1 receptors on vascular smooth muscle by nonselectively blocking the alpha-1a, alpha-1b, and alpha-1d subtypes[A180688,A4649]. This action on blood vessels decreases systemic peripheral vascular resistance, reducing blood pressure, exerting minimal effects on the heart rate due to its receptor selectivity.[A180649,A180676] Norepinephrine-activated alpha-1 receptors located on the prostate gland and bladder neck normally cause contraction of regional muscular tissue, obstructing urinary flow and contributing to the symptoms of benign prostatic hypertrophy.  Alpha-1 antagonism causes smooth muscle relaxation in the prostate and bladder, effectively relieving urinary frequency, urgency, weak urinary stream, and other unpleasant effects of BPH.[A180655] Recently, doxazosin was found to cause apoptosis of hERG potassium channels in an in vitro setting, possibly contributing to a risk of heart failure with doxazosin use.[A15296,A180697,A180700] \", \"neighbor_flag\": \"N\", \"pubmed_ids\": [24092799], \"resource_name\": \"DrugBank\", \"resource_version\": \"5.1\", \"target_resource_id\": \"P10635\"}, {\"cofactor_in_ch_ikey\": \"GLUUGHFHXGJENI-UHFFFAOYSA-N\", \"cofactor_smiles\": \"C1CNCCN1\", \"cofactor_chem_comp_id\": \"PZE\", \"cofactor_name\": \"Piperazine\", \"cofactor_resource_id\": \"DB00592\", \"mechanism_of_action\": \"Piperazine is a GABA receptor agonist. Piperzine binds directly and selectively to muscle membrane GABA receptors, presumably causing hyperpolarization of nerve endings, resulting in flaccid paralysis of the worm. While the worm is paralyzed, it is dislodged from the intestinal lumen and expelled live from the body by normal intestinal peristalsis.\", \"neighbor_flag\": \"N\", \"pubmed_ids\": [15228152], \"resource_name\": \"DrugBank\", \"resource_version\": \"5.1\", \"target_resource_id\": \"P10635\"}, {\"cofactor_in_ch_ikey\": \"SGUAFYQXFOLMHL-UHFFFAOYSA-N\", \"cofactor_smiles\": \"CC(CCC1=CC=CC=C1)NCC(O)C1=CC(C(N)=O)=C(O)C=C1\", \"cofactor_name\": \"Labetalol\", \"cofactor_resource_id\": \"DB00598\", \"mechanism_of_action\": \"Labetalol non-selectively antagonizes beta-adrenergic receptors, and selectively antagonizes alpha-1-adrenergic receptors.[A181901] Following oral administration, labetalol has 3 times the beta-blocking ability than alpha-blocking ability.[A181901] This increases to 6.9 times following intravenous administration.[A181901] Antagonism of alpha-1-adrenergic receptors leads to vasodilation and decreased vascular resistance.[A181907] This leads to a decrease in blood pressure that is most pronounced while standing.[A181910] Antagonism of beta-1-adrenergic receptors leads to a slight decrease in heart rate.[L7727] Antagonism of beta-2-adrenergic receptors leads to some of the side effects of labetalol such as bronchospasms, however this may be slightly attenuated by alpha-1-adrenergic antagonism.[A181910] Labetalol leads to sustained vasodilation over the long term without a significant decrease in cardiac output or stroke volume, and a minimal decrease in heart rate.[A181907,A181910]\", \"neighbor_flag\": \"N\", \"pubmed_ids\": [1613128, 17542770], \"resource_name\": \"DrugBank\", \"resource_version\": \"5.1\", \"target_resource_id\": \"P10635\"}, {\"cofactor_in_ch_ikey\": \"SPBDXSGPUHCETR-JFUDTMANSA-N\", \"cofactor_smiles\": \"[H][C@@]12OC\\\\C3=C/C=C/[C@H](C)[C@H](O[C@H]4C[C@H](OC)[C@@H](O[C@H]5C[C@H](OC)[C@@H](O)[C@H](C)O5)[C@H](C)O4)\\\\C(C)=C\\\\C[C@]4([H])C[C@@]([H])(C[C@]5(CC[C@H](C)[C@]([H])(O5)C(C)C)O4)OC(=O)[C@]([H])(C=C(C)[C@H]1O)[C@@]23O.[H][C@@]12OC\\\\C3=C/C=C/[C@H](C)[C@H](O[C@H]4C[C@H](OC)[C@@H](O[C@H]5C[C@H](OC)[C@@H](O)[C@H](C)O5)[C@H](C)O4)\\\\C(C)=C\\\\C[C@]4([H])C[C@@]([H])(C[C@]5(CC[C@H](C)[C@]([H])(O5)[C@@H](C)CC)O4)OC(=O)[C@]([H])(C=C(C)[C@H]1O)[C@@]23O\", \"cofactor_name\": \"Ivermectin\", \"cofactor_resource_id\": \"DB00602\", \"mechanism_of_action\": \"Ivermectin binds selectively and with high affinity to glutamate-gated chloride ion channels in invertebrate muscle and nerve cells of the microfilaria. This binding causes an increase in the permeability of the cell membrane to chloride ions and results in hyperpolarization of the cell, leading to paralysis and death of the parasite. Ivermectin also is believed to act as an agonist of the neurotransmitter gamma-aminobutyric acid (GABA), thereby disrupting GABA-mediated central nervous system (CNS) neurosynaptic transmission. Ivermectin may also impair normal intrauterine development of _O. volvulus_ microfilariae and may inhibit their release from the uteri of gravid female worms.\", \"neighbor_flag\": \"N\", \"resource_name\": \"DrugBank\", \"resource_version\": \"5.1\", \"target_resource_id\": \"P10635\"}, {\"cofactor_in_ch_ikey\": \"DCSUBABJRXZOMT-IRLDBZIGSA-N\", \"cofactor_smiles\": \"CO[C@H]1CN(CCCOC2=CC=C(F)C=C2)CC[C@H]1NC(=O)C1=CC(Cl)=C(N)C=C1OC\", \"cofactor_name\": \"Cisapride\", \"cofactor_resource_id\": \"DB00604\", \"mechanism_of_action\": \"Cisapride acts through the stimulation of the serotonin 5-HT<sub>4</sub> receptors which increases acetylcholine release in the enteric nervous system (specifically the myenteric plexus). This results in increased tone and amplitude of gastric (especially antral) contractions, relaxation of the pyloric sphincter and the duodenal bulb, and increased peristalsis of the duodenum and jejunum resulting in accelerated gastric emptying and intestinal transit.\", \"neighbor_flag\": \"N\", \"pubmed_ids\": [10859153], \"resource_name\": \"DrugBank\", \"resource_version\": \"5.1\", \"target_resource_id\": \"P10635\"}, {\"cofactor_in_ch_ikey\": \"WHTVZRBIWZFKQO-UHFFFAOYSA-N\", \"cofactor_smiles\": \"CCN(CC)CCCC(C)NC1=CC=NC2=CC(Cl)=CC=C12\", \"cofactor_chem_comp_id\": \"CLQ\", \"cofactor_name\": \"Chloroquine\", \"cofactor_resource_id\": \"DB00608\", \"mechanism_of_action\": \"Chloroquine inhibits the action of heme polymerase in malarial trophozoites, preventing the conversion of heme to hemazoin.[A191700,A183080,A191781] _Plasmodium_ species continue to accumulate toxic heme, killing the parasite.[A191700]\\r\\n\\r\\nChloroquine passively diffuses through cell membranes and into endosomes, lysosomes, and Golgi vesicles; where it becomes protonated, trapping the chloroquine in the organelle and raising the surrounding pH.[A191676,A191628] The raised pH in endosomes, prevent virus particles from utilizing their activity for fusion and entry into the cell.[A191625]\\r\\n\\r\\nChloroquine does not affect the level of ACE2 expression on cell surfaces, but inhibits terminal glycosylation of ACE2, the receptor that SARS-CoV and SARS-CoV-2 target for cell entry.[A191628,A191625] ACE2 that is not in the glycosylated state may less efficiently interact with the SARS-CoV-2 spike protein, further inhibiting viral entry.[A191625]\", \"neighbor_flag\": \"N\", \"pubmed_ids\": [12756207, 9764961, 10896408], \"resource_name\": \"DrugBank\", \"resource_version\": \"5.1\", \"target_resource_id\": \"P10635\"}, {\"cofactor_in_ch_ikey\": \"OVCDSSHSILBFBN-UHFFFAOYSA-N\", \"cofactor_smiles\": \"CCN(CC)CC1=C(O)C=CC(NC2=C3C=CC(Cl)=CC3=NC=C2)=C1\", \"cofactor_chem_comp_id\": \"CQA\", \"cofactor_name\": \"Amodiaquine\", \"cofactor_resource_id\": \"DB00613\", \"mechanism_of_action\": \"The mechanism of plasmodicidal action of amodiaquine is not completely certain. Like other quinoline derivatives, it is thought to inhibit heme polymerase activity. This results in accumulation of free heme, which is toxic to the parasites. The drug binds the free heme preventing the parasite from converting it to a form less toxic. This drug-heme complex is toxic and disrupts membrane function.\", \"neighbor_flag\": \"N\", \"pubmed_ids\": [16783563, 11124226], \"resource_name\": \"DrugBank\", \"resource_version\": \"5.1\", \"target_resource_id\": \"P10635\"}, {\"cofactor_in_ch_ikey\": \"KTUFNOKKBVMGRW-UHFFFAOYSA-N\", \"cofactor_smiles\": \"CN1CCN(CC2=CC=C(C=C2)C(=O)NC2=CC(NC3=NC=CC(=N3)C3=CN=CC=C3)=C(C)C=C2)CC1\", \"cofactor_chem_comp_id\": \"STI\", \"cofactor_name\": \"Imatinib\", \"cofactor_resource_id\": \"DB00619\", \"mechanism_of_action\": \"Imatinib mesylate is a protein-tyrosine kinase inhibitor that inhibits the BCR-ABL tyrosine kinase, the constitutively active tyrosine kinase created by the Philadelphia chromosome abnormality in CML.[L42080]Although the function of normal BCR is still unclear, ABL activation is overexpressed in various tumors and is heavily implicated in cancer cells growth and survival.[A249305,A249310] Imatinib inhibits the BCR-ABL protein by binding to the ATP pocket in the active site, thus preventing downstream phosphorylation of target protein.[A249305]\\r\\n\\r\\nImatinib is also an inhibitor of the receptor tyrosine kinases for platelet-derived growth factor (PDGF) and stem cell factor\\r\\n(SCF), c-Kit, and inhibits PDGF- and SCF-mediated cellular events. In vitro, imatinib inhibits proliferation and induces\\r\\napoptosis in GIST cells, which express an activating c-Kit mutation.[L42080]\", \"neighbor_flag\": \"N\", \"pubmed_ids\": [19515014], \"resource_name\": \"DrugBank\", \"resource_version\": \"5.1\", \"target_resource_id\": \"P10635\"}, {\"cofactor_in_ch_ikey\": \"ZBBHBTPTTSWHBA-UHFFFAOYSA-N\", \"cofactor_smiles\": \"COC(=O)C1=C(C)NC(C)=C(C1C1=CC(=CC=C1)[N+]([O-])=O)C(=O)OCCN(C)CC1=CC=CC=C1\", \"cofactor_name\": \"Nicardipine\", \"cofactor_resource_id\": \"DB00622\", \"mechanism_of_action\": \"By deforming the channel, inhibiting ion-control gating mechanisms, and/or interfering with the release of calcium from the sarcoplasmic reticulum, nicardipine inhibits the influx of extracellular calcium across the myocardial and vascular smooth muscle cell membranes The decrease in intracellular calcium inhibits the contractile processes of the myocardial smooth muscle cells, causing dilation of the coronary and systemic arteries, increased oxygen delivery to the myocardial tissue, decreased total peripheral resistance, decreased systemic blood pressure, and decreased afterload.\", \"neighbor_flag\": \"N\", \"pubmed_ids\": [15863898, 10805063], \"resource_name\": \"DrugBank\", \"resource_version\": \"5.1\", \"target_resource_id\": \"P10635\"}, {\"cofactor_in_ch_ikey\": \"PLDUPXSUYLZYBN-UHFFFAOYSA-N\", \"cofactor_smiles\": \"OCCN1CCN(CCCN2C3=CC=CC=C3SC3=C2C=C(C=C3)C(F)(F)F)CC1\", \"cofactor_name\": \"Fluphenazine\", \"cofactor_resource_id\": \"DB00623\", \"mechanism_of_action\": \"Fluphenazine blocks postsynaptic mesolimbic dopaminergic D1 and D2 receptors in the brain; depresses the release of hypothalamic and hypophyseal hormones and is believed to depress the reticular activating system thus affecting basal metabolism, body temperature, wakefulness, vasomotor tone, and emesis.\", \"neighbor_flag\": \"N\", \"pubmed_ids\": [10460810], \"resource_name\": \"DrugBank\", \"resource_version\": \"5.1\", \"target_resource_id\": \"P10635\"}, {\"cofactor_in_ch_ikey\": \"XPOQHMRABVBWPR-ZDUSSCGKSA-N\", \"cofactor_smiles\": \"FC(F)(F)[C@]1(OC(=O)NC2=C1C=C(Cl)C=C2)C#CC1CC1\", \"cofactor_chem_comp_id\": \"EFZ\", \"cofactor_name\": \"Efavirenz\", \"cofactor_resource_id\": \"DB00625\", \"mechanism_of_action\": \"Similar to zidovudine, efavirenz inhibits the activity of viral RNA-directed DNA polymerase (i.e., reverse transcriptase). Antiviral activity of efavirenz is dependent on intracellular conversion to the active triphosphorylated form. The rate of efavirenz phosphorylation varies, depending on cell type. It is believed that inhibition of reverse transcriptase interferes with the generation of DNA copies of viral RNA, which, in turn, are necessary for synthesis of new virions. Intracellular enzymes subsequently eliminate the HIV particle that previously had been uncoated, and left unprotected, during entry into the host cell. Thus, reverse transcriptase inhibitors are virustatic and do not eliminate HIV from the body. Even though human DNA polymerase is less susceptible to the pharmacologic effects of triphosphorylated efavirenz, this action may nevertheless account for some of the drug's toxicity.\", \"neighbor_flag\": \"N\", \"pubmed_ids\": [11225565, 23385314], \"resource_name\": \"DrugBank\", \"resource_version\": \"5.1\", \"target_resource_id\": \"P10635\"}, {\"cofactor_in_ch_ikey\": \"PVNIIMVLHYAWGP-UHFFFAOYSA-N\", \"cofactor_smiles\": \"OC(=O)C1=CN=CC=C1\", \"cofactor_chem_comp_id\": \"NIO\", \"cofactor_name\": \"Niacin\", \"cofactor_resource_id\": \"DB00627\", \"mechanism_of_action\": \"Niacin performs a number of functions in the body and so has many mechanisms, not all of which have been fully described.[A19555] Niacin can decrease lipids and apolipoprotein B (apo B)-containing lipoproteins by modulating triglyceride synthesis in the liver, which degrades apo B, or by modulating lipolysis in adipose tissue.[A19555]\\r\\n\\r\\nNiacin inhibits hepatocyte diacylglycerol acyltransferase-2.[A19555] This action prevents the final step of triglyceride synthesis in hepatocytes, limiting available triglycerides for very low density lipoproteins (VLDL).[A19555] This activity also leads to intracellular degradation of apo B and decreased production of low density lipoproteins, the catabolic product of VLDL.[A19555]\\r\\n\\r\\nNiacin also inhibits a high density lipoprotein (HDL) catabolism receptor, which increases the levels and half life of HDL.[A19555]\", \"neighbor_flag\": \"N\", \"pubmed_ids\": [15081432], \"resource_name\": \"DrugBank\", \"resource_version\": \"5.1\", \"target_resource_id\": \"P10635\"}, {\"cofactor_in_ch_ikey\": \"CUHVIMMYOGQXCV-NSHDSACASA-N\", \"cofactor_smiles\": \"C[C@H](C1=CNC=N1)C1=C(C)C(C)=CC=C1\", \"cofactor_chem_comp_id\": \"CZX\", \"cofactor_name\": \"Dexmedetomidine\", \"cofactor_resource_id\": \"DB00633\", \"mechanism_of_action\": \"Dexmedetomidine is a specific and selective alpha-2 adrenoceptor agonist. By binding to the presynaptic alpha-2 adrenoceptors, it inhibits the release if norepinephrine, therefore, terminate the propagation of pain signals. Activation of the postsynaptic alpha-2 adrenoceptors inhibits the sympathetic activity decreases blood pressure and heart rate.\", \"neighbor_flag\": \"N\", \"pubmed_ids\": [9152607], \"resource_name\": \"DrugBank\", \"resource_version\": \"5.1\", \"target_resource_id\": \"P10635\"}, {\"cofactor_in_ch_ikey\": \"GXDALQBWZGODGZ-UHFFFAOYSA-N\", \"cofactor_smiles\": \"COC1=CC=C(CCN2CCC(CC2)NC2=NC3=CC=CC=C3N2CC2=CC=C(F)C=C2)C=C1\", \"cofactor_chem_comp_id\": \"XB7\", \"cofactor_name\": \"Astemizole\", \"cofactor_resource_id\": \"DB00637\", \"mechanism_of_action\": \"Astemizole competes with histamine for binding at H<sub>1</sub>-receptor sites in the GI tract, uterus, large blood vessels, and bronchial muscle. This reversible binding of astemizole to H<sub>1</sub>-receptors suppresses the formation of edema, flare, and pruritus resulting from histaminic activity. As the drug does not readily cross the blood-brain barrier and preferentially binds at H1 receptors in the peripehery rather than within the brain, CNS depression is minimal. Astemizole may also act on H<sub>3</sub>-receptors, producing adverse effects.\", \"neighbor_flag\": \"N\", \"pubmed_ids\": [11259984], \"resource_name\": \"DrugBank\", \"resource_version\": \"5.1\", \"target_resource_id\": \"P10635\"}, {\"cofactor_in_ch_ikey\": \"RYMZZMVNJRMUDD-HGQWONQESA-N\", \"cofactor_smiles\": \"[H][C@]12[C@H](C[C@@H](C)C=C1C=C[C@H](C)[C@@H]2CC[C@@H]1C[C@@H](O)CC(=O)O1)OC(=O)C(C)(C)CC\", \"cofactor_chem_comp_id\": \"A1BYZ\", \"cofactor_name\": \"Simvastatin\", \"cofactor_resource_id\": \"DB00641\", \"mechanism_of_action\": \"Simvastatin is a prodrug in which the 6-membered lactone ring of simvastatin is hydrolyzed <i>in vivo</i> to generate the beta,delta-dihydroxy acid, an active metabolite structurally similar to HMG-CoA (hydroxymethylglutaryl CoA). Once hydrolyzed, simvastatin competes with HMG-CoA for HMG-CoA reductase, a hepatic microsomal enzyme, which catalyzes the conversion of HMG-CoA to mevalonate, an early rate-limiting step in cholesterol biosynthesis.[A181421] Simvastatin acts primarily in the liver, where decreased hepatic cholesterol concentrations stimulate the upregulation of hepatic low density lipoprotein (LDL) receptors which increases hepatic uptake of LDL. Simvastatin also inhibits hepatic synthesis of very low density lipoprotein (VLDL).[F4655, F4658] The overall effect is a decrease in plasma LDL and VLDL. \\r\\n\\r\\nAt therapeutic doses, the HMG-CoA enzyme is not completely blocked by simvastatin activity, thereby allowing biologically necessary amounts of mevalonate to remain available. As mevalonate is an early step in the biosynthetic pathway for cholesterol, therapy with simvastatin would also not be expected to cause any accumulation of potentially toxic sterols. In addition, HMG-CoA is metabolized readily back to acetyl-CoA, which participates in many biosynthetic processes in the body.[F4658]\\r\\n\\r\\nIn vitro and in vivo animal studies also demonstrate that simvastatin exerts vasculoprotective effects independent of its lipid-lowering properties, also known as the pleiotropic effects of statins.[A181424] This includes improvement in endothelial function, enhanced stability of atherosclerotic plaques, reduced oxidative stress and inflammation, and inhibition of the thrombogenic response.\\r\\n\\r\\nStatins have also been found to bind allosterically to \\u03b22 integrin function-associated antigen-1 (LFA-1), which plays an important role in leukocyte trafficking and in T cell activation.[A181559]\", \"neighbor_flag\": \"N\", \"pubmed_ids\": [15285699], \"resource_name\": \"DrugBank\", \"resource_version\": \"5.1\", \"target_resource_id\": \"P10635\"}, {\"cofactor_in_ch_ikey\": \"XLMALTXPSGQGBX-GCJKJVERSA-N\", \"cofactor_smiles\": \"CCC(=O)O[C@@](CC1=CC=CC=C1)([C@H](C)CN(C)C)C1=CC=CC=C1\", \"cofactor_name\": \"Dextropropoxyphene\", \"cofactor_resource_id\": \"DB00647\", \"mechanism_of_action\": \"Propoxyphene acts as a weak agonist at OP1, OP2, and OP3 opiate receptors within the central nervous system (CNS). Propoxyphene primarily affects OP3 receptors, which are coupled with G-protein receptors and function as modulators, both positive and negative, of synaptic transmission via G-proteins that activate effector proteins. Binding of the opiate stimulates the exchange of GTP for GDP on the G-protein complex. As the effector system is adenylate cyclase and cAMP located at the inner surface of the plasma membrane, opioids decrease intracellular cAMP by inhibiting adenylate cyclase. Subsequently, the release of nociceptive neurotransmitters such as substance P, GABA, dopamine, acetylcholine, and noradrenaline is inhibited. Opioids such as propoxyphene also inhibit the release of vasopressin, somatostatin, insulin, and glucagon. Opioids close N-type voltage-operated calcium channels (OP2-receptor agonist) and open calcium-dependent inwardly rectifying potassium channels (OP3 and OP1 receptor agonist). This results in hyperpolarization and reduced neuronal excitability.\", \"neighbor_flag\": \"N\", \"pubmed_ids\": [9143866, 7826826, 2349617], \"resource_name\": \"DrugBank\", \"resource_version\": \"5.1\", \"target_resource_id\": \"P10635\"}, {\"cofactor_in_ch_ikey\": \"PHLBKPHSAVXXEF-UHFFFAOYSA-N\", \"cofactor_smiles\": \"ClC1=CC=CC(=C1)N1CCN(CCCN2N=C3C=CC=CN3C2=O)CC1\", \"cofactor_name\": \"Trazodone\", \"cofactor_resource_id\": \"DB00656\", \"mechanism_of_action\": \"The mechanism of action of trazodone is not fully understood, however, it is known to inhibit the reuptake of serotonin and block both histamine and alpha-1-adrenergic receptors.[T646]  Despite the fact that trazodone is frequently considered a selective serotonin reuptake inhibitor, several reports have shown that other mechanisms including antagonism at serotonin 5-HT1a, 5-HT1c, and 5-HT2 receptor subtypes may occur.[A181177,T646] The strongest antagonism of trazodone is reported to occur at the serotonin \\r\\n5-HT21c receptors, preventing serotonin uptake.[A985] In addition to acting on serotonin receptors, trazodone has been shown to inhibit serotonin transporters.[A4334,A181457]  The antidepressant effects of trazodone result from the inhibition of receptor uptake, which normally decreases circulating neurotransmitters, contributing to depressive symptoms.[A181186,A175840] \", \"neighbor_flag\": \"N\", \"pubmed_ids\": [18238857, 27643409, 20373668, 22294487, 26518198], \"resource_name\": \"DrugBank\", \"resource_version\": \"5.1\", \"target_resource_id\": \"P10635\"}, {\"cofactor_in_ch_ikey\": \"SGTNSNPWRIOYBX-UHFFFAOYSA-N\", \"cofactor_smiles\": \"COC1=C(OC)C=C(CCN(C)CCCC(C#N)(C(C)C)C2=CC(OC)=C(OC)C=C2)C=C1\", \"cofactor_name\": \"Verapamil\", \"cofactor_resource_id\": \"DB00661\", \"mechanism_of_action\": \"Verapamil inhibits L-type calcium channels by binding to a specific area of their alpha-1 subunit,[L10478]Cav1.2, which is highly expressed on L-type calcium channels in vascular smooth muscle and myocardial tissue where these channels are responsible for the control of peripheral vascular resistance and heart contractility.[A175396] Calcium influx through these channels allows for the propagation of action potentials necessary for the contraction of muscle tissue and the heart's electrical pacemaker activity. Verapamil binds to these channels in a voltage- and frequency-dependent manner, meaning affinity is increased 1) as vascular smooth muscle membrane potential is reduced, and 2) with excessive depolarizing stimulus.[L10478] \\r\\n\\r\\nVerapamil's mechanism of action in the treatment of angina and hypertension is likely due to the mechanism described above. Inhibition of calcium influx prevents the contraction of vascular smooth muscle, causing relaxation/dilation of blood vessels throughout the peripheral circulation - this lowers systemic vascular resistance (i.e. afterload) and thus blood pressure. This reduction in vascular resistance also reduces the force against which the heart must push, decreasing myocardial energy consumption and oxygen requirements and thus alleviating angina.[L8791]\\r\\n\\r\\nElectrical activity through the AV node is responsible for determining heart rate, and this activity is dependent upon calcium influx through L-type calcium channels. By inhibiting these channels and decreasing the influx of calcium, verapamil prolongs the refractory period of the AV node and slows conduction, thereby slowing and controlling the heart rate in patients with arrhythmia.[L8791]\\r\\n\\r\\nVerapamil's mechanism of action in the treatment of cluster headaches is unclear, but is thought to result from an effect on other calcium channels (e.g. N-, P-, Q-, or T-type).[A13983]\\r\\n\\r\\nVerapamil is known to interact with other targets, including other calcium channels,[A188490,A13984,A188502,A15331] potassium channels,[A188496,A13985,A13983] and adrenergic receptors.[A20291,A31755]\", \"neighbor_flag\": \"N\", \"pubmed_ids\": [11996015], \"resource_name\": \"DrugBank\", \"resource_version\": \"5.1\", \"target_resource_id\": \"P10635\"}, {\"cofactor_in_ch_ikey\": \"ASUTZQLVASHGKV-JDFRZJQESA-N\", \"cofactor_smiles\": \"[H][C@]12C[C@@H](O)C=C[C@]11CCN(C)CC3=C1C(O2)=C(OC)C=C3\", \"cofactor_chem_comp_id\": \"GNT\", \"cofactor_name\": \"Galantamine\", \"cofactor_resource_id\": \"DB00674\", \"mechanism_of_action\": \"Alzheimer\\u2019s disease is characterized by progressive, irreversible degeneration of acetylcholine-producing neurons, cognitive impairment, and the accumulation of neurofibrillary tangles and amyloid plaques.[A182993,A203558] The cholinergic system plays a critical role in memory, alongside other important neural functions such as attention, learning, stress response, wakefulness and sleep, and sensory information. Studies show that acetylcholine (ACh) is involved in the modulation of acquisition, encoding, consolidation, reconsolidation, extinction, and retrieval of memory. The gradual loss of cholinergic neurons in Alzheimer\\u2019s disease (AD) may, therefore, contribute to the memory loss exhibited by AD patients.[A203558] \\r\\n\\r\\nAcetylcholinesterase is secreted by cholinergic neurons to rapidly hydrolyze ACh at the synaptic cleft to release acetate and choline. Choline is later recycled back into the presynaptic cholinergic neuron via reuptake by the high-affinity choline transporter. There is some evidence demonstrating the potential involvement of the acetylcholinesterase enzyme in the formation of amyloid fibrils.[A203558] Galantamine competitively and reversibly inhibits the anticholinesterase enzyme in the CNS (namely in the frontal cortex and hippocampal regions) [A1022] by binding to the choline-binding site and acyl-binding pocket of the enzyme active site.[A1019] By blocking the breakdown of ACh, galantamine enhances ACh levels in the synaptic cleft.[A203558] \\r\\n\\r\\nNicotinic acetylcholine receptors (nAChR) in the CNS are mostly expressed at the presynaptic neuronal membrane to control the release of multiple neurotransmitters, such as ACh, glutamate, GABA, dopamine, serotonin, norepinephrine.[A182993,A203558] Agonists of nAChRs improve performance in cognitive tasks, while antagonists of nAChR impair cognitive processes.[A203558] Some studies show a decrease in the expression and activity of nAChRs in patients with AD, which may explain the reduction in central cholinergic neurotransmission in these patients.[A1022] Galantamine binds to nAChRs at the allosteric site,[A182993,A203591] leading to a conformational change of the receptor, increased ACh release, and increased activity of neighbouring glutaminergic and serotoninergic neurons.[A182993] The modulation of nAChRs facilitates both excitatory and inhibitory cholinergic transmissions in brain tissues and increases receptor sensitivity. The modulated release of other neurotransmitters by galantamine may also contribute to the upregulation of nAChRs and amelioration of behavioural symptoms in AD.[A182993]\", \"neighbor_flag\": \"N\", \"pubmed_ids\": [12162759, 14674789, 12177686, 12751272], \"resource_name\": \"DrugBank\", \"resource_version\": \"5.1\", \"target_resource_id\": \"P10635\"}, {\"cofactor_in_ch_ikey\": \"NKANXQFJJICGDU-QPLCGJKRSA-N\", \"cofactor_smiles\": \"CC\\\\C(=C(/C1=CC=CC=C1)C1=CC=C(OCCN(C)C)C=C1)C1=CC=CC=C1\", \"cofactor_chem_comp_id\": \"CTX\", \"cofactor_name\": \"Tamoxifen\", \"cofactor_resource_id\": \"DB00675\", \"mechanism_of_action\": \"Tamoxifen competitively inhibits estrogen binding to its receptor, which is critical for it's activity in breast cancer cells.[A1025] Tamoxifen leads to a decrease in tumor growth factor \\u03b1 and insulin-like growth factor 1, and an increase in sex hormone binding globulin.[A1025] The increase in sex hormon binding globulin limits the amount of freely available estradiol.[A1025] These changes reduce levels of factors that stimulate tumor growth.[A1025]\\r\\n\\r\\nTamoxifen has also been shown to induce apoptosis in estrogen receptor positive cells.[A182195] This action is thought to be the result of inhibition of protein kinase C, which prevents DNA synthesis.[A182195] Alternate theories for the apoptotic effect of tamoxifen comes from the approximately 3 fold increase in intracellular and mitochondrial calcium ion levels after administration or the induction of tumor growth factor \\u03b2.[A182195]\", \"neighbor_flag\": \"N\", \"pubmed_ids\": [20425602, 20120834, 20120835, 15159443, 12124303], \"resource_name\": \"DrugBank\", \"resource_version\": \"5.1\", \"target_resource_id\": \"P10635\"}, {\"cofactor_in_ch_ikey\": \"KLBQZWRITKRQQV-UHFFFAOYSA-N\", \"cofactor_smiles\": \"CSC1=CC2=C(SC3=CC=CC=C3N2CCC2CCCCN2C)C=C1\", \"cofactor_name\": \"Thioridazine\", \"cofactor_resource_id\": \"DB00679\", \"mechanism_of_action\": \"Thioridazine blocks postsynaptic mesolimbic dopaminergic D1 and D2 receptors in the brain; blocks alpha-adrenergic effect, depresses the release of hypothalamic and hypophyseal hormones and is believed to depress the reticular activating system thus affecting basal metabolism, body temperature, wakefulness, vasomotor tone, and emesis.\", \"neighbor_flag\": \"N\", \"pubmed_ids\": [10688273, 9352572], \"resource_name\": \"DrugBank\", \"resource_version\": \"5.1\", \"target_resource_id\": \"P10635\"}, {\"cofactor_in_ch_ikey\": \"YSEXMKHXIOCEJA-FVFQAYNVSA-N\", \"cofactor_smiles\": \"[H][C@@]12CC3=CN(C)C4=CC=CC(=C34)[C@]1(C[C@@H](COC(=O)C1=CN=CC(Br)=C1)CN2C)OC\", \"cofactor_name\": \"Nicergoline\", \"cofactor_resource_id\": \"DB00699\", \"mechanism_of_action\": \"Nicergoline acts by inhibiting the postsynaptic alpha(1)-adrenoceptors on vascular smooth muscle. This inhibits the vasoconstrictor effect of circulating and locally released catecholamines (epinephrine and norepinephrine), resulting in peripheral vasodilation. Therefore the mechanism of Nicergoline is to increase vascular circulation in the brain, thereby enhancing the transmission of nerve signals across the nerve fibres, which secrete acetylcholine as a neural transmitter.\", \"neighbor_flag\": \"N\", \"pubmed_ids\": [8971425, 25243157], \"resource_name\": \"DrugBank\", \"resource_version\": \"5.1\", \"target_resource_id\": \"P10635\"}, {\"cofactor_in_ch_ikey\": \"YMARZQAQMVYCKC-OEMFJLHTSA-N\", \"cofactor_smiles\": \"CC(C)CN(C[C@@H](O)[C@H](CC1=CC=CC=C1)NC(=O)O[C@H]1CCOC1)S(=O)(=O)C1=CC=C(N)C=C1\", \"cofactor_chem_comp_id\": \"478\", \"cofactor_name\": \"Amprenavir\", \"cofactor_resource_id\": \"DB00701\", \"mechanism_of_action\": \"Amprenavir inhibits the HIV viral proteinase enzyme which prevents cleavage of the gag-pol polyprotein, resulting in noninfectious, immature viral particles.\", \"neighbor_flag\": \"N\", \"pubmed_ids\": [10868554], \"resource_name\": \"DrugBank\", \"resource_version\": \"5.1\", \"target_resource_id\": \"P10635\"}, {\"cofactor_in_ch_ikey\": \"WHBIGIKBNXZKFE-UHFFFAOYSA-N\", \"cofactor_smiles\": \"CC(C)NC1=C(N=CC=C1)N1CCN(CC1)C(=O)C1=CC2=C(N1)C=CC(NS(C)(=O)=O)=C2\", \"cofactor_chem_comp_id\": \"SPP\", \"cofactor_name\": \"Delavirdine\", \"cofactor_resource_id\": \"DB00705\", \"mechanism_of_action\": \"Delavirdine binds directly to viral reverse transcriptase (RT) and blocks the RNA-dependent and DNA-dependent DNA polymerase activities by disrupting the enzyme's catalytic site.\", \"neighbor_flag\": \"N\", \"pubmed_ids\": [11124228, 9660845], \"resource_name\": \"DrugBank\", \"resource_version\": \"5.1\", \"target_resource_id\": \"P10635\"}, {\"cofactor_in_ch_ikey\": \"DRHKJLXJIQTDTD-OAHLLOKOSA-N\", \"cofactor_smiles\": \"CCOC1=CC=CC=C1OCCN[C@H](C)CC1=CC(=C(OC)C=C1)S(N)(=O)=O\", \"cofactor_chem_comp_id\": \"JGX\", \"cofactor_name\": \"Tamsulosin\", \"cofactor_resource_id\": \"DB00706\", \"mechanism_of_action\": \"Tamsulosin is a blocker of alpha-1A and alpha-1D adrenoceptors.[Label,A1078] About 70% of the alpha-1 adrenoceptors in the prostate are of the alpha-1A subtype.[Label] By blocking these adrenoceptors, smooth muscle in the prostate is relaxed and urinary flow is improved.[Label] The blocking of alpha-1D adrenoceptors relaxes the detrusor muscles of the bladder which prevents storage symptoms.[A1078] The specificity of tamsulosin focuses the effects to the target area while minimizing effects in other areas.[Label]\", \"neighbor_flag\": \"N\", \"pubmed_ids\": [9849639], \"resource_name\": \"DrugBank\", \"resource_version\": \"5.1\", \"target_resource_id\": \"P10635\"}, {\"cofactor_in_ch_ikey\": \"AHOUBRCZNHFOSL-YOEHRIQHSA-N\", \"cofactor_smiles\": \"FC1=CC=C(C=C1)[C@@H]1CCNC[C@H]1COC1=CC2=C(OCO2)C=C1\", \"cofactor_chem_comp_id\": \"8PR\", \"cofactor_name\": \"Paroxetine\", \"cofactor_resource_id\": \"DB00715\", \"mechanism_of_action\": \"Paroxetine enhances serotonergic activity via the inhibition presynaptic reuptake of serotonin by the serotonin (SERT) receptor.[A5492,A181772] This inhibition raises the level of serotonin in the synaptic cleft, relieving various symptoms. This drug has been demonstrated to be a stronger inhibitor of serotonin reuptake than other members of the same drug class, including [Citalopram], [Fluoxetine], and [Fluvoxamine].[A31914] The mechanism of action of paroxetine in relieving the vasomotor symptoms of menopause is unknown, according to the Brisdelle prescribing information[L7703], but may occur due to its effects on thermoregulation.[A181973]\\r\\n\\r\\nParoxetine shows a clinically insignificant affinity for adrenergic alpha-1 and alpha-2 receptors and \\u03b2-adrenergic receptors, dopamine D1 and D2 receptors, histamine H1 receptors and serotonin 5-HT1A, 5-HT2A and 5-HT2C receptors.[A31914] This drug shows some affinity for muscarinic cholinergic receptors and 5-H2B receptors.[A181829,A181847] The delayed onset of paroxetine therapeutic effects may be explained by the initial paroxetine actions on the 5-HT neurons.  In rats, paroxetine activates 5-HT1A receptors when it is first administered, inhibiting the stimulation of the  5-HT neurons and subsequent release of serotonin at the synaptic cleft.[A31914]\", \"neighbor_flag\": \"N\", \"pubmed_ids\": [18537577, 8968657, 9333110, 25943764, 25974703], \"resource_name\": \"DrugBank\", \"resource_version\": \"5.1\", \"target_resource_id\": \"P10635\"}, {\"cofactor_in_ch_ikey\": \"ZSCDBOWYZJWBIY-UHFFFAOYSA-N\", \"cofactor_smiles\": \"CC(CN(C)C)CN1C2=CC=CC=C2CCC2=CC=CC=C12\", \"cofactor_name\": \"Trimipramine\", \"cofactor_resource_id\": \"DB00726\", \"mechanism_of_action\": \"Trimipramine's mechanism of action differs from other tricyclic antidepressants. Trimipramine acts by decreasing the reuptake of norepinephrine and serotonin (5-HT).\", \"neighbor_flag\": \"N\", \"pubmed_ids\": [8968657, 8272570, 14520122], \"resource_name\": \"DrugBank\", \"resource_version\": \"5.1\", \"target_resource_id\": \"P10635\"}, {\"cofactor_in_ch_ikey\": \"OELFLUMRDSZNSF-BRWVUGGUSA-N\", \"cofactor_smiles\": \"CC(C)[C@H]1CC[C@@H](CC1)C(=O)N[C@H](CC1=CC=CC=C1)C(O)=O\", \"cofactor_name\": \"Nateglinide\", \"cofactor_resource_id\": \"DB00731\", \"mechanism_of_action\": \"Nateglinide activity is dependent on the presence functioning \\u03b2 cells and glucose. In contrast to sulfonylurea insulin secretatogogues, nateglinide has no effect on insulin release in the absence of glucose. Rather, it potentiates the effect of extracellular glucose on ATP-sensitive potassium channel and has little effect on insulin levels between meals and overnight. As such, nateglinide is more effective at reducing postprandial blood glucose levels than fasting blood glucose levels and requires a longer duration of therapy (approximately one month) before decreases in fasting blood glucose are observed. The insulinotropic effects of nateglinide are highest at intermediate glucose levels (3 to 10 mmol/L) and it does not increase insulin release already stimulated by high glucose concentrations (greater than 15 mmol/L). Nateglinide appears to be selective for pancreatic \\u03b2 cells and does not appear to affect skeletal or cardiac muscle or thyroid tissue.\", \"neighbor_flag\": \"N\", \"pubmed_ids\": [15005635], \"resource_name\": \"DrugBank\", \"resource_version\": \"5.1\", \"target_resource_id\": \"P10635\"}, {\"cofactor_in_ch_ikey\": \"RAPZEAPATHNIPO-UHFFFAOYSA-N\", \"cofactor_smiles\": \"CC1=C(CCN2CCC(CC2)C2=NOC3=C2C=CC(F)=C3)C(=O)N2CCCCC2=N1\", \"cofactor_chem_comp_id\": \"8NU\", \"cofactor_name\": \"Risperidone\", \"cofactor_resource_id\": \"DB00734\", \"mechanism_of_action\": \"Though its precise mechanism of action is not fully understood, current focus is on the ability of risperidone to inhibit the D2 dopaminergic receptors and 5-HT2A serotonergic receptors in the brain. Schizophrenia is thought to result from an excess of dopaminergic D2 and serotonergic 5-HT2A activity, resulting in overactivity of central mesolimbic pathways and mesocortical pathways, respectively.[A1115, A1116, A1117]\\r\\n\\r\\nD2 dopaminergic receptors are transiently inhibited by risperidone, reducing dopaminergic neurotransmission, therefore decreasing positive symptoms of schizophrenia, such as delusions and hallucinations.[A251765] Risperidone binds transiently and with loose affinity to the dopaminergic D2 receptor, with an ideal receptor occupancy of 60-70% for optimal effect.[A1119,A31773] Rapid dissociation of risperidone from the D2 receptors contributes to decreased risk of extrapyramidal symptoms (EPS), which occur with permanent and high occupancy blockade of D2 dopaminergic receptors.[A1118,A1119] Low-affinity binding and rapid dissociation from the D2 receptor distinguish risperidone from the traditional antipsychotic drugs. A higher occupancy rate of D2 receptors is said to increase the risk of extrapyramidal symptoms and is therefore to be avoided.[A1118,A1119,A31771] \\r\\n \\r\\nIncreased serotonergic mesocortical activity in schizophrenia results in negative symptoms, such as depression and decreased motivation. The high-affinity binding of risperidone to 5-HT2A receptors leads to a decrease in serotonergic activity. In addition, 5-HT2A receptor blockade results in decreased risk of extrapyramidal symptoms, likely by increasing dopamine release from the frontal cortex, and not the nigrostriatal tract. Dopamine level is therefore not completely inhibited.[A1117,A1119] Through the above mechanisms, both serotonergic and D2 blockade by risperidone are thought to synergistically work to decrease the risk of extrapyramidal symptoms. \\r\\n \\r\\nRisperidone has also been said to be an antagonist of alpha-1 (\\u03b11), alpha-2 (\\u03b12), and histamine (H1) receptors.[A37034] Blockade of these receptors is thought to improve symptoms of schizophrenia, however the exact mechanism of action on these receptors is not fully understood at this time.[L12885]\", \"neighbor_flag\": \"N\", \"pubmed_ids\": [10048600, 19910717, 19902987, 19817501, 11560868], \"resource_name\": \"DrugBank\", \"resource_version\": \"5.1\", \"target_resource_id\": \"P10635\"}, {\"cofactor_in_ch_ikey\": \"OCJYIGYOJCODJL-UHFFFAOYSA-N\", \"cofactor_smiles\": \"CC1=CC(CN2CCN(CC2)C(C2=CC=CC=C2)C2=CC=C(Cl)C=C2)=CC=C1\", \"cofactor_name\": \"Meclizine\", \"cofactor_resource_id\": \"DB00737\", \"mechanism_of_action\": \"Vomiting is a centrally regulated reflex mechanism that initiates from the vomiting center and the chemoreceptor trigger zone (CTZ) located in the medulla. Motion sickness is also regulated by CTZ. The blood-brain barrier near the CTZ is relatively permeable to circulating mediators and CTZ can transmit impulses to vomiting center located in the brainstem. Different receptors responding to different factors, including histamine, 5-HT, enkephalins, substance P, and dopamine, are expressed along the brainstem to activate respective pathways and contribute to the control of vomiting. Histamine H1 receptors are expressed on the vestibular nuclei and nucleus of the solitary tract (NTS) that are activated by motion sickness and stimuli from the pharynx and stomach. When activated, H1 receptor signaling from these nuclei is transmitted to the CTZ and vomiting centre.[T28] \\r\\n\\r\\nThrough its antagonistic action on the H1 receptors, meclizine primarily works by inhibiting signaling pathway transduction through histaminergic neurotransmission from the vestibular nuclei and NTS to the CTZ and medullary vomiting center.[A179581] Meclizine may also decrease the labyrinth excitability and vestibular stimulation.[L6760]\", \"neighbor_flag\": \"N\", \"resource_name\": \"DrugBank\", \"resource_version\": \"5.1\", \"target_resource_id\": \"P10635\"}, {\"cofactor_in_ch_ikey\": \"XDRYMKDFEDOLFX-UHFFFAOYSA-N\", \"cofactor_smiles\": \"NC(=N)C1=CC=C(OCCCCCOC2=CC=C(C=C2)C(N)=N)C=C1\", \"cofactor_chem_comp_id\": \"PNT\", \"cofactor_name\": \"Pentamidine\", \"cofactor_resource_id\": \"DB00738\", \"mechanism_of_action\": \"The mode of action of pentamidine is not fully understood. It is thought that the drug interferes with nuclear metabolism producing inhibition of the synthesis of DNA, RNA, phospholipids, and proteins.\", \"neighbor_flag\": \"N\", \"pubmed_ids\": [12920490, 28756612], \"resource_name\": \"DrugBank\", \"resource_version\": \"5.1\", \"target_resource_id\": \"P10635\"}, {\"cofactor_in_ch_ikey\": \"YFGHCGITMMYXAQ-UHFFFAOYSA-N\", \"cofactor_smiles\": \"NC(=O)CS(=O)C(C1=CC=CC=C1)C1=CC=CC=C1\", \"cofactor_name\": \"Modafinil\", \"cofactor_resource_id\": \"DB00745\", \"mechanism_of_action\": \"The exact mechanism of action is unclear, although <i>in vitro</i> studies have shown it to inhibit the reuptake of dopamine by binding to the dopamine reuptake pump, and lead to an increase in extracellular dopamine. Modafinil activates glutamatergic circuits while inhibiting GABA. Modafinil is thought to have less potential for abuse than other stimulants due to the absence of any significant euphoric or pleasurable effects. It is possible that modafinil acts by a synergistic combination of mechanisms including direct inhibition of dopamine reuptake, indirect inhibition of noradrenalin reuptake in the VLPO and orexin activation. Modafinil has partial alpha 1B-adrenergic agonist effects by directly stimulating the receptors.\", \"neighbor_flag\": \"N\", \"pubmed_ids\": [29178272], \"resource_name\": \"DrugBank\", \"resource_version\": \"5.1\", \"target_resource_id\": \"P10635\"}, {\"cofactor_in_ch_ikey\": \"WHWZLSFABNNENI-UHFFFAOYSA-N\", \"cofactor_smiles\": \"NC1=NCC2N1C1=CC=CC=C1CC1=CC=CC=C21\", \"cofactor_name\": \"Epinastine\", \"cofactor_resource_id\": \"DB00751\", \"mechanism_of_action\": \"Epinastine has a multiaction effect that inhibits the allergic response in 3 ways: 1. stabilizes mast cells by preventing mast cell degranulation to control the allergic response, 2. prevents histamine binding to both the H1- and H<sub>2</sub>-receptors to stop itching and provide lasting protection, and 3. prevents the release of proinflammatory chemical mediators from the blood vessel to halt progression of the allergic response.\", \"neighbor_flag\": \"N\", \"pubmed_ids\": [9485522], \"resource_name\": \"DrugBank\", \"resource_version\": \"5.1\", \"target_resource_id\": \"P10635\"}, {\"cofactor_in_ch_ikey\": \"AELCINSCMGFISI-UHFFFAOYSA-N\", \"cofactor_smiles\": \"NC1CC1C1=CC=CC=C1\", \"cofactor_chem_comp_id\": \"GJZ\", \"cofactor_name\": \"Tranylcypromine\", \"cofactor_resource_id\": \"DB00752\", \"mechanism_of_action\": \"Tranylcypromine irreversibly and nonselectively inhibits monoamine oxidase (MAO). Within neurons, MAO appears to regulate the levels of monoamines released upon synaptic firing. Since depression is associated with low levels of monoamines, the inhibition of MAO serves to ease depressive symptoms, as this results in an increase in the concentrations of these amines within the CNS.\", \"neighbor_flag\": \"N\", \"pubmed_ids\": [15049511, 11353760], \"resource_name\": \"DrugBank\", \"resource_version\": \"5.1\", \"target_resource_id\": \"P10635\"}, {\"cofactor_in_ch_ikey\": \"UKTAZPQNNNJVKR-KJGYPYNMSA-N\", \"cofactor_smiles\": \"[H][C@@]1(C[C@@]2([H])C[C@]3([H])C[C@@]([H])(C1)N2CC3=O)OC(=O)C1=CNC2=C1C=CC=C2\", \"cofactor_name\": \"Dolasetron\", \"cofactor_resource_id\": \"DB00757\", \"mechanism_of_action\": \"Dolasetron is a selective serotonin 5-HT<sub>3</sub> receptor antagonist. In vivo, the drug is rapidly converted into its major active metabolite, hydrodolasetron, which seems to be largely responsible for the drug's pharmacological activity. The antiemetic activity of the drug is brought about through the inhibition of 5-HT<sub>3</sub> receptors present both centrally (medullary chemoreceptor zone) and peripherally (GI tract). This inhibition of 5-HT<sub>3</sub> receptors in turn inhibits the visceral afferent stimulation of the vomiting center, likely indirectly at the level of the area postrema, as well as through direct inhibition of serotonin activity within the area postrema and the chemoreceptor trigger zone.\", \"neighbor_flag\": \"N\", \"pubmed_ids\": [16192915, 8723743, 22427733], \"resource_name\": \"DrugBank\", \"resource_version\": \"5.1\", \"target_resource_id\": \"P10635\"}, {\"cofactor_in_ch_ikey\": \"PMRYVIKBURPHAH-UHFFFAOYSA-N\", \"cofactor_smiles\": \"CN1C=CNC1=S\", \"cofactor_chem_comp_id\": \"MMZ\", \"cofactor_name\": \"Methimazole\", \"cofactor_resource_id\": \"DB00763\", \"mechanism_of_action\": \"Methimazole's primary mechanism of action appears to be interference in an early step in thyroid hormone synthesis involving thyroid peroxidase (TPO), however the exact method through which methimazole inhibits this step is unclear.[A184559]  TPO, along with hydrogen peroxide, normally catalyzes the conversion of iodide to iodine and then further catalyzes the incorporation of this iodine onto the 3 and/or 5 positions of the phenol rings of tyrosine residues in thyroglobulin. These thyroglobulin molecules then degrade within thyroid follicular cells to form either thyroxine (T<sub>4</sub>) or tri-iodothyronine (T<sub>3</sub>), which are the main hormones produced by the thyroid gland.[A184697]\\r\\n\\r\\nMethimazole may directly inhibit TPO, but has been shown in vivo to instead act as a competitive substrate for TPO, thus becoming iodinated itself and interfering with the iodination of thyroglobulin.[A184559] Another proposed theory is that methimazole\\u2019s sulfur moiety may interact directly with the iron atom at the centre of TPO\\u2019s heme molecule, thus inhibiting its ability to iodinate tyrosine residues.[A184694] Other proposed mechanisms with weaker evidence include methimazole binding directly to thyroglobulin or direct inhibition of thyroglobulin itself.[A184559]\", \"neighbor_flag\": \"N\", \"pubmed_ids\": [9172960], \"resource_name\": \"DrugBank\", \"resource_version\": \"5.1\", \"target_resource_id\": \"P10635\"}, {\"cofactor_in_ch_ikey\": \"RMUCZJUITONUFY-UHFFFAOYSA-N\", \"cofactor_smiles\": \"NNCCC1=CC=CC=C1\", \"cofactor_name\": \"Phenelzine\", \"cofactor_resource_id\": \"DB00780\", \"mechanism_of_action\": \"The basic mechanism of action of phenelzine acts as an inhibitor and substrate of monoamine oxidase which subsequently causes an elevation in brain levels of catecholamines and serotonin. It also presents a similar structure to amphetamine which explains the effect on the uptake and release of dopamine, noradrenaline, and serotonin. Phenelzine has been reported to inhibit tyrosine aminotransferase, aromatic amino acid decarboxylase, and dopamine B-hydroxylase.[A31925]\", \"neighbor_flag\": \"N\", \"pubmed_ids\": [16669850], \"resource_name\": \"DrugBank\", \"resource_version\": \"5.1\", \"target_resource_id\": \"P10635\"}, {\"cofactor_in_ch_ikey\": \"UFLGIAIHIAPJJC-UHFFFAOYSA-N\", \"cofactor_smiles\": \"CN(C)CCN(CC1=CC=CC=C1)C1=CC=CC=N1\", \"cofactor_name\": \"Tripelennamine\", \"cofactor_resource_id\": \"DB00792\", \"mechanism_of_action\": \"Tripelennamine binds to the histamine H1 receptor. This blocks the action of endogenous histamine, which subsequently leads to temporary relief of the negative symptoms brought on by histamine.\", \"neighbor_flag\": \"N\", \"pubmed_ids\": [9616188, 11936702], \"resource_name\": \"DrugBank\", \"resource_version\": \"5.1\", \"target_resource_id\": \"P10635\"}, {\"cofactor_in_ch_ikey\": \"LDMWSLGGVTVJPG-UHFFFAOYSA-N\", \"cofactor_smiles\": \"CC1=CC(=NN=C1NCCN1CCOCC1)C1=CC=CC=C1\", \"cofactor_name\": \"Minaprine\", \"cofactor_resource_id\": \"DB00805\", \"mechanism_of_action\": \"Minaprine binds to serotonin type 2 receptors and to dopamine D1 and D2 type receptors. It also binds to the serotonin reuptake pump. Therefore, minaprine blocks the reuptake of both dopamine and serotonin. It is also, to a slight degree, cholinomimetic. Thus it may exhibit both mood-brightening and nootropic properties. It also acts as a reversible inhibitor of MAO-A (RIMA).It has also been found to inhibit acetylcholinesterase.\", \"neighbor_flag\": \"N\", \"pubmed_ids\": [19661215, 27942231], \"resource_name\": \"DrugBank\", \"resource_version\": \"5.1\", \"target_resource_id\": \"P10635\"}, {\"cofactor_in_ch_ikey\": \"YSXKPIUOCJLQIE-UHFFFAOYSA-N\", \"cofactor_smiles\": \"OC(CCN1CCCCC1)(C1CC2CC1C=C2)C1=CC=CC=C1\", \"cofactor_name\": \"Biperiden\", \"cofactor_resource_id\": \"DB00810\", \"mechanism_of_action\": \"Parkinsonism is thought to result from an imbalance between the excitatory (cholinergic) and inhibitory (dopaminergic) systems in the corpus striatum. The mechanism of action of centrally active anticholinergic drugs such as biperiden is considered to relate to competitive antagonism of acetylcholine at cholinergic receptors in the corpus striatum, which then restores the balance.\", \"neighbor_flag\": \"N\", \"pubmed_ids\": [9342584, 14571354], \"resource_name\": \"DrugBank\", \"resource_version\": \"5.1\", \"target_resource_id\": \"P10635\"}, {\"cofactor_in_ch_ikey\": \"VKHAHZOOUSRJNA-GCNJZUOMSA-N\", \"cofactor_smiles\": \"[H][C@@]12CC[C@@](O)(C#CC)[C@@]1(C)C[C@H](C1=CC=C(C=C1)N(C)C)C1=C3CCC(=O)C=C3CC[C@@]21[H]\", \"cofactor_chem_comp_id\": \"486\", \"cofactor_name\": \"Mifepristone\", \"cofactor_resource_id\": \"DB00834\", \"mechanism_of_action\": \"The anti-progestational activity of mifepristone results from competitive interaction with progesterone at progesterone-receptor sites. Based on studies with various oral doses in several animal species (mouse, rat, rabbit and monkey), the compound inhibits the activity of endogenous or exogenous progesterone. The termination of pregnancy results.\\r\\n\\r\\nIn the treatment of Cushing's syndrome, Mifepristone blocks the binding of cortisol to its receptor. It does not decrease cortisol production but reduces the effects of excess cortisol, such as high blood sugar levels.\", \"neighbor_flag\": \"N\", \"pubmed_ids\": [9918590], \"resource_name\": \"DrugBank\", \"resource_version\": \"5.1\", \"target_resource_id\": \"P10635\"}, {\"cofactor_in_ch_ikey\": \"RDOIQAHITMMDAJ-UHFFFAOYSA-N\", \"cofactor_smiles\": \"CN(C)C(=O)C(CCN1CCC(O)(CC1)C1=CC=C(Cl)C=C1)(C1=CC=CC=C1)C1=CC=CC=C1\", \"cofactor_chem_comp_id\": \"A1CMV\", \"cofactor_name\": \"Loperamide\", \"cofactor_resource_id\": \"DB00836\", \"mechanism_of_action\": \"Enteric neurons synthesize and release endogenous opioid peptides and other neurotransmitters, such as acetylcholine and substance P. Endogenous opioids bind to opioid receptors expressed on these neurons to regulate gastrointestinal signalling, motility, and balance of fluids and electrolytes.[A251630]\\r\\n\\r\\nLoperamide acts on the mu (\\u03bc)-opioid receptor expressed on the circular and longitudinal intestinal muscle.[A251610] Receptor binding leads to the recruitment of G-protein receptor kinases and the activation of downstream molecular cascades that inhibit enteric nerve activity.[A251630] By inhibiting the excitability of enteric neurons, loperamide suppresses neurotransmitter release, pre-synaptic and post-synaptic inhibition of transmission of excitatory and inhibitory motor pathways, and secretomotor pathways.[A251630] Loperamide inhibits the release of acetylcholine and prostaglandins,[L42790] thereby reducing propulsive peristalsis and increasing intestinal transit time.[A251615, L42790] Loperamide stimulates the intestinal absorption of water and electrolytes by inhibiting calmodulin.[A251615] Loperamide can bind to and hyperpolarize submucosal secretomotor neurons, promoting dry, hard stools.[A251630]\", \"neighbor_flag\": \"N\", \"pubmed_ids\": [15365656], \"resource_name\": \"DrugBank\", \"resource_version\": \"5.1\", \"target_resource_id\": \"P10635\"}, {\"cofactor_in_ch_ikey\": \"ADEBPBSSDYVVLD-UHFFFAOYSA-N\", \"cofactor_smiles\": \"COC1=C(OC)C=C2C(=O)C(CC3CCN(CC4=CC=CC=C4)CC3)CC2=C1\", \"cofactor_name\": \"Donepezil\", \"cofactor_resource_id\": \"DB00843\", \"mechanism_of_action\": \"\\r\\nThe commonly accepted cholinergic hypothesis[A182369] proposes that a portion of the cognitive and behavioral decline associated with Alzheimer's are the result of decreased cholinergic transmission in the central nervous system. Donepezil selectively and reversibly inhibits the acetylcholinesterase enzyme, which normally breaks down acetylcholine. The main pharmacological actions of this drug are believed to occur as the result of this enzyme inhibition, enhancing cholinergic transmission, which relieves the symptoms of Alzheimer's dementia. In addition to the above, other mechanisms of action of donepezil are possible, including the opposition of glutamate-induced excitatory transmission via downregulation of NMDA receptors and the regulation of amyloid proteins, which have demonstrated significant effects on the disease process of Alzheimer's.[A182333,A182351,A182444] Other possible targets for donepezil may also include the inhibition various inflammatory signaling pathways, exerting neuroprotective effects.[A182339,A182393]\", \"neighbor_flag\": \"N\", \"pubmed_ids\": [19515014, 26952092], \"resource_name\": \"DrugBank\", \"resource_version\": \"5.1\", \"target_resource_id\": \"P10635\"}, {\"cofactor_in_ch_ikey\": \"WDQPAMHFFCXSNU-BGABXYSRSA-N\", \"cofactor_smiles\": \"CC(C)N=C1C=C2N(C3=CC=C(Cl)C=C3)C3=C(C=CC=C3)N=C2C=C1NC1=CC=C(Cl)C=C1\", \"cofactor_name\": \"Clofazimine\", \"cofactor_resource_id\": \"DB00845\", \"mechanism_of_action\": \"Although the precise mechanism(s) of action of clofazimine have not been elucidated, its antimicrobial activity appears to be membrane-directed. It was previously thought that, due to its lipophilicity, clofazimine participated in the generation of intracellular reactive oxygen species (ROS) via redox cycling, specifically H<sub>2</sub>O<sub>2</sub> and superoxide, which then exerted an antimicrobial effect.[A203144] A more recent and compelling theory involves clofazimine interacting with bacterial membrane phospholipids to generate antimicrobial lysophospholipids - bactericidal efficacy may, then, arise from the combined membrane-destabilizing effects of both clofazimine and lysophospholipids, which interfere with K+ uptake and, ultimately, ATP production.[A203144,L13802]\\r\\n\\r\\nThe anti-inflammatory activity of clofazimine is the result of its inhibition of T-lymphocyte activation and proliferation.[L13802] Several mechanisms have been proposed, including direct antagonism of T-cell Kv 1.3 potassium channels and indirect action by promoting the release of E-series prostaglandins and reactive oxygen species from bystander neutrophils and monocytes.\", \"neighbor_flag\": \"N\", \"resource_name\": \"DrugBank\", \"resource_version\": \"5.1\", \"target_resource_id\": \"P10635\"}, {\"cofactor_in_ch_ikey\": \"RGCVKNLCSQQDEP-UHFFFAOYSA-N\", \"cofactor_smiles\": \"OCCN1CCN(CCCN2C3=CC=CC=C3SC3=C2C=C(Cl)C=C3)CC1\", \"cofactor_name\": \"Perphenazine\", \"cofactor_resource_id\": \"DB00850\", \"mechanism_of_action\": \"Binds to the dopamine D1 and dopamine D2 receptors and inhibits their activity. The mechanism of the anti-emetic effect is due predominantly to blockage of the dopamine D2 neurotransmitter receptors in the chemoreceptor trigger zone and vomiting centre. Perphenazine also binds the alpha andrenergic receptor. This receptor's action is mediated by association with G proteins that activate a phosphatidylinositol-calcium second messenger system.\", \"neighbor_flag\": \"N\", \"pubmed_ids\": [10688273, 16910628, 8689810, 9333110, 9616188], \"resource_name\": \"DrugBank\", \"resource_version\": \"5.1\", \"target_resource_id\": \"P10635\"}, {\"cofactor_in_ch_ikey\": \"DOMXUEMWDBAQBQ-WEVVVXLNSA-N\", \"cofactor_smiles\": \"CN(C\\\\C=C\\\\C#CC(C)(C)C)CC1=CC=CC2=CC=CC=C12\", \"cofactor_name\": \"Terbinafine\", \"cofactor_resource_id\": \"DB00857\", \"mechanism_of_action\": \"Terbinafine inhibits the enzyme squalene monooxygenase (also called squalene epoxidase), preventing the conversion of squalene to 2,3-oxydosqualene, a step in the synthesis of ergosterol.[A1279,A1281,L9068] This inhibition leads to decreased ergosterol, which would normally be incorporated into the cell wall, and accumulation of squalene.[A1281,L9068]\\r\\n\\r\\nGeneration of a large number of squalene containing vesicles in the cytoplasm may leach other lipids away from, and further weaken, the cell wall.[A1281]\", \"neighbor_flag\": \"N\", \"pubmed_ids\": [10383919, 12412819, 11475469, 10340911], \"resource_name\": \"DrugBank\", \"resource_version\": \"5.1\", \"target_resource_id\": \"P10635\"}, {\"cofactor_in_ch_ikey\": \"SECKRCOLJRRGGV-UHFFFAOYSA-N\", \"cofactor_smiles\": \"CCCC1=NC(C)=C2N1NC(=NC2=O)C1=C(OCC)C=CC(=C1)S(=O)(=O)N1CCN(CC)CC1\", \"cofactor_chem_comp_id\": \"VDN\", \"cofactor_name\": \"Vardenafil\", \"cofactor_resource_id\": \"DB00862\", \"mechanism_of_action\": \"Vardenafil inhibits cyclic guanosine monophosphate (GMP) specific phosphodiesterase type 5 (PDE5), which is responsible for the degradation of cyclic GMP in the corpus cavernosum located around the penis. Penile erection during sexual stimulation is caused by increased penile blood flow resulting from the relaxation of penile arteries and corpus cavernosal smooth muscle. This response is mediated by the release of nitric oxide (NO) from nerve terminals and endothelial cells, which stimulates the synthesis of cyclic GMP in smooth muscle cells. Cyclic GMP causes smooth muscle relaxation and increased blood flow into the corpus cavernosum. The tissue concentration of cyclic GMP is regulated by both the rates of synthesis and degradation via phosphodiesterases (PDEs), and the most abundant PDE in the human corpus cavernosum is PDE5. Therefore, the inhibition of PDE5 by vardenafil enhances erectile function by increasing the amount of cyclic GMP.[L45563]\", \"neighbor_flag\": \"N\", \"resource_name\": \"DrugBank\", \"resource_version\": \"5.1\", \"target_resource_id\": \"P10635\"}, {\"cofactor_in_ch_ikey\": \"VMXUWOKSQNHOCA-UHFFFAOYSA-N\", \"cofactor_smiles\": \"CNC(NCCSCC1=CC=C(CN(C)C)O1)=C[N+]([O-])=O\", \"cofactor_name\": \"Ranitidine\", \"cofactor_resource_id\": \"DB00863\", \"mechanism_of_action\": \"After a meal, the hormone gastrin, produced by cells in the lining of the stomach, stimulates the release of histamine, which then binds to histamine H2 receptors, leading to the secretion of gastric acid. Ranitidine reduces the secretion of gastric acid by reversible binding to histamine (H2) receptors, which are found on gastric parietal cells. This process leads to the inhibition of histamine binding to this receptor, causing the reduction of gastric acid secretion. The relief of gastric-acid related symptoms can occur as soon as 60 minutes after administration of a single dose, and the effects can last from 4-10 hours, providing fast and effective symptomatic relief.[A176774,T533,L10818]\", \"neighbor_flag\": \"N\", \"pubmed_ids\": [10223772, 20439629], \"resource_name\": \"DrugBank\", \"resource_version\": \"5.1\", \"target_resource_id\": \"P10635\"}, {\"cofactor_in_ch_ikey\": \"PAZJSJFMUHDSTF-UHFFFAOYSA-N\", \"cofactor_smiles\": \"CC(C)NCC(O)COC1=CC=CC=C1CC=C\", \"cofactor_name\": \"Alprenolol\", \"cofactor_resource_id\": \"DB00866\", \"mechanism_of_action\": \"Alprenolol non-selectively blocks beta-1 adrenergic receptors mainly in the heart, inhibiting the effects of epinephrine and norepinephrine resulting in a decrease in heart rate and blood pressure. Also, with a more minor effect, by binding beta-2 receptors in the juxtaglomerular apparatus, alprenolol inhibits the production of renin, thereby inhibiting angiotensin II and aldosterone production and therefore inhibits the vasoconstriction and water retention due to angiotensin II and aldosterone, respectively.\", \"neighbor_flag\": \"N\", \"pubmed_ids\": [25341854, 25369508], \"resource_name\": \"DrugBank\", \"resource_version\": \"5.1\", \"target_resource_id\": \"P10635\"}, {\"cofactor_in_ch_ikey\": \"FELGMEQIXOGIFQ-UHFFFAOYSA-N\", \"cofactor_smiles\": \"CN1C2=C(C3=CC=CC=C13)C(=O)C(CN1C=CN=C1C)CC2\", \"cofactor_chem_comp_id\": \"S87\", \"cofactor_name\": \"Ondansetron\", \"cofactor_resource_id\": \"DB00904\", \"mechanism_of_action\": \"Ondansetron is a selective antagonist of the serotonin receptor subtype, 5-HT3 [F3178, F3181, F3184].\\r\\n\\r\\nCytotoxic chemotherapy and radiotherapy are associated with the release of serotonin (5-HT) from enterochromaffin cells of the small intestine, presumably initiating a vomiting reflex through stimulation of 5-HT3 receptors located on vagal afferents [F3178, F3181, F3184]. Ondansetron may block the initiation of this reflex. Activation of vagal afferents may also cause a central release of serotonin from the chemoreceptor trigger zone of the area postrema, located on the floor of the fourth ventricle [F3178, F3181, F3184]. Thus, the antiemetic effect of ondansetron is probably due to the selective antagonism of 5-HT3 receptors on neurons located in either the peripheral or central nervous systems, or both [F3178, F3181, F3184].\\r\\n\\r\\nAlthough the mechanisms of action of ondansetron in treating postoperative nausea and vomiting and cytotoxic induced nausea and vomiting may share similar pathways, the role of ondansetron in opiate-induced emesis has not yet been formally established [F3181, F3184].\", \"neighbor_flag\": \"N\", \"pubmed_ids\": [16192915, 8591723], \"resource_name\": \"DrugBank\", \"resource_version\": \"5.1\", \"target_resource_id\": \"P10635\"}, {\"cofactor_in_ch_ikey\": \"ZPUCINDJVBIVPJ-LJISPDSOSA-N\", \"cofactor_smiles\": \"[H][C@]12CC[C@]([H])([C@H]([C@H](C1)OC(=O)C1=CC=CC=C1)C(=O)OC)N2C\", \"cofactor_chem_comp_id\": \"COC\", \"cofactor_name\": \"Cocaine\", \"cofactor_resource_id\": \"DB00907\", \"mechanism_of_action\": \"Cocaine produces anesthesia by inhibiting excitation of nerve endings or by blocking conduction in peripheral nerves. This is achieved by reversibly binding to and inactivating sodium channels. Sodium influx through these channels is necessary for the depolarization of nerve cell membranes and subsequent propagation of impulses along the course of the nerve. Cocaine is the only local anesthetic with vasoconstrictive properties. This is a result of its blockade of norepinephrine reuptake in the autonomic nervous system. Cocaine binds differentially to the dopamine, serotonin, and norepinephrine transport proteins and directly prevents the re-uptake of dopamine, serotonin, and norepinephrine into pre-synaptic neurons. Its effect on dopamine levels is most responsible for the addictive property of cocaine.\", \"neighbor_flag\": \"N\", \"pubmed_ids\": [17470523], \"resource_name\": \"DrugBank\", \"resource_version\": \"5.1\", \"target_resource_id\": \"P10635\"}, {\"cofactor_in_ch_ikey\": \"LOUPRKONTZGTKE-LHHVKLHASA-N\", \"cofactor_smiles\": \"[H][C@@]12CCN(C[C@@H]1C=C)[C@]([H])(C2)[C@@H](O)C1=C2C=C(OC)C=CC2=NC=C1\", \"cofactor_chem_comp_id\": \"QDN\", \"cofactor_name\": \"Quinidine\", \"cofactor_resource_id\": \"DB00908\", \"mechanism_of_action\": \"Quinidine has a complex electrophysiological profile that has not been fully elucidated. The antiarrhythmic actions of this drug are mediated through effects on sodium channels in Purkinje fibers. Quinidine blocks the rapid sodium channel (I<sub>Na</sub>), decreasing the phase zero of rapid depolarization of the action potential.[A250050] Quinidine also reduces repolarizing K<sup>+</sup> currents (I<sub>Kr</sub>, I<sub>Ks</sub>), the inward rectifier potassium current (I<sub>K1</sub>), and the transient outward potassium current I<sub>to</sub>, as well as the L-type calcium current I<sub>Ca</sub> and the late I<sub>Na</sub> inward current.[A250050] The reduction of these currents leads to the prolongation of the action potential duration. By shortening the plateau but prolonging late depolarization, quinidine facilitates the formation of early afterdepolarisation (EAD).[A250050] Additionally, in patients with malaria, quinidine acts primarily as an intra-erythrocytic schizonticide, and is gametocidal to _Plasmodium vivax_ and _P. malariae_, but not to _P. falciparum_.[L42420,L3719]\", \"neighbor_flag\": \"Y\", \"pubmed_ids\": [22459173, 12703961, 9758674, 10702886, 11061580, 16162505], \"resource_name\": \"DrugBank\", \"resource_version\": \"5.1\", \"target_resource_id\": \"P10635\"}, {\"cofactor_in_ch_ikey\": \"ICFJFFQQTFMIBG-UHFFFAOYSA-N\", \"cofactor_smiles\": \"NC(=N)NC(=N)NCCC1=CC=CC=C1\", \"cofactor_chem_comp_id\": \"8CV\", \"cofactor_name\": \"Phenformin\", \"cofactor_resource_id\": \"DB00914\", \"mechanism_of_action\": \"Phenformin binds to the AMP-activated protein kinase (AMPK). AMPK is an ultra-sensitive cellular energy sensor that monitors energy consumption and down-regulates ATP-consuming processes when activated. The biguanide phenformin has been shown to independently decrease ion transport processes, influence cellular metabolism and activate AMPK. Phenformin's hypoglycemic activity is related the effect it has in activating AMPK and fooling insulin sensitive cells into thinking that insulin levels are low and causing the body to use glucose as if in a state of low caloric consumption. This drug also seems to inhibit several varients of ATP-sensitive potassium channels (namely the receptor subtype Kir6.1).\", \"neighbor_flag\": \"N\", \"pubmed_ids\": [24913012, 23233435], \"resource_name\": \"DrugBank\", \"resource_version\": \"5.1\", \"target_resource_id\": \"P10635\"}, {\"cofactor_in_ch_ikey\": \"WKEMJKQOLOHJLZ-UHFFFAOYSA-N\", \"cofactor_smiles\": \"CN(C)CCC1=CNC2=C1C=C(CS(=O)(=O)N1CCCC1)C=C2\", \"cofactor_name\": \"Almotriptan\", \"cofactor_resource_id\": \"DB00918\", \"mechanism_of_action\": \"Almotriptan binds with high affinity to human 5-HT<sub>1B</sub> and 5-HT<sub>1D</sub> receptors leading to cranial blood vessel constriction.\", \"neighbor_flag\": \"N\", \"pubmed_ids\": [15762767, 12642466], \"resource_name\": \"DrugBank\", \"resource_version\": \"5.1\", \"target_resource_id\": \"P10635\"}, {\"cofactor_in_ch_ikey\": \"RMRJXGBAOAMLHD-IHFGGWKQSA-N\", \"cofactor_smiles\": \"CO[C@]12CC[C@@]3(C[C@@H]1[C@](C)(O)C(C)(C)C)[C@H]1CC4=C5C(O[C@@H]2[C@@]35CCN1CC1CC1)=C(O)C=C4\", \"cofactor_name\": \"Buprenorphine\", \"cofactor_resource_id\": \"DB00921\", \"mechanism_of_action\": \"Buprenorphine is a partial agonist at the mu-opioid receptor and an antagonist at the kappa-opioid receptor. It demonstrates a high affinity for the mu-opioid receptor but has lower intrinsic activity compared to other full mu-opioid agonists such as [heroin], [oxycodone], or [methadone].[A186292] This means that buprenorphine preferentially binds the opioid receptor and displaces lower affinity opioids without activating the receptor to a comparable degree. Clinically, this results in a slow onset of action and a clinical phenomenon known as the \\\"ceiling effect\\\" where once a certain dose is reached buprenorphine's effects plateau. This effect can be beneficial, however, as dose-related side effects such as respiratory depression, sedation, and intoxication also plateau at around 32mg, resulting in a lower risk of overdose compared to [methadone] and other full agonist opioids.[A186215,A186218] It also means that opioid-dependent patients do not experience sedation or euphoria at the same rate that they might experience with more potent opioids, improving quality of life for patients with severe pain and reducing the reinforcing effects of opioids which can lead to drug-seeking behaviours.[A186280]\\r\\n\\r\\nBuprenorphine's high affinity, but low intrinsic activity for the mu-opioid receptor also means that if it is started in opioid-dependent individuals, it will displace the other opioids without creating an equal opioid effect and cause a phenomenon known as \\\"precipitated withdrawal\\\" which is characterized by a rapid and intense onset of withdrawal symptoms (i.e. anxiety, restlessness, gastrointestinal distress, diaphoresis, intense drug cravings, and tachycardia). Individuals must therefore be in a state of mild to moderate withdrawal before starting therapy with buprenorphine. \\r\\n\\r\\nBuprenorphine is commercially available as the brand name product Suboxone which is formulated in a 4:1 fixed-dose combination product along with [naloxone], a non-selective competitive opioid receptor antagonist. Combination of an opioid agonist with an opioid antagonist may seem counterintuitive, however this combination with naloxone is intended to reduce the abuse potential of Suboxone, as naloxone is poorly absorbed by the oral route (and has no effect when taken orally), but would reverse the opioid agonist effects of buprenorphine if injected intravenously.[A186289,L46571] \", \"neighbor_flag\": \"N\", \"pubmed_ids\": [15684471, 12756210, 12033517], \"resource_name\": \"DrugBank\", \"resource_version\": \"5.1\", \"target_resource_id\": \"P10635\"}, {\"cofactor_in_ch_ikey\": \"JURKNVYFZMSNLP-UHFFFAOYSA-N\", \"cofactor_smiles\": \"CN(C)CCC=C1C2=CC=CC=C2C=CC2=CC=CC=C12\", \"cofactor_name\": \"Cyclobenzaprine\", \"cofactor_resource_id\": \"DB00924\", \"mechanism_of_action\": \"The exact mechanism of action of cyclobenzaprine has not been fully elucidated in humans, and much of the information available regarding its mechanism has been ascertained from early animal studies. There is some evidence that cyclobenzaprine exerts its effects at the supraspinal level, specifically within the locus coeruleus of the brainstem, with little-to-no action at neuromuscular junctions or directly on skeletal musculature[L8411,A184982]. Action on the brainstem is thought to result in diminished activity of efferent alpha and gamma motor neurons, likely mediated by inhibition of coeruleus-spinal or reticulospinal pathways, and ultimately depressed spinal cord interneuron activity.[A184982]\\r\\n\\r\\nMore recently it has been suggested that inhibition of descending serotonergic pathways in the spinal cord via action on 5-HT2 receptors may contribute to cyclobenzaprine\\u2019s observed effects.[A5896,A184982,A4862]\", \"neighbor_flag\": \"N\", \"pubmed_ids\": [8818577], \"resource_name\": \"DrugBank\", \"resource_version\": \"5.1\", \"target_resource_id\": \"P10635\"}, {\"cofactor_in_ch_ikey\": \"SUJUHGSWHZTSEU-FYBSXPHGSA-N\", \"cofactor_smiles\": \"[H][C@@](CC)(C1=CC(NS(=O)(=O)C2=NC=C(C=C2)C(F)(F)F)=CC=C1)C1=C(O)C[C@@](CCC)(CCC2=CC=CC=C2)OC1=O\", \"cofactor_chem_comp_id\": \"TPV\", \"cofactor_name\": \"Tipranavir\", \"cofactor_resource_id\": \"DB00932\", \"mechanism_of_action\": \"Tipranavir (TPV) is a non-peptidic HIV-1 protease inhibitor that inhibits the processing of the viral Gag and Gag-Pol polyproteins in HIV-1 infected cells, thus preventing formation of mature virions. Two mechanisms are suggested in regards to the potency of tipranavir: 1. Tipravanir may bind to the active site of the protease enzyme with fewer hydrogen bonds than peptidic protease inhibitors, which results in increased flexibility, allowing it to fit into the active site of the enzyme in viruses that have become resistance to other protease inhibitors. This also enables tipranavir to adjust to amino acid substitutions at the active site. 2. Tipranavir's strong hydrogen bonding interaction with the amide backbone of the protease active site Asp30 may lead to its activity against resistant viruses.\", \"neighbor_flag\": \"N\", \"pubmed_ids\": [20103582, 20147896], \"resource_name\": \"DrugBank\", \"resource_version\": \"5.1\", \"target_resource_id\": \"P10635\"}, {\"cofactor_in_ch_ikey\": \"SLVMESMUVMCQIY-UHFFFAOYSA-N\", \"cofactor_smiles\": \"CN1CCCCC1CCN1C2=C(SC3=C1C=C(C=C3)S(C)=O)C=CC=C2\", \"cofactor_name\": \"Mesoridazine\", \"cofactor_resource_id\": \"DB00933\", \"mechanism_of_action\": \"Based upon animal studies, mesoridazine, as with other phenothiazines, acts indirectly on reticular formation, whereby neuronal activity into reticular formation is reduced without affecting its intrinsic ability to activate the cerebral cortex. In addition, the phenothiazines exhibit at least part of their activities through depression of hypothalamic centers. Neurochemically, the phenothiazines are thought to exert their effects by a central adrenergic blocking action.\", \"neighbor_flag\": \"N\", \"pubmed_ids\": [12682803, 10942178], \"resource_name\": \"DrugBank\", \"resource_version\": \"5.1\", \"target_resource_id\": \"P10635\"}, {\"cofactor_in_ch_ikey\": \"QSLMDECMDJKHMQ-UHFFFAOYSA-N\", \"cofactor_smiles\": \"CNCCCC12CCC(C3=CC=CC=C13)C1=CC=CC=C21\", \"cofactor_name\": \"Maprotiline\", \"cofactor_resource_id\": \"DB00934\", \"mechanism_of_action\": \"Maprotiline exerts its antidepressant action by inhibition of presynaptic uptake of catecholamines, thereby increasing their concentration at the synaptic clefts of the brain. In single doses, the effect of maprotiline on the EEG revealed a rise in the alpha-wave density, a reduction of the alpha-wave frequency and an increase in the alpha-wave amplitude. However, as with other tricyclic antidepressants, maprotiline lowers the convulsive threshold. Maprotiline acts as an antagonist at central presynaptic &alpha;<sub>2</sub>-adrenergic inhibitory autoreceptors and hetero-receptors, an action that is postulated to result in an increase in central noradrenergic and serotonergic activity. Maprotiline is also a moderate peripheral &alpha;<sub>1</sub> adrenergic antagonist, which may explain the occasional orthostatic hypotension reported in association with its use. Maprotiline also inhibits the amine transporter, delaying the reuptake of noradrenaline and norepinephrine. Lastly, maprotiline is a strong inhibitor of the histamine H<sub>1</sub> receptor, which explains its sedative actions.\", \"neighbor_flag\": \"N\", \"pubmed_ids\": [12071336, 8018460], \"resource_name\": \"DrugBank\", \"resource_version\": \"5.1\", \"target_resource_id\": \"P10635\"}, {\"cofactor_in_ch_ikey\": \"QRXWMOHMRWLFEY-UHFFFAOYSA-N\", \"cofactor_smiles\": \"NNC(=O)C1=CC=NC=C1\", \"cofactor_chem_comp_id\": \"NIZ\", \"cofactor_name\": \"Isoniazid\", \"cofactor_resource_id\": \"DB00951\", \"mechanism_of_action\": \"Isoniazid is a prodrug and must be activated by bacterial catalase. Specficially, activation is associated with reduction of the mycobacterial ferric KatG catalase-peroxidase by hydrazine and reaction with oxygen to form an oxyferrous enzyme complex. Once activated, isoniazid inhibits the synthesis of mycoloic acids, an essential component of the bacterial cell wall. At therapeutic levels isoniazid is bacteriocidal against actively growing intracellular and extracellular <i>Mycobacterium tuberculosis</i> organisms. Specifically isoniazid inhibits InhA, the enoyl reductase from <i>Mycobacterium tuberculosis</i>, by forming a covalent adduct with the NAD cofactor. It is the INH-NAD adduct that acts as a slow, tight-binding competitive inhibitor of InhA.\", \"neighbor_flag\": \"N\", \"pubmed_ids\": [11158730], \"resource_name\": \"DrugBank\", \"resource_version\": \"5.1\", \"target_resource_id\": \"P10635\"}, {\"cofactor_in_ch_ikey\": \"ULFRLSNUDGIQQP-UHFFFAOYSA-N\", \"cofactor_smiles\": \"CN(C)CCC1=CNC2=C1C=C(CN1C=NC=N1)C=C2\", \"cofactor_name\": \"Rizatriptan\", \"cofactor_resource_id\": \"DB00953\", \"mechanism_of_action\": \"There are several physiological and molecular processes implicated in the pathophysiology of migraine. Vasodilation of intracranial extracerebral blood vessels, particularly those supplying the dura mater, has been associated with migraine pain.[A1460, A258928] Activation of the trigeminovascular system leads to the release of vasoactive neuropeptides (such as substance P, calcitonin gene-related peptide (CGRP), and neurokinin A) from the trigeminal nerve innervating the intracranial vessels and dura mater. Vasoactive neuropeptides cause perivascular inflammation and vasodilation in the periphery. Migraine-associated nausea and vomiting are thought to arise from the activation of central and nociceptive sensory neurons that project to autonomic brain-stem nuclei and higher subcortical and cortical pain processing centres.[A1460] An imbalance in serotonin (5-HT) levels has also been documented: 5-HT binds to 5-HT<sub>1B</sub> and 5-HT<sub>1D</sub> receptors to promote trigeminal neuronal firing and vasoconstriction.[A1460, A258968]\\r\\n\\r\\nRizatriptan is a selective agonist at the 5-HT<sub>1B</sub> and 5-HT<sub>1D</sub> receptors on intracranial blood vessels and sensory nerves of the trigeminal system. It binds to these receptors with high affinity.[L46018] The exact mechanism of action of rizatriptan has not been fully elucidated; however, several documented pharmacological actions of rizatriptan may contribute to its antimigraine effects. Rizatriptan causes vasoconstriction of intracranial extracerebral blood vessels, which is thought to occur primarily via 5-HT<sub>1B</sub> receptors. Rizatriptan also inhibits nociceptive neurotransmission in trigeminal pain pathways. It attenuates the release of vasoactive neuropeptides by the trigeminal nerve, which is thought to occur via neurogenic and central 5-HT<sub>1D</sub> receptors.[A1460, A258918, A258928] Rizatriptan inhibited neurogenic dural vasodilation and plasma protein extravasation in animal studies.[A1460, A5971, A258918, A258928]\", \"neighbor_flag\": \"N\", \"resource_name\": \"DrugBank\", \"resource_version\": \"5.1\", \"target_resource_id\": \"P10635\"}, {\"cofactor_in_ch_ikey\": \"LLPOLZWFYMWNKH-CMKMFDCUSA-N\", \"cofactor_smiles\": \"[H][C@@]12OC3=C(OC)C=CC4=C3[C@@]11CCN(C)[C@]([H])(C4)[C@]1([H])CCC2=O\", \"cofactor_name\": \"Hydrocodone\", \"cofactor_resource_id\": \"DB00956\", \"mechanism_of_action\": \"Hydrocodone binds to the mu opioid receptor (MOR) with the highest affinity followed by the delta opioid receptors (DOR).[A182165] Hydrocodone's agonist effect at the MOR is considered to contribute the most to its analgesic effects. Both MOR and DOR are Gi/o coupled and and produces its signal through activation of inward rectifier potassium (GIRK) channels, inhibition of voltage gated calcium channel opening, and decreased adenylyl cyclase activity.[T116] In the dorsal horn of the spinal cord, activation of pre-synaptic MOR on primary afferents the inhibition of calcium channel opening and increased activity of GIRK channels hyperpolarizes the neuron and prevents release of neurotransmitters. Post-synaptic MOR can also prevent activation of neurons by glutamate through the aforementioned mechanisms. \\r\\n\\r\\nHydrocodone can also produce several actions in the brain similarly to other opioids. \\r\\nActivation of MOR in the periaquaductal gray (PAG) inhibits the GABAergic tone on medulo-spinal neurons.[T116,A176495] This allows these neurons, which project to the dorsal horn of the spinal cord, to suppress pain signalling in secondary afferents by activating inhibitory interneurons. MOR can also inhibit GABAergic neurons in the ventral tegmental area, removing the inhibitory tone on dopaminergic neurons in the nucleus accumbens and contributing to the activation of the brain's reward and addiction pathway. The inhibitory action or MOR likely contributes to respiratory depression, sedation, and suppression of the cough reflex. \\r\\n\\r\\nActivation of DOR may contribute to analgesia through the above mechanisms but has not been well studied.[A176495]\", \"neighbor_flag\": \"N\", \"pubmed_ids\": [14998425, 25156930], \"resource_name\": \"DrugBank\", \"resource_version\": \"5.1\", \"target_resource_id\": \"P10635\"}, {\"cofactor_in_ch_ikey\": \"JZQKKSLKJUAGIC-UHFFFAOYSA-N\", \"cofactor_smiles\": \"CC(C)NCC(O)COC1=CC=CC2=C1C=CN2\", \"cofactor_name\": \"Pindolol\", \"cofactor_resource_id\": \"DB00960\", \"mechanism_of_action\": \"The beta-1 adrenoceptor is a G-protein-coupled receptor.[A230948] Agonism of the beta-1 adrenoceptor allows the Gs subunit to upregulate adenylyl cyclase, converting ATP to cyclic AMP (cAMP).[A230948] Increased concentrations of cAMP activate cAMP-dependant kinase A, phosphorylating calcium channels, raising intracellular calcium, increasing calcium exchange through the sarcoplasmic reticulum, and increasing cardiac inotropy.[A230948] cAMP-dependant kinase A also phosphorylates myosin light chains, increasing smooth muscle contractility.[A230948] Increased smooth muscle contractility in the kidney releases renin.[A230948]\\r\\n\\r\\nPindolol is a non-selective beta blocker.[A230958] Blocking beta-1 adrenergic receptors in the heart results in decreased heart rate and blood pressure.[A230958] By blocking beta-1 receptors in the juxtaglomerular apparatus, pindolol inhibits the release of renin, which inhibits angiotensin II and aldosterone release.[A230948,A230953] Reduced angiotensin II inhibits vasoconstriction and reduced aldosterone inhibits water retention.[A230948,A230953]\\r\\n\\r\\nBeta-2 adrenoceptors located in the kidneys and peripheral blood vessels use a similar mechanism to activate cAMP-dependant kinase A to increase smooth muscle contractility.[A230973] Blocking of the beta-2 adrenoceptor relaxes smooth muscle, leading to vasodilation.[A230973]\", \"neighbor_flag\": \"N\", \"pubmed_ids\": [1472073, 1675413], \"resource_name\": \"DrugBank\", \"resource_version\": \"5.1\", \"target_resource_id\": \"P10635\"}, {\"cofactor_in_ch_ikey\": \"MBUVEWMHONZEQD-UHFFFAOYSA-N\", \"cofactor_smiles\": \"CN1CCCC(CC1)N1N=C(CC2=CC=C(Cl)C=C2)C2=CC=CC=C2C1=O\", \"cofactor_name\": \"Azelastine\", \"cofactor_resource_id\": \"DB00972\", \"mechanism_of_action\": \"Azelastine is primarily a selective antagonist of histamine H1-receptors, with a lesser affinity for H2-receptors, used for the symptomatic treatment of allergies.[A1518,A1517,L8240,L8270] Histamine H1-receptors are G-protein-coupled receptors with 7 transmembrane spanning domains[A184328] that are found on nerve endings, smooth muscle cells, and glandular cells.[A687] Following allergen exposure in sensitized individuals, IgE-receptor cross-linking on mast cells results in the release of histamine, which binds to H1-receptors and contributes to typical allergic symptoms such as itching, sneezing, and congestion.[A687] \\r\\n\\r\\nThough its primary mode of action is thought to be via H1-receptor antagonism, azelastine (like other second-generation antihistamines) appears to affect other mediators of allergic symptomatology. Azelastine has mast cell-stabilizing properties that prevent the release of interleukin-6, tryptase, histamine, and TNF-alpha[A1518] from mast cells, and has been shown to reduce mediators of mast cell degranulation such as leukotrienes in the nasal lavage of patients with rhinitis,[A1517] as well as inhibiting their production and release from eosinophils (potentially via inhibition of phospholipase A<sub>2</sub> and leukotriene C<sub>4</sub> synthase).[A1518,A184373] Additionally, patients using oral azelastine were observed to have significantly reduced concentrations of substance P and bradykinin in nasal secretions[A1518], both of which may play a role in nasal itching and sneezing in patients with allergic rhinitis.\", \"neighbor_flag\": \"N\", \"pubmed_ids\": [10570018, 10383922], \"resource_name\": \"DrugBank\", \"resource_version\": \"5.1\", \"target_resource_id\": \"P10635\"}, {\"cofactor_in_ch_ikey\": \"BPZSYCZIITTYBL-UHFFFAOYSA-N\", \"cofactor_smiles\": \"COC1=CC=C(CC(C)NCC(O)C2=CC(NC=O)=C(O)C=C2)C=C1\", \"cofactor_name\": \"Formoterol\", \"cofactor_resource_id\": \"DB00983\", \"mechanism_of_action\": \"Formoterol is a relatively selective long-acting agonist of beta<sub>2</sub>-adrenergic receptors,[L10986,L11223] although it does carry some degree of activity at beta<sub>1</sub> and beta<sub>3</sub> receptors.[A15544] Beta<sub>2</sub> receptors are found predominantly in bronchial smooth muscle (with a relatively minor amount found in cardiac tissue) whereas beta<sub>1</sub> receptors are the predominant adrenergic receptors found in the heart - for this reason, selectivity for beta<sub>2</sub> receptors is desirable in the treatment of pulmonary diseases such as COPD and asthma.[L10986] Formoterol has demonstrated an approximately 200-fold greater activity at beta<sub>2</sub> receptors over beta<sub>1</sub> receptors.[L10986]\\r\\n\\r\\nOn a molecular level, activation of beta receptors by agonists like formoterol stimulates intracellular adenylyl cyclase, an enzyme responsible for the conversion of ATP to cyclic AMP (cAMP). The increased levels of cAMP in bronchial smooth muscle tissue result in relaxation of these muscles and subsequent dilation of the airways, as well as inhibition of the release of hypersensitivity mediators (e.g. histamine, leukotrienes) from culprit cells, especially mast cells.[L10986]\", \"neighbor_flag\": \"N\", \"resource_name\": \"DrugBank\", \"resource_version\": \"5.1\", \"target_resource_id\": \"P10635\"}, {\"cofactor_in_ch_ikey\": \"ANGKOCUUWGHLCE-UHFFFAOYSA-N\", \"cofactor_smiles\": \"C[N+]1(C)CCC(C1)OC(=O)C(O)(C1CCCC1)C1=CC=CC=C1\", \"cofactor_name\": \"Glycopyrronium\", \"cofactor_resource_id\": \"DB00986\", \"mechanism_of_action\": \"Glycopyrronium is a muscarinic antagonist with the highest affinity for M1 receptors, followed by M3, M2/M4, and M5.[L33115] \\r\\n\\r\\nMuscarinic receptors M1 to M4 are found in the lung, although M3 is predominantly responsible for bronchoconstriction and airway secretions.[A18287,L33145,L33115] Secretions from salivary[A233545] and sweat[A233550] glands, as well as gastric acid secretions,[A233555] are also predominantly mediated by the M3 receptor. Salivary[A233545] and gastric acid[A233555] secretions are also partially mediated by the M1 receptor. Antagonism of these receptors decreases the volume of their respective secretions, and in the case of the gastrointestinal system, reduces the acidity of the stomach.[A233560]\\r\\n\\r\\nIn the cardiovascular system, muscarinic receptors M1 to M5 are all present, however the function of M5 has not been described in literature.[A233560] Under normal circumstances, stimulation of the vagal nerve lowers the heart rate, potentially leading to intraoperative bradycardia.[A233560] Studies in mice suggest that this stimulation is predominantly mediated by the M3 receptor, and mutant knockout mice are not susceptible to these effects.[A233560]\", \"neighbor_flag\": \"N\", \"resource_name\": \"DrugBank\", \"resource_version\": \"5.1\", \"target_resource_id\": \"P10635\"}, {\"cofactor_in_ch_ikey\": \"AOJJSUZBOXZQNB-TZSSRYMLSA-N\", \"cofactor_smiles\": \"COC1=CC=CC2=C1C(=O)C1=C(O)C3=C(C[C@](O)(C[C@@H]3O[C@H]3C[C@H](N)[C@H](O)[C@H](C)O3)C(=O)CO)C(O)=C1C2=O\", \"cofactor_chem_comp_id\": \"DM2\", \"cofactor_name\": \"Doxorubicin\", \"cofactor_resource_id\": \"DB00997\", \"mechanism_of_action\": \"Generally, doxorubicin is thought to exert its antineoplastic activity through 2 primary mechanisms: intercalation into DNA and disrupt topoisomerase-mediated repairs and free radicals-mediated cellular damages.[A257614]\\r\\n\\r\\nDoxorubicin can intercalate into DNA through the anthraquinone ring, which stabilizes the complex by forming hydrogen bonds with DNA bases.[A257659] Intercalation of doxorubicin can introduce torsional stress into the polynucleotide structure, thus destabilizing nucleosome structures and leading to nucleosome eviction and replacement.[A257664,A18538] Additionally, the doxorubicin-DNA complex can interfere with topoisomerase II enzyme activity by preventing relegation of topoisomerase-mediated DNA breaks, thus inhibiting replication and transcription and inducing apoptosis.[A257669,A257674] \\r\\n\\r\\nMoreover, doxorubicin can be metabolized by microsomal NADPH-cytochrome P-450 reductase into a semiquinone radical, which can be reoxidized in the presence of oxygen to form oxygen radicals.[A1579,A257584] Reactive oxygen species have been known to cause cellular damage through various mechanisms, including lipid peroxidation and membrane damage, DNA damage, oxidative stress, and apoptosis.[A257634] Although free radicals generated from this pathway can be deactivated by catalase and superoxide dismutase, tumor and myocardial cells tend to lack these enzymes, thus explaining doxorubicin's effectiveness against cancer cells and tendency to cause cardiotoxicity.[A1579,A257584,A1578]\\r\\n\", \"neighbor_flag\": \"N\", \"pubmed_ids\": [8258200], \"resource_name\": \"DrugBank\", \"resource_version\": \"5.1\", \"target_resource_id\": \"P10635\"}, {\"cofactor_in_ch_ikey\": \"VDHAWDNDOKGFTD-MRXNPFEDSA-N\", \"cofactor_smiles\": \"C[C@@H](NCCCC1=CC(=CC=C1)C(F)(F)F)C1=CC=CC2=CC=CC=C12\", \"cofactor_chem_comp_id\": \"YP4\", \"cofactor_name\": \"Cinacalcet\", \"cofactor_resource_id\": \"DB01012\", \"mechanism_of_action\": \"Cinacalcet directly lowers parathyroid hormone levels by increasing the sensitivity of the calcium sensing receptors to activation by extracellular calcium, resulting in the inhibition of PTH secretion. The reduction in PTH is associated with a concomitant decrease in serum calcium levels.\", \"neighbor_flag\": \"N\", \"pubmed_ids\": [19566113, 16368445], \"resource_name\": \"DrugBank\", \"resource_version\": \"5.1\", \"target_resource_id\": \"P10635\"}, {\"cofactor_in_ch_ikey\": \"RZTAMFZIAATZDJ-UHFFFAOYSA-N\", \"cofactor_smiles\": \"CCOC(=O)C1=C(C)NC(C)=C(C1C1=C(Cl)C(Cl)=CC=C1)C(=O)OC\", \"cofactor_name\": \"Felodipine\", \"cofactor_resource_id\": \"DB01023\", \"mechanism_of_action\": \"Felodipine decreases arterial smooth muscle contractility and subsequent vasoconstriction by inhibiting the influx of calcium ions through voltage-gated L-type calcium channels. It reversibly competes against nitrendipine and other DHP CCBs for DHP binding sites in vascular smooth muscle and cultured rabbit atrial cells. Calcium ions entering the cell through these channels bind to calmodulin. Calcium-bound calmodulin then binds to and activates myosin light chain kinase (MLCK). Activated MLCK catalyzes the phosphorylation of the regulatory light chain subunit of myosin, a key step in muscle contraction. Signal amplification is achieved by calcium-induced calcium release from the sarcoplasmic reticulum through ryanodine receptors. Inhibition of the initial influx of calcium decreases the contractile activity of arterial smooth muscle cells and results in vasodilation. The vasodilatory effects of felodipine result in an overall decrease in blood pressure. Felodipine may be used to treat mild to moderate essential hypertension.\", \"neighbor_flag\": \"N\", \"pubmed_ids\": [10640508, 25028073], \"resource_name\": \"DrugBank\", \"resource_version\": \"5.1\", \"target_resource_id\": \"P10635\"}, {\"cofactor_in_ch_ikey\": \"XMAYWYJOQHXEEK-UHFFFAOYSA-N\", \"cofactor_smiles\": \"CC(=O)N1CCN(CC1)C1=CC=C(OCC2COC(CN3C=CN=C3)(O2)C2=CC=C(Cl)C=C2Cl)C=C1\", \"cofactor_chem_comp_id\": \"KTN\", \"cofactor_name\": \"Ketoconazole\", \"cofactor_resource_id\": \"DB01026\", \"mechanism_of_action\": \"Ketoconazole interacts with 14-&alpha;-sterol demethylase, a cytochrome P-450 enzyme necessary for the conversion of lanosterol to ergosterol.[A181802,T116] This results in inhibition of ergosterol synthesis and increased fungal cellular permeability due to reduced amounts of ergosterol present in the fungal cell membrane. This metabolic inhibition also results in accumulation of 14\\u03b1-methyl-3,6-diol, a toxic metabolite. The increase in membrane fluidity is also thought to produce impairment of membrane-bound enzyme systems as components become less closely packed.\", \"neighbor_flag\": \"N\", \"pubmed_ids\": [15618748], \"resource_name\": \"DrugBank\", \"resource_version\": \"5.1\", \"target_resource_id\": \"P10635\"}, {\"cofactor_in_ch_ikey\": \"RFKMCNOHBTXSMU-UHFFFAOYSA-N\", \"cofactor_smiles\": \"COC(F)(F)C(Cl)Cl\", \"cofactor_name\": \"Methoxyflurane\", \"cofactor_resource_id\": \"DB01028\", \"mechanism_of_action\": \"Methoxyflurane induces a reduction in junctional conductance by decreasing gap junction channel opening times and increasing gap junction channel closing times. Methoxyflurane also activates calcium dependent ATPase in the sarcoplasmic reticulum by increasing the fluidity of the lipid membrane. It also appears to bind the D subunit of ATP synthase and NADH dehydogenase. Methoxyflurane also binds to the GABA receptor, the large conductance Ca<sup>2+</sup> activated potassium channel, the glutamate receptor and the glycine receptor.\", \"neighbor_flag\": \"N\", \"pubmed_ids\": [8214760], \"resource_name\": \"DrugBank\", \"resource_version\": \"5.1\", \"target_resource_id\": \"P10635\"}, {\"cofactor_in_ch_ikey\": \"REQCZEXYDRLIBE-UHFFFAOYSA-N\", \"cofactor_smiles\": \"CCN(CC)CCNC(=O)C1=CC=C(N)C=C1\", \"cofactor_name\": \"Procainamide\", \"cofactor_resource_id\": \"DB01035\", \"mechanism_of_action\": \"Procainamide is sodium channel blocker. It stabilizes the neuronal membrane by inhibiting the ionic fluxes required for the initiation and conduction of impulses thereby effecting local anesthetic action.\", \"neighbor_flag\": \"N\", \"pubmed_ids\": [10634131], \"resource_name\": \"DrugBank\", \"resource_version\": \"5.1\", \"target_resource_id\": \"P10635\"}, {\"cofactor_in_ch_ikey\": \"OOGJQPCLVADCPB-HXUWFJFHSA-N\", \"cofactor_smiles\": \"CC(C)N(CC[C@H](C1=CC=CC=C1)C1=C(O)C=CC(C)=C1)C(C)C\", \"cofactor_name\": \"Tolterodine\", \"cofactor_resource_id\": \"DB01036\", \"mechanism_of_action\": \"Both tolterodine and its active metabolite, 5-hydroxymethyltolterodine, act as competitive antagonists at muscarinic receptors. This antagonism results in inhibition of bladder contraction, decrease in detrusor pressure, and an incomplete emptying of the bladder.\", \"neighbor_flag\": \"N\", \"pubmed_ids\": [19515014, 9630826, 20530222], \"resource_name\": \"DrugBank\", \"resource_version\": \"5.1\", \"target_resource_id\": \"P10635\"}, {\"cofactor_in_ch_ikey\": \"MEZLKOACVSPNER-GFCCVEGCSA-N\", \"cofactor_smiles\": \"C[C@H](CC1=CC=CC=C1)N(C)CC#C\", \"cofactor_name\": \"Selegiline\", \"cofactor_resource_id\": \"DB01037\", \"mechanism_of_action\": \"Although the mechanisms for selegiline's beneficial action in the treatment of Parkinson's disease are not fully understood, the selective, irreversible inhibition of monoamine oxidase type B (MAO-B) is thought to be of primary importance. MAO-B is involved in the oxidative deamination of dopamine in the brain. Selegiline binds to MAO-B within the nigrostriatal pathways in the central nervous system, thus blocking microsomal metabolism of dopamine and enhancing the dopaminergic activity in the substantial nigra. Selegiline may also increase dopaminergic activity through mechanisms other than inhibition of MAO-B. At higher doses, selegiline can also inhibit monozmine oxidase type A (MAO-A), allowing it to be used for the treatment of depression.\", \"neighbor_flag\": \"N\", \"pubmed_ids\": [16447756, 11996015], \"resource_name\": \"DrugBank\", \"resource_version\": \"5.1\", \"target_resource_id\": \"P10635\"}, {\"cofactor_in_ch_ikey\": \"XIQVNETUBQGFHX-UHFFFAOYSA-N\", \"cofactor_smiles\": \"CCN(CC)CC#CCOC(=O)C(O)(C1CCCCC1)C1=CC=CC=C1\", \"cofactor_name\": \"Oxybutynin\", \"cofactor_resource_id\": \"DB01062\", \"mechanism_of_action\": \"Oxybutynin acts to relax the bladder by inhibiting the muscarinic action of acetylcholine on smooth muscle, and not skeletal muscle.[L8648]\\r\\nThe active of oxybutynin is metabolite is N-desethyloxybutynin. It competitively inhibits the postganglionic type 1, 2 and 3 muscarinic receptors. The above actions lead to increased urine capacity in the bladder, decreasing urinary urgency and frequency.  In addition, oxybutynin delays the initial desire to void.[T689,L8648]\", \"neighbor_flag\": \"N\", \"pubmed_ids\": [9584328], \"resource_name\": \"DrugBank\", \"resource_version\": \"5.1\", \"target_resource_id\": \"P10635\"}, {\"cofactor_in_ch_ikey\": \"PWWVAXIEGOYWEE-UHFFFAOYSA-N\", \"cofactor_smiles\": \"CC(CN1C2=CC=CC=C2SC2=CC=CC=C12)N(C)C\", \"cofactor_name\": \"Promethazine\", \"cofactor_resource_id\": \"DB01069\", \"mechanism_of_action\": \"Promethazine is a an antagonist of histamine H1, post-synaptic mesolimbic dopamine, alpha adrenergic, muscarinic, and NMDA receptors.[A189907,A190153,A190159] The antihistamine action is used to treat allergic reactions.[A190150] Antagonism of muscarinic and NMDA receptors contribute to its use as a sleep aid, as well as for anxiety and tension.[A190159] Antagonism of histamine H1, muscarinic, and dopamine receptors in the medullary vomiting center make promethazine useful in the treatment of nausea and vomiting.[A190171]\", \"neighbor_flag\": \"N\", \"pubmed_ids\": [16670408, 8946477, 11936702], \"resource_name\": \"DrugBank\", \"resource_version\": \"5.1\", \"target_resource_id\": \"P10635\"}, {\"cofactor_in_ch_ikey\": \"HOKDBMAJZXIPGC-UHFFFAOYSA-N\", \"cofactor_smiles\": \"C(C1CN2CCC1CC2)N1C2=CC=CC=C2SC2=CC=CC=C12\", \"cofactor_name\": \"Mequitazine\", \"cofactor_resource_id\": \"DB01071\", \"mechanism_of_action\": \"Mequitazine binds to the histamine H1 receptor sites on effector cells in the gastrointestinal tract, blood vessels, and respiratory tract. This blocks the action of endogenous histamine, which subsequently leads to temporary relief of the negative symptoms brought on by histamine.\", \"neighbor_flag\": \"N\", \"pubmed_ids\": [9454781], \"resource_name\": \"DrugBank\", \"resource_version\": \"5.1\", \"target_resource_id\": \"P10635\"}, {\"cofactor_in_ch_ikey\": \"CYXKNKQEMFBLER-UHFFFAOYSA-N\", \"cofactor_smiles\": \"C(C(C1CCCCC1)C1CCCCC1)C1CCCCN1\", \"cofactor_name\": \"Perhexiline\", \"cofactor_resource_id\": \"DB01074\", \"mechanism_of_action\": \"Perhexiline binds to the mitochondrial enzyme carnitine palmitoyltransferase (CPT)-1 and CPT-2. It acts by shifting myocardial substrate utilisation from long chain fatty acids to carbohydrates through inhibition of CPT-1 and, to a lesser extent, CPT-2, resulting in increased glucose and lactate utilization. This results in increased ATP production for the same O2 consumption as before and consequently increases myocardial efficiency.\", \"neighbor_flag\": \"N\", \"pubmed_ids\": [17050648, 15025744], \"resource_name\": \"DrugBank\", \"resource_version\": \"5.1\", \"target_resource_id\": \"P10635\"}, {\"cofactor_in_ch_ikey\": \"ZZVUWRFHKOJYTH-UHFFFAOYSA-N\", \"cofactor_smiles\": \"CN(C)CCOC(C1=CC=CC=C1)C1=CC=CC=C1\", \"cofactor_chem_comp_id\": \"2PM\", \"cofactor_name\": \"Diphenhydramine\", \"cofactor_resource_id\": \"DB01075\", \"mechanism_of_action\": \"Diphenhydramine predominantly works via the antagonism of H1 (Histamine 1) receptors [L5263, L5266, L5269, F3379, A174541]. Such H1 receptors are located on respiratory smooth muscles, vascular endothelial cells, the gastrointestinal tract (GIT), cardiac tissue, immune cells, the uterus, and the central nervous system (CNS) neurons [L5263, L5266, L5269, F3379, A174541]. When the H1 receptor is stimulated in these tissues it produces a variety of actions including increased vascular permeability, promotion of vasodilation causing flushing, decreased atrioventricular (AV) node conduction time, stimulation of sensory nerves of airways producing coughing, smooth muscle contraction of bronchi and the GIT, and eosinophilic chemotaxis that promotes the allergic immune response [L5263, L5266, L5269, F3379, A174541].\\r\\n\\r\\nUltimately, diphenhydramine functions as an inverse agonist at H1 receptors, and subsequently reverses effects of histamine on capillaries, reducing allergic reaction symptoms [L5263, L5266, L5269, F3379, A174541]. Moreover, since diphenhydramine is a first-generation antihistamine, it readily crosses the blood-brain barrier and inversely agonizes the H1 CNS receptors, resulting in drowsiness, and suppressing the medullary cough center [L5263, L5266, L5269, F3379, A174541].\\r\\n\\r\\nFurthermore, H1 receptors are similar to muscarinic receptors [L5263, L5266, L5269, F3379, A174541]. Consequently, diphenhydramine also acts as an antimuscarinic [L5263, L5266, L5269, F3379, A174541]. It does so by behaving as a competitive antagonist of muscarinic acetylcholine receptors, resulting in its use as an antiparkinson medication [L5263, L5266, L5269, F3379, A174541].\\r\\n\\r\\nLastly, diphenhydramine has also demonstrated activity as an intracellular sodium channel blocker, resulting in possible local anesthetic properties [L5263].\", \"neighbor_flag\": \"N\", \"pubmed_ids\": [9616188, 17020955, 11270914], \"resource_name\": \"DrugBank\", \"resource_version\": \"5.1\", \"target_resource_id\": \"P10635\"}, {\"cofactor_in_ch_ikey\": \"XUKUURHRXDUEBC-KAYWLYCHSA-N\", \"cofactor_smiles\": \"CC(C)C1=C(C(=O)NC2=CC=CC=C2)C(=C(N1CC[C@@H](O)C[C@@H](O)CC(O)=O)C1=CC=C(F)C=C1)C1=CC=CC=C1\", \"cofactor_chem_comp_id\": \"117\", \"cofactor_name\": \"Atorvastatin\", \"cofactor_resource_id\": \"DB01076\", \"mechanism_of_action\": \"Atorvastatin is a statin medication and a competitive inhibitor of the enzyme HMG-CoA (3-hydroxy-3-methylglutaryl coenzyme A) reductase, which catalyzes the conversion of HMG-CoA to mevalonate, an early rate-limiting step in cholesterol biosynthesis.[A177388,A181421] Atorvastatin acts primarily in the liver, where decreased hepatic cholesterol concentrations stimulate the upregulation of hepatic low-density lipoprotein (LDL) receptors, which increases hepatic uptake of LDL. Atorvastatin also reduces Very-Low-Density Lipoprotein-Cholesterol (VLDL-C), serum triglycerides (TG) and Intermediate Density Lipoproteins (IDL), as well as the number of apolipoprotein B (apo B) containing particles, but increases High-Density Lipoprotein Cholesterol (HDL-C). \\r\\n\\r\\n_In vitro_ and _in vivo_ animal studies also demonstrate that atorvastatin exerts vasculoprotective effects independent of its lipid-lowering properties, also known as the pleiotropic effects of statins.[A181424] These effects include improvement in endothelial function, enhanced stability of atherosclerotic plaques, reduced oxidative stress and inflammation, and inhibition of the thrombogenic response. Statins were also found to bind allosterically to \\u03b22 integrin function-associated antigen-1 (LFA-1), which plays an essential role in leukocyte trafficking and T cell activation.[A181559]\", \"neighbor_flag\": \"N\", \"pubmed_ids\": [11523064], \"resource_name\": \"DrugBank\", \"resource_version\": \"5.1\", \"target_resource_id\": \"P10635\"}, {\"cofactor_in_ch_ikey\": \"IKBKZGMPCYNSLU-RGVLZGJSSA-N\", \"cofactor_smiles\": \"CCCCCNC(=N)N\\\\N=C\\\\C1=CNC2=C1C=C(OC)C=C2\", \"cofactor_chem_comp_id\": \"A1IVL\", \"cofactor_name\": \"Tegaserod\", \"cofactor_resource_id\": \"DB01079\", \"mechanism_of_action\": \"Irritable bowel syndrome (IBS) is a complex functional disorder comprised of various abnormal and discomforting effects on the gastrointestinal tract and bowel function [A176669, F4223, F4226, F4229]. Although the cause of IBS has yet to be formally elucidated, patient experience has demonstrated that the disorder is typically associated with abdominal pain, abdominal distension, cramping or bloating, variations in urgency for bowel movements, feelings of incomplete evacuation, gastroesophageal reflux, and various other effects [A176669, F4223, F4226, F4229]. In particular, IBS that features constipation as a predominant effect is categorized as constipation-predominant IBS, or IBS-C [F4223, F4229].\\r\\n\\r\\nConcurrently, 5-Hydroxytryptamine (5-HT, or serotonin) has demonstrated the ability to elicit significant regulatory actions on gastrointestinal motility [A11044]. Specifically, it has been shown that the activation of 5-HT(4) receptors located on motor neurons and interneurons in the gastrointestinal wall can cause the release of acetylcholine, substance P, and calcitonin gene-related peptide that can all facilitate the propulsion of material through the gut [A11044]. Moreover, when 5-HT(4) receptors located in smooth muscle cells are also activated, activities that may alleviate symptoms of IBS-C like esophageal relaxation and the inhibition of human colonic circular muscle contraction can also occur [A11044]. Additionally, activating 5-HT(4) on enteric neurons and enterocytes also cause natural fluid secretion in the gut - an action which also strongly assists in promoting the movement of content along the gastrointestinal tract [A11044].\\r\\n\\r\\nAlternatively, it has also been observed that 5-HT may participate in generating visceral hyperalgesia in IBS, an observation supported in part by the finding of increased amounts of 5-HT and its metabolites in the plasma of patients experiencing IBS [A176762] It has therefore also been proposed that antagonism of 5-HT(2B) receptors can lead to inhibition of both 5-HT mediated gastrointestinal motility and visceral hypersensitivity [A11044].\\r\\n\\r\\nSubsequently, because tegaserod is considered to be an agonist of the 5-HT(4) receptor and an antagonist of the 5-HT(2B) receptor at clinically relevant levels, it is believed that tegaserod may elicit its mechanism of action by facilitating activities associated with the activation and antagonism of the 5-HT(4) and 5-HT(2B) receptors, like stimulating peristaltic gastrointestinal reflexes and intestinal secretion, inhibiting visceral sensitivity, enhancing basal motor activity, and normalizing impaired motility throughout the gastrointestinal tract, among other actions [A11044, A176762, F4223, F4226, F4229]. \", \"neighbor_flag\": \"N\", \"pubmed_ids\": [11560869], \"resource_name\": \"DrugBank\", \"resource_version\": \"5.1\", \"target_resource_id\": \"P10635\"}, {\"cofactor_in_ch_ikey\": \"BLFLLBZGZJTVJG-UHFFFAOYSA-N\", \"cofactor_smiles\": \"CCOC(=O)C1=CC=C(N)C=C1\", \"cofactor_name\": \"Benzocaine\", \"cofactor_resource_id\": \"DB01086\", \"mechanism_of_action\": \"Benzocaine diffuses into nerve cells where it binds to sodium channels, preventing the channels from opening, and blocking the influx of sodium ions.[A231129,A6271,A231219] Nerve cells unable to allow sodium into cells cannot depolarize and conduct nerve impulses.[A6271,A231219]\", \"neighbor_flag\": \"N\", \"pubmed_ids\": [25010377], \"resource_name\": \"DrugBank\", \"resource_version\": \"5.1\", \"target_resource_id\": \"P10635\"}, {\"cofactor_in_ch_ikey\": \"INDBQLZJXZLFIT-UHFFFAOYSA-N\", \"cofactor_smiles\": \"COC1=CC(NC(C)CCCN)=C2N=CC=CC2=C1\", \"cofactor_name\": \"Primaquine\", \"cofactor_resource_id\": \"DB01087\", \"mechanism_of_action\": \"Primaquine's mechanism of action is not well understood. It may be acting by generating reactive oxygen species or by interfering with the electron transport in the parasite. Also, although its mechanism of action is unclear, primaquine may bind to and alter the properties of protozoal DNA.\", \"neighbor_flag\": \"N\", \"pubmed_ids\": [7621845], \"resource_name\": \"DrugBank\", \"resource_version\": \"5.1\", \"target_resource_id\": \"P10635\"}, {\"cofactor_in_ch_ikey\": \"IAZDPXIOMUYVGZ-UHFFFAOYSA-N\", \"cofactor_smiles\": \"CS(C)=O\", \"cofactor_chem_comp_id\": \"DMS\", \"cofactor_name\": \"Dimethyl sulfoxide\", \"cofactor_resource_id\": \"DB01093\", \"mechanism_of_action\": \"The mechanism of dimethyl sulfoxide's actions is not well understood. Dimethyl sulfoxide has demonstrated antioxidant activity in certain biological settings. For example, the cardiovascular protective effect of dimethyl sulfoxide in copper-deficient rats is thought to occur by an antioxidant mechanism. It is also thought that dimethyl sulfoxide's possible anti-inflammatory activity is due to antioxidant action.\", \"neighbor_flag\": \"Y\", \"pubmed_ids\": [9929510], \"resource_name\": \"DrugBank\", \"resource_version\": \"5.1\", \"target_resource_id\": \"P10635\"}, {\"cofactor_in_ch_ikey\": \"FJLGEFLZQAZZCD-VAWYXSNFSA-N\", \"cofactor_smiles\": \"CC(C)N1C(\\\\C=C\\\\C(O)CC(O)CC(O)=O)=C(C2=CC=CC=C12)C1=CC=C(F)C=C1\", \"cofactor_chem_comp_id\": \"115\", \"cofactor_name\": \"Fluvastatin\", \"cofactor_resource_id\": \"DB01095\", \"mechanism_of_action\": \"Fluvastatin selectively and competitively inhibits the hepatic enzyme hydroxymethylglutaryl-coenzyme A (HMG-CoA) reductase. HMG-CoA reductase is responsible for converting HMG-CoA to mevalonate, the rate-limiting step in cholesterol biosynthesis. Inhibition results in a decrease in hepatic cholesterol levels which stimulates the synthesis of LDL receptors and increases hepatic uptake of LDL cholesterol. The end result is decreased levels of plasma total and LDL cholesterol. \", \"neighbor_flag\": \"N\", \"pubmed_ids\": [11523064, 11368292, 19515014], \"resource_name\": \"DrugBank\", \"resource_version\": \"5.1\", \"target_resource_id\": \"P10635\"}, {\"cofactor_in_ch_ikey\": \"XCGYUJZMCCFSRP-UHFFFAOYSA-N\", \"cofactor_smiles\": \"CC(C)NCC1CCC2=CC(CO)=C(C=C2N1)[N+]([O-])=O\", \"cofactor_name\": \"Oxamniquine\", \"cofactor_resource_id\": \"DB01096\", \"mechanism_of_action\": \"Oxamniquine may associate with an irreversible inhibition of the nucleic acid metabolism of the parasites. A hypothesis has been put forth that the drug is activated by a single step, in which a schistosome sulfotransferase enzyme converts oxamniquine into an ester (probably acetate, phosphate, or sulfate). Subsequently, the ester spontaneously dissociates, the resulting electrophilic reactant is capable of alkylation of schistosome DNA.\", \"neighbor_flag\": \"N\", \"pubmed_ids\": [7621845], \"resource_name\": \"DrugBank\", \"resource_version\": \"5.1\", \"target_resource_id\": \"P10635\"}, {\"cofactor_in_ch_ikey\": \"YVUQSNJEYSNKRX-UHFFFAOYSA-N\", \"cofactor_smiles\": \"FC1=CC=C(C=C1)C(CCCN1CCC(CC1)N1C(=O)NC2=CC=CC=C12)C1=CC=C(F)C=C1\", \"cofactor_chem_comp_id\": \"1II\", \"cofactor_name\": \"Pimozide\", \"cofactor_resource_id\": \"DB01100\", \"mechanism_of_action\": \"The ability of pimozide to suppress motor and phonic tics in Tourette's Disorder is thought to be primarily a function of its dopaminergic blocking activity. Pimozide binds and inhibits the dopamine D2 receptor in the CNS. \", \"neighbor_flag\": \"N\", \"pubmed_ids\": [9580580], \"resource_name\": \"DrugBank\", \"resource_version\": \"5.1\", \"target_resource_id\": \"P10635\"}, {\"cofactor_in_ch_ikey\": \"VGKDLMBJGBXTGI-SJCJKPOMSA-N\", \"cofactor_smiles\": \"CN[C@H]1CC[C@@H](C2=CC(Cl)=C(Cl)C=C2)C2=CC=CC=C12\", \"cofactor_chem_comp_id\": \"SRE\", \"cofactor_name\": \"Sertraline\", \"cofactor_resource_id\": \"DB01104\", \"mechanism_of_action\": \"Sertraline selectively inhibits the reuptake of serotonin (5-HT) at the presynaptic neuronal membrane, thereby increasing serotonergic activity. This results in an increased synaptic concentration of serotonin in the CNS, which leads to numerous functional changes associated with enhanced serotonergic neurotransmission.[T28,L9016] These changes are believed to be responsible for the antidepressant action and beneficial effects in obsessive-compulsive (and other anxiety related disorders). It has been hypothesized that obsessive-compulsive disorder, like depression, is also caused by the disregulation of serotonin.[A187165]\\r\\n\\r\\nIn animal studies, chronic administration of sertraline results in down-regulation of brain norepinephrine receptors.[L9016] Sertraline displays affinity for sigma-1 and 2 receptor binding sites[A31941], but binds with stronger affinity to sigma-1 binding sites.[A31940] In vitro, sertraline shows little to no affinity for GABA, dopaminergic, serotonergic (5HT1A, 5HT1B, 5HT2), or benzodiazepine receptors.[L9016] It exerts weak inhibitory actions on the neuronal uptake of norepinephrine and dopamine[A1844] and exhibits no inhibitory effects on the monoamine oxidase enzyme.[L9016]\", \"neighbor_flag\": \"N\", \"pubmed_ids\": [8968657, 16910628, 12143142, 15547048], \"resource_name\": \"DrugBank\", \"resource_version\": \"5.1\", \"target_resource_id\": \"P10635\"}, {\"cofactor_in_ch_ikey\": \"BYBLEWFAAKGYCD-UHFFFAOYSA-N\", \"cofactor_smiles\": \"ClC1=CC(Cl)=C(COC(CN2C=CN=C2)C2=C(Cl)C=C(Cl)C=C2)C=C1\", \"cofactor_name\": \"Miconazole\", \"cofactor_resource_id\": \"DB01110\", \"mechanism_of_action\": \"Miconazole is an azole antifungal used to treat a variety of conditions, including those caused by _Candida_ overgrowth. Unique among the azoles, miconazole is thought to act through three main mechanisms.[A203636] The primary mechanism of action is through inhibition of the CYP450 14\\u03b1-lanosterol demethylase enzyme, which results in altered ergosterol production and impaired cell membrane composition and permeability, which in turn leads to cation, phosphate, and low molecular weight protein leakage.[A203636, A203639]\\r\\n\\r\\nIn addition, miconazole inhibits fungal peroxidase and catalase while not affecting NADH oxidase activity, leading to increased production of reactive oxygen species (ROS).[A203636, A203639, A203642] Increased intracellular ROS leads to downstream pleiotropic effects and eventual apoptosis.[A203636]\\r\\n\\r\\nLastly, likely as a result of lanosterol demethylation inhibition, miconazole causes a rise in intracellular levels of farnesol. This molecule participates in quorum sensing in _Candida_, preventing the transition from yeast to mycelial forms and thereby the formation of biofilms, which are more resistant to antibiotics.[A203645, A203648] In addition, farnesol is an inhibitor of drug efflux ABC transporters, namely _Candida_ CaCdr1p and CaCdr2p, which may additionally contribute to increased effectiveness of azole drugs.[A203648]\", \"neighbor_flag\": \"N\", \"pubmed_ids\": [16141569, 11854151], \"resource_name\": \"DrugBank\", \"resource_version\": \"5.1\", \"target_resource_id\": \"P10635\"}, {\"cofactor_in_ch_ikey\": \"SOYKEARSMXGVTM-UHFFFAOYSA-N\", \"cofactor_smiles\": \"CN(C)CCC(C1=CC=C(Cl)C=C1)C1=CC=CC=N1\", \"cofactor_name\": \"Chlorpheniramine\", \"cofactor_resource_id\": \"DB01114\", \"mechanism_of_action\": \"Chlorpheniramine binds to the histamine H1 receptor. This blocks the action of endogenous histamine, which subsequently leads to temporary relief of the negative symptoms brought on by histamine.\", \"neighbor_flag\": \"N\", \"pubmed_ids\": [9616188, 7648771, 11994058, 11936702], \"resource_name\": \"DrugBank\", \"resource_version\": \"5.1\", \"target_resource_id\": \"P10635\"}, {\"cofactor_in_ch_ikey\": \"HYIMSNHJOBLJNT-UHFFFAOYSA-N\", \"cofactor_smiles\": \"COC(=O)C1=C(C)NC(C)=C(C1C1=CC=CC=C1[N+]([O-])=O)C(=O)OC\", \"cofactor_chem_comp_id\": \"C5U\", \"cofactor_name\": \"Nifedipine\", \"cofactor_resource_id\": \"DB01115\", \"mechanism_of_action\": \"Nifedipine blocks voltage gated L-type calcium channels in vascular smooth muscle and myocardial cells.[A190204] This blockage prevents the entry of calcium ions into cells during depolarization, reducing peripheral arterial vascular resistance and dilating coronary arteries.[A190204] These actions reduce blood pressure and increase the supply of oxygen to the heart, alleviating angina.[A190204]\", \"neighbor_flag\": \"N\", \"pubmed_ids\": [10640508], \"resource_name\": \"DrugBank\", \"resource_version\": \"5.1\", \"target_resource_id\": \"P10635\"}, {\"cofactor_in_ch_ikey\": \"IYIKLHRQXLHMJQ-UHFFFAOYSA-N\", \"cofactor_smiles\": \"CCCCC1=C(C(=O)C2=CC(I)=C(OCCN(CC)CC)C(I)=C2)C2=C(O1)C=CC=C2\", \"cofactor_chem_comp_id\": \"BBI\", \"cofactor_name\": \"Amiodarone\", \"cofactor_resource_id\": \"DB01118\", \"mechanism_of_action\": \"Amiodarone is considered a class III anti-arrhythmic drug. It blocks potassium currents that cause repolarization of the heart muscle during the third phase of the cardiac action potential. As a result amiodarone increases the duration of the action potential as well as the effective refractory period for cardiac cells (myocytes). Therefore, cardiac muscle cell excitability is reduced, preventing and treating abnormal heart rhythms.[A183137,A189747]\\r\\n\\r\\nUnique from other members of the class III anti-arrhythmic drug class, amiodarone also interferes with the functioning of beta-adrenergic receptors, sodium channels, and calcium channels channels. These actions, at times, can lead to undesirable effects, such as hypotension, bradycardia, and Torsades de pointes (TdP).[L11265] In addition to the above, amiodarone may increase activity of peroxisome proliferator-activated receptors, leading to steatogenic changes in the liver or other organs.[A20227,A20650] Finally, amiodarone has been found to bind to the thyroid receptor due to its iodine content, potentially leading to amiodarone induced hypothyroidism or thyrotoxicosis.[A182168]\", \"neighbor_flag\": \"N\", \"pubmed_ids\": [19515014, 12688833, 10718780, 17220566, 7897605], \"resource_name\": \"DrugBank\", \"resource_version\": \"5.1\", \"target_resource_id\": \"P10635\"}, {\"cofactor_in_ch_ikey\": \"LKJPYSCBVHEWIU-UHFFFAOYSA-N\", \"cofactor_smiles\": \"CC(O)(CS(=O)(=O)C1=CC=C(F)C=C1)C(=O)NC1=CC(=C(C=C1)C#N)C(F)(F)F\", \"cofactor_name\": \"Bicalutamide\", \"cofactor_resource_id\": \"DB01128\", \"mechanism_of_action\": \"Bicalutamide competes with androgen for the binding of androgen receptors, consequently blocking the action of androgens of adrenal and testicular origin which stimulate the growth of normal and malignant prostatic tissue.\", \"neighbor_flag\": \"N\", \"pubmed_ids\": [15509184], \"resource_name\": \"DrugBank\", \"resource_version\": \"5.1\", \"target_resource_id\": \"P10635\"}, {\"cofactor_in_ch_ikey\": \"YREYEVIYCVEVJK-UHFFFAOYSA-N\", \"cofactor_smiles\": \"COCCCOC1=C(C)C(CS(=O)C2=NC3=CC=CC=C3N2)=NC=C1\", \"cofactor_name\": \"Rabeprazole\", \"cofactor_resource_id\": \"DB01129\", \"mechanism_of_action\": \"Rabeprazole belongs to a class of antisecretory compounds (substituted benzimidazole proton-pump inhibitors) that do not exhibit anticholinergic or histamine H2-receptor antagonist properties, but suppress gastric acid secretion by inhibiting the gastric H<sup>+</sup>/K<sup>+</sup>ATPase (hydrogen-potassium adenosine triphosphatase) at the secretory surface of the gastric parietal cell. Because this enzyme is regarded as the acid (proton) pump within the parietal cell, rabeprazole has been characterized as a gastric proton-pump inhibitor. Rabeprazole blocks the final step of gastric acid secretion. In gastric parietal cells, rabeprazole is protonated, accumulates, and is transformed to an active sulfenamide. When studied in vitro, rabeprazole is chemically activated at pH 1.2 with a half-life of 78 seconds.\", \"neighbor_flag\": \"N\", \"pubmed_ids\": [15258107, 22648560], \"resource_name\": \"DrugBank\", \"resource_version\": \"5.1\", \"target_resource_id\": \"P10635\"}, {\"cofactor_in_ch_ikey\": \"SSOLNOMRVKKSON-UHFFFAOYSA-N\", \"cofactor_smiles\": \"CC(C)NC(=N)NC(=N)NC1=CC=C(Cl)C=C1\", \"cofactor_chem_comp_id\": \"XEW\", \"cofactor_name\": \"Proguanil\", \"cofactor_resource_id\": \"DB01131\", \"mechanism_of_action\": \"Proguanil inhibits the dihydrofolate reductase of plasmodia and thereby blocks the biosynthesis of purines and pyrimidines, which are essential for DNA synthesis and cell multiplication. This leads to failure of nuclear division at the time of schizont formation in erythrocytes and liver.\", \"neighbor_flag\": \"N\", \"pubmed_ids\": [11124226], \"resource_name\": \"DrugBank\", \"resource_version\": \"5.1\", \"target_resource_id\": \"P10635\"}, {\"cofactor_in_ch_ikey\": \"OGHNVEJMJSYVRP-UHFFFAOYSA-N\", \"cofactor_smiles\": \"COC1=CC=CC=C1OCCNCC(O)COC1=CC=CC2=C1C1=CC=CC=C1N2\", \"cofactor_name\": \"Carvedilol\", \"cofactor_resource_id\": \"DB01136\", \"mechanism_of_action\": \"Carvedilol inhibits exercise induce tachycardia through its inhibition of beta adrenoceptors.[A182306] Carvedilol's action on alpha-1 adrenergic receptors relaxes smooth muscle in vasculature, leading to reduced peripheral vascular resistance and an overall reduction in blood pressure.[A1929,A182306] At higher doses, calcium channel blocking and antioxidant activity can also be seen.[A1929] The antioxidant activity of carvedilol prevents oxidation of low density lipoprotein and its uptake into coronary circulation.[A1929]\", \"neighbor_flag\": \"N\", \"pubmed_ids\": [19515014], \"resource_name\": \"DrugBank\", \"resource_version\": \"5.1\", \"target_resource_id\": \"P10635\"}, {\"cofactor_in_ch_ikey\": \"ODQWQRRAPPTVAG-UHFFFAOYSA-N\", \"cofactor_smiles\": \"[H]C(CCN(C)C)=C1C2=CC=CC=C2COC2=CC=CC=C12\", \"cofactor_name\": \"Doxepin\", \"cofactor_resource_id\": \"DB01142\", \"mechanism_of_action\": \"Doxepin exact mechanism of action is not very clear. However, doxepin is known to be a selective histamine H1 receptor blocker.[A177163] This effect on histamine receptors indicates effectiveness in skin conditions.[T249]\\r\\n\\r\\nBreaking its function according to the different effect, doxepin's antidepressive action is primarily associated with the inhibition of the central nervous system biogenic amine reuptake; more specifically, norepinephrine and serotonin at synaptic nerve terminals. This effect increases the level of monoamines in the synaptic site which in order increases the activity at the post-synaptic neuron receptor sites.[T388] It has been suggested that doxepin also desensitizes both serotonin 1A receptors and beta-adrenergic receptors.[T249]\\r\\n\\r\\nIt is known that the lack of dopamine transporters in the frontal cortex and the transmission of dopamine in this region is largely inactivated by the effect of norepinephrine reuptake. Hence, doxepin action on the frontal cortex is suggested to increase dopamine neurotransmission in this area.[T249]\", \"neighbor_flag\": \"N\", \"pubmed_ids\": [15520506, 15168101, 12360109, 11037801], \"resource_name\": \"DrugBank\", \"resource_version\": \"5.1\", \"target_resource_id\": \"P10635\"}, {\"cofactor_in_ch_ikey\": \"VRBKIVRKKCLPHA-UHFFFAOYSA-N\", \"cofactor_smiles\": \"CCC1=NN(CCCN2CCN(CC2)C2=CC(Cl)=CC=C2)C(=O)N1CCOC1=CC=CC=C1\", \"cofactor_name\": \"Nefazodone\", \"cofactor_resource_id\": \"DB01149\", \"mechanism_of_action\": \"Within the serotonergic system, nefazodone acts as an antagonist at type 2 serotonin (5-HT<sub>2</sub>) post-synaptic receptors and, like fluoxetine-type antidepressants, inhibits pre-synaptic serotonin (5-HT) reuptake. These mechanisms increase the amount of serotonin available to interact with 5-HT receptors. Within the noradrenergic system, nefazodone inhibits norepinephrine uptake minimally. Nefazodone also antagonizes alpha(1)-adrenergic receptors, producing sedation, muscle relaxation, and a variety of cardiovascular effects. Nefazodone's affinity for benzodiazepine, cholinergic, dopaminergic, histaminic, and beta or alpha(2)-adrenergic receptors is not significant.\", \"neighbor_flag\": \"N\", \"pubmed_ids\": [10445380, 9342502], \"resource_name\": \"DrugBank\", \"resource_version\": \"5.1\", \"target_resource_id\": \"P10635\"}, {\"cofactor_in_ch_ikey\": \"HCYAFALTSJYZDH-UHFFFAOYSA-N\", \"cofactor_smiles\": \"CNCCCN1C2=CC=CC=C2CCC2=CC=CC=C12\", \"cofactor_chem_comp_id\": \"DSM\", \"cofactor_name\": \"Desipramine\", \"cofactor_resource_id\": \"DB01151\", \"mechanism_of_action\": \"Desipramine is a tricyclic antidepressant (TCA) that selectively blocks reuptake of norepinephrine (noradrenaline) from the neuronal synapse. It also inhibits serotonin reuptake, but to a lesser extent compared to tertiary amine TCAs such as imipramine. Inhibition of neurotransmitter reuptake increases stimulation of the post-synaptic neuron.  Chronic use of desipramine also leads to down-regulation of beta-adrenergic receptors in the cerebral cortex and sensitization of serotonergic receptors. An overall increase in serotonergic transmission likely confers desipramine its antidepressant effects. Desipramine also possesses minor anticholinergic activity, through its affinity for muscarinic receptors. TCAs are believed to act by restoring normal levels of neurotransmitters via synaptic reuptake inhibition and by increasing serotonergic neurotransmission via serotonergic receptor sensitization in the central nervous system.\", \"neighbor_flag\": \"N\", \"pubmed_ids\": [8968657, 11996013, 15802801, 9884317], \"resource_name\": \"DrugBank\", \"resource_version\": \"5.1\", \"target_resource_id\": \"P10635\"}, {\"cofactor_in_ch_ikey\": \"SNPPWIUOZRMYNY-UHFFFAOYSA-N\", \"cofactor_smiles\": \"CC(NC(C)(C)C)C(=O)C1=CC(Cl)=CC=C1\", \"cofactor_name\": \"Bupropion\", \"cofactor_resource_id\": \"DB01156\", \"mechanism_of_action\": \"Bupropion is a norepinephrine/dopamine-reuptake inhibitor (NDRI) that exerts its pharmacological effects by weakly inhibiting the enzymes involved in the uptake of the neurotransmitters norepinephrine and dopamine from the synaptic cleft, therefore prolonging their duration of action within the neuronal synapse and the downstream effects of these neurotransmitters. More specifically, bupropion binds to the norepinephrine transporter (NET) and the dopamine transporter (DAT).[A6399,A178810] \\r\\n\\r\\nBupropion was originally classified as an \\\"atypical\\\" antidepressant because it does not exert the same effects as the classical antidepressants such as Monoamine Oxidase Inhibitors (MAOIs), Tricyclic Antidepressants (TCAs), or Selective Serotonin Reuptake Inhibitors (SSRIs). While it has comparable effectiveness to typical first-line options for the treatment of depression such as SSRIs,[A178798,A178804] bupropion is a unique option for the treatment of MDD as it lacks any clinically relevant serotonergic effects, typical of other mood medications, or any effects on histamine or adrenaline receptors.[A6399,A178840] Lack of activity at these receptors results in a more tolerable side effect profile; bupropion is less likely to cause sexual side effects, sedation, or weight gain as compared to SSRIs or TCAs, for example.[A178804,A178807]\\r\\n\\r\\nWhen used as an aid to smoking cessation, bupropion is thought to confer its anti-craving and anti-withdrawal effects by inhibiting dopamine reuptake, which is thought to be involved in the reward pathways associated with nicotine, and through the antagonism of the nicotinic acetylcholinergic receptor (AChR), thereby blunting the effects of nicotine.[A178825,A1966,A16508] Furthermore, the stimulatory effects produced by bupropion in the central nervous system are similar to nicotine's effects, making low doses of bupropion a suitable option as a nicotine substitute.[A179062]  \\r\\n\\r\\nWhen used in combination with [naltrexone] in the marketed product Contrave\\u24c7 for chronic weight management, the two components are thought to have effects on areas of the brain involved in the regulation of food intake. This includes the hypothalamus, which is involved in appetite regulation, and the mesolimbic dopamine circuit, which is involved in reward pathways.[L6562] Studies have shown that the combined activity of bupropion and [naltrexone] increase the firing rate of hypothalamic pro-opiomelanocortin (POMC) neurons and blockade of opioid receptor-mediated POMC auto-inhibition, which are associated with a reduction in food intake and increased energy expenditure.[L6562,A179038,A179050] This combination was also found to reduce food intake when injected directly into the ventral tegmental area of the mesolimbic circuit in mice, which is an area associated with the regulation of reward pathways.[L6562]\", \"neighbor_flag\": \"N\", \"pubmed_ids\": [17009913, 15876900, 27836670], \"resource_name\": \"DrugBank\", \"resource_version\": \"5.1\", \"target_resource_id\": \"P10635\"}, {\"cofactor_in_ch_ikey\": \"RRGUKTPIGVIEKM-UHFFFAOYSA-N\", \"cofactor_smiles\": \"O=C1CCC2=C(N1)C=CC(OCCCCC1=NN=NN1C1CCCCC1)=C2\", \"cofactor_name\": \"Cilostazol\", \"cofactor_resource_id\": \"DB01166\", \"mechanism_of_action\": \"Cilostazol and several of its metabolites are cyclic AMP (cAMP) phosphodiesterase III inhibitors (PDE III inhibitors), inhibiting phosphodiesterase activity and suppressing cAMP degradation with a resultant increase in cAMP in platelets and blood vessels, leading to inhibition of platelet aggregation and vasodilation.\", \"neighbor_flag\": \"N\", \"pubmed_ids\": [10702888], \"resource_name\": \"DrugBank\", \"resource_version\": \"5.1\", \"target_resource_id\": \"P10635\"}, {\"cofactor_in_ch_ikey\": \"YHXISWVBGDMDLQ-UHFFFAOYSA-N\", \"cofactor_smiles\": \"ClC1=CC=C(C=C1)C(=O)NCCN1CCOCC1\", \"cofactor_name\": \"Moclobemide\", \"cofactor_resource_id\": \"DB01171\", \"mechanism_of_action\": \"The mechanism of action of moclobemide involves the selective, reversible inhibition of MAO-A. This inhibition leads to a decrease in the metabolism and destruction of monoamines in the neurotransmitters. This results in an increase in the monoamines, relieving depressive symptoms [A31901, A31902].\", \"neighbor_flag\": \"N\", \"pubmed_ids\": [8880082, 9489930], \"resource_name\": \"DrugBank\", \"resource_version\": \"5.1\", \"target_resource_id\": \"P10635\"}, {\"cofactor_in_ch_ikey\": \"QVYRGXJJSLMXQH-UHFFFAOYSA-N\", \"cofactor_smiles\": \"CN(C)CCOC(C1=CC=CC=C1)C1=CC=CC=C1C\", \"cofactor_name\": \"Orphenadrine\", \"cofactor_resource_id\": \"DB01173\", \"mechanism_of_action\": \"Orphenadrine binds and inhibits both histamine H1 receptors and NMDA receptors. It restores the motor disturbances induced by neuroleptics, in particular the hyperkinesia. The dopamine deficiency in the striatum increases the stimulating effects of the cholinergic system. This stimulation is counteracted by the anticholinergic effect of orphenadrine. It may have a relaxing effect on skeletal muscle spasms and it has a mood elevating effect.\", \"neighbor_flag\": \"N\", \"pubmed_ids\": [9172960, 12813002, 10583023], \"resource_name\": \"DrugBank\", \"resource_version\": \"5.1\", \"target_resource_id\": \"P10635\"}, {\"cofactor_in_ch_ikey\": \"WSEQXVZVJXJVFP-FQEVSTJZSA-N\", \"cofactor_smiles\": \"CN(C)CCC[C@]1(OCC2=C1C=CC(=C2)C#N)C1=CC=C(F)C=C1\", \"cofactor_chem_comp_id\": \"68P\", \"cofactor_name\": \"Escitalopram\", \"cofactor_resource_id\": \"DB01175\", \"mechanism_of_action\": \"Escitalopram, like other selective serotonin re-uptake inhibitors, enhances serotonergic activity by binding to the orthosteric (i.e. primary) binding site on the serotonin transporter (SERT), the same site to which endogenous 5-HT binds, and thus prevents the re-uptake of serotonin into the presynaptic neuron.[A185420,A39738,A185726] Escitalopram, along with [paroxetine], is also considered an allosteric serotonin re-uptake inhibitor - it binds to a secondary allosteric site on the SERT molecule to more strongly inhibit 5-HT re-uptake. Its combination of orthosteric and allosteric activity on SERT allows for greater extracellular 5-HT levels, a faster onset of action, and greater efficacy as compared to other SSRIs. [A185825,A185726] The sustained elevation of synaptic 5-HT eventually causes desensitization of 5-HT<sub>1A</sub> auto-receptors, which normally shut down endogenous 5-HT release in the presence of excess 5-HT - this desensitization may be necessary for the full clinical effect of SSRIs and may be responsible for their typically prolonged onset of action.[A185828,A185726]\\r\\n\\r\\nEscitalopram has shown little-to-no binding affinity at a number of other receptors, such as histamine and muscarinic receptors, and minor activity at these off-targets may explain some of its adverse effects.[L8513,L8516,L8522,A185726]\", \"neighbor_flag\": \"N\", \"pubmed_ids\": [8968657, 24302953, 19710642, 17375980], \"resource_name\": \"DrugBank\", \"resource_version\": \"5.1\", \"target_resource_id\": \"P10635\"}, {\"cofactor_in_ch_ikey\": \"XDXDZDZNSLXDNA-TZNDIEGXSA-N\", \"cofactor_smiles\": \"C[C@@H]1O[C@H](C[C@H](N)[C@@H]1O)O[C@H]1C[C@@](O)(CC2=C1C(O)=C1C(=O)C3=CC=CC=C3C(=O)C1=C2O)C(C)=O\", \"cofactor_chem_comp_id\": \"DM5\", \"cofactor_name\": \"Idarubicin\", \"cofactor_resource_id\": \"DB01177\", \"mechanism_of_action\": \"Idarubicin has antimitotic and cytotoxic activity through a number of proposed mechanisms of action: Idarubicin forms complexes with DNA by intercalation between base pairs, and it inhibits topoisomerase II activity by stabilizing the DNA-topoisomerase II complex, preventing the religation portion of the ligation-religation reaction that topoisomerase II catalyzes.\", \"neighbor_flag\": \"N\", \"pubmed_ids\": [15204103], \"resource_name\": \"DrugBank\", \"resource_version\": \"5.1\", \"target_resource_id\": \"P10635\"}, {\"cofactor_in_ch_ikey\": \"JWHAUXFOSRPERK-UHFFFAOYSA-N\", \"cofactor_smiles\": \"CCCNCC(O)COC1=C(C=CC=C1)C(=O)CCC1=CC=CC=C1\", \"cofactor_name\": \"Propafenone\", \"cofactor_resource_id\": \"DB01182\", \"mechanism_of_action\": \"The electrophysiological effect of propafenone manifests itself in a reduction of upstroke velocity (Phase 0) of the monophasic action potential. In Purkinje fibers, and to a lesser extent myocardial fibers, propafenone reduces the fast inward current carried by sodium ions, which is responsible for the drugs antiarrhythmic actions. Diastolic excitability threshold is increased and effective refractory period prolonged. Propafenone reduces spontaneous automaticity and depresses triggered activity. At very high concentrations in vitro, propafenone can inhibit the slow inward current carried by calcium but this calcium antagonist effect probably does not contribute to antiarrhythmic efficacy.\", \"neighbor_flag\": \"N\", \"pubmed_ids\": [8423765, 10917404], \"resource_name\": \"DrugBank\", \"resource_version\": \"5.1\", \"target_resource_id\": \"P10635\"}, {\"cofactor_in_ch_ikey\": \"FGXWKSZFVQUSTL-UHFFFAOYSA-N\", \"cofactor_smiles\": \"ClC1=CC2=C(C=C1)N(C1CCN(CCCN3C(=O)NC4=CC=CC=C34)CC1)C(=O)N2\", \"cofactor_chem_comp_id\": \"A1IVJ\", \"cofactor_name\": \"Domperidone\", \"cofactor_resource_id\": \"DB01184\", \"mechanism_of_action\": \"Domperidone acts as a gastrointestinal emptying (delayed) adjunct and peristaltic stimulant. The gastroprokinetic properties of domperidone are related to its peripheral dopamine receptor blocking properties. Domperidone facilitates gastric emptying and decreases small bowel transit time by increasing esophageal and gastric peristalsis and by lowering esophageal sphincter pressure. Antiemetic: The antiemetic properties of domperidone are related to its dopamine receptor blocking activity at both the chemoreceptor trigger zone and at the gastric level. It has strong affinities for the D2 and D3 dopamine receptors, which are found in the chemoreceptor trigger zone, located just outside the blood brain barrier, which - among others - regulates nausea and vomiting\", \"neighbor_flag\": \"N\", \"pubmed_ids\": [15327587, 19094160], \"resource_name\": \"DrugBank\", \"resource_version\": \"5.1\", \"target_resource_id\": \"P10635\"}, {\"cofactor_in_ch_ikey\": \"DBGIVFWFUFKIQN-VIFPVBQESA-N\", \"cofactor_smiles\": \"CCN[C@@H](C)CC1=CC=CC(=C1)C(F)(F)F\", \"cofactor_name\": \"Dexfenfluramine\", \"cofactor_resource_id\": \"DB01191\", \"mechanism_of_action\": \"Dexfenfluramine binds to the serotonin reuptake pump. This causes inhbition of serotonin reuptake. The increased levels of serotonin lead to greater serotonin receptor activation which in turn lead to enhancement of serotoninergic transmission in the centres of feeding behavior located in the hypothalamus. This suppresses the appetite for carbohydrates.\", \"neighbor_flag\": \"N\", \"pubmed_ids\": [9825834, 8730977], \"resource_name\": \"DrugBank\", \"resource_version\": \"5.1\", \"target_resource_id\": \"P10635\"}, {\"cofactor_in_ch_ikey\": \"UQCNKQCJZOAFTQ-ISWURRPUSA-N\", \"cofactor_smiles\": \"[H][C@@]12OC3=C(O)C=CC4=C3[C@@]11CCN(C)[C@]([H])(C4)[C@]1(O)CCC2=O\", \"cofactor_name\": \"Oxymorphone\", \"cofactor_resource_id\": \"DB01192\", \"mechanism_of_action\": \"Oxymorphone interacts predominantly with the opioid mu-receptor. These mu-binding sites are discretely distributed in the human brain, with high densities in the posterior amygdala, hypothalamus, thalamus, nucleus caudatus, putamen, and certain cortical areas. They are also found on the terminal axons of primary afferents within laminae I and II (substantia gelatinosa) of the spinal cord and in the spinal nucleus of the trigeminal nerve. Also, it has been shown that oxymorphone binds to and inhibits GABA inhibitory interneurons via mu-receptors. These interneurons normally inhibit the descending pain inhibition pathway. So, without the inhibitory signals, pain modulation can proceed downstream.\", \"neighbor_flag\": \"N\", \"pubmed_ids\": [20642550, 20590587, 16678548], \"resource_name\": \"DrugBank\", \"resource_version\": \"5.1\", \"target_resource_id\": \"P10635\"}, {\"cofactor_in_ch_ikey\": \"GOEMGAFJFRBGGG-UHFFFAOYSA-N\", \"cofactor_smiles\": \"CCCC(=O)NC1=CC=C(OCC(O)CNC(C)C)C(=C1)C(C)=O\", \"cofactor_name\": \"Acebutolol\", \"cofactor_resource_id\": \"DB01193\", \"mechanism_of_action\": \"Acebutolol is a selective &beta;1-receptor antagonist. Activation of &beta;1-receptors by epinephrine increases the heart rate and the blood pressure, and the heart consumes more oxygen. Acebutolol blocks these receptors, lowering the heart rate and blood pressure. This drug then has the reverse effect of epinephrine. In addition, beta blockers prevent the release of renin, which is a hormone produced by the kidneys which leads to constriction of blood vessels.\", \"neighbor_flag\": \"N\", \"pubmed_ids\": [27836712, 14732961, 17125412], \"resource_name\": \"DrugBank\", \"resource_version\": \"5.1\", \"target_resource_id\": \"P10635\"}, {\"cofactor_in_ch_ikey\": \"DJBNUMBKLMJRSA-UHFFFAOYSA-N\", \"cofactor_smiles\": \"FC(F)(F)COC1=CC(C(=O)NCC2CCCCN2)=C(OCC(F)(F)F)C=C1\", \"cofactor_name\": \"Flecainide\", \"cofactor_resource_id\": \"DB01195\", \"mechanism_of_action\": \"Flecainide blocks fast inward sodium channels and slowly unbinds during diastole, prolonging the refractory period of the heart.[A186931] This blockade also shortens the duration of action potentials through the Purkinjie fibers.[A186931] Flecainide also prevents delayed rectifier potassium channels from opening, lengthening the action potential through ventricular and atrial muscle fibers.[A186931] Finally, flecainide also blocks ryanodine receptor opening, reducing calcium release from sarcoplasmic reticulum, which reduces depolarization of cells.[A186931]\", \"neighbor_flag\": \"N\", \"pubmed_ids\": [19660006, 20435235, 8801060, 25717355], \"resource_name\": \"DrugBank\", \"resource_version\": \"5.1\", \"target_resource_id\": \"P10635\"}, {\"cofactor_in_ch_ikey\": \"GQYIWUVLTXOXAJ-UHFFFAOYSA-N\", \"cofactor_smiles\": \"ClCCN(N=O)C(=O)NC1CCCCC1\", \"cofactor_name\": \"Lomustine\", \"cofactor_resource_id\": \"DB01206\", \"mechanism_of_action\": \"Lomustine is a highly lipophilic nitrosourea compound which undergoes hydrolysis in vivo to form reactive metabolites. These metabolites cause alkylation and cross-linking of DNA (at the O6 position of guanine-containing bases) and RNA, thus inducing cytotoxicity. Other biologic effects include inhibition of DNA synthesis and some cell cycle phase specificity. Nitrosureas generally lack cross-resistance with other alkylating agents. As lomustine is a nitrosurea, it may also inhibit several key processes such as carbamoylation and modification of cellular proteins.\", \"neighbor_flag\": \"N\", \"pubmed_ids\": [8258200], \"resource_name\": \"DrugBank\", \"resource_version\": \"5.1\", \"target_resource_id\": \"P10635\"}, {\"cofactor_in_ch_ikey\": \"IXHBTMCLRNMKHZ-LBPRGKRZSA-N\", \"cofactor_smiles\": \"CC(C)(C)NC[C@H](O)COC1=CC=CC2=C1CCCC2=O\", \"cofactor_name\": \"Levobunolol\", \"cofactor_resource_id\": \"DB01210\", \"mechanism_of_action\": \"Levobunolol's mechanism of action in reducing IOP is not clearly defined, but is believed to be due to a reduction of the production of aqueous humor via blockage of endogenous catecholamine-stimulated increases in cyclic adenosine monophosphate (AMP) concentrations within the ciliary processes.\", \"neighbor_flag\": \"N\", \"pubmed_ids\": [17125412, 14732961, 27836712], \"resource_name\": \"DrugBank\", \"resource_version\": \"5.1\", \"target_resource_id\": \"P10635\"}, {\"cofactor_in_ch_ikey\": \"BQIPXWYNLPYNHW-UHFFFAOYSA-N\", \"cofactor_smiles\": \"CC(C)NCC(O)COC1=C(C)C(C)=C(OC(C)=O)C(C)=C1\", \"cofactor_name\": \"Metipranolol\", \"cofactor_resource_id\": \"DB01214\", \"mechanism_of_action\": \"Although it is known that metipranolol binds the beta1 and beta2 adrenergic receptors, the mechanism of metipranolol's action is not known. It has no significant intrinsic sympathomimetic activity, and has only weak local anesthetic (membrane-stabilizing) and myocardial depressant activity. It appears that the ophthalmic beta-adrenergic blocking agents reduce aqueous humor production, as demonstrated by tonography and fluorophotometry. A slight increase in aqueous humor outflow may be an additional mechanism.\", \"neighbor_flag\": \"N\", \"pubmed_ids\": [17125412, 14732961, 27836712], \"resource_name\": \"DrugBank\", \"resource_version\": \"5.1\", \"target_resource_id\": \"P10635\"}, {\"cofactor_in_ch_ikey\": \"FOHHNHSLJDZUGQ-UHFFFAOYSA-N\", \"cofactor_smiles\": \"CCCCN(CCCC)CCC(O)C1=C2C=CC(=CC2=C2C=C(Cl)C=C(Cl)C2=C1)C(F)(F)F\", \"cofactor_name\": \"Halofantrine\", \"cofactor_resource_id\": \"DB01218\", \"mechanism_of_action\": \"The mechanism of action of Halofantrine may be similar to that of chloroquine, quinine, and mefloquine; by forming toxic complexes with ferritoporphyrin IX that damage the membrane of the parasite.\", \"neighbor_flag\": \"N\", \"pubmed_ids\": [8554939, 10896408], \"resource_name\": \"DrugBank\", \"resource_version\": \"5.1\", \"target_resource_id\": \"P10635\"}, {\"cofactor_in_ch_ikey\": \"URKOMYMAXPYINW-UHFFFAOYSA-N\", \"cofactor_smiles\": \"OCCOCCN1CCN(CC1)C1=NC2=CC=CC=C2SC2=CC=CC=C12\", \"cofactor_name\": \"Quetiapine\", \"cofactor_resource_id\": \"DB01224\", \"mechanism_of_action\": \"Although the mechanism of action of quetiapine is not fully understood, several proposed mechanisms exist. In schizophrenia, its actions could occur from the antagonism of dopamine type 2 (D2) and serotonin 2A (5HT2A) receptors. In bipolar depression and major depression, quetiapine's actions may be attributed to the binding of this drug or its metabolite to the norepinephrine transporter. Additional effects of quetiapine, including somnolence, orthostatic hypotension, and anticholinergic effects, may result from the antagonism of H1 receptors, adrenergic \\u03b11 receptors, and muscarinic M1 receptors, respectively.[A2189,A185438,L8546]\", \"neighbor_flag\": \"N\", \"pubmed_ids\": [15516294, 16841513, 22688609], \"resource_name\": \"DrugBank\", \"resource_version\": \"5.1\", \"target_resource_id\": \"P10635\"}, {\"cofactor_in_ch_ikey\": \"PJWPNDMDCLXCOM-UHFFFAOYSA-N\", \"cofactor_smiles\": \"COC1=CC=C(C=C1)C(=O)NC1=CC=CC=C1CCC1CCCCN1C\", \"cofactor_name\": \"Encainide\", \"cofactor_resource_id\": \"DB01228\", \"mechanism_of_action\": \"Encainide is a sodium channel blocker, binding to voltage gated sodium channels. It stabilizes the neuronal membrane by inhibiting the ionic fluxes required for the initiation and conduction of impulses. Ventricular excitability is depressed and the stimulation threshold of the ventricle is increased during diastole.\", \"neighbor_flag\": \"N\", \"pubmed_ids\": [11851634], \"resource_name\": \"DrugBank\", \"resource_version\": \"5.1\", \"target_resource_id\": \"P10635\"}, {\"cofactor_in_ch_ikey\": \"QWAXKHKRTORLEM-UGJKXSETSA-N\", \"cofactor_smiles\": \"[H][C@@]12CCCC[C@]1([H])CN(C[C@@H](O)[C@H](CC1=CC=CC=C1)NC(=O)[C@H](CC(N)=O)NC(=O)C1=NC3=C(C=CC=C3)C=C1)[C@@H](C2)C(=O)NC(C)(C)C\", \"cofactor_chem_comp_id\": \"ROC\", \"cofactor_name\": \"Saquinavir\", \"cofactor_resource_id\": \"DB01232\", \"mechanism_of_action\": \"The HIV lifecycle is comprised of 3 distinct stages: assembly, involving creation and packaging of essential viral components; budding, wherein the viral particle crosses the host cell plasma membrane and forms a lipid envelope; and maturation, wherein the viral particle alters its structure and becomes infectious.[A191712] At the center of this lifecycle is the Gag polyprotein which, along with the products of its proteolysis, coordinate these stages and function as the major structural proteins of the virus. The HIV-1 protease enzyme, a dimeric aspartic protease, is the enzyme responsible for cleaving the Gag polyprotein and thus plays a critical role in many aspects of the HIV viral lifecycle.[A191712]\\r\\n\\r\\nSaquinavir is an inhibitor of the HIV-1 protease enzyme.[L3450] Its design is based on the \\\"peptidomimetic\\\" principle, wherein the molecule contains a hydroxyethylene scaffold that mimics the normal peptide linkage (cleaved by HIV protease) but which itself cannot be cleaved.[A191757] By preventing HIV-1 protease activity, and thus the proteolysis of the Gag polyprotein, saquinavir results in the production of immature, non-infectious viral particles.\", \"neighbor_flag\": \"N\", \"pubmed_ids\": [9758674], \"resource_name\": \"DrugBank\", \"resource_version\": \"5.1\", \"target_resource_id\": \"P10635\"}, {\"cofactor_in_ch_ikey\": \"TTWJBBZEZQICBI-UHFFFAOYSA-N\", \"cofactor_smiles\": \"CCN(CC)CCNC(=O)C1=CC(Cl)=C(N)C=C1OC\", \"cofactor_name\": \"Metoclopramide\", \"cofactor_resource_id\": \"DB01233\", \"mechanism_of_action\": \"Metoclopramide causes antiemetic effects by inhibiting dopamine D2 and serotonin 5-HT3 receptors in the chemoreceptor trigger zone (CTZ) located in the area postrema of the brain.[A184880,T683] Administration of this drug leads to prokinetic effects via inhibitory actions on presynaptic and postsynaptic D2 receptors, agonism of serotonin 5-HT4 receptors, and antagonism of muscarinic receptor inhibition. This action enhances the release of acetylcholine, causing increased lower esophageal sphincter (LES) and gastric tone, accelerating gastric emptying and transit through the gut. Metoclopramide antagonizes the dopamine D2 receptors. Dopamine exerts relaxant effect on the gastrointestinal tract through binding to muscular D2 receptors.[A184880,T683,L8414]\", \"neighbor_flag\": \"N\", \"pubmed_ids\": [24010633, 11854155, 22688139], \"resource_name\": \"DrugBank\", \"resource_version\": \"5.1\", \"target_resource_id\": \"P10635\"}, {\"cofactor_in_ch_ikey\": \"CEUORZQYGODEFX-UHFFFAOYSA-N\", \"cofactor_smiles\": \"ClC1=CC=CC(N2CCN(CCCCOC3=CC4=C(CCC(=O)N4)C=C3)CC2)=C1Cl\", \"cofactor_chem_comp_id\": \"9SC\", \"cofactor_name\": \"Aripiprazole\", \"cofactor_resource_id\": \"DB01238\", \"mechanism_of_action\": \"The antipsychotic action of aripiprazole is likely due to its partial agonist activity on D2 and 5-HT<sub>1A</sub> receptors as well as its antagonist activity at 5-HT<sub>2A</sub> receptors; however, the exact mechanism has not been fully elucidated.[A4393,L45859,L4620] One of the mechanisms that have been proposed is that aripiprazole both stimulates and inhibits dopamine as it engages the D2 receptor. It lowers dopamine neuronal firing at high dopamine concentrations and increases dopamine firing at low concentrations. Its partial agonist activity gives aripiprazole an intermediate level of dopaminergic neuronal tone between full agonist and antagonist of the D2 receptor.[A258699] In addition, some adverse effects may be due to action on other receptors.[L4620] For example, orthostatic hypotension may be explained by antagonism of the adrenergic alpha-1 receptors.[L4620,A4393]\", \"neighbor_flag\": \"N\", \"pubmed_ids\": [17214606, 15257633, 15770075], \"resource_name\": \"DrugBank\", \"resource_version\": \"5.1\", \"target_resource_id\": \"P10635\"}, {\"cofactor_in_ch_ikey\": \"GDLIGKIOYRNHDA-UHFFFAOYSA-N\", \"cofactor_smiles\": \"CN(C)CCCN1C2=CC=CC=C2CCC2=C1C=C(Cl)C=C2\", \"cofactor_chem_comp_id\": \"CXX\", \"cofactor_name\": \"Clomipramine\", \"cofactor_resource_id\": \"DB01242\", \"mechanism_of_action\": \"Clomipramine is a strong, but not completely selective serotonin reuptake inhibitor (SRI), as the active main metabolite desmethyclomipramine acts preferably as an inhibitor of noradrenaline reuptake. &alpha;<sub>1</sub>-receptor blockage and &beta;-down-regulation have been noted and most likely play a role in the short term effects of clomipramine. A blockade of sodium-channels and NDMA-receptors might, as with other tricyclics, account for its effect in chronic pain, in particular the neuropathic type.\", \"neighbor_flag\": \"N\", \"pubmed_ids\": [8667235], \"resource_name\": \"DrugBank\", \"resource_version\": \"5.1\", \"target_resource_id\": \"P10635\"}, {\"cofactor_in_ch_ikey\": \"UIEATEWHFDRYRU-UHFFFAOYSA-N\", \"cofactor_smiles\": \"CC(C)COCC(CN(CC1=CC=CC=C1)C1=CC=CC=C1)N1CCCC1\", \"cofactor_chem_comp_id\": \"BEP\", \"cofactor_name\": \"Bepridil\", \"cofactor_resource_id\": \"DB01244\", \"mechanism_of_action\": \"Bepridil has inhibitory effects on both the slow calcium (L-type) and fast sodium inward currents in myocardial and vascular smooth muscle, interferes with calcium binding to calmodulin, and blocks both voltage and receptor operated calcium channels. Bepridil inhibits the transmembrane influx of calcium ions into cardiac and vascular smooth muscle. This has been demonstrated in isolated myocardial and vascular smooth muscle preparations in which both the slope of the calcium dose response curve and the maximum calcium-induced inotropic response were significantly reduced by bepridil. In cardiac myocytes <i>in vitro</i>, bepridil was shown to be tightly bound to actin. Bepridil regularly reduces heart rate and arterial pressure at rest and at a given level of exercise by dilating peripheral arterioles and reducing total peripheral resistance (afterload) against which the heart works.\", \"neighbor_flag\": \"N\", \"pubmed_ids\": [26195225, 16508157], \"resource_name\": \"DrugBank\", \"resource_version\": \"5.1\", \"target_resource_id\": \"P10635\"}, {\"cofactor_in_ch_ikey\": \"CJBJHOAVZSMMDJ-HEXNFIEUSA-N\", \"cofactor_smiles\": \"[H][C@@]12CCO[C@]1([H])OC[C@@H]2OC(=O)N[C@@H](CC1=CC=CC=C1)[C@H](O)CN(CC(C)C)S(=O)(=O)C1=CC=C(N)C=C1\", \"cofactor_chem_comp_id\": \"017\", \"cofactor_name\": \"Darunavir\", \"cofactor_resource_id\": \"DB01264\", \"mechanism_of_action\": \"The HIV-1 protease enzyme is necessary for viral precursor protein processing and viral maturation in preparation for infection, and is therefore a target for antiretroviral therapy for HIV.  Protease inhibitors are used as a part of highly active antiretroviral therapy (HAART) in patients diagnosed with HIV infection. It has been shown to effectively suppress the virus, leading to significantly decreased morbidity and mortality rates.[A2281]\\r\\n\\r\\nDarunavir, a HIV protease inhibitor, prevents HIV replication through binding to the enzyme, stopping the dimerization and the catalytic activity of HIV-1 protease. In particular, it inhibits the cleavage of HIV encoded Gag-Pol proteins[A191556] in cells that have been infected with the virus, halting the formation of mature virus particles, which spread the infection. The close contact that darunavir makes with the primary chains of the active site amino acids (Asp-29 and Asp-30) on the protease likely contributes to its potency and efficacy against resistant variants of HIV-1.[A2281] \\r\\n\\r\\nDarunavir is known to bind to different sites on the enzyme: the active site cavity and the surface of one of the flexible flaps in the protease dimer. Darunavir can adapt to changes in the shape of a protease enzyme due to its molecular flexibility.[A2281,A191526]\", \"neighbor_flag\": \"N\", \"resource_name\": \"DrugBank\", \"resource_version\": \"5.1\", \"target_resource_id\": \"P10635\"}, {\"cofactor_in_ch_ikey\": \"PMXMIIMHBWHSKN-UHFFFAOYSA-N\", \"cofactor_smiles\": \"CC1=C(CCN2CCC(CC2)C2=NOC3=C2C=CC(F)=C3)C(=O)N2CCCC(O)C2=N1\", \"cofactor_name\": \"Paliperidone\", \"cofactor_resource_id\": \"DB01267\", \"mechanism_of_action\": \"Paliperidone is the major active metabolite of risperidone. The mechanism of action of paliperidone, as with other drugs having efficacy in schizophrenia, is unknown, but it has been proposed that the drug's therapeutic activity in schizophrenia is mediated through a combination of central dopamine Type 2 (D2) and serotonin Type 2 (5HT2A) receptor antagonism.\", \"neighbor_flag\": \"N\", \"pubmed_ids\": [15767244], \"resource_name\": \"DrugBank\", \"resource_version\": \"5.1\", \"target_resource_id\": \"P10635\"}, {\"cofactor_in_ch_ikey\": \"BPZSYCZIITTYBL-YJYMSZOUSA-N\", \"cofactor_smiles\": \"COC1=CC=C(C[C@@H](C)NC[C@H](O)C2=CC(NC=O)=C(O)C=C2)C=C1\", \"cofactor_chem_comp_id\": \"H98\", \"cofactor_name\": \"Arformoterol\", \"cofactor_resource_id\": \"DB01274\", \"mechanism_of_action\": \"While it is recognized that \\u03b22-receptors are the predominant adrenergic receptors in bronchial smooth muscle and \\u03b21-receptors are the predominant receptors in the heart, data indicate that there are also \\u03b22-receptors in the human heart comprising 10% to 50% of the total beta-adrenergic receptors. The precise function of these receptors has not been established, but they raise the possibility that even highly selective \\u03b22-agonists may have cardiac effects. The pharmacologic effects of \\u03b22-adrenoceptor agonist drugs, including arformoterol, are at least in part attributable to the stimulation of intracellular adenyl cyclase, the enzyme that catalyzes the conversion of adenosine triphosphate (ATP) to cyclic-3,5-adenosine monophosphate (cyclic AMP). Increased intracellular cyclic AMP levels cause relaxation of bronchial smooth muscle and inhibition of the release of proinflammatory mediators from cells, especially from mast cells. In vitro tests show that arformoterol is an inhibitor of the release of mast cell mediators, such as histamine and leukotrienes, from the human lung. Arformoterol also inhibits histamine-induced plasma albumin extravasation in anesthetized guinea pigs and inhibits allergen-induced eosinophil influx in dogs with airway hyper-response.\", \"neighbor_flag\": \"N\", \"pubmed_ids\": [17627976, 10671910], \"resource_name\": \"DrugBank\", \"resource_version\": \"5.1\", \"target_resource_id\": \"P10635\"}, {\"cofactor_in_ch_ikey\": \"HXLAFSUPPDYFEO-UHFFFAOYSA-N\", \"cofactor_smiles\": \"COC1=C(OC)C=C(CCNCC(O)COC2=CC=CC(C)=C2)C=C1\", \"cofactor_name\": \"Bevantolol\", \"cofactor_resource_id\": \"DB01295\", \"mechanism_of_action\": \"Animal experiments confirm both agonist and antagonist effects on alpha-receptors, in addition to antagonist activity at beta-1 receptors. By binding and antagonizing beta-1 receptors Bevantolol inhibits the normal normal epinephrine-mediated sympathetic actions such as increased heart rate. This has the effect of decreasing preload and blood pressure.\", \"neighbor_flag\": \"N\", \"pubmed_ids\": [17125412, 14732961, 27836712], \"resource_name\": \"DrugBank\", \"resource_version\": \"5.1\", \"target_resource_id\": \"P10635\"}, {\"cofactor_in_ch_ikey\": \"DURULFYMVIFBIR-UHFFFAOYSA-N\", \"cofactor_smiles\": \"CC(C)NCC(O)COC1=CC=C(NC(C)=O)C=C1\", \"cofactor_name\": \"Practolol\", \"cofactor_resource_id\": \"DB01297\", \"mechanism_of_action\": \"Like other beta-adrenergic antagonists, practolol competes with adrenergic neurotransmitters such as catecholamines for binding at sympathetic receptor sites. Like propranolol and timolol, practolol binds at beta(1)-adrenergic receptors in the heart and vascular smooth muscle, inhibiting the effects of the catecholamines epinephrine and norepinephrine and decreasing heart rate, cardiac output, and systolic and diastolic blood pressure.\", \"neighbor_flag\": \"N\", \"pubmed_ids\": [17125412, 14732961, 27836712], \"resource_name\": \"DrugBank\", \"resource_version\": \"5.1\", \"target_resource_id\": \"P10635\"}, {\"cofactor_name\": \"St. John's Wort\", \"cofactor_resource_id\": \"DB01323\", \"neighbor_flag\": \"N\", \"pubmed_ids\": [21168483], \"resource_name\": \"DrugBank\", \"resource_version\": \"5.1\", \"target_resource_id\": \"P10635\"}, {\"cofactor_in_ch_ikey\": \"KQXKVJAGOJTNJS-HNNXBMFYSA-N\", \"cofactor_smiles\": \"CC(C)(C)NC[C@H](O)COC1=CC=CC=C1C1CCCC1\", \"cofactor_name\": \"Penbutolol\", \"cofactor_resource_id\": \"DB01359\", \"mechanism_of_action\": \"Penbutolol acts on the \\u03b21 adrenergic receptors in both the heart and the kidney. When \\u03b21 receptors are activated by catecholamines, they stimulate a coupled G protein that leads to the conversion of adenosine triphosphate (ATP) to cyclic adenosine monophosphate (cAMP). The increase in cAMP leads to activation of protein kinase A (PKA), which alters the movement of calcium ions in heart muscle and increases the heart rate. Penbutolol blocks the catecholamine activation of \\u03b21 adrenergic receptors and decreases heart rate, which lowers blood pressure.\", \"neighbor_flag\": \"N\", \"pubmed_ids\": [27836712, 14732961, 17125412], \"resource_name\": \"DrugBank\", \"resource_version\": \"5.1\", \"target_resource_id\": \"P10635\"}, {\"cofactor_in_ch_ikey\": \"HBNPJJILLOYFJU-VMPREFPWSA-N\", \"cofactor_smiles\": \"COCC(=O)O[C@]1(CCN(C)CCCC2=NC3=CC=CC=C3N2)CCC2=C(C=CC(F)=C2)[C@@H]1C(C)C\", \"cofactor_chem_comp_id\": \"MWV\", \"cofactor_name\": \"Mibefradil\", \"cofactor_resource_id\": \"DB01388\", \"mechanism_of_action\": \"Mibefradil is a tetralol calcium channel blocking agent that inhibits the influx of calcium ions across both the T (low-voltage) and L (high-voltage) calcium channels of cardiac and vascular smooth muscle, with a greater selectivity for T channels. Vasodilation occurs in vascular smooth muscle, causing a decrease in peripheral vascular resistance and a resulting decrease in blood pressure. Mibefradil causes a slight increase in cardiac output during chronic dosing. Mibefradil slows sinus and atrioventricular (AV) node conduction, producing a slight reduction in heart rate and a slight increase in the PR interval. It has also been shown to slightly lengthen the corrected sinus node recovery time and AH interval and to raise the Wenckebach point. The mechanism by which mibefradil reduces angina is not known, but is thought to be attributed to a reduction in heart rate, total peripheral resistance (afterload), and the heart rate&ndash;systolic blood pressure product at any given level of exercise. The result of these effects is a decrease in cardiac workload and myocardial oxygen demand.\", \"neighbor_flag\": \"N\", \"pubmed_ids\": [18411403], \"resource_name\": \"DrugBank\", \"resource_version\": \"5.1\", \"target_resource_id\": \"P10635\"}, {\"cofactor_in_ch_ikey\": \"BLGXFZZNTVWLAY-SCYLSFHTSA-N\", \"cofactor_smiles\": \"[H][C@@]12CC[C@H](O)[C@H](C(=O)OC)[C@@]1([H])C[C@]1([H])N(CCC3=C1NC1=CC=CC=C31)C2\", \"cofactor_name\": \"Yohimbine\", \"cofactor_resource_id\": \"DB01392\", \"mechanism_of_action\": \"Yohimbine is a pre-synaptic alpha 2-adrenergic blocking agent. The exact mechanism for its use in impotence has not been fully elucidated. However, yohimbine may exert its beneficial effect on erectile ability through blockade of central alpha 2-adrenergic receptors producing an increase in sympathetic drive secondary to an increase in norepinephrine release and in firing rate of cells in the brain noradrenergic nuclei. Yohimbine-mediated norepinephrine release at the level of the corporeal tissues may also be involved. In addition, beneficial effects may involve other neurotransmitters such as dopamine and serotonin and cholinergic receptors.\", \"neighbor_flag\": \"N\", \"pubmed_ids\": [15289791], \"resource_name\": \"DrugBank\", \"resource_version\": \"5.1\", \"target_resource_id\": \"P10635\"}, {\"cofactor_in_ch_ikey\": \"VRQVVMDWGGWHTJ-CQSZACIVSA-N\", \"cofactor_smiles\": \"COC1=CC2=C(SC3=C(C=CC=C3)N2C[C@H](C)CN(C)C)C=C1\", \"cofactor_name\": \"Methotrimeprazine\", \"cofactor_resource_id\": \"DB01403\", \"mechanism_of_action\": \"Methotrimeprazine's antipsychotic effect is largely due to its antagonism of dopamine receptors in the brain. In addition, its binding to 5HT2 receptors may also play a role. \", \"neighbor_flag\": \"N\", \"pubmed_ids\": [10954064, 11888334, 18728628, 25369508], \"resource_name\": \"DrugBank\", \"resource_version\": \"5.1\", \"target_resource_id\": \"P10635\"}, {\"cofactor_in_ch_ikey\": \"LERNTVKEWCAPOY-DZZGSBJMSA-N\", \"cofactor_smiles\": \"[H][C@]12O[C@@]1([H])[C@]1([H])C[C@@]([H])(C[C@@]2([H])[N+]1(C)C)OC(=O)C(O)(C1=CC=CS1)C1=CC=CS1\", \"cofactor_chem_comp_id\": \"0HK\", \"cofactor_name\": \"Tiotropium\", \"cofactor_resource_id\": \"DB01409\", \"mechanism_of_action\": \"Tiotropium is an antagonist of muscarinic receptors M<sub>1</sub> to M<sub>5</sub>.[A180163,L7084,L7087,L7090,L7093] Inhibition of the M<sub>3</sub> receptor in the smooth muscle of the lungs leads to relaxation of smooth muscle and bronchodilation.[A180163,L7084,L7087,L7090,L7093]\", \"neighbor_flag\": \"N\", \"pubmed_ids\": [15350163, 26908999], \"resource_name\": \"DrugBank\", \"resource_version\": \"5.1\", \"target_resource_id\": \"P10635\"}, {\"cofactor_in_ch_ikey\": \"LUKZNWIVRBCLON-GXOBDPJESA-N\", \"cofactor_smiles\": \"[H][C@@]12C[C@@]3([H])[C@]4([H])CCC5=CC(=O)C=C[C@]5(C)[C@@]4([H])[C@@H](O)C[C@]3(C)[C@@]1(O[C@@H](O2)C1CCCCC1)C(=O)COC(=O)C(C)C\", \"cofactor_name\": \"Ciclesonide\", \"cofactor_resource_id\": \"DB01410\", \"mechanism_of_action\": \"Glucocorticoids such as ciclesonide can inhibit leukocyte infiltration at the site of inflammation, interfere with mediators of inflammatory response, and suppress humoral immune responses. The antiinflammatory actions of glucocorticoids are thought to involve phospholipase A2 inhibitory proteins, lipocortins, which control the biosynthesis of potent mediators of inflammation such as prostaglandins and leukotrienes. Ciclesonide reduces inflammatory reaction by limiting the capillary dilatation and permeability of the vascular structures. These compounds restrict the accumulation of polymorphonuclear leukocytes and macrophages and reduce the release of vasoactive kinins. Recent research suggests that corticosteroids may inhibit the release of arachidonic acid from phospholipids, thereby reducing the formation of prostaglandins. Ciclesonide is a glucocorticoid receptor agonist. On binding, the corticoreceptor-ligand complex translocates itself into the cell nucleus, where it binds to many glucocorticoid response elements (GRE) in the promoter region of the target genes. The DNA bound receptor then interacts with basic transcription factors, causing an increase or decrease in expression of specific target genes, including suppression of IL2 (interleukin 2) expression.\", \"neighbor_flag\": \"N\", \"pubmed_ids\": [16435573], \"resource_name\": \"DrugBank\", \"resource_version\": \"5.1\", \"target_resource_id\": \"P10635\"}, {\"cofactor_in_ch_ikey\": \"RMMXTBMQSGEXHJ-UHFFFAOYSA-N\", \"cofactor_smiles\": \"CN(C)C1=C(C)N(C)N(C1=O)C1=CC=CC=C1\", \"cofactor_name\": \"Aminophenazone\", \"cofactor_resource_id\": \"DB01424\", \"mechanism_of_action\": \"Aminophenazone is metabolized very slowly by normal newborn babies. In older infants, a higher amount of exhaled 13-CO2 is observed.\", \"neighbor_flag\": \"N\", \"pubmed_ids\": [19515014, 10199594], \"resource_name\": \"DrugBank\", \"resource_version\": \"5.1\", \"target_resource_id\": \"P10635\"}, {\"cofactor_in_ch_ikey\": \"NZLBHDRPUJLHCE-UHFFFAOYSA-N\", \"cofactor_smiles\": \"CCN(CC)CCCN(C1CC2=CC=CC=C2C1)C1=CC=CC=C1\", \"cofactor_name\": \"Aprindine\", \"cofactor_resource_id\": \"DB01429\", \"neighbor_flag\": \"N\", \"pubmed_ids\": [8485023], \"resource_name\": \"DrugBank\", \"resource_version\": \"5.1\", \"target_resource_id\": \"P10635\"}, {\"cofactor_in_ch_ikey\": \"VEQOALNAAJBPNY-UHFFFAOYSA-N\", \"cofactor_smiles\": \"CN1N(C(=O)C=C1C)C1=CC=CC=C1\", \"cofactor_name\": \"Antipyrine\", \"cofactor_resource_id\": \"DB01435\", \"mechanism_of_action\": \"Antipyrine is thought to act primarily in the CNS, increasing the pain threshold by inhibiting both isoforms of cyclooxygenase, COX-1, COX-2, and COX-3 enzymes involved in prostaglandin (PG) synthesis.\", \"neighbor_flag\": \"N\", \"pubmed_ids\": [8681486, 8801065], \"resource_name\": \"DrugBank\", \"resource_version\": \"5.1\", \"target_resource_id\": \"P10635\"}, {\"cofactor_in_ch_ikey\": \"JMBQKKAJIKAWKF-UHFFFAOYSA-N\", \"cofactor_smiles\": \"CCC1(CCC(=O)NC1=O)C1=CC=CC=C1\", \"cofactor_name\": \"Glutethimide\", \"cofactor_resource_id\": \"DB01437\", \"mechanism_of_action\": \"Glutethimide seems to be a GABA agonist which helps induce sedation. It also induces CYP 2D6. When taken with codeine, it enables the body to convert higher amounts of codeine (higher than the average 5 - 10%) to morphine. This combination of effects enhances sedation.\", \"neighbor_flag\": \"N\", \"pubmed_ids\": [37713619], \"resource_name\": \"DrugBank\", \"resource_version\": \"5.1\", \"target_resource_id\": \"P10635\"}, {\"cofactor_in_ch_ikey\": \"SHXWCVYOXRDMCX-UHFFFAOYSA-N\", \"cofactor_smiles\": \"CNC(C)CC1=CC2=C(OCO2)C=C1\", \"cofactor_name\": \"Midomafetamine\", \"cofactor_resource_id\": \"DB01454\", \"mechanism_of_action\": \"It enters neurons via carriage by the monoamine transporters. Once inside, MDMA inhibits the vesicular monoamine transporter, which results in increased concentrations of serotonin, norepinephrine, and dopamine into the cytoplasm, and induces their release by reversing their respective transporters through a process known as phosphorylation. It also acts as a weak 5-HT1 and 5-HT2 receptor agonist.\\r\\nMDMA's unusual entactogenic effects have been hypothesized to be, at least partly, the result of indirect oxytocin secretion via activation of the serotonin system. Oxytocin is a hormone released following events like hugging, orgasm, and childbirth, and is thought to facilitate bonding and the establishment of trust. Based on studies in rats, MDMA is believed to cause the release of oxytocin, at least in part, by both directly and indirectly agonizing the serotonin 5-HT1A receptor.\", \"neighbor_flag\": \"N\", \"pubmed_ids\": [12036392], \"resource_name\": \"DrugBank\", \"resource_version\": \"5.1\", \"target_resource_id\": \"P10635\"}, {\"cofactor_in_ch_ikey\": \"OGDVEMNWJVYAJL-LEPYJNQMSA-N\", \"cofactor_smiles\": \"[H][C@@]12OC3=C(OCC)C=CC4=C3[C@@]11CCN(C)[C@]([H])(C4)[C@]1([H])C=C[C@@H]2O\", \"cofactor_name\": \"Ethylmorphine\", \"cofactor_resource_id\": \"DB01466\", \"mechanism_of_action\": \"Ethylmorphine is metabolized by the liver enzyme cytochrome P450 2D6 to morphine. The precise mechanism of the analgesic action of morphine is unknown. However, specific CNS opiate receptors have been identified and likely play a role in the expression of analgesic effects. Morphine first acts on the mu-opioid receptors. The mechanism of respiratory depression involves a reduction in the responsiveness of the brain stem respiratory centers to increases in carbon dioxide tension and to electrical stimulation.\\r\\nIt has been shown that morphine binds to and inhibits GABA inhibitory interneurons. These interneurons normally inhibit the descending pain inhibition pathway. So, without the inhibitory signals, pain modulation can proceed downstream.\", \"neighbor_flag\": \"N\", \"pubmed_ids\": [7654478, 7756104], \"resource_name\": \"DrugBank\", \"resource_version\": \"5.1\", \"target_resource_id\": \"P10635\"}, {\"cofactor_in_ch_ikey\": \"NEGYEDYHPHMHGK-UHFFFAOYSA-N\", \"cofactor_smiles\": \"COC1=CC=C(CC(C)N)C=C1\", \"cofactor_name\": \"4-Methoxyamphetamine\", \"cofactor_resource_id\": \"DB01472\", \"mechanism_of_action\": \"4-Methoxyamphetamine is a seratogenic drug of the amphetamine class. The drug acts as a potent and selective serotonin releasing agent. It binds to alpha receptors to mediate these effects.\", \"neighbor_flag\": \"N\", \"pubmed_ids\": [9264312], \"resource_name\": \"DrugBank\", \"resource_version\": \"5.1\", \"target_resource_id\": \"P10635\"}, {\"cofactor_in_ch_ikey\": \"RBOXVHNMENFORY-DNJOTXNNSA-N\", \"cofactor_smiles\": \"[H][C@@]12OC3=C4C(C[C@H]5N(C)CC[C@@]14[C@@]5([H])CC[C@@H]2O)=CC=C3OC\", \"cofactor_name\": \"Dihydrocodeine\", \"cofactor_resource_id\": \"DB01551\", \"mechanism_of_action\": \"Dihydrocodeine is metabolized to dihydromorphine -- a highly active metabolite with a high affinity for mu opioid receptors. [3]\", \"neighbor_flag\": \"N\", \"pubmed_ids\": [9431830, 12420793, 7586928, 12665158], \"resource_name\": \"DrugBank\", \"resource_version\": \"5.1\", \"target_resource_id\": \"P10635\"}, {\"cofactor_in_ch_ikey\": \"BVURVTVDNWSNFN-UHFFFAOYSA-N\", \"cofactor_smiles\": \"CC(=O)OC1(CCN(CCC2=CC=CC=C2)CC1)C1=CC=CC=C1\", \"cofactor_name\": \"1-(2-Phenylethyl)-4-phenyl-4-acetoxypiperidine\", \"cofactor_resource_id\": \"DB01562\", \"neighbor_flag\": \"N\", \"pubmed_ids\": [12006905], \"resource_name\": \"DrugBank\", \"resource_version\": \"5.1\", \"target_resource_id\": \"P10635\"}, {\"cofactor_in_ch_ikey\": \"KWTSXDURSIMDCE-QMMMGPOBSA-N\", \"cofactor_smiles\": \"C[C@H](N)CC1=CC=CC=C1\", \"cofactor_chem_comp_id\": \"1WE\", \"cofactor_name\": \"Dextroamphetamine\", \"cofactor_resource_id\": \"DB01576\", \"mechanism_of_action\": \"The exact mechanism of amphetamines as a class is not known. Dextroamphetamine acts by preventing reuptake, increasing release, and stimulating reverse-transport of dopamine in synaptic clefts in the striatum.[A177253] Newer evidence shows amphetamines may also alter the number of dopamine transporters in synaptic clefts.[A177220]\", \"neighbor_flag\": \"N\", \"resource_name\": \"DrugBank\", \"resource_version\": \"5.1\", \"target_resource_id\": \"P10635\"}, {\"cofactor_in_ch_ikey\": \"MYWUZJCMWCOHBA-VIFPVBQESA-N\", \"cofactor_smiles\": \"CN[C@@H](C)CC1=CC=CC=C1\", \"cofactor_chem_comp_id\": \"B40\", \"cofactor_name\": \"Metamfetamine\", \"cofactor_resource_id\": \"DB01577\", \"mechanism_of_action\": \"Methamphetamine enters the brain and triggers a cascading release of norepinephrine, dopamine and serotonin. To a lesser extent methamphetamine acts as a dopaminergic and adrenergic reuptake inhibitor and in high concentrations as a monamine oxidase inhibitor (MAOI). The mechanism of action involved in producing the beneficial behavioral changes seen in hyperkinetic children receiving methamphetamine is unknown.\", \"neighbor_flag\": \"N\", \"pubmed_ids\": [11505218, 9311621], \"resource_name\": \"DrugBank\", \"resource_version\": \"5.1\", \"target_resource_id\": \"P10635\"}, {\"cofactor_in_ch_ikey\": \"CEMAWMOMDPGJMB-UHFFFAOYSA-N\", \"cofactor_smiles\": \"CC(C)NCC(O)COC1=CC=CC=C1OCC=C\", \"cofactor_name\": \"Oxprenolol\", \"cofactor_resource_id\": \"DB01580\", \"mechanism_of_action\": \"Like other beta-adrenergic antagonists, oxprenolol competes with adrenergic neurotransmitters such as catecholamines for binding at sympathetic receptor sites. Like propranolol and timolol, oxprenolol binds at beta(1)-adrenergic receptors in the heart and vascular smooth muscle, inhibiting the effects of the catecholamines epinephrine and norepinephrine and decreasing heart rate, cardiac output, and systolic and diastolic blood pressure. It also blocks beta-2 adrenergic receptors located in bronchiole smooth muscle, causing vasoconstriction. By binding beta-2 receptors in the juxtaglomerular apparatus, oxprenolol inhibits the production of renin, thereby inhibiting angiotensin II and aldosterone production. Oxprenolol therefore inhibits the vasoconstriction and water retention due to angiotensin II and aldosterone, respectively.\", \"neighbor_flag\": \"N\", \"pubmed_ids\": [17125412, 14732961, 27836712, 17559204], \"resource_name\": \"DrugBank\", \"resource_version\": \"5.1\", \"target_resource_id\": \"P10635\"}, {\"cofactor_in_ch_ikey\": \"HKVAMNSJSFKALM-GKUWKFKPSA-N\", \"cofactor_smiles\": \"[H][C@@]1(C[C@@H](C)[C@]2([H])CC(=O)[C@H](C)\\\\C=C(C)\\\\[C@@H](O)[C@@H](OC)C(=O)[C@H](C)C[C@H](C)\\\\C=C\\\\C=C\\\\C=C(C)\\\\[C@H](C[C@]3([H])CC[C@@H](C)[C@@](O)(O3)C(=O)C(=O)N3CCCC[C@@]3([H])C(=O)O2)OC)CC[C@@H](OCCO)[C@@H](C1)OC\", \"cofactor_name\": \"Everolimus\", \"cofactor_resource_id\": \"DB01590\", \"mechanism_of_action\": \"Everolimus is a mTOR inhibitor that binds with high affinity to the FK506 binding protein-12 (FKBP-12), thereby forming a drug complex that inhibits the activation of mTOR. This inhibition reduces the activity of effectors downstream, which leads to a blockage in the progression of cells from G1 into S phase, and subsequently inducing cell growth arrest and apoptosis. Everolimus also inhibits the expression of hypoxia-inducible factor, leading to a decrease in the expression of vascular endothelial growth factor. The result of everolimus inhibition of mTOR is a reduction in cell proliferation, angiogenesis, and glucose uptake.\", \"neighbor_flag\": \"N\", \"resource_name\": \"DrugBank\", \"resource_version\": \"5.1\", \"target_resource_id\": \"P10635\"}, {\"cofactor_in_ch_ikey\": \"FBOUYBDGKBSUES-VXKWHMMOSA-N\", \"cofactor_smiles\": \"O=C(O[C@H]1CN2CCC1CC2)N1CCC2=CC=CC=C2[C@@H]1C1=CC=CC=C1\", \"cofactor_name\": \"Solifenacin\", \"cofactor_resource_id\": \"DB01591\", \"mechanism_of_action\": \"Solifenacin is a competitive muscarinic receptor antagonist.[L7511] It has the highest affinity for M3, M1, and M2 muscarinic receptors.[A181247] 80% of the muscarinic receptors in the bladder are M2, while 20% are M3.[A181262] Solifenacin's antagonism of the M3 receptor prevents contraction of the detrusor muscle, while antagonism of the M2 receptor may prevent contraction of smooth muscle in the bladder.[A181262]\", \"neighbor_flag\": \"N\", \"pubmed_ids\": [19566112], \"resource_name\": \"DrugBank\", \"resource_version\": \"5.1\", \"target_resource_id\": \"P10635\"}, {\"cofactor_in_ch_ikey\": \"KJHKTHWMRKYKJE-SUGCFTRWSA-N\", \"cofactor_smiles\": \"CC(C)[C@H](N1CCCNC1=O)C(=O)N[C@H](C[C@H](O)[C@H](CC1=CC=CC=C1)NC(=O)COC1=C(C)C=CC=C1C)CC1=CC=CC=C1\", \"cofactor_chem_comp_id\": \"AB1\", \"cofactor_name\": \"Lopinavir\", \"cofactor_resource_id\": \"DB01601\", \"mechanism_of_action\": \"The HIV lifecycle is comprised of 3 distinct stages: assembly, involving creation and packaging of essential viral components; budding, wherein the viral particle crosses the host cell plasma membrane and forms a lipid envelope; and maturation, wherein the viral particle alters its structure and becomes infectious.[A191712] At the center of this lifecycle is the Gag polyprotein which, along with the products of its proteolysis, coordinate these stages and function as the major structural proteins of the virus. The HIV-1 protease enzyme, a dimeric aspartic protease, is the enzyme responsible for cleaving the Gag polyprotein and thus plays a critical role in many aspects of the HIV viral lifecycle.[A191712]\\r\\n\\r\\nLopinavir is an inhibitor of the HIV-1 protease enzyme.[L11163] Its design is based on the \\\"peptidomimetic\\\" principle, wherein the molecule contains a hydroxyethylene scaffold which mimics the normal peptide linkage (cleaved by HIV protease) but which itself cannot be cleaved.[A191757] By preventing HIV-1 protease activity, and thus the proteolysis of the Gag polyprotein, lopinavir results in the production of immature, non-infectious viral particles.\", \"neighbor_flag\": \"N\", \"pubmed_ids\": [12724045, 21953914], \"resource_name\": \"DrugBank\", \"resource_version\": \"5.1\", \"target_resource_id\": \"P10635\"}, {\"cofactor_in_ch_ikey\": \"XXSMGPRMXLTPCZ-UHFFFAOYSA-N\", \"cofactor_smiles\": \"CCN(CCO)CCCC(C)NC1=C2C=CC(Cl)=CC2=NC=C1\", \"cofactor_name\": \"Hydroxychloroquine\", \"cofactor_resource_id\": \"DB01611\", \"mechanism_of_action\": \"The exact mechanisms of hydroxychloroquine are unknown. It has been shown that hydroxychloroquine accumulates in the lysosomes of the malaria parasite, raising the pH of the vacuole.[A183074] This activity interferes with the parasite's ability to proteolyse hemoglobin, preventing the normal growth and replication of the parasite.[A183074] Hydroxychloroquine can also interfere with the action of parasitic heme polymerase, an enzyme that uses ferriprotoporphyrin IX (FP) released from hemoglobin as a substrate to form beta-hematin. By reducing the activity of heme polymerase without inhibiting the release of FP, hydroxychloroquine leads to the accumulation of FP in a toxic form.[A183080]\\r\\n\\r\\nHydroxychloroquine accumulation in human organelles also raise their pH, which inhibits antigen processing, prevents the alpha and beta chains of the major histocompatibility complex (MHC) class II from dimerizing, inhibits antigen presentation of the cell, and reduces the inflammatory response.[A183074] Elevated pH in the vesicles may alter the recycling of MHC complexes so that only the high affinity complexes are presented on the cell surface.[A183074] Self peptides bind to MHC complexes with low affinity and so they will be less likely to be presented to autoimmune T cells.[A183074] Hydroxychloroquine also reduces the release of cytokines like interleukin-1 and tumor necrosis factor, possibly through inhibition of Toll-like receptors.[A183074,A198852]\\r\\n\\r\\nThe raised pH in endosomes, prevent virus particles (such as SARS-CoV and SARS-CoV-2) from utilizing their activity for fusion and entry into the cell.[A191625]\\r\\n\\r\\nHydroxychloroquine inhibits terminal glycosylation of ACE2, the receptor that SARS-CoV and SARS-CoV-2 target for cell entry.[A191628,A191625] ACE2 that is not in the glycosylated state may less efficiently interact with the SARS-CoV-2 spike protein, further inhibiting viral entry.[A191625]\", \"neighbor_flag\": \"N\", \"pubmed_ids\": [10848718, 32356252], \"resource_name\": \"DrugBank\", \"resource_version\": \"5.1\", \"target_resource_id\": \"P10635\"}, {\"cofactor_in_ch_ikey\": \"JOMHSQGEWSNUKU-UHFFFAOYSA-N\", \"cofactor_smiles\": \"CN(C)S(=O)(=O)C1=CC2=C(SC3=CC=CC=C3N2CCCN2CCC(CCO)CC2)C=C1\", \"cofactor_name\": \"Pipotiazine\", \"cofactor_resource_id\": \"DB01621\", \"mechanism_of_action\": \"Pipotiazine acts as an antagonist (blocking agent) on different postsysnaptic receptors -on dopaminergic-receptors (subtypes D1, D2, D3 and D4 - different antipsychotic properties on productive and unproductive symptoms), on serotonergic-receptors (5-HT1 and 5-HT2, with anxiolytic, antidepressive and antiaggressive properties as well as an attenuation of extrapypramidal side-effects, but also leading to weight gain, fall in blood pressure, sedation and ejaculation difficulties), on histaminergic-receptors (H1-receptors, sedation, antiemesis, vertigo, fall in blood pressure and weight gain), alpha1/alpha2-receptors (antisympathomimetic properties, lowering of blood pressure, reflex tachycardia, vertigo, sedation, hypersalivation and incontinence as well as sexual dysfunction, but may also attenuate pseudoparkinsonism - controversial) and finally on muscarinic (cholinergic) M1/M2-receptors (causing anticholinergic symptoms like dry mouth, blurred vision, obstipation, difficulty/inability to urinate, sinus tachycardia, ECG-changes and loss of memory, but the anticholinergic action may attenuate extrapyramidal side-effects).\\r\\n\", \"neighbor_flag\": \"N\", \"pubmed_ids\": [19902987, 15797796], \"resource_name\": \"DrugBank\", \"resource_version\": \"5.1\", \"target_resource_id\": \"P10635\"}, {\"cofactor_in_ch_ikey\": \"GFBKORZTTCHDGY-UWVJOHFNSA-N\", \"cofactor_smiles\": \"CN(C)S(=O)(=O)C1=CC2=C(SC3=CC=CC=C3\\\\C2=C\\\\CCN2CCN(C)CC2)C=C1\", \"cofactor_name\": \"Thiothixene\", \"cofactor_resource_id\": \"DB01623\", \"mechanism_of_action\": \"Thiothixene acts as an antagonist (blocking agent) on different postsysnaptic receptors -on dopaminergic-receptors (subtypes D1, D2, D3 and D4 - different antipsychotic properties on productive and unproductive symptoms), on serotonergic-receptors (5-HT1 and 5-HT2, with anxiolytic, antidepressive and antiaggressive properties as well as an attenuation of extrapypramidal side-effects, but also leading to weight gain, fall in blood pressure, sedation and ejaculation difficulties), on histaminergic-receptors (H1-receptors, sedation, antiemesis, vertigo, fall in blood pressure and weight gain), alpha1/alpha2-receptors (antisympathomimetic properties, lowering of blood pressure, reflex tachycardia, vertigo, sedation, hypersalivation and incontinence as well as sexual dysfunction, but may also attenuate pseudoparkinsonism - controversial) and finally on muscarinic (cholinergic) M1/M2-receptors (causing anticholinergic symptoms like dry mouth, blurred vision, obstipation, difficulty/inability to urinate, sinus tachycardia, ECG-changes and loss of memory, but the anticholinergic action may attenuate extrapyramidal side-effects).\", \"neighbor_flag\": \"N\", \"pubmed_ids\": [10460810], \"resource_name\": \"DrugBank\", \"resource_version\": \"5.1\", \"target_resource_id\": \"P10635\"}, {\"cofactor_in_ch_ikey\": \"WFPIAZLQTJBIFN-DVZOWYKESA-N\", \"cofactor_smiles\": \"OCCN1CCN(CC\\\\C=C2\\\\C3=C(SC4=C2C=C(Cl)C=C4)C=CC=C3)CC1\", \"cofactor_name\": \"Zuclopenthixol\", \"cofactor_resource_id\": \"DB01624\", \"mechanism_of_action\": \"Zuclopenthixol is a typical antipsychotic neuroleptic drug of the thioxanthene class. It mainly acts by antagonism of D1 and D2 dopamine receptors. Zuclopenthixol also has high affinity for alpha1-adrenergic and 5-HT2 receptors. It has weaker histamine H1 receptor blocking activity, and even lower affinity for muscarinic cholinergic and alpha2-adrenergic receptors.\", \"neighbor_flag\": \"N\", \"pubmed_ids\": [20946203, 26514968], \"resource_name\": \"DrugBank\", \"resource_version\": \"5.1\", \"target_resource_id\": \"P10635\"}, {\"cofactor_in_ch_ikey\": \"MNJVRJDLRVPLFE-UHFFFAOYSA-N\", \"cofactor_smiles\": \"CC1=NC=C(C=C1)C1=C(C=C(Cl)C=N1)C1=CC=C(C=C1)S(C)(=O)=O\", \"cofactor_chem_comp_id\": \"5CH\", \"cofactor_name\": \"Etoricoxib\", \"cofactor_resource_id\": \"DB01628\", \"mechanism_of_action\": \"Like any other COX-2 selective inhibitor Etoricoxib selectively inhibits isoform 2 of cyclo-oxigenase enzyme (COX-2), preventing production of prostaglandins (PGs) from arachidonic acid.\", \"neighbor_flag\": \"N\", \"pubmed_ids\": [19515014, 9311621], \"resource_name\": \"DrugBank\", \"resource_version\": \"5.1\", \"target_resource_id\": \"P10635\"}, {\"cofactor_in_ch_ikey\": \"DFPAKSUCGFBDDF-UHFFFAOYSA-N\", \"cofactor_smiles\": \"NC(=O)C1=CC=CN=C1\", \"cofactor_chem_comp_id\": \"NCA\", \"cofactor_name\": \"Nicotinamide\", \"cofactor_resource_id\": \"DB02701\", \"neighbor_flag\": \"N\", \"pubmed_ids\": [15081432], \"resource_name\": \"DrugBank\", \"resource_version\": \"5.1\", \"target_resource_id\": \"P10635\"}, {\"cofactor_in_ch_ikey\": \"IECPWNUMDGFDKC-MZJAQBGESA-N\", \"cofactor_smiles\": \"[H][C@@]12C[C@@H](O)[C@@]3([H])[C@@]4(C)CC[C@@H](O)[C@@H](C)[C@]4([H])CC[C@]3(C)[C@@]1(C)C[C@H](OC(C)=O)\\\\C2=C(\\\\CCC=C(C)C)C(O)=O\", \"cofactor_chem_comp_id\": \"FUA\", \"cofactor_name\": \"Fusidic acid\", \"cofactor_resource_id\": \"DB02703\", \"mechanism_of_action\": \"Fusidic acid works by interfering with bacterial protein synthesis, specifically by preventing the translocation of the elongation factor G (EF-G) from the ribosome. It also can inhibit chloramphenicol acetyltransferase enzymes.\", \"neighbor_flag\": \"N\", \"pubmed_ids\": [29027845, 27571049], \"resource_name\": \"DrugBank\", \"resource_version\": \"5.1\", \"target_resource_id\": \"P10635\"}, {\"cofactor_in_ch_ikey\": \"LUKBXSAWLPMMSZ-OWOJBTEDSA-N\", \"cofactor_smiles\": \"OC1=CC=C(\\\\C=C\\\\C2=CC(O)=CC(O)=C2)C=C1\", \"cofactor_chem_comp_id\": \"STL\", \"cofactor_name\": \"Resveratrol\", \"cofactor_resource_id\": \"DB02709\", \"mechanism_of_action\": \"Resveratrol suppresses NF-kappaB (NF-kappaB) activation in HSV infected cells. Reports have indicated that HSV activates NF-kappaB during productive infection and this may be an essential aspect of its replication scheme [PMID: 9705914]. \", \"neighbor_flag\": \"N\", \"pubmed_ids\": [26391142, 20716633], \"resource_name\": \"DrugBank\", \"resource_version\": \"5.1\", \"target_resource_id\": \"P10635\"}, {\"cofactor_in_ch_ikey\": \"CPJSUEIXXCENMM-UHFFFAOYSA-N\", \"cofactor_smiles\": \"CCOC1=CC=C(NC(C)=O)C=C1\", \"cofactor_chem_comp_id\": \"N4E\", \"cofactor_name\": \"Phenacetin\", \"cofactor_resource_id\": \"DB03783\", \"neighbor_flag\": \"N\", \"resource_name\": \"DrugBank\", \"resource_version\": \"5.1\", \"target_resource_id\": \"P10635\"}, {\"cofactor_in_ch_ikey\": \"REFJWTPEDVJJIY-UHFFFAOYSA-N\", \"cofactor_smiles\": \"OC1=CC2=C(C(O)=C1)C(=O)C(O)=C(O2)C1=CC=C(O)C(O)=C1\", \"cofactor_chem_comp_id\": \"QUE\", \"cofactor_name\": \"Quercetin\", \"cofactor_resource_id\": \"DB04216\", \"mechanism_of_action\": \"Quercetin is a specific quinone reductase 2 (QR2) inhibitor, an enzyme (along with the human QR1 homolog) which catalyzes metabolism of toxic quinolines. Inhibition of QR2 in plasmodium may potentially cause lethal oxidative stress. The inhibition of antioxidant activity in plasmodium may contribute to killing the malaria causing parasites. \", \"neighbor_flag\": \"N\", \"pubmed_ids\": [29491651], \"resource_name\": \"DrugBank\", \"resource_version\": \"5.1\", \"target_resource_id\": \"P10635\"}, {\"cofactor_in_ch_ikey\": \"NYMGNSNKLVNMIA-UHFFFAOYSA-N\", \"cofactor_smiles\": \"CC(C)NNC(=O)C1=CC=NC=C1\", \"cofactor_name\": \"Iproniazid\", \"cofactor_resource_id\": \"DB04818\", \"neighbor_flag\": \"N\", \"pubmed_ids\": [16669850], \"resource_name\": \"DrugBank\", \"resource_version\": \"5.1\", \"target_resource_id\": \"P10635\"}, {\"cofactor_in_ch_ikey\": \"VAYOSLLFUXYJDT-RDTXWAMCSA-N\", \"cofactor_smiles\": \"[H][C@@]12CC3=CNC4=CC=CC(=C34)C1=C[C@H](CN2C)C(=O)N(CC)CC\", \"cofactor_chem_comp_id\": \"7LD\", \"cofactor_name\": \"Lysergic acid diethylamide\", \"cofactor_resource_id\": \"DB04829\", \"neighbor_flag\": \"N\", \"pubmed_ids\": [18454322], \"resource_name\": \"DrugBank\", \"resource_version\": \"5.1\", \"target_resource_id\": \"P10635\"}, {\"cofactor_in_ch_ikey\": \"JWPGJSVJDAJRLW-UHFFFAOYSA-N\", \"cofactor_smiles\": \"NC(=N)N1CCC2=CC=CC=C2C1\", \"cofactor_name\": \"Debrisoquine\", \"cofactor_resource_id\": \"DB04840\", \"mechanism_of_action\": \"Debrisoquin acts at the sympathetic neuroeffector junction by inhibiting or interfering with the release and/or distribution of norepinephrine, rather than acting at the effector cell by inhibiting the association of norepinephrine with its receptors. It is taken up by norepinephrine transporters. It becomes concentrated in NE transmitter vesicles, replacing NE in these vesicles. This leads to a gradual depletion of NE stores in the nerve endings. Once inside the terminal it blocks the release of noradrenaline in response to arrival of an action potential. In contrast to ganglionic blocking agents, debrisoquin suppresses equally the responses mediated by alpha-and beta-adrenergic receptors but does not produce parasympathetic blockade. Since sympathetic blockade results in modest decreases in peripheral resistance and cardiac output, debrisoquin lowers blood pressure in the supine position. It further reduces blood pressure by decreasing the degree of vasoconstriction that normally results from reflex sympathetic nervous activity upon assumption of the upright posture, thus reducing venous return and cardiac output more.\", \"neighbor_flag\": \"N\", \"resource_name\": \"DrugBank\", \"resource_version\": \"5.1\", \"target_resource_id\": \"P10635\"}, {\"cofactor_in_ch_ikey\": \"SMANXXCATUTDDT-QPJJXVBHSA-N\", \"cofactor_smiles\": \"FC1=CC=C(C=C1)C(N1CCN(C\\\\C=C\\\\C2=CC=CC=C2)CC1)C1=CC=C(F)C=C1\", \"cofactor_name\": \"Flunarizine\", \"cofactor_resource_id\": \"DB04841\", \"mechanism_of_action\": \"Flunarizine inhibits the influx of extracellular calcium through myocardial and vascular membrane pores by physically plugging the channel. The decrease in intracellular calcium inhibits the contractile processes of smooth muscle cells, causing dilation of the coronary and systemic arteries, increased oxygen delivery to the myocardial tissue, decreased total peripheral resistance, decreased systemic blood pressure, and decreased afterload.\", \"neighbor_flag\": \"N\", \"pubmed_ids\": [19515014, 8323546, 8951176], \"resource_name\": \"DrugBank\", \"resource_version\": \"5.1\", \"target_resource_id\": \"P10635\"}, {\"cofactor_in_ch_ikey\": \"MKJIEFSOBYUXJB-UHFFFAOYSA-N\", \"cofactor_smiles\": \"COC1=C(OC)C=C2C3CC(=O)C(CC(C)C)CN3CCC2=C1\", \"cofactor_name\": \"Tetrabenazine\", \"cofactor_resource_id\": \"DB04844\", \"mechanism_of_action\": \"Tetrabenazine is a reversible human vesicular monoamine transporter type 2 inhibitor (Ki = 100 nM). It acts within the basal ganglia and promotes depletion of monoamine neurotransmitters serotonin, norepinephrine, and dopamine from stores. It also decreases uptake into synaptic vesicles. Dopamine is required for fine motor movement, so the inhibition of its transmission is efficacious for hyperkinetic movement. Tetrabenazine exhibits weak in vitro binding affinity at the dopamine D2 receptor (Ki = 2100 nM).\", \"neighbor_flag\": \"N\", \"pubmed_ids\": [20442355], \"resource_name\": \"DrugBank\", \"resource_version\": \"5.1\", \"target_resource_id\": \"P10635\"}, {\"cofactor_in_ch_ikey\": \"JOATXPAWOHTVSZ-UHFFFAOYSA-N\", \"cofactor_smiles\": \"CCN(CC)C(=O)NC1=CC=C(OCC(O)CNC(C)(C)C)C(=C1)C(C)=O\", \"cofactor_name\": \"Celiprolol\", \"cofactor_resource_id\": \"DB04846\", \"mechanism_of_action\": \"Celiprolol is a vasoactive beta-1 selective adrenoceptor antagonist with partial beta-2 agonist activity. The beta-2 agonist activity is thought to account for its mild vasodilating properties. It lowers blood pressure in hypertensive patients at rest and on exercise. The effects on heart rate and cardiac output are dependent on the pre-existing background level of sympathetic tone.\\r\\nUnder conditions of stress such as exercise, celiprolol attenuates chronotropic and inotropic responses to sympathetic stimulation. However, at rest minimal impairment of cardiac function is seen. \", \"neighbor_flag\": \"N\", \"pubmed_ids\": [17125412, 14732961, 27836712], \"resource_name\": \"DrugBank\", \"resource_version\": \"5.1\", \"target_resource_id\": \"P10635\"}, {\"cofactor_in_ch_ikey\": \"ZQTNQVWKHCQYLQ-UHFFFAOYSA-N\", \"cofactor_smiles\": \"CCCCN(CCCC)CCCOC1=CC=C(C=C1)C(=O)C1=C(CCCC)OC2=C1C=C(NS(C)(=O)=O)C=C2\", \"cofactor_name\": \"Dronedarone\", \"cofactor_resource_id\": \"DB04855\", \"mechanism_of_action\": \"Atrial fibrillation is the most common type of arrhythmia that is caused by abnormal electrical activity in the atria. In atrial fibrillation, tachyarrhythmia, or fast heart rate, can either be paroxysmal (less than 7 days) or persistent (more than 7 days). Atrial fibrillation causes turbulent and abnormal blood flow through the heart chambers, leading to decreased the effectiveness of the heart to pump blood and an increased likelihood of thrombus formation within the atria which can ultimately dislodge and cause a stroke.[L8980] \\r\\n\\r\\nDronedarone achieves heart rate and rhythm control in atrial fibrillation. _In vitro_, dronedarone decreased the maximum rate of the rise of an action potential in a concentration- and frequency-dependent manner.[A186071] Cardiac action potentials are generated by ionic currents of multiple voltage-gated ion channels, including potassium, sodium, and calcium channels.[A187129] Dronedarone is a multichannel blocker that meets the criteria of all four Vaughan Williams antiarrhythmic drug classes[A34604] but the contribution of each of these activities to the drug's antiarrhythmic effect is unknown.[L8699] Dronedarone inhibits rapid Na+ currents rate-dependently (class Ib), non-competitively antagonizes \\u03b1\\u2013 and \\u03b2-adrenergic receptors (class II), blocks K+ outward currents (class III) and blocks slow Ca2+ inward currents (class IV).[A34604] More specifically, it decreases delayed-rectifier K+ current (IKr), slowly activating delayed-rectifier K+ current (IKs), inward rectifier potassium current (IK1), peak Na+ current (INa) and L-type Ca2+ current (ICa (L)).[A186071,A186077] Dronedarone ultimately increases refractory periods, decelerates cardiac conduction, and prolongs cardiac action potential and refractory periods.[A34604,L8684]\", \"neighbor_flag\": \"N\", \"pubmed_ids\": [20074258, 22971242, 28942006, 25505590], \"resource_name\": \"DrugBank\", \"resource_version\": \"5.1\", \"target_resource_id\": \"P10635\"}, {\"cofactor_in_ch_ikey\": \"KOHIRBRYDXPAMZ-UHFFFAOYSA-N\", \"cofactor_smiles\": \"OC(CNCC(O)C1CCC2=C(O1)C=CC(F)=C2)C1CCC2=C(O1)C=CC(F)=C2\", \"cofactor_name\": \"Nebivolol\", \"cofactor_resource_id\": \"DB04861\", \"mechanism_of_action\": \"Nebivolol is a highly selective beta-1 adrenergic receptor antagonist[A182579] with weak beta-2 adrenergic receptor antagonist activity.[A182585] Blocking beta-1 adrenergic receptors by d-nebivolol leads to decreased resting heart rate, exercise heart rate, myocardial contracility, systolic blood pressure, and diastolic blood pressure.[A182603,A182579,A182585,A182615] The selectivity of d-nebivolol limits the magnitude of beta blocker adverse effects in the airways or relating to insulin sensitivity.[A182615] Nebivolol also inhibits aldosterone, and beta-1 antagonism in the juxtaglomerular apparatus also inhibits the release of renin.[A182615] Decreased aldosterone leads to decreased blood volume, and decreased renin leads to reduced vasoconstriction.[A182615] l-nebivolol is responsible for beta-3 adrenergic receptor agonist activity that stimulates endothelial nitric oxide synthase, increasing nitric oxide levels; leading to vasodilation, decreased peripheral vascular resistance, increased stroke volume, ejection fraction, and cardiac output.[A2762,A182603,A182579,A182585,A182615] The vasodilation, reduced oxidative stress, and reduced platelet volume and aggregation of nebivolol may lead to benefits in heart failure patients.[A182603]\", \"neighbor_flag\": \"N\", \"pubmed_ids\": [16961165], \"resource_name\": \"DrugBank\", \"resource_version\": \"5.1\", \"target_resource_id\": \"P10635\"}, {\"cofactor_in_ch_ikey\": \"HHZIURLSWUIHRB-UHFFFAOYSA-N\", \"cofactor_smiles\": \"CC1=CN(C=N1)C1=CC(NC(=O)C2=CC=C(C)C(NC3=NC=CC(=N3)C3=CN=CC=C3)=C2)=CC(=C1)C(F)(F)F\", \"cofactor_chem_comp_id\": \"NIL\", \"cofactor_name\": \"Nilotinib\", \"cofactor_resource_id\": \"DB04868\", \"mechanism_of_action\": \"Chronic myelogenous leukaemia (CML) is caused by the BCR-ABL oncogene. Nilotinib inhibits the tyrosine kinase activity of the BCR-ABL protein. Nilotinib fits into the ATP-binding site of the BCR-ABL protein with higher affinity than imatinib, over-riding resistance caused by mutations. The ability of AMN107 to inhibit TEL-platelet-derived growth factor receptor-beta (TEL-PDGFRbeta), which causes chronic myelomonocytic leukaemia, and FIP1-like-1-PDGFRalpha, which causes hypereosinophilic syndrome, suggests potential use of AMN107 for myeloproliferative diseases characterised by these kinase fusions (Stover et al, 2005; Weisberg et al, 2005). AMN107 also inhibits the c-Kit receptor kinase, including the D816V-mutated variant of KIT, at pharmacologically achievable concentrations, supporting potential utility in the treatment of mastocytosis, and gastrointestinal stromal tumours (Weisberg et al, 2005; von Bubnoff et al, 2005; Gleixner et al, 2006).\", \"neighbor_flag\": \"N\", \"pubmed_ids\": [20810928, 19108785], \"resource_name\": \"DrugBank\", \"resource_version\": \"5.1\", \"target_resource_id\": \"P10635\"}, {\"cofactor_in_ch_ikey\": \"XTTZERNUQAFMOF-QMMMGPOBSA-N\", \"cofactor_smiles\": \"C[C@H]1CNCCC2=CC=C(Cl)C=C12\", \"cofactor_chem_comp_id\": \"T4U\", \"cofactor_name\": \"Lorcaserin\", \"cofactor_resource_id\": \"DB04871\", \"mechanism_of_action\": \"Although the exact mechanism is unknown, it is believed to involve the selective activation of 5-HT2C receptors in the anorexigenic pro-opiomelanocortin neurons in the arcuate nucleus of the hypothalamus. This results in decreased food intake and satiety by promoting the release of alpha-melanocortin stimulating hormone, which acts on melanocortin-4 receptors.\", \"neighbor_flag\": \"N\", \"pubmed_ids\": [22266842], \"resource_name\": \"DrugBank\", \"resource_version\": \"5.1\", \"target_resource_id\": \"P10635\"}, {\"cofactor_in_ch_ikey\": \"USRHYDPUVLEVMC-FQEVSTJZSA-N\", \"cofactor_smiles\": \"CN(C)[C@@H](CCOC1=CC=CC2=CC=CC=C12)C1=CC=CC=C1\", \"cofactor_name\": \"Dapoxetine\", \"cofactor_resource_id\": \"DB04884\", \"mechanism_of_action\": \"The drug's mechanism of action is thought to be related to inhibition of neuronal reuptake of serotonin and subsequent potentiation of serotonin activity. The central ejaculatory neural circuit comprises spinal and cerebral areas that form a highly interconnected network. The sympathetic, parasympathetic, and somatic spinal centers, under the influence of sensory genital and cerebral stimuli integrated and processed at the spinal cord level, act in synergy to command physiologic events occurring during ejaculation. Experimental evidence indicates that serotonin (5-HT), throughout brain descending pathways, exerts an inhibitory role on ejaculation. To date, three 5-HT receptor subtypes (5-HT(1A), 5-HT(1B), and 5-HT(2C)) have been postulated to mediate 5-HT's modulating activity on ejaculation.\", \"neighbor_flag\": \"N\", \"pubmed_ids\": [23024705], \"resource_name\": \"DrugBank\", \"resource_version\": \"5.1\", \"target_resource_id\": \"P10635\"}, {\"cofactor_in_ch_ikey\": \"OFYVIGTWSQPCLF-UHFFFAOYSA-N\", \"cofactor_smiles\": \"CC1=CC=C(C=C1)C12CC1CNC2\", \"cofactor_name\": \"Bicifadine\", \"cofactor_resource_id\": \"DB04889\", \"mechanism_of_action\": \"Preclinical studies and clinical trials indicate that bicifadine's analgesic properties result through the enhancement and prolongation of norepinephrine and serotonin actions, however other actions may be involved.\", \"neighbor_flag\": \"N\", \"pubmed_ids\": [17881661], \"resource_name\": \"DrugBank\", \"resource_version\": \"5.1\", \"target_resource_id\": \"P10635\"}, {\"cofactor_in_ch_ikey\": \"NFIXBCVWIPOYCD-UHFFFAOYSA-N\", \"cofactor_smiles\": \"CCN(CC)CCOC1=CC=C(CC2=CC=CC=C2)C=C1\", \"cofactor_name\": \"Tesmilifene\", \"cofactor_resource_id\": \"DB04905\", \"mechanism_of_action\": \"Although the exact mechanism of action is not known, one study (PMID: 16413681) proposes that tesmilifene may be an activating p-gp substrate, which enables the p-gp pump to extrude typical p-gp substrates (such as anthracyclines or taxanes) more efficiently. This process consumes ATP, since the p-gp is absolutely, and highly dependent on ATP hydrolysis. The mechanism of cell death is likely to result not from the presence of chemotherapy inside the cell (in fact the chemotherapy is extruded) but, directly or indirectly, from the enhanced consumption of ATP. The ATP may be consumed below a threshold necessary for survival, or, (more likely) the enhanced ATP production required to maintain ATP levels may result in the generation of reactive oxygen species (ROS) to an extent that overwhelms the cell\\u2019s ability to inactivate them. The result would be additional cell death, but only in the mdr+ population. The doxorubicin would continue to act on the drug sensitive remainder of the cell population, but without the help of tesmilifene.\", \"neighbor_flag\": \"N\", \"pubmed_ids\": [10755318], \"resource_name\": \"DrugBank\", \"resource_version\": \"5.1\", \"target_resource_id\": \"P10635\"}, {\"cofactor_in_ch_ikey\": \"VHFGEBVPHAGQPI-LXKZPTCJSA-N\", \"cofactor_smiles\": \"CN[C@H](CC(C)C)C(=O)N[C@@H]1[C@H](O)C2=CC=C(OC3=C(O[C@@H]4O[C@H](CO)[C@@H](O)[C@H](O)[C@H]4O[C@H]4C[C@](C)(NCC5=CC=C(C=C5)C5=CC=C(Cl)C=C5)[C@@H](O)[C@H](C)O4)C4=CC(=C3)[C@@H](NC(=O)[C@H](CC(N)=O)NC1=O)C(=O)N[C@@H]1C3=CC(=C(O)C=C3)C3=C(O)C=C(O)C=C3[C@H](NC(=O)[C@@H](NC1=O)[C@H](O[C@H]1C[C@](C)(N)[C@@H](O)[C@H](C)O1)C1=CC(Cl)=C(O4)C=C1)C(O)=O)C(Cl)=C2\", \"cofactor_name\": \"Oritavancin\", \"cofactor_resource_id\": \"DB04911\", \"mechanism_of_action\": \"The cell wall is vital for the survival and replication of bacteria, making it a primary target for antibiotic therapy.[A193428] Oritavancin works against susceptible gram-positive organisms via three separate mechanisms. Firstly, it binds to the stem peptide of peptidoglycan precursors, inhibiting transglycosylation (polymerization). This process normally occurs during cell wall synthesis. Secondly, oritavancin inhibits crosslinking during bacterial cell wall biosynthesis via binding to cell wall pentaglycyl peptide bridging segments. Finally, this drug also acts by disrupting the bacterial cell membrane, interfering with its integrity, which eventually leads to cell death by various mechanisms.[A193416,A193425,L8492]\", \"neighbor_flag\": \"N\", \"pubmed_ids\": [25673895, 26831328], \"resource_name\": \"DrugBank\", \"resource_version\": \"5.1\", \"target_resource_id\": \"P10635\"}, {\"cofactor_in_ch_ikey\": \"KPBZROQVTHLCDU-UHFFFAOYSA-N\", \"cofactor_smiles\": \"CCCC(=O)OCOC(=O)C1=C(C)NC(C)=C(C1C1=CC=CC(Cl)=C1Cl)C(=O)OC\", \"cofactor_name\": \"Clevidipine\", \"cofactor_resource_id\": \"DB04920\", \"mechanism_of_action\": \"Possibly by deforming the channel, inhibiting ion-control gating mechanisms, and/or interfering with the release of calcium from the sarcoplasmic reticulum, clevidipine inhibits the influx of extracellular calcium across both the myocardial and vascular smooth muscle cell membranes. The resultant inhibition of the contractile processes of the myocardial smooth muscle cells leads to dilation of the coronary and systemic arteries and improved oxygen delivery to the myocardial tissue.\", \"neighbor_flag\": \"N\", \"pubmed_ids\": [16501008], \"resource_name\": \"DrugBank\", \"resource_version\": \"5.1\", \"target_resource_id\": \"P10635\"}, {\"cofactor_in_ch_ikey\": \"LUMKNAVTFCDUIE-VHXPQNKSSA-N\", \"cofactor_smiles\": \"OCCOC1=CC=C(C=C1)C(=C(\\\\CCCl)C1=CC=CC=C1)\\\\C1=CC=CC=C1\", \"cofactor_name\": \"Ospemifene\", \"cofactor_resource_id\": \"DB04938\", \"mechanism_of_action\": \"Ospemifene is a next generation SERM (selective estrogen receptor modulator) that selectively binds to estrogen receptors and either stimulates or blocks estrogen's activity in different tissue types. It has an agonistic effect on the endometrium.\", \"neighbor_flag\": \"N\", \"resource_name\": \"DrugBank\", \"resource_version\": \"5.1\", \"target_resource_id\": \"P10635\"}, {\"cofactor_in_ch_ikey\": \"XMXHEBAFVSFQEX-UHFFFAOYSA-N\", \"cofactor_smiles\": \"COC1=C(OCCCN2CCC(CC2)C2=NOC3=C2C=CC(F)=C3)C=CC(=C1)C(C)=O\", \"cofactor_name\": \"Iloperidone\", \"cofactor_resource_id\": \"DB04946\", \"mechanism_of_action\": \"The exact mechanism of action of iloperidone in schizophrenia and bipolar I disorder has not been fully elucidated. It is believed that the drug mechanism of action may be related to its antagonism at the dopamine D2 and 5-HT2A receptors.[L50527]\", \"neighbor_flag\": \"N\", \"pubmed_ids\": [9732390, 21034370], \"resource_name\": \"DrugBank\", \"resource_version\": \"5.1\", \"target_resource_id\": \"P10635\"}, {\"cofactor_in_ch_ikey\": \"KSMAGQUYOIHWFS-UHFFFAOYSA-N\", \"cofactor_smiles\": \"CC(OC1=C(Cl)C=CC=C1Cl)C1=NCCN1\", \"cofactor_name\": \"Lofexidine\", \"cofactor_resource_id\": \"DB04948\", \"mechanism_of_action\": \"Lofexidine is a potent alpha2-adrenergic receptor agonist with some moderate agonistic affinity towards Alpha-1A adrenergic receptor and 5-HT1a, 5-HT7, 5HT2c and 5HT1d receptors.[L2801]\\r\\n\\r\\nThe alpha2-adrenergic receptor is normally targeted by norepinephrine and its activation inhibits the synthesis of cAMP which in turn leads to potassium efflux and suppression of neural firing and inhibition of norepinephrine release. All of this activity can reduce the heart rate, blood pressure, and attenuate sympathetic stress response.[L2801]\\r\\n\\r\\nOpioids inhibit cAMP in the noradrenergic neurons and their discontinuation produces a rise in the level of cAMP. This will generate an increase in norepinephrine which is associated with the symptoms of withdrawal. The magnitude of the effect is augmented by chronic opioid use due to the compensatory mechanisms of continuous negative feedback. Therefore, chronic opioid use translates into an exacerbated production of cAMP and norepinephrine release.[L2801]\\r\\n\\r\\nLofexidine replaces the opioid-driven inhibition of cAMP production by activating the alpha2-adrenergic receptor and moderating the symptoms of opioid withdrawal. This effect is performed without interacting with opioid receptors which mediate other activities of opioid dependence or addiction.[L2801]\", \"neighbor_flag\": \"N\", \"resource_name\": \"DrugBank\", \"resource_version\": \"5.1\", \"target_resource_id\": \"P10635\"}, {\"cofactor_in_ch_ikey\": \"ISWRGOKTTBVCFA-UHFFFAOYSA-N\", \"cofactor_smiles\": \"CC1=CN(C(=O)C=C1)C1=CC=CC=C1\", \"cofactor_name\": \"Pirfenidone\", \"cofactor_resource_id\": \"DB04951\", \"mechanism_of_action\": \"The exact mechanism of action of pirfenidone is not fully understood.[L26801] It is suggested that the antioxidant effects of pirfenidone contribute to its anti-inflammatory effects, leading to antifibrotic effects.[A251370] \\r\\n\\r\\nPirfenidone attenuates the production of transforming growth factor-\\u03b21 (TGF-\\u03b21), a key profibrotic and pro-inflammatory cytokine implicated in idiopathic pulmonary fibrosis (IPF). By suppressing TGF-\\u03b21, pirfenidone inhibits TGF-\\u03b21-induced differentiation of human lung fibroblasts into myofibroblasts, thereby preventing excess collagen synthesis and extracellular matrix production.[A225556,A225571,A225576,A225581,A251365]\\r\\n\\r\\nSome evidence suggests that pirfenidone downregulates pro-inflammatory cytokines, including TNF-\\u03b1, interleukin-1 (IL-1), IL-6, interferon-gamma (IFN-\\u03b3),[A225556,A225576,A251365] and platelet-derived growth factor (PDGF).[A251365] Animal models demonstrated that pirfenidone promotes the production of anti-inflammatory IL-10 and prevents the accumulation of various inflammatory cells, including lymphocytes, macrophages and neutrophils.[A251365] In animal models, pirfenidone inhibited the influx of inflammatory cells and ameliorated bleomycin-induced pulmonary vascular permeability.[A225556] Several _in vitro_ studies show that pirfenidone mediates antioxidant actions by scavenging reactive oxygen species (ROS) and inhibiting lipid peroxidation, thereby reducing cellular injury in IPF.[A251365] \", \"neighbor_flag\": \"N\", \"resource_name\": \"DrugBank\", \"resource_version\": \"5.1\", \"target_resource_id\": \"P10635\"}, {\"cofactor_in_ch_ikey\": \"MREBEPTUUMTTIA-UHFFFAOYSA-N\", \"cofactor_smiles\": \"CN1CCN(CCCCN2C(=O)CN(N=CC3=CC=C(O3)C3=CC=C(Cl)C=C3)C2=O)CC1\", \"cofactor_name\": \"Azimilide\", \"cofactor_resource_id\": \"DB04957\", \"mechanism_of_action\": \"The mechanism of action of azimilide is to block both the slowly conducting (I(Ks)) and rapidly conducting (I(Kr)) rectifier potassium currents in cardiac cells. This differs from other class III agents that block I(Kr) exclusively or in combination with sodium, calcium, or transient outward (I(to)) potassium current channels. It also has blocking effects on sodium (I(Na)) and calcium currents (I(CaL)). Its effects on reentrant circuits in infarct border zones causing ventricular tachyarrhythmias are unknown. \", \"neighbor_flag\": \"N\", \"pubmed_ids\": [16052551], \"resource_name\": \"DrugBank\", \"resource_version\": \"5.1\", \"target_resource_id\": \"P10635\"}, {\"cofactor_in_ch_ikey\": \"PGTVWKLGGCQMBR-FLBATMFCSA-N\", \"cofactor_smiles\": \"[H][C@@]12CC[C@H](C(C)=O)[C@@]1(C)CC[C@@]1([H])[C@@]2([H])CC[C@@]2([H])C[C@](C)(O)CC[C@]12C\", \"cofactor_name\": \"Ganaxolone\", \"cofactor_resource_id\": \"DB05087\", \"mechanism_of_action\": \"Ganaxolone belongs to a novel class of neuroactive steroids sometimes referred to as \\\"epalons\\\", which are potent and specific positive allosteric modulators of \\u03b3-aminobutyric acid type A (GABA<sub>A</sub>) receptors in the central nervous system (CNS).[A245990] It binds GABA<sub>A</sub> at one of several potential binding sites, all of which are distinct from the benzodiazepine binding site.[A3197] By enhancing the inhibitory effects of GABA<sub>A</sub> receptors, endogenous and exogenous neurosteroids have been associated with anxiolytic, sedative, and anticonvulsant effects, amongst others.[A245995]\\r\\n\\r\\nWhile the precise mechanism of action of ganaxolone in the treatment of seizures associated with CDD is unknown, its anticonvulsant effects are likely due to positive allosteric GABA<sub>A</sub> modulation[L41130]\", \"neighbor_flag\": \"N\", \"resource_name\": \"DrugBank\", \"resource_version\": \"5.1\", \"target_resource_id\": \"P10635\"}, {\"cofactor_in_ch_ikey\": \"PKVRCIRHQMSYJX-AIFWHQITSA-N\", \"cofactor_smiles\": \"[H][C@@]12[C@@H]3SC[C@]4(NCCC5=C4C=C(OC)C(O)=C5)C(=O)OC[C@H](N1[C@@H](O)[C@@H]1CC4=CC(C)=C(OC)C(O)=C4[C@H]2N1C)C1=C2OCOC2=C(C)C(OC(C)=O)=C31\", \"cofactor_chem_comp_id\": \"ECT\", \"cofactor_name\": \"Trabectedin\", \"cofactor_resource_id\": \"DB05109\", \"mechanism_of_action\": \"Trabectedin interacts with the minor groove of DNA and alkylates guanine at the N2 position, which bends towards the major groove. In this manner, it is thought that the drug affects various transcription factors involved in cell proliferation, particularly via the transcription-coupled nucleotide excision repair system. Trabectedin blocks the cell cycle at the G2 phase, while cells at the G1 phase are most sensitive to the drug. It also inhibits overexpression of the multidrug resistance-1 gene (MDR-1) coding for the P-glycoprotein that is a major factor responsible for cells developing resistance to cancer drugs. The agent is also thought to interfere with the nucleotide excision repair pathways of cancer cells, suggesting that it could be effective in the treatment of many cancer types including melanoma and sarcoma, as well as lung, breast, ovarian, endometrial and prostate cancers; clinical evaluations are underway in these indications.\\r\\n\", \"neighbor_flag\": \"N\", \"pubmed_ids\": [18191164], \"resource_name\": \"DrugBank\", \"resource_version\": \"5.1\", \"target_resource_id\": \"P10635\"}, {\"cofactor_in_ch_ikey\": \"BSMCAPRUBJMWDF-KRWDZBQOSA-N\", \"cofactor_smiles\": \"OC1(CN(C1)C(=O)C1=C(NC2=C(F)C=C(I)C=C2)C(F)=C(F)C=C1)[C@@H]1CCCCN1\", \"cofactor_chem_comp_id\": \"EUI\", \"cofactor_name\": \"Cobimetinib\", \"cofactor_resource_id\": \"DB05239\", \"mechanism_of_action\": \"Cobimetinib is a reversible inhibitor of mitogen-activated protein kinase (MAPK)/extracellular signal-regulated kinase 1 (MEK1) and MEK2. MEK proteins are upstream regulators of the extracellular signal-related kinase (ERK) pathway, which promotes cellular proliferation. BRAF V600E and K mutations result in constitutive activation of the BRAF pathway which includes MEK1 and MEK2. In mice implanted with tumor cell lines expressing BRAF V600E, cobimetinib inhibited tumor cell growth.[L43717] \\r\\n\\r\\nCobimetinib and vemurafenib target two different kinases in the RAS/RAF/MEK/ERK pathway. Compared to either drug alone, coadministration of cobimetinib and vemurafenib resulted in increased apoptosis in vitro and reduced tumor growth in mouse implantation models of tumor cell lines harboring BRAF V600E mutations. Cobimetinib also prevented vemurafenib-mediated growth enhancement of a wild-type BRAF tumor cell line in an in vivo mouse implantation model.[L43717]  \", \"neighbor_flag\": \"N\", \"resource_name\": \"DrugBank\", \"resource_version\": \"5.1\", \"target_resource_id\": \"P10635\"}, {\"cofactor_in_ch_ikey\": \"KFQYTPMOWPVWEJ-INIZCTEOSA-N\", \"cofactor_smiles\": \"CCCN(CCC1=CC=CS1)[C@H]1CCC2=C(O)C=CC=C2C1\", \"cofactor_chem_comp_id\": \"R5F\", \"cofactor_name\": \"Rotigotine\", \"cofactor_resource_id\": \"DB05271\", \"mechanism_of_action\": \"Rotigotine, a member of the dopamine agonist class of drugs, is delivered continuously through the skin (transdermal) using a silicone-based patch that is replaced every 24 hours. A dopamine agonist works by activating dopamine receptors in the body, mimicking the effect of the neurotransmitter dopamine. The precise mechanism of action of rotigotine as a treatment for Restless Legs Syndrome is unknown but is thought to be related to its ability to stimulate dopamine \", \"neighbor_flag\": \"N\", \"pubmed_ids\": [18691132], \"resource_name\": \"DrugBank\", \"resource_version\": \"5.1\", \"target_resource_id\": \"P10635\"}, {\"cofactor_in_ch_ikey\": \"RKEWSXXUOLRFBX-UHFFFAOYSA-N\", \"cofactor_smiles\": \"CC(C)COC1=CC=C(CNC(=O)N(CC2=CC=C(F)C=C2)C2CCN(C)CC2)C=C1\", \"cofactor_chem_comp_id\": \"A1L11\", \"cofactor_name\": \"Pimavanserin\", \"cofactor_resource_id\": \"DB05316\", \"mechanism_of_action\": \"Parkinson's disease psychosis (PDP) is an imbalance of serotonin and dopamine from disruption of the normal balance between the serotonergic and dopaminergic receptors and neurotransmitters in the brain.[A232778]\\r\\n\\r\\nThe mechanism by which pimavanserin treats hallucinations and delusions associated with Parkinson\\u2019s disease psychosis is not fully established. It is possible that pimavanserin acts via inverse agonist and antagonist activity at serotonin 5-HT<sub>2A</sub> receptors with limited effects on serotonin 5-HT<sub>2C</sub> receptors. Pimavanserin is an inverse agonist and antagonist of serotonin 5-HT<sub>2A</sub> receptors with high binding affinity, demonstrating low binding affinity to serotonin 5-HT<sub>2C</sub> receptors. In addition, this drug exhibits low affinity binding to sigma 1 receptors.[L32883]  Pimavanserin lacks activity at muscarinic, dopaminergic, adrenergic, and histaminergic receptors, preventing various undesirable effects typically associated with antipsychotics.[A232773]\", \"neighbor_flag\": \"N\", \"pubmed_ids\": [29497575], \"resource_name\": \"DrugBank\", \"resource_version\": \"5.1\", \"target_resource_id\": \"P10635\"}, {\"cofactor_in_ch_ikey\": \"WVLHHLRVNDMIAR-IBGZPJMESA-N\", \"cofactor_smiles\": \"NCCCCN(CC1=NC2=CC=CC=C2N1)[C@H]1CCCC2=C1N=CC=C2\", \"cofactor_chem_comp_id\": \"A1D8L\", \"cofactor_name\": \"Mavorixafor\", \"cofactor_resource_id\": \"DB05501\", \"mechanism_of_action\": \"WHIM syndrome is a rare primary immunodeficiency disorder predominantly linked to heterozygous gain-of-function mutations in the C-terminus of the C-X-C chemokine receptor 4 (CXCR4), which is a chemokine receptor that regulates immune cell trafficking and homeostasis.[A263647, A263652, A263627] CXCR4 is a G protein-coupled receptor (GPCR) that activates downstream pathways such as G-protein signalling, calcium mobilization, and ERK/AKT activation.[A263632] CXC Chemokine Ligand 12 (CXCL12), previously known as stromal-derived factor-1\\u03b1 (SDF-1\\u03b1), is a sole ligand of CXCR4 [A263627] that binds to the receptor and promotes the trafficking and homing of leukocytes to and from the bone marrow compartment.[L50642] Gain-of-function mutations in the CXCR4 receptor gene result in desensitization defects and increased responsiveness to CXCL12, overactivation of CXCR4 downstream pathways, and the retention of leukocytes in the bone marrow.[A263652, L50647] Due to a reduced number of mature neutrophils and lymphocytes, patients with WHIM syndrome experience a variety of manifestations of the disorder,[L50647] including panleukopenia and an increased susceptibility to infections and malignancy.[A263652]\\r\\n\\r\\nMavorixafor is an orally bioavailable CXCR4 antagonist that blocks the binding of CXCL12 to CXCR4. Mavorixafor inhibits the response to CXCL12 in both wild-type and mutated CXCR4 variants associated with WHIM syndrome.[L50642] Treatment with mavorixafor results in increased mobilization of neutrophils and lymphocytes from the bone marrow into the peripheral circulation.[L50642] \", \"neighbor_flag\": \"N\", \"resource_name\": \"DrugBank\", \"resource_version\": \"5.1\", \"target_resource_id\": \"P10635\"}, {\"cofactor_in_ch_ikey\": \"GZOSMCIZMLWJML-VJLLXTKPSA-N\", \"cofactor_smiles\": \"[H][C@@]12CC=C(C3=CC=CN=C3)[C@@]1(C)CC[C@@]1([H])[C@@]2([H])CC=C2C[C@@H](O)CC[C@]12C\", \"cofactor_chem_comp_id\": \"AER\", \"cofactor_name\": \"Abiraterone\", \"cofactor_resource_id\": \"DB05812\", \"mechanism_of_action\": \"17\\u03b1-hydroxylase/C17,20-lyase (CYP17) is a key enzyme in androgen biosynthesis. It is primarily expressed in testicular, adrenal, and prostatic tumours. CYP17 catalyzes the 17\\u03b1-hydroxylation of pregnenolone and progesterone to their 17\\u03b1-hydroxy derivative, followed by subsequent cleavage of the C 20,21-acetyl group to yield dehydroepiandrosterone (DHEA) and androstenedione. DHEA and androstenedione are precursors of testosterone.[A260870, L40968] Aberrant androgen levels and unregulated androgen receptor signalling have been implicated in the development and progression of various prostate cancers.[A260875] Androgen-sensitive prostatic carcinoma responds to treatment that decreases androgen levels. Androgen deprivation therapies, such as treatment with GnRH agonists or orchiectomy, decrease androgen production in the testes but do not affect androgen production by the adrenals or in the tumour.[A3810, L40968]\\r\\n\\r\\nAbiraterone inhibits CYP17 to block androgen production. Inhibition of CYP17 can also result in increased mineralocorticoid production by the adrenals.[L40968] \", \"neighbor_flag\": \"N\", \"pubmed_ids\": [23064959], \"resource_name\": \"DrugBank\", \"resource_version\": \"5.1\", \"target_resource_id\": \"P10635\"}, {\"cofactor_in_ch_ikey\": \"KPWSJANDNDDRMB-QAQDUYKDSA-N\", \"cofactor_smiles\": \"CN(C)C(=O)N[C@H]1CC[C@H](CCN2CCN(CC2)C2=C(Cl)C(Cl)=CC=C2)CC1\", \"cofactor_chem_comp_id\": \"7RU\", \"cofactor_name\": \"Cariprazine\", \"cofactor_resource_id\": \"DB06016\", \"mechanism_of_action\": \"While recent research points to the involvement of multiple neurotransmitters in the development and maintenance of schizophrenia and bipolar disorders, the dopamine hypothesis has been and continues to be a key theory in understanding the pathophysiology of these psychiatric disorders. Dopamine is a neurotransmitter that plays several important roles in cells, and most importantly, it is a crucial neurotransmitter involved in reward processing and motivation. The nigrostriatal, mesolimbic, and mesocortical systems consist of dopaminergic projections. The dopamine hypothesis states that dopaminergic aberrations are observed in schizophrenia and bipolar disorders.[A189156,A247105] For example, hyperactive dopamine D2 receptor activity has been associated with positive symptoms of schizophrenia, such as hallucinations and delusions. On the other hand, alterations in dopamine D3 receptors may be involved in producing negative symptoms of schizophrenia.[A189156] It was stated that hyperdopaminergia, caused by elevations in D2/3 receptor availability and a hyperactive reward processing network, underlies the development of mania in bipolar disorder.[A247105]\\r\\n\\r\\nThe exact mechanism of action of cariprazine is not fully elucidated. Cariprazine potently binds to both of these receptors, more preferably to D3 receptors with higher affinity.[A3941] Preclinical studies suggest that D3 receptor blockade is associated with exerting pro-cognitive and antidepressant effects and attenuating negative symptoms in schizophrenia.[A247095] This unique mechanism of action differs from that of other antipsychotic agents that mostly target D2 and 5-HT<sub>2A</sub> receptors.[A247055] Cariprazine is also a partial agonist at 5-HT<sub>1A</sub> receptors, an antagonist at 5-HT<sub>2B</sub> and 5-HT<sub>2A</sub> receptors, an antagonist at histamine H1 receptors. It also binds to 5-HT<sub>2C</sub>, alpha (\\u03b1)-1A adrenergic, and alpha (\\u03b1)-1B adrenergic receptors with low affinity.[A3941,A247095]\", \"neighbor_flag\": \"N\", \"pubmed_ids\": [23320989], \"resource_name\": \"DrugBank\", \"resource_version\": \"5.1\", \"target_resource_id\": \"P10635\"}, {\"cofactor_in_ch_ikey\": \"ZISJNXNHJRQYJO-CMDGGOBGSA-N\", \"cofactor_smiles\": \"CC(C)C1=C(O)C=C(\\\\C=C\\\\C2=CC=CC=C2)C=C1O\", \"cofactor_chem_comp_id\": \"A1LWH\", \"cofactor_name\": \"Tapinarof\", \"cofactor_resource_id\": \"DB06083\", \"mechanism_of_action\": \"Tapinarof is a therapeutic aryl hydrocarbon receptor-modulating agent (TAMA) that binds to and activates the aryl hydrocarbon receptor (AhR). AhR is a ligand-dependent transcription factor that regulates gene expression in a variety of cell types, including macrophages, T-cells, antigen-presenting cells, fibroblasts, and keratinocytes.[A248790] Upon binding to its ligand, AhR heterodimerizes with AhR nuclear translocator (ARNT) to form a complex with a high affinity for DNA binding.[A248790, A248730] The AhR-ligand/ARNT complex can then bind to the specific DNA recognition sites to transcribe AhR-responsive genes.[A248790, A248730] Additionally, AhR also exerts its effect through other transcription factors such as the nuclear factor \\u03baB and nuclear factor erythroid 2-related factor 2 (Nrf2), a downstream product of AhR-induced transcription that has antioxidant properties.[A248795,A248790]  \\r\\n\\r\\nDysregulation of AhR is one of the hallmarks of psoriasis, as psoriasis patients have a higher serum concentration of AhR compared to healthy individuals.[A248785] Treatment of AhR ligands in vitro also results in a gene expression profile that is implicated in the pathogenesis of psoriasis.[A248785, A248730] For instance, AhR activation causes the expansion and differentiation of Th17 and Th22, two major T cells responsible for releasing inflammatory cytokines IL-17 and IL-22.[A248850, A248785, A248730]. Additionally, AhR activation also recruits persistent skin resident memory T cells, thus contributing to the chronicity of psoriasis.[A248860] However, the specific binding of tapinarof to AhR modulates a unique set of genes that are dysregulated in psoriasis, distinctive from other AhR ligands.[A248730, A248790] Further, tapinarof also induces barrier protein expression, such as filaggrin, hornerin, and involucrin, to restore the skin barrier and epidermal function and decrease oxidative stress.[A248790, A248785, A248860] It is currently unknown why AhR ligands like tapinarof can reduce psoriatic inflammations in one setting but upregulate inflammatory genes in another setting.[A248730] \\r\\n\\r\\nIt is possible that the anti-inflammatory effect of tapinarof as an AhR agonist might be due to Nrf2.[A248730] Although Nrf2 is a known downstream effector of AhR, not all AhR agonists activate this pathway. For instance, 2,3,7,8-tetrachlorodibenzo-p-dioxin, an AhR agonist, does not show any antioxidant activity after AhR activation.[A248780] Therefore, it is hypothesized that the dual AhR/Nrf2 action of tapinarof is essential to the effect of tapinarof in treating psoriasis.[A248785]\\r\\n\\r\\n\", \"neighbor_flag\": \"N\", \"pubmed_ids\": [29389078], \"resource_name\": \"DrugBank\", \"resource_version\": \"5.1\", \"target_resource_id\": \"P10635\"}, {\"cofactor_in_ch_ikey\": \"HUNGUWOZPQBXGX-UHFFFAOYSA-N\", \"cofactor_smiles\": \"O=C(CC1=CC=C(C=N1)C1=CC=C(OCCN2CCOCC2)C=C1)NCC1=CC=CC=C1\", \"cofactor_chem_comp_id\": \"DN0\", \"cofactor_name\": \"Tirbanibulin\", \"cofactor_resource_id\": \"DB06137\", \"mechanism_of_action\": \"Src tyrosine kinases regulate normal cell growth: the expression of Src kinase is upregulated during the normal hair cycle during the proliferative anagen phase. Additionally, Src tyrosine kinases act as key modulators of cancer cell proliferation, survival, angiogenesis, migration, invasion and metastasis. Src is frequently upregulated in various epithelial tumours including colon, breast and pancreas compared with the adjacent normal tissues. The expression and activity of Src are also enhanced in human actinic keratosis, which is characterized by hyperproliferative premalignant skin lesions.[A225746] The pathogenesis of actinic keratosis commonly involves skin inflammation, oxidative stress, immunosuppression, impaired apoptosis, mutagenesis, dysregulation of keratinocyte growth and proliferation, and tissue remodelling.[A225741] _In vitro_ studies suggest that Src plays a predominant role in the early stages of human skin tumour development, rather than at later stages of tumour progression.[A225746] \\r\\n\\r\\nThe exact mechanism of tirbanibulin as a topical treatment of actinic keratosis has not been fully elucidated;[L27786] however, it mainly works by inhibiting fast proliferating cells.[A225721] Tirbanibulin is a non-ATP competitive Src kinase inhibitor and tubulin polymerization inhibitor. It binds to the peptide substrate binding site of Src, a primary target of tirbanibulin, and blocking its downstream signalling pathways that promote cancer cell migration, proliferation, and survival.[A225721,A225731] Tublin is responsible for cell migration, protein transport, and mitosis: tibranibulin directly binds to the colchicine-binding site of beta-tubulin and causes induces tubulin depolymerization.[A225716] It is also hypothesized that inhibition of Src can also contribute to the inhibitory effects on microtubule polymerization.[A225791] At low nanomolar concentrations, tirbanibulin induces G2/M phase cell cycle arrest in a reversible [A225716,A225731] and dose-dependent manner. By inhibiting microtubule polymerization, tirbanibulin also induces mitotic catastrophe.[A225791]\", \"neighbor_flag\": \"N\", \"resource_name\": \"DrugBank\", \"resource_version\": \"5.1\", \"target_resource_id\": \"P10635\"}, {\"cofactor_in_ch_ikey\": \"GZKLJWGUPQBVJQ-UHFFFAOYSA-N\", \"cofactor_smiles\": \"FC1=CC=C(C=C1)N1C=C(C2CCN(CCN3CCNC3=O)CC2)C2=C1C=CC(Cl)=C2\", \"cofactor_name\": \"Sertindole\", \"cofactor_resource_id\": \"DB06144\", \"mechanism_of_action\": \"Sertindole is an antipsychotic drug with affinity for dopamine D2, serotonin 5-HT2A and 5-HT2C, and alpha1-adrenoreceptors. Preclinical studies suggest that sertindole acts preferentially on limbic and cortical dopaminergic neurons and clinical trials have confirmed that sertindole is effective at a low dopamine D2 occupancy level. \", \"neighbor_flag\": \"N\", \"pubmed_ids\": [10422890, 17214606], \"resource_name\": \"DrugBank\", \"resource_version\": \"5.1\", \"target_resource_id\": \"P10635\"}, {\"cofactor_in_ch_ikey\": \"UEQUQVLFIPOEMF-UHFFFAOYSA-N\", \"cofactor_smiles\": \"CN1CCN2C(C1)C1=CC=CC=C1CC1=CC=CC=C21\", \"cofactor_name\": \"Mianserin\", \"cofactor_resource_id\": \"DB06148\", \"mechanism_of_action\": \"Mianserin's mechanism of therapeutic action is not well understood, although it apparently blocks alpha-adrenergic, histamine H1, and some types of serotonin receptors.\", \"neighbor_flag\": \"N\", \"pubmed_ids\": [12143142, 8764331, 10497148], \"resource_name\": \"DrugBank\", \"resource_version\": \"5.1\", \"target_resource_id\": \"P10635\"}, {\"cofactor_in_ch_ikey\": \"ZSBOMTDTBDDKMP-OAHLLOKOSA-N\", \"cofactor_smiles\": \"CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O\", \"cofactor_chem_comp_id\": \"T22\", \"cofactor_name\": \"Alogliptin\", \"cofactor_resource_id\": \"DB06203\", \"mechanism_of_action\": \"Alogliptin inhibits dipeptidyl peptidase 4 (DPP-4), which normally degrades the incretins glucose-dependent insulinotropic polypeptide (GIP) and glucagon like peptide 1 ( GLP-1). The inhibition of DPP-4 increases the amount of active plasma incretins which helps with glycemic control. GIP and GLP-1 stimulate glucose dependent secretion of insulin in pancreatic beta cells. GLP-1 has the additional effects of suppressing glucose dependent glucagon secretion, inducing satiety, reducing food intake, and reducing gastric emptying.\", \"neighbor_flag\": \"N\", \"resource_name\": \"DrugBank\", \"resource_version\": \"5.1\", \"target_resource_id\": \"P10635\"}, {\"cofactor_in_ch_ikey\": \"KWTWDQCKEHXFFR-SMDDNHRTSA-N\", \"cofactor_smiles\": \"CC[C@H]([C@@H](C)CN(C)C)C1=CC(O)=CC=C1\", \"cofactor_name\": \"Tapentadol\", \"cofactor_resource_id\": \"DB06204\", \"mechanism_of_action\": \"Tapentadol is a centrally-acting synthetic analgesic. Although their clinical relevance is unclear, tapentadol is believed to have two main mechanisms of action.[L47286] Tapentadol is a selective mu-opioid receptor (MOR) agonist: it binds to MOR with an affinity greater than or equal to ten-fold affinity compared to delta- and kappa-opioid receptors.[A36596] Tapentadol also inhibits noradrenaline reuptake, thereby increasing noradrenaline levels and activating alpha-2 receptors to promote analgesia.[A36596, A260731] Tapentadol is a weak serotonin reuptake inhibitor; however, this action does not contribute to its analgesic effect.[A36596]\", \"neighbor_flag\": \"N\", \"pubmed_ids\": [27580162], \"resource_name\": \"DrugBank\", \"resource_version\": \"5.1\", \"target_resource_id\": \"P10635\"}, {\"cofactor_in_ch_ikey\": \"VSWBSWWIRNCQIJ-UHFFFAOYSA-N\", \"cofactor_smiles\": \"CN1CC2C(C1)C1=C(OC3=CC=C(Cl)C=C23)C=CC=C1\", \"cofactor_name\": \"Asenapine\", \"cofactor_resource_id\": \"DB06216\", \"mechanism_of_action\": \"Asenapine is an atypical antipsychotic multireceptor neuroleptic drug which shows strong 5HT2A (serotonin) and D2 (dopamine) receptor antagonism, which has been shown to enhance dopamine (DA) and acetylcholine (Ach) efflux in rat brains. Asenapine may improve cognitive function and negative symptoms in patients with schizophrenia. \", \"neighbor_flag\": \"N\", \"pubmed_ids\": [21655346, 24793403], \"resource_name\": \"DrugBank\", \"resource_version\": \"5.1\", \"target_resource_id\": \"P10635\"}, {\"cofactor_in_ch_ikey\": \"VBHQKCBVWWUUKN-KZNAEPCWSA-N\", \"cofactor_smiles\": \"COC1=C(OC)C=C(CCO[C@@H]2CCCC[C@H]2N2CC[C@@H](O)C2)C=C1\", \"cofactor_name\": \"Vernakalant\", \"cofactor_resource_id\": \"DB06217\", \"mechanism_of_action\": \"Vernakalant blocks atrial voltage-gated sodium channels in a dose and frequency-dependent manner and inhibits late sodium current (INa)which confers its effect on intra-atrial conduction. This current blockade enhance and onset of drug action accelerates in higher heart rate as the affinity of vernakalant for INa also increases. Its binding offset is quick once the heart rate slows [A19198]. It also blocks Kv 1.5 channel and its early activating potassium channels (IKur) and inhibits acetylcholine-activated potassium channels (IKAch), which are specific to the atrium and cause prolongation of atrial refractoriness. Vernakalant also blocks Kv4.3 channel and its cardiac transient outward potassium current (Ito), which is involved more with atrial than ventricular refractoriness [A19203]. \\r\\nVernakalant minimally blocks hERG channels and its rapidly activating/delayed rectifying potassium current (IKr) which accounts for mild QT prolongation. QRS widening due to INa blockade also contributes to QT prolongation [A19197]. \", \"neighbor_flag\": \"N\", \"pubmed_ids\": [18927241], \"resource_name\": \"DrugBank\", \"resource_version\": \"5.1\", \"target_resource_id\": \"P10635\"}, {\"cofactor_in_ch_ikey\": \"CBPNZQVSJQDFBE-FUXHJELOSA-N\", \"cofactor_smiles\": \"OCC(C)(CO)C(=O)O[C@@H]1CC[C@@H](C[C@@H](C)[C@]2([H])CC(=O)[C@H](C)\\\\C=C(C)\\\\[C@@H](O)[C@@H](OC)C(=O)[C@H](C)C[C@H](C)\\\\C=C\\\\C=C\\\\C=C(C)\\\\[C@@H](OC)C[C@]3([H])CC[C@@H](C)[C@@](O)(O3)C(=O)C(=O)N3CCCC[C@H]3C(=O)O2)C[C@H]1OC\", \"cofactor_chem_comp_id\": \"A4I\", \"cofactor_name\": \"Temsirolimus\", \"cofactor_resource_id\": \"DB06287\", \"mechanism_of_action\": \"Temsirolimus is an inhibitor of mTOR (mammalian target of rapamycin). Temsirolimus binds to an intracellular protein (FKBP-12), and the protein-drug complex inhibits the activity of mTOR that controls cell division. Inhibition of mTOR activity resulted in a G1 growth arrest in treated tumor cells. When mTOR was inhibited, its ability to phosphorylate p70S6k and S6 ribosomal protein, which are downstream of mTOR in the PI3 kinase/AKT pathway was blocked. In in vitro studies using renal cell carcinoma cell lines, temsirolimus inhibited the activity of mTOR and resulted in reduced levels of the hypoxia-inducible factors HIF-1 and HIF-2 alpha, and the vascular endothelial growth factor.\", \"neighbor_flag\": \"N\", \"resource_name\": \"DrugBank\", \"resource_version\": \"5.1\", \"target_resource_id\": \"P10635\"}, {\"cofactor_in_ch_ikey\": \"JVHXJTBJCFBINQ-ADAARDCZSA-N\", \"cofactor_smiles\": \"CCOC1=CC=C(CC2=C(Cl)C=CC(=C2)[C@@H]2O[C@H](CO)[C@@H](O)[C@H](O)[C@H]2O)C=C1\", \"cofactor_chem_comp_id\": \"LE6\", \"cofactor_name\": \"Dapagliflozin\", \"cofactor_resource_id\": \"DB06292\", \"mechanism_of_action\": \"Dapagliflozin inhibits the sodium-glucose cotransporter 2(SGLT2) which is primarily located in the proximal tubule of the nephron.[A6757] SGLT2 facilitates 90% of glucose reabsorption in the kidneys and so its inhibition allows for glucose to be excreted in the urine.[A6757] This excretion allows for better glycemic control and potentially weight loss in patients with type 2 diabetes mellitus.[A6757] \", \"neighbor_flag\": \"N\", \"pubmed_ids\": [24105299], \"resource_name\": \"DrugBank\", \"resource_version\": \"5.1\", \"target_resource_id\": \"P10635\"}, {\"cofactor_in_ch_ikey\": \"SETFNECMODOHTO-UHFFFAOYSA-N\", \"cofactor_smiles\": \"NS(=O)(=O)C1=CC=C(C=C1)S(=O)(=O)NC1=CC=CC2=C1NC=C2Cl\", \"cofactor_chem_comp_id\": \"EF6\", \"cofactor_name\": \"Indisulam\", \"cofactor_resource_id\": \"DB06370\", \"mechanism_of_action\": \"E7070 is a novel sulfonamide antitumoragent that exhibits potent antitumoractivity in vitro and in vivo. This compound affects cell cycleprogression in human tumor cells\", \"neighbor_flag\": \"N\", \"pubmed_ids\": [14739663], \"resource_name\": \"DrugBank\", \"resource_version\": \"5.1\", \"target_resource_id\": \"P10635\"}, {\"cofactor_in_ch_ikey\": \"ICMWWNHDUZJFDW-DHODBPELSA-N\", \"cofactor_smiles\": \"[H][C@@]12CC[C@](C)(O)[C@@]1(C)CC[C@@]1([H])[C@@]2([H])CC[C@@]2([H])CC(=O)\\\\C(C[C@]12C)=C/O\", \"cofactor_name\": \"Oxymetholone\", \"cofactor_resource_id\": \"DB06412\", \"mechanism_of_action\": \"Oxymethalone is a 17 alpha-alkylated anabolic-androgenic steroid and a synthetic derivative of testosterone, whose anabolic effects are used to treat muscle wasting in HIV patients. The effects of testosterone in humans and other vertebrates occur by way of two main mechanisms: by activation of the androgen receptor (directly or as DHT), and by conversion to estradiol and activation of certain estrogen receptors. Free testosterone (T) is transported into the cytoplasm of target tissue cells, where it can bind to the androgen receptor, or can be reduced to 5\\u03b1-dihydrotestosterone (DHT) by the cytoplasmic enzyme 5\\u03b1-reductase. DHT binds to the same androgen receptor even more strongly than T, so that its androgenic potency is about 2.5 times that of T. The T-receptor or DHT-receptor complex undergoes a structural change that allows it to move into the cell nucleus and bind directly to specific nucleotide sequences of the chromosomal DNA. The areas of binding are called hormone response elements (HREs), and influence transcriptional activity of certain genes, producing the androgen effects.\", \"neighbor_flag\": \"N\", \"pubmed_ids\": [11440282], \"resource_name\": \"DrugBank\", \"resource_version\": \"5.1\", \"target_resource_id\": \"P10635\"}, {\"cofactor_in_ch_ikey\": \"YGYBFMRFXNDIPO-QGZVFWFLSA-N\", \"cofactor_smiles\": \"O=C1N(CCCCNC[C@H]2CCC3=CC=CC=C3O2)S(=O)(=O)C2=CC=CC=C12\", \"cofactor_name\": \"Repinotan\", \"cofactor_resource_id\": \"DB06506\", \"mechanism_of_action\": \"Repinotan is a 5-HT1A receptor agonist which inhibits glutamate induced depolarization. The effect of repinotan in neuronal cells has been reported to be mediated by a variety of mechanisms/signaling pathways, including activation of the anti-apoptotic phosphatidylinositol 3-kinase (PI-3K) pathway, inhibition of glutamate release (probably via opening of K+ channels leading to membrane hyperpolarization), extracellular-regulated kinase (Erk)-stimulated Bcl-2 expression or inhibition of caspase-3 activity, and increased release of the neurite extension factor S-100 beta.\", \"neighbor_flag\": \"N\", \"pubmed_ids\": [16547395], \"resource_name\": \"DrugBank\", \"resource_version\": \"5.1\", \"target_resource_id\": \"P10635\"}, {\"cofactor_in_ch_ikey\": \"QOBGWWQAMAPULA-RLLQIKCJSA-N\", \"cofactor_smiles\": \"[H][C@]12CC[C@](C)(C1(C)C)[C@@](C2)(OCCN(C)C)C1=CC=CC=C1\", \"cofactor_name\": \"Deramciclane\", \"cofactor_resource_id\": \"DB06512\", \"mechanism_of_action\": \"Deramciclane is a new putative non-benzodiazepine-type anxiolytic compound. It is a selective serotonin 5-HT(2A) and 5-HT(2C) receptor antagonist and has also inverse agonist properties.\", \"neighbor_flag\": \"N\", \"pubmed_ids\": [14730412], \"resource_name\": \"DrugBank\", \"resource_version\": \"5.1\", \"target_resource_id\": \"P10635\"}, {\"cofactor_in_ch_ikey\": \"CUIHSIWYWATEQL-UHFFFAOYSA-N\", \"cofactor_smiles\": \"CN(C1=CC2=NN(C)C(C)=C2C=C1)C1=CC=NC(NC2=CC=C(C)C(=C2)S(N)(=O)=O)=N1\", \"cofactor_name\": \"Pazopanib\", \"cofactor_resource_id\": \"DB06589\", \"mechanism_of_action\": \"Pazopanib is a second-generation multitargeted tyrosine kinase inhibitor against vascular endothelial growth factor receptor-1, -2, and -3, platelet-derived growth factor receptor-alpha, platelet-derived growth factor receptor-beta, and c-kit. These receptor targets are part of the angiogenesis pathway that facilitates the formation of tumour blood vessel for tumour survival and growth. \", \"neighbor_flag\": \"N\", \"pubmed_ids\": [21395357, 20881954], \"resource_name\": \"DrugBank\", \"resource_version\": \"5.1\", \"target_resource_id\": \"P10635\"}, {\"cofactor_in_ch_ikey\": \"BMGQWWVMWDBQGC-IIFHNQTCSA-N\", \"cofactor_smiles\": \"CO[C@@H]1[C@@H](C[C@H]2O[C@]1(C)N1C3=C(C=CC=C3)C3=C1C1=C(C4=C(C=CC=C4)N21)C1=C3CNC1=O)N(C)C(=O)C1=CC=CC=C1\", \"cofactor_chem_comp_id\": \"2K2\", \"cofactor_name\": \"Midostaurin\", \"cofactor_resource_id\": \"DB06595\", \"mechanism_of_action\": \"It potently inhibits multiple receptor tyrosine kinases. Midostaurin and its major active metabolites CGP62221 and CGP52421 inhibit the activity of protein kinase C alpha (PKCalpha), VEGFR2, KIT, PDGFR and WT and/or mutant FLT3 tyrosine kinases. Inhibition of FLT3 receptor signalling cascades induces apoptosis of target leukemia cells expressing target receptors and mast cells, in addition to its antiproliferative activity toward multiple cancer cell lines [A19108]. \\r\\nMidostaurin also interacts with organic anion transporter (OATP) 1A1 and multidrug resistance protein (MRP)-2 according to preliminary in vitro studies.\", \"neighbor_flag\": \"N\", \"pubmed_ids\": [28270565], \"resource_name\": \"DrugBank\", \"resource_version\": \"5.1\", \"target_resource_id\": \"P10635\"}, {\"cofactor_in_ch_ikey\": \"FPOHNWQLNRZRFC-ZHACJKMWSA-N\", \"cofactor_smiles\": \"CC1=C(CCNCC2=CC=C(\\\\C=C\\\\C(=O)NO)C=C2)C2=CC=CC=C2N1\", \"cofactor_chem_comp_id\": \"LBH\", \"cofactor_name\": \"Panobinostat\", \"cofactor_resource_id\": \"DB06603\", \"mechanism_of_action\": \"Panobinostat is a deacetylase (DAC) inhibitor. DACs, also known as histone DACs (HDAC), are responsible for regulating the acetylation of about 1750 proteins in the body; their functions are involved in many biological processes including DNA replication and repair, chromatin remodelling, transcription of genes, progression of the cell-cycle, protein degradation and cytoskeletal reorganization. In multiple myeloma, there is an overexpression of DAC proteins. Panobinostat inhibits class I (HDACs 1, 2, 3, 8), class II (HDACs 4, 5, 6, 7, 9, 10) and class IV (HDAC 11) proteins. Panobinostat's antitumor activity is believed to be attributed to epigenetic modulation of gene expression and inhibition of protein metabolism. Panobinostat also exhibits cytotoxic synergy with bortezomib, a proteasome inhibitor concurrently used in treatment of multiple myeloma. \", \"neighbor_flag\": \"N\", \"pubmed_ids\": [26503877, 26504410], \"resource_name\": \"DrugBank\", \"resource_version\": \"5.1\", \"target_resource_id\": \"P10635\"}, {\"cofactor_in_ch_ikey\": \"LBHLFPGPEGDCJG-UHFFFAOYSA-N\", \"cofactor_smiles\": \"COC1=CC(C)=C2C(OC3=CC=CC(=C3)C(F)(F)F)=C(OC)C=C(NC(C)CCCN)C2=N1\", \"cofactor_name\": \"Tafenoquine\", \"cofactor_resource_id\": \"DB06608\", \"mechanism_of_action\": \"The mechanism of action of tafenoquine is not well established but studies have reported a longer and more effective action when compared to primaquine.[A35671] The active moiety of tafenoquine, 5,6 ortho quinone tafenoquine, seems to be redox cycled by _P. falciparum_ which are upregulated in gametocytes and liver stages. Once inside, the oxidated metabolite produces hydrogen peroxide and hydroxyl radicals. It is thought that these radicals produce leads to the parasite death.[A35677]\\r\\n\\r\\nOn the other hand, tafenoquine inhibits heme polymerase in blood stage of parasites which explains the activity against blood stages of parasites.[A35677]\", \"neighbor_flag\": \"N\", \"pubmed_ids\": [27528800], \"resource_name\": \"DrugBank\", \"resource_version\": \"5.1\", \"target_resource_id\": \"P10635\"}, {\"cofactor_in_ch_ikey\": \"RSWOJTICKMKTER-QXLBVTBOSA-N\", \"cofactor_smiles\": \"[H]C(C)(OC(=O)N(C)C1=C(COC(=O)CNC)C=CC=N1)[N+]1=CN(C[C@](O)(C2=C(F)C=CC(F)=C2)[C@@]([H])(C)C2=NC(=CS2)C2=CC=C(C=C2)C#N)N=C1\", \"cofactor_name\": \"Isavuconazonium\", \"cofactor_resource_id\": \"DB06636\", \"mechanism_of_action\": \"Isavuconazonium sulfate is the prodrug of isavuconazole, an azole antifungal. Isavuconazole inhibits the synthesis of ergosterol, a key component of the fungal cell membrane, by inhibiting cytochrome P-450-dependent enzyme lanosterol 14-alpha-demethylase (Erg11p). This enzyme is responsible for the conversion of lanosterol to ergosterol. An accumulation of methylated sterol precursors and a depletion of ergosterol within the fungal cell membrane weaken the membrane structure and function. Mammalian cell demethylation is less sensitive to isavuconazole inhibition.[L49211] \\r\\n\\r\\n\", \"neighbor_flag\": \"N\", \"resource_name\": \"DrugBank\", \"resource_version\": \"5.1\", \"target_resource_id\": \"P10635\"}, {\"cofactor_in_ch_ikey\": \"NEMGRZFTLSKBAP-LBPRGKRZSA-N\", \"cofactor_smiles\": \"C[C@H](NCC1=CC=C(OCC2=CC(F)=CC=C2)C=C1)C(N)=O\", \"cofactor_name\": \"Safinamide\", \"cofactor_resource_id\": \"DB06654\", \"mechanism_of_action\": \"Safinamide is a unique molecule with multiple mechanisms of action and a very high therapeutic index. It combines potent, selective, and reversible inhibition of MAO-B with blockade of voltage-dependent Na+ and Ca2+ channels and inhibition of glutamate release. Safinamide has neuroprotective and neurorescuing effects in MPTP-treated mice, in the rat kainic acid, and in the gerbil ischemia model.\", \"neighbor_flag\": \"N\", \"resource_name\": \"DrugBank\", \"resource_version\": \"5.1\", \"target_resource_id\": \"P10635\"}, {\"cofactor_in_ch_ikey\": \"RONZAEMNMFQXRA-MRXNPFEDSA-N\", \"cofactor_smiles\": \"[H][C@]12CN(C)CCN1C1=C(CC3=CC=CC=C23)C=CC=N1\", \"cofactor_name\": \"Esmirtazapine\", \"cofactor_resource_id\": \"DB06678\", \"neighbor_flag\": \"N\", \"pubmed_ids\": [21246188], \"resource_name\": \"DrugBank\", \"resource_version\": \"5.1\", \"target_resource_id\": \"P10635\"}, {\"cofactor_in_ch_ikey\": \"SGEGOXDYSFKCPT-UHFFFAOYSA-N\", \"cofactor_smiles\": \"NC(=O)C1=CC2=CC(=CC=C2O1)N1CCN(CCCCC2=CNC3=C2C=C(C=C3)C#N)CC1\", \"cofactor_chem_comp_id\": \"YG7\", \"cofactor_name\": \"Vilazodone\", \"cofactor_resource_id\": \"DB06684\", \"mechanism_of_action\": \"Vilazodone selectively inhibits serotonin reuptake in the central nervous system as well as acting as a partial agonist of 5HT-1A receptors[Label,A38477]. The exact mechanism for how these effects translate to its antidepressant effects are not known[Label], though there is an association between these effects and antidepressive activity[A6947].\", \"neighbor_flag\": \"N\", \"pubmed_ids\": [22346333], \"resource_name\": \"DrugBank\", \"resource_version\": \"5.1\", \"target_resource_id\": \"P10635\"}, {\"cofactor_in_ch_ikey\": \"YECBIJXISLIIDS-UHFFFAOYSA-N\", \"cofactor_smiles\": \"COC1=CC=C(CN(CCN(C)C)C2=NC=CC=C2)C=C1\", \"cofactor_chem_comp_id\": \"Y5E\", \"cofactor_name\": \"Mepyramine\", \"cofactor_resource_id\": \"DB06691\", \"mechanism_of_action\": \"Mepyramine is a histamine H1 receptor inverse agonist. It binds to a G protein-coupled form of the receptor and promotes a G protein-coupled inactive state of the H1 receptor that interferes with the Gq/11-mediated signaling. Mepyramine competes with histamine for binding at H<sub>1</sub>-receptor sites on the effector cell surface, resulting in suppression of histaminic edema, flare, and pruritus. The sedative properties of Mepyramine occur at the subcortical level of the CNS.\", \"neighbor_flag\": \"N\", \"pubmed_ids\": [7853212, 11903961], \"resource_name\": \"DrugBank\", \"resource_version\": \"5.1\", \"target_resource_id\": \"P10635\"}, {\"cofactor_in_ch_ikey\": \"KYYIDSXMWOZKMP-UHFFFAOYSA-N\", \"cofactor_smiles\": \"CN(C)CC(C1=CC=C(O)C=C1)C1(O)CCCCC1\", \"cofactor_name\": \"Desvenlafaxine\", \"cofactor_resource_id\": \"DB06700\", \"mechanism_of_action\": \"The exact mechanism of the antidepressant action of desvenlafaxine is unknown but is thought to be related to the potentiation of serotonin and norepinephrine in the central nervous system, through inhibition of their reuptake.[L47936] Particularly, desvenlafaxine has been found to inhibit the serotonin, norepinephrine, and dopamine transporters with varying degrees of affinity. Desvenlafaxine inhibits serotonin transporters with 10 times the affinity of norepinephrine transporters, and dopamine transporters with the lowest affinity.[A6991] \", \"neighbor_flag\": \"N\", \"resource_name\": \"DrugBank\", \"resource_version\": \"5.1\", \"target_resource_id\": \"P10635\"}, {\"cofactor_in_ch_ikey\": \"DCCSDBARQIPTGU-HSZRJFAPSA-N\", \"cofactor_smiles\": \"CC(C)N(CC[C@H](C1=CC=CC=C1)C1=C(OC(=O)C(C)C)C=CC(CO)=C1)C(C)C\", \"cofactor_name\": \"Fesoterodine\", \"cofactor_resource_id\": \"DB06702\", \"mechanism_of_action\": \"Fesoterodine, once converted to its active metabolite, 5-hydroxymethyltolterodine, acts as a competitive antagonists at muscarinic receptors. This results in the inhibition of bladder contraction, decrease in detrusor pressure, and an incomplete emptying of the bladder.\", \"neighbor_flag\": \"N\", \"pubmed_ids\": [19000553, 21545485, 19347334, 19761716], \"resource_name\": \"DrugBank\", \"resource_version\": \"5.1\", \"target_resource_id\": \"P10635\"}, {\"cofactor_in_ch_ikey\": \"DYLGFOYVTXJFJP-MYYYXRDXSA-N\", \"cofactor_smiles\": \"CCCCN(CCCC)CC(O)C1=C2C(=CC(Cl)=C1)\\\\C(=C/C1=CC=C(Cl)C=C1)C1=C2C=CC(Cl)=C1\", \"cofactor_name\": \"Lumefantrine\", \"cofactor_resource_id\": \"DB06708\", \"mechanism_of_action\": \"The exact mechanism by which lumefantrine exerts its antimalarial effect is unknown. However, available data suggest that lumefantrine inhibits the formation of &beta;-hematin by forming a complex with hemin and inhibits nucleic acid and protein synthesis. \", \"neighbor_flag\": \"N\", \"resource_name\": \"DrugBank\", \"resource_version\": \"5.1\", \"target_resource_id\": \"P10635\"}, {\"cofactor_in_ch_ikey\": \"SSEBTPPFLLCUMN-UHFFFAOYSA-N\", \"cofactor_smiles\": \"CCC1=CC=CC2=C1OC(=C2)C(O)CNC(C)(C)C\", \"cofactor_name\": \"Bufuralol\", \"cofactor_resource_id\": \"DB06726\", \"neighbor_flag\": \"N\", \"resource_name\": \"DrugBank\", \"resource_version\": \"5.1\", \"target_resource_id\": \"P10635\"}, {\"cofactor_in_ch_ikey\": \"SLRCCWJSBJZJBV-ZQDZILKHSA-N\", \"cofactor_smiles\": \"[H][C@@]12CCCCN1C[C@@H]1C[C@H]2CN2CCCC[C@]12[H]\", \"cofactor_name\": \"Sparteine\", \"cofactor_resource_id\": \"DB06727\", \"neighbor_flag\": \"N\", \"pubmed_ids\": [16025294, 10594487], \"resource_name\": \"DrugBank\", \"resource_version\": \"5.1\", \"target_resource_id\": \"P10635\"}, {\"cofactor_in_ch_ikey\": \"QWCJHSGMANYXCW-UHFFFAOYSA-N\", \"cofactor_smiles\": \"NC1=CC=C(C=C1)S(=O)(=O)NC1=CC=NN1C1=CC=CC=C1\", \"cofactor_name\": \"Sulfaphenazole\", \"cofactor_resource_id\": \"DB06729\", \"mechanism_of_action\": \"Sulfaphenazole is a sulfonamide antibacterial. In bacteria, antibacterial sulfonamides act as competitive inhibitors of the enzyme dihydropteroate synthetase (DHPS), an enzyme involved in folate synthesis. As such, the microorganism will be \\\"starved\\\" of folate and die.\", \"neighbor_flag\": \"N\", \"pubmed_ids\": [8886607, 10821163], \"resource_name\": \"DrugBank\", \"resource_version\": \"5.1\", \"target_resource_id\": \"P10635\"}, {\"cofactor_in_ch_ikey\": \"GKIRPKYJQBWNGO-OCEACIFDSA-N\", \"cofactor_smiles\": \"CCN(CC)CCOC1=CC=C(C=C1)C(=C(\\\\Cl)C1=CC=CC=C1)\\\\C1=CC=CC=C1\", \"cofactor_chem_comp_id\": \"53Q\", \"cofactor_name\": \"Enclomiphene\", \"cofactor_resource_id\": \"DB06735\", \"neighbor_flag\": \"N\", \"pubmed_ids\": [18445989], \"resource_name\": \"DrugBank\", \"resource_version\": \"5.1\", \"target_resource_id\": \"P10635\"}, {\"cofactor_in_ch_ikey\": \"WVDDGKGOMKODPV-UHFFFAOYSA-N\", \"cofactor_smiles\": \"OCC1=CC=CC=C1\", \"cofactor_chem_comp_id\": \"010\", \"cofactor_name\": \"Benzyl alcohol\", \"cofactor_resource_id\": \"DB06770\", \"mechanism_of_action\": \"Benzyl alcohol inhibits lice from closing their respiratory spiracles, allowing the vehicle to obstruct the spiracles and causing the lice to asphyxiate.\", \"neighbor_flag\": \"N\", \"pubmed_ids\": [11717179], \"resource_name\": \"DrugBank\", \"resource_version\": \"5.1\", \"target_resource_id\": \"P10635\"}, {\"cofactor_in_ch_ikey\": \"AFNXATANNDIXLG-UHFFFAOYSA-N\", \"cofactor_smiles\": \"ClC1=CC=C(CSC(CN2C=CN=C2)C2=C(Cl)C=C(Cl)C=C2)C=C1\", \"cofactor_name\": \"Sulconazole\", \"cofactor_resource_id\": \"DB06820\", \"mechanism_of_action\": \"The mechanism of action of sulconazole is not well established; however, it is thought to be similar to other imidazole derivatives.[A7141] The function of imidazoles can be attributed to their structural resemblance to purines essential to metabolism. Imidazoles inhibit lanosterol 14-alpha demethylase, a cytochrome P-450-dependent enzyme in fungi responsible for converting lanosterol to ergosterol. Since ergosterol is required to maintain the integrity of the fungi membrane, the inhibition of lanosterol 14-alpha demethylase leads to increased fungal cellular permeability. Therefore, the use of an imidazole such as sulconazole inhibits fungal growth.[A32287,A255612]\", \"neighbor_flag\": \"N\", \"resource_name\": \"DrugBank\", \"resource_version\": \"5.1\", \"target_resource_id\": \"P10635\"}, {\"cofactor_in_ch_ikey\": \"LENAVORGWBTPJR-UHFFFAOYSA-N\", \"cofactor_smiles\": \"NCC1=CC=C(O1)C1=CC=CN=C1\", \"cofactor_chem_comp_id\": \"D3G\", \"cofactor_name\": \"(5-(PYRIDIN-3-YL)FURAN-2-YL)METHANAMINE\", \"cofactor_resource_id\": \"DB07621\", \"neighbor_flag\": \"N\", \"pubmed_ids\": [37713619], \"resource_name\": \"DrugBank\", \"resource_version\": \"5.1\", \"target_resource_id\": \"P10635\"}, {\"cofactor_in_ch_ikey\": \"UUOJIACWOAYWEZ-UHFFFAOYSA-N\", \"cofactor_smiles\": \"CC1=CC2=C(N1)C=CC=C2OCC(CNC(C)(C)C)OC(=O)C1=CC=CC=C1\", \"cofactor_name\": \"Bopindolol\", \"cofactor_resource_id\": \"DB08807\", \"mechanism_of_action\": \"Bopindolol (as pindolol) non-selectively blocks beta-1 adrenergic receptors mainly in the heart, inhibiting the effects of epinephrine and norepinephrine resulting in a decrease in heart rate and blood pressure. By binding beta-2 receptors in the juxtaglomerular apparatus, Pindolol inhibits the production of renin, thereby inhibiting angiotensin II and aldosterone production and therefore inhibits the vasoconstriction and water retention due to angiotensin II and aldosterone, respectively.\", \"neighbor_flag\": \"N\", \"pubmed_ids\": [27836712, 14732961, 17125412], \"resource_name\": \"DrugBank\", \"resource_version\": \"5.1\", \"target_resource_id\": \"P10635\"}, {\"cofactor_in_ch_ikey\": \"HQIRNZOQPUAHHV-UHFFFAOYSA-N\", \"cofactor_smiles\": \"CC1=CC(OCC(O)CNC(C)(C)C)=C(Cl)C=C1\", \"cofactor_name\": \"Bupranolol\", \"cofactor_resource_id\": \"DB08808\", \"mechanism_of_action\": \"Bupranolol competes with sympathomimetic neurotransmitters such as catecholamines for binding at beta(1)-adrenergic receptors in the heart, inhibiting sympathetic stimulation. This results in a reduction in resting heart rate, cardiac output, systolic and diastolic blood pressure, and reflex orthostatic hypotension.\", \"neighbor_flag\": \"N\", \"pubmed_ids\": [27836712, 14732961, 17125412], \"resource_name\": \"DrugBank\", \"resource_version\": \"5.1\", \"target_resource_id\": \"P10635\"}, {\"cofactor_in_ch_ikey\": \"YIBOMRUWOWDFLG-ONEGZZNKSA-N\", \"cofactor_smiles\": \"CC1=CC(\\\\C=C\\\\C#N)=CC(C)=C1NC1=CC=NC(NC2=CC=C(C=C2)C#N)=N1\", \"cofactor_chem_comp_id\": \"T27\", \"cofactor_name\": \"Rilpivirine\", \"cofactor_resource_id\": \"DB08864\", \"mechanism_of_action\": \"Rilpivirine is a non-competitive NNRTI that binds to reverse transcriptase.[L7069] Its binding results in the blockage of RNA and DNA- dependent DNA polymerase activities, like HIV-1 replication. It does not present activity against human DNA polymerases \\u03b1, \\u03b2 and \\u03b3.[L1032,L7069] Rilpivirine's flexible structure around the aromatic rings allows the adaptation to changes in the non-nucleoside RT binding pocket, reducing the likelihood of viral mutations conferring resistance.[A31335]\", \"neighbor_flag\": \"N\", \"pubmed_ids\": [23428312], \"resource_name\": \"DrugBank\", \"resource_version\": \"5.1\", \"target_resource_id\": \"P10635\"}, {\"cofactor_in_ch_ikey\": \"GPXBXXGIAQBQNI-UHFFFAOYSA-N\", \"cofactor_smiles\": \"CCCS(=O)(=O)NC1=C(F)C(C(=O)C2=CNC3=NC=C(C=C23)C2=CC=C(Cl)C=C2)=C(F)C=C1\", \"cofactor_chem_comp_id\": \"032\", \"cofactor_name\": \"Vemurafenib\", \"cofactor_resource_id\": \"DB08881\", \"mechanism_of_action\": \"Vemurafenib is an orally available inhibitor of mutated BRAF-serine-threonine kinase. Vemurafenif is a small molecule that interacts as a competitive inhibitor of the mutated species of BRAF. It is especially potent against the BRAF V600E mutation. Vemurafenib blocks downstream processes to inhibit tumour growth and eventually trigger apoptosis. Vemurafenib does not have antitumour effects against melanoma cell lines with the wild-type BRAF mutation.[L1014]\", \"neighbor_flag\": \"N\", \"pubmed_ids\": [23094782], \"resource_name\": \"DrugBank\", \"resource_version\": \"5.1\", \"target_resource_id\": \"P10635\"}, {\"cofactor_in_ch_ikey\": \"PBAPPPCECJKMCM-IBGZPJMESA-N\", \"cofactor_smiles\": \"NC1=NC(CC(=O)NC2=CC=C(CCNC[C@H](O)C3=CC=CC=C3)C=C2)=CS1\", \"cofactor_chem_comp_id\": \"H6U\", \"cofactor_name\": \"Mirabegron\", \"cofactor_resource_id\": \"DB08893\", \"mechanism_of_action\": \"Mirabegron is a potent and selective agonist of beta-3 adrenergic receptors. The activation of beta-3 receptors relaxes detrusor smooth muscle during the storage phase of the urinary bladder fill-void cycle, which increases the bladder's storage capacity thereby alleviating feelings of urgency and frequency.[L32853]\", \"neighbor_flag\": \"N\", \"pubmed_ids\": [23625188, 22509825], \"resource_name\": \"DrugBank\", \"resource_version\": \"5.1\", \"target_resource_id\": \"P10635\"}, {\"cofactor_in_ch_ikey\": \"PHXJVRSECIGDHY-UHFFFAOYSA-N\", \"cofactor_smiles\": \"CN1CCN(CC2=CC=C(NC(=O)C3=CC(C#CC4=CN=C5C=CC=NN45)=C(C)C=C3)C=C2C(F)(F)F)CC1\", \"cofactor_chem_comp_id\": \"0LI\", \"cofactor_name\": \"Ponatinib\", \"cofactor_resource_id\": \"DB08901\", \"mechanism_of_action\": \"Ponatinib is a multi-target kinase inhibitor. Its primary cellular target is the Bcr-Abl tyrosine kinase protein which is constitutively active and promotes the progression of CML. This protein arises from the fused Bcr and Abl gene- what is commonly known as the Philadelphia chromosome. Ponatinib is unique in that it is especially useful in the treatment of resistant CML because it inhibits the tyrosine kinase activity of Abl and T315I mutant kinases. The T315I mutation confers resistance in cells as it prevents other Bcr-Abl inhibitors from binding to the Abl kinase. Other targets that ponatinib inhibits are members of the VEGFR, PDGFR, FGFR, EPH receptors and SRC families of kinases, and KIT, RET, TIE2, and FLT3. A decrease in tumour size expressing native or T315I mutant BCR-ABL have been observed in rats. \", \"neighbor_flag\": \"N\", \"pubmed_ids\": [28882992], \"resource_name\": \"DrugBank\", \"resource_version\": \"5.1\", \"target_resource_id\": \"P10635\"}, {\"cofactor_in_ch_ikey\": \"ZSDBFLMJVAGKOU-UHFFFAOYSA-N\", \"cofactor_smiles\": \"O=C(CCCC1=CC=CC=C1)OCC(COC(=O)CCCC1=CC=CC=C1)OC(=O)CCCC1=CC=CC=C1\", \"cofactor_name\": \"Glycerol phenylbutyrate\", \"cofactor_resource_id\": \"DB08909\", \"mechanism_of_action\": \"The toxic accumulation of ammonia in the blood and brain arise from urea cycle disorders in which patients are deficient in critical enzymes or transporters that are involved in the synthesis of urea from ammonia. Glycerol phenylbutyrate is a prodrug - the major metabolite, phenylacetate (PAA) is the molecule that binds to nitrogen. PAA conjugates with glutamine (which contains 2 molecules of nitrogen) via acetylation in the liver and kidneys to form phenylacetylglutamine (PAGN), which is excreted by the kidneys. PAGN, like urea, contains 2 moles of nitrogen and provides an alternate vehicle for waste nitrogen excretion.  \", \"neighbor_flag\": \"N\", \"resource_name\": \"DrugBank\", \"resource_version\": \"5.1\", \"target_resource_id\": \"P10635\"}, {\"cofactor_in_ch_ikey\": \"GJJFMKBJSRMPLA-DZGCQCFKSA-N\", \"cofactor_smiles\": \"CCN(CC)C(=O)[C@]1(C[C@H]1CN)C1=CC=CC=C1\", \"cofactor_name\": \"Levomilnacipran\", \"cofactor_resource_id\": \"DB08918\", \"mechanism_of_action\": \"Levomilnacipran is a potent and selective selective serotonin and norepinephrine reuptake inhibitor (SNRI). The exact mechanism of the antidepressant action of levomilnacipran is unknown but is thought to be related to the potentiation of serotonin and norepinephrine in the central nervous system through inhibition of reuptake at serotonin and norepinephrine transporters.[L47946] Like milnacipran, levomilnacipran is a more potent inhibitor of the norepinephrine transporter than the serotonin transporter:[A38560] it exhibits over a 15-fold higher selectivity for norepinephrine versus serotonin reuptake inhibition.[A261176]\", \"neighbor_flag\": \"N\", \"pubmed_ids\": [26572745], \"resource_name\": \"DrugBank\", \"resource_version\": \"5.1\", \"target_resource_id\": \"P10635\"}, {\"cofactor_in_ch_ikey\": \"FBVFZWUMDDXLLG-HDICACEKSA-N\", \"cofactor_smiles\": \"[H][C@@]12CCCC[C@]1([H])C(=O)N(CCCCN1CCN(CC1)C1=NSC3=CC=CC=C13)C2=O\", \"cofactor_name\": \"Perospirone\", \"cofactor_resource_id\": \"DB08922\", \"mechanism_of_action\": \"Antagonism at D2 receptors is believed to relieve the positive symptoms of schizophrenia such as delusions, hallucinations, and thought disorders. Perospirone targets the mesolimbic patway to reverse the overactivity of the dopaminergic signalling via D2 receptors [T28]. 5-HT2A antagonism is thought to allevaite the negative symptoms and cognitive impairments of schizophrenia. These receptors are Gi/Go coupled receptors that lead to decreased neurotransmitter release and neuronal inhibition when activated, thus play a role in dopamine release regulation. Perospirone targets these receptors in the nigrostriatal pathway to reduce dopamine release and function. In contrast, 5-HT2A receptor antagonism may improve the negative symptoms by enhancing dopamine and glutamate release in the mesocortical pathway [T28]. 5-HT1A receptor activation further inhibits the release of 5-HT into the synaptic cleft. \", \"neighbor_flag\": \"N\", \"pubmed_ids\": [15257064], \"resource_name\": \"DrugBank\", \"resource_version\": \"5.1\", \"target_resource_id\": \"P10635\"}, {\"cofactor_in_ch_ikey\": \"MPGBPFMOOXKQRX-UHFFFAOYSA-N\", \"cofactor_smiles\": \"CC(C)NCC(O)COC1=CC=CC2=C1C=CC2\", \"cofactor_name\": \"Indenolol\", \"cofactor_resource_id\": \"DB08952\", \"neighbor_flag\": \"N\", \"pubmed_ids\": [27836712, 14732961, 17125412], \"resource_name\": \"DrugBank\", \"resource_version\": \"5.1\", \"target_resource_id\": \"P10635\"}, {\"cofactor_in_ch_ikey\": \"ZPQPDBIHYCBNIG-UHFFFAOYSA-N\", \"cofactor_smiles\": \"CC(C)NCC(O)COC1=CC=CC2=C1OC(=C2)C(C)=O\", \"cofactor_name\": \"Befunolol\", \"cofactor_resource_id\": \"DB09013\", \"neighbor_flag\": \"N\", \"pubmed_ids\": [27836712, 14732961, 17125412], \"resource_name\": \"DrugBank\", \"resource_version\": \"5.1\", \"target_resource_id\": \"P10635\"}, {\"cofactor_in_ch_ikey\": \"FJZZPCZKBUKGGU-AUSIDOKSSA-N\", \"cofactor_smiles\": \"CCCCCCCC(=O)N[C@H](CN1CCCC1)[C@H](O)C1=CC=C2OCCOC2=C1\", \"cofactor_name\": \"Eliglustat\", \"cofactor_resource_id\": \"DB09039\", \"mechanism_of_action\": \"Eliglustat is a glucosylceramide synthase inhibitor used for the treatment of type 1 Gaucher disease.[L41404] Gaucher disease is a rare genetic disorder characterized by the deficiency of acid \\u03b2-glucosidase, an enzyme that converts glucosylceramide (also known as glucocerebroside) into glucose and ceramide. In patients with Gaucher disease, glucosylceramide is accumulated in the lysosomes of macrophages, leading to the formation of foam cells or Gaucher cells.[L41404] Gaucher cells infiltrate the liver, spleen, bone marrow and other organs, leading to complications such as anemia, thrombocytopenia and hepatosplenomegaly.[L41404,A246384]\\r\\n\\r\\nEliglustat reduces the production of glucosylceramide by inhibiting glucosylceramide synthase, a rate-limiting enzyme in the production of glycosphingolipids.[L41404,A182192] This lowers the amount of glucosylceramide that is available in lysosomes, and balances the deficiency of acid \\u03b2-glucosidase.[L41404,A246384]\", \"neighbor_flag\": \"N\", \"pubmed_ids\": [25239269], \"resource_name\": \"DrugBank\", \"resource_version\": \"5.1\", \"target_resource_id\": \"P10635\"}, {\"cofactor_in_ch_ikey\": \"WAXQNWCZJDTGBU-UHFFFAOYSA-N\", \"cofactor_smiles\": \"CN(C(=O)C(C)(C)C1=CC(=CC(=C1)C(F)(F)F)C(F)(F)F)C1=CN=C(C=C1C1=CC=CC=C1C)N1CCN(C)CC1\", \"cofactor_chem_comp_id\": \"GAW\", \"cofactor_name\": \"Netupitant\", \"cofactor_resource_id\": \"DB09048\", \"mechanism_of_action\": \"Delayed emesis (vomiting) has been largely associated with the activation of tachykinin family neurokinin 1 (NK1) receptors (broadly distributed in the central and peripheral nervous systems) by substance P. As shown in in vitro and in vivo studies, netupitant inhibits substance P mediated responses.\", \"neighbor_flag\": \"N\", \"pubmed_ids\": [23748441], \"resource_name\": \"DrugBank\", \"resource_version\": \"5.1\", \"target_resource_id\": \"P10635\"}, {\"cofactor_in_ch_ikey\": \"XNKCCCKFOQNXKV-ZRSCBOBOSA-N\", \"cofactor_smiles\": \"COCCOCCOCCOCCOCCOCCOCCO[C@H]1CC[C@@]2(O)[C@H]3CC4=CC=C(O)C5=C4[C@@]2(CCN3CC=C)[C@H]1O5\", \"cofactor_name\": \"Naloxegol\", \"cofactor_resource_id\": \"DB09049\", \"mechanism_of_action\": \"Naloxegol is an antagonist of opioid binding at the mu-opioid receptor. When administered at the recommended dose levels, naloxegol functions as a peripherally-acting mu-opioid receptor antagonist in tissues such as the gastrointestinal tract, thereby decreasing the constipating effects of opioids. Naloxegol has shown more than 6000 fold selectivity for the peripheral mu receptors, and its PEGylated form restricts its action only to the periphery, not affecting the pain-relieving mechanism of opioids in the central nervous system.\", \"neighbor_flag\": \"N\", \"pubmed_ids\": [25471070], \"resource_name\": \"DrugBank\", \"resource_version\": \"5.1\", \"target_resource_id\": \"P10635\"}, {\"cofactor_in_ch_ikey\": \"XYFPWWZEPKGCCK-GOSISDBHSA-N\", \"cofactor_smiles\": \"NC1=NC=NC2=C1C(=NN2[C@@H]1CCCN(C1)C(=O)C=C)C1=CC=C(OC2=CC=CC=C2)C=C1\", \"cofactor_chem_comp_id\": \"1E8\", \"cofactor_name\": \"Ibrutinib\", \"cofactor_resource_id\": \"DB09053\", \"mechanism_of_action\": \"Ibrutinib is an inhibitor of Bruton\\u2019s tyrosine kinase (BTK). It forms a covalent bond with a cysteine residue in the active site of BTK (Cys481), leading to its inhibition. The inhibition of BTK plays a role in the B-cell receptor signaling and thus, the presence of ibrutinib prevents the phosphorylation of downstream substrates such as PLC-\\u03b3.[A32306] \", \"neighbor_flag\": \"N\", \"pubmed_ids\": [25488930], \"resource_name\": \"DrugBank\", \"resource_version\": \"5.1\", \"target_resource_id\": \"P10635\"}, {\"cofactor_in_ch_ikey\": \"QHMBSVQNZZTUGM-ZWKOTPCHSA-N\", \"cofactor_smiles\": \"CCCCCC1=CC(O)=C([C@@H]2C=C(C)CC[C@H]2C(C)=C)C(O)=C1\", \"cofactor_chem_comp_id\": \"P0T\", \"cofactor_name\": \"Cannabidiol\", \"cofactor_resource_id\": \"DB09061\", \"mechanism_of_action\": \"The exact mechanism of action of CBD and THC is not currently fully understood. However, it is known that CBD acts on cannabinoid (CB) receptors of the endocannabinoid system, which are found in numerous areas of the body, including the peripheral and central nervous systems, including the brain. The endocannabinoid system regulates many physiological responses of the body including pain, memory, appetite, and mood. More specifically, CB1 receptors can be found within the pain pathways of the brain and spinal cord where they may affect CBD-induced analgesia and anxiolysis, and CB2 receptors have an effect on immune cells, where they may affect CBD-induced anti-inflammatory processes. \\r\\n\\r\\nCBD has been shown to act as a negative allosteric modulator of the cannabinoid CB1 receptor, the most abundant G-Protein Coupled Receptor (GPCR) in the body [A32469]. Allosteric regulation of a receptor is achieved through the modulation of the activity of a receptor on a functionally distinct site from the agonist or antagonist binding site. The negative allosteric modulatory effects of CBD are therapeutically important as direct agonists are limited by their psychomimetic effects while direct antagonists are limited by their depressant effects [A32469]. \", \"neighbor_flag\": \"N\", \"pubmed_ids\": [24160757, 34493602, 30583596, 31433338], \"resource_name\": \"DrugBank\", \"resource_version\": \"5.1\", \"target_resource_id\": \"P10635\"}, {\"cofactor_in_ch_ikey\": \"ZCIGNRJZKPOIKD-CQXVEOKZSA-N\", \"cofactor_smiles\": \"CC(C)C1=NC(CN(C)C(=O)N[C@@H](CCN2CCOCC2)C(=O)N[C@H](CC[C@H](CC2=CC=CC=C2)NC(=O)OCC2=CN=CS2)CC2=CC=CC=C2)=CS1\", \"cofactor_chem_comp_id\": \"A1APA\", \"cofactor_name\": \"Cobicistat\", \"cofactor_resource_id\": \"DB09065\", \"mechanism_of_action\": \"Cobicistat is a mechanism-based inhibitor of cytochrome P450 3A (CYP3A) isoforms. Inhibition of CYP3A-mediated metabolism by cobicistat increases the systemic exposure of CYP3A substrates atazanavir and darunavir and therefore enables increased anti-viral activity at a lower dosage. Cobicistat does not have any anti-HIV activity on its own. \", \"neighbor_flag\": \"N\", \"pubmed_ids\": [20043009], \"resource_name\": \"DrugBank\", \"resource_version\": \"5.1\", \"target_resource_id\": \"P10635\"}, {\"cofactor_in_ch_ikey\": \"YQNWZWMKLDQSAC-UHFFFAOYSA-N\", \"cofactor_smiles\": \"CC1=CC=C(SC2=CC=CC=C2N2CCNCC2)C(C)=C1\", \"cofactor_chem_comp_id\": \"VTX\", \"cofactor_name\": \"Vortioxetine\", \"cofactor_resource_id\": \"DB09068\", \"mechanism_of_action\": \"Vortioxetine is classified as a serotonin modulator and simulator (SMS) as it has a multimodal mechanism of action towards the serotonin neurotransmitter system whereby it simultaneously modulates one or more serotonin receptors and inhibits the reuptake of serotonin. More specifically, vortioxetine acts via the following biological mechanisms: as a serotonin reuptake inhibitor (SRI) through inhibition of the serotonin transporter, while also acting as a partial agonist of the 5-HT1B receptor, an agonist of 5-HT1A, and antagonist of the 5-HT3, 5-HT1D, and 5-HT7 receptors.\", \"neighbor_flag\": \"N\", \"pubmed_ids\": [22496396], \"resource_name\": \"DrugBank\", \"resource_version\": \"5.1\", \"target_resource_id\": \"P10635\"}, {\"cofactor_in_ch_ikey\": \"FVTWTVQXNAJTQP-UHFFFAOYSA-N\", \"cofactor_smiles\": \"OC(C1=CC=CC=C1)(C1=CC=CC=C1)C12CC[N+](CCOCC3=CC=CC=C3)(CC1)CC2\", \"cofactor_name\": \"Umeclidinium\", \"cofactor_resource_id\": \"DB09076\", \"mechanism_of_action\": \"Umeclidinium is a long-acting muscarinic antagonist, which is often referred to as an anticholinergic. It has similar affinity to the subtypes of muscarinic receptors M1 to M5. In the airways, it exhibits pharmacological effects through inhibition of M3 receptors at the smooth muscle leading to bronchodilation. The competitive and reversible nature of antagonism was shown with human and animal origin receptors and isolated organ preparations. In preclinical in vitro as well as in vivo studies, prevention of methacholine- and acetylcholine-induced bronchoconstrictive effects was dose-dependent and lasted longer than 24 hours. The clinical relevance of these findings is unknown. The bronchodilation following inhalation of umeclidinium is predominantly a site-specific effect.[L44466]\", \"neighbor_flag\": \"N\", \"pubmed_ids\": [24004659], \"resource_name\": \"DrugBank\", \"resource_version\": \"5.1\", \"target_resource_id\": \"P10635\"}, {\"cofactor_in_ch_ikey\": \"WOSKHXYHFSIKNG-UHFFFAOYSA-N\", \"cofactor_smiles\": \"COC1=C(C=C2C(OC3=CC=C(NC(=O)NC4CC4)C(Cl)=C3)=CC=NC2=C1)C(N)=O\", \"cofactor_chem_comp_id\": \"LEV\", \"cofactor_name\": \"Lenvatinib\", \"cofactor_resource_id\": \"DB09078\", \"mechanism_of_action\": \"Lenvatinib is a receptor tyrosine kinase (RTK) inhibitor that inhibits the kinase activities of vascular endothelial growth factor (VEGF) receptors VEGFR1 (FLT1), VEGFR2 (KDR), and VEGFR3 (FLT4). Lenvatinib also inhibits other RTKs that have been implicated in pathogenic angiogenesis, tumor growth, and cancer progression in addition to their normal cellular functions, including fibroblast growth factor (FGF) receptors FGFR1, 2, 3, and 4; the platelet derived growth factor receptor alpha (PDGFR\\u03b1), KIT, and RET.\", \"neighbor_flag\": \"N\", \"resource_name\": \"DrugBank\", \"resource_version\": \"5.1\", \"target_resource_id\": \"P10635\"}, {\"cofactor_in_ch_ikey\": \"IBLNKMRFIPWSOY-FNORWQNLSA-N\", \"cofactor_smiles\": \"CC(C)(C)C(O)\\\\C=C\\\\C1=CC2=C(OCO2)C=C1\", \"cofactor_name\": \"Stiripentol\", \"cofactor_resource_id\": \"DB09118\", \"mechanism_of_action\": \"The mechanism by which stiripentol exerts its anticonvulsant effect in humans has not been fully elucidated. Possible mechanisms of action include direct effects mediated through the gamma-aminobutyric acid GABA<sub>A</sub> receptor and indirect effects involving inhibition of cytochrome P450 activity with a resulting increase in blood levels of clobazam and its active metabolite.[L42500] \\r\\n\\r\\nStiripentol is a positive allosteric modulator of GABA<sub>A</sub> receptors in the brain that enhances the opening duration of the channel by binding to a site different than the benzodiazepine binding site.[A19739] It binds to GABA<sub>A</sub> receptors containing any of the \\u03b1, \\u03b2, \\u03b3, or \\u03b4-subunits but displays the most potent potency when bound to receptors containing \\u03b13 or \\u03b4 subunits.[A19742] Stiripentol also binds to GABA<sub>A</sub> receptor-dependent chloride channels via a barbiturate-like mechanism.[A250830] Stiripentol potentiates GABA transmission by enhancing the release of GABA,[A19739, A19740] reducing synaptosomal uptake of GABA,[L880] and inhibiting GABA transaminase-mediated breakdown of GABA.[L880]\\r\\n\\r\\nStiripentol is an inhibitor of lactate dehydrogenase (LDH), which is involved in the energy metabolism of neurons and regulation of neuronal excitation. The drug binds to the site separate from the enzyme's lactate and pyruvate binding sites, thereby inhibiting both pyruvate-to-lactate conversion and lactate-to-pyruvate conversion.[A19741] By inhibiting LDH, stiripentol may induce hyperpolarization, thereby reducing neuronal excitability.[A250830] LDH inhibitors, including stiripentol, mimic a ketogenic diet, where the energy source in the brain is switched from glucose to mainly ketone bodies. The ketone bodies directly regulate neuronal excitation and seizures via ATP-sensitive potassium channels and vesicular glutamate transporters.[A19741] Stiripentol is also suggested to exhibit neuroprotective properties, which may reduce injury caused by oxygen-glucose deprivation and glutamate excess.[A250830]\", \"neighbor_flag\": \"N\", \"resource_name\": \"DrugBank\", \"resource_version\": \"5.1\", \"target_resource_id\": \"P10635\"}, {\"cofactor_in_ch_ikey\": \"ZKIAIYBUSXZPLP-UHFFFAOYSA-N\", \"cofactor_smiles\": \"O=C1NC2=CC(OCCCCN3CCN(CC3)C3=C4C=CSC4=CC=C3)=CC=C2C=C1\", \"cofactor_name\": \"Brexpiprazole\", \"cofactor_resource_id\": \"DB09128\", \"mechanism_of_action\": \"Although the exact mechanism of action of brexpiprazole in psychiatric disorders has not been fully elucidated, the efficacy of brexpiprazole may be attributed to combined partial agonist activity at 5-HT<sub>1A</sub> and dopamine D2 receptors, and antagonist activity at 5-HT<sub>2A</sub> receptors. Brexpiprazole binds to these receptors with subnanomolar affinities.[A7782, A259626, L46417] These therapeutic targets have been implicated in psychiatric conditions such as schizophrenia and depression. Partial D2 receptor agonism allows the drug to stimulate D2 receptors under low dopamine conditions, while attenuating their activation when dopamine levels are high. Partial agonism at 5-HT<sub>1A</sub> receptors may be tied to improved memory function and cognitive performance. Antagonism at \\u03b1-adrenergic receptors has also been implicated in schizophrenia and depression.[A182186, A259641]\", \"neighbor_flag\": \"N\", \"pubmed_ids\": [26310190], \"resource_name\": \"DrugBank\", \"resource_version\": \"5.1\", \"target_resource_id\": \"P10635\"}, {\"cofactor_in_ch_ikey\": \"PHTUQLWOUWZIMZ-GZTJUZNOSA-N\", \"cofactor_smiles\": \"CN(C)CC\\\\C=C1/C2=CC=CC=C2CSC2=CC=CC=C12\", \"cofactor_name\": \"Dosulepin\", \"cofactor_resource_id\": \"DB09167\", \"mechanism_of_action\": \"By binding to noradrenaline transporter (NAT) and serotonin transporter (SERT) in an equipotent manner and inhibiting the reuptake activity, dosulepin increases the free levels of noradrenaline and 5HT at the synaptic cleft. It is shown that the main metabolite northiaden is a more potent inhibitor of noradrenaline uptake than the parent drug [A19758]. \\r\\n\\r\\nDosulepin displays affinity towards \\u03b12-adrenoceptors and to a lesser extent, \\u03b11-adrenoceptors [A6584]. Inhibition of presynaptic \\u03b12-adrenoceptors by dosulepin facilitates noradrenaline release and further potentiates the antidepressant effects [A19758]. It also downregulates central \\u03b2-adrenoceptors by causing a decline in the number of receptors and reduces noradrenaline-induced cyclic AMP formation [L881, A19758]. \\r\\nDosulepin binds to 5HT1A and 5HT2A receptors in the cerebral cortex and hippocampus as an antagonist. 5HT1A receptors are autoreceptors that inhibit 5HT release and 5HT2A receptors are Gi/Go-coupled receptors that reduces dopamine release upon activation [T28]. Antagonism at 5HT2A receptors may also improve sleep patterns. Dosulepin also binds to muscarinic acetylcholine receptors and causes antimuscarinic side effects such as dry mouth. By acting as an antagonist at histamine type 1 (H1) receptors, dosulepin mediates a sedative effect. \\r\\n\\r\\nMain metabolites northiaden, dothiepin sulphoxide and northiaden sulphoxide may also bind to 5HT, \\u03b12 and H1 receptors, although with less affinity compared to the parent drug [A19755].\", \"neighbor_flag\": \"N\", \"pubmed_ids\": [17471183], \"resource_name\": \"DrugBank\", \"resource_version\": \"5.1\", \"target_resource_id\": \"P10635\"}, {\"cofactor_in_ch_ikey\": \"QQOMYEQLWQJRKK-UHFFFAOYSA-N\", \"cofactor_smiles\": \"CCCC(=O)N(C1CCN(CCC2=CC=CC=C2)CC1)C1=CC=CC=C1\", \"cofactor_name\": \"Butyrfentanyl\", \"cofactor_resource_id\": \"DB09173\", \"mechanism_of_action\": \"Butyrfentanyl is a \\u00b5 opioid receptor agonist similar to fentanyl.[L7811]\", \"neighbor_flag\": \"N\", \"pubmed_ids\": [30930421], \"resource_name\": \"DrugBank\", \"resource_version\": \"5.1\", \"target_resource_id\": \"P10635\"}, {\"cofactor_in_ch_ikey\": \"NBRBXGKOEOGLOI-UHFFFAOYSA-N\", \"cofactor_smiles\": \"COC1=C(C=C(C=C1C1=CC2=CC=C(NS(C)(=O)=O)C=C2C=C1)N1C=CC(=O)NC1=O)C(C)(C)C\", \"cofactor_name\": \"Dasabuvir\", \"cofactor_resource_id\": \"DB09183\", \"mechanism_of_action\": \"Dasabuvir is a non-nucleoside inhibitor of the HCV RNA-dependent RNA polymerase encoded by the NS5B gene, which is essential for replication of the viral genome [FDA Label]. Based on drug resistance mapping studies of HCV genotypes 1a and 1b, dasabuvir targets the palm domain of the NS5B polymerase, and is therefore referred to as a non-nucleoside NS5B-palm polymerase inhibitor. The EC50 values of dasabuvir against genotype 1a-H77 and 1b-Con1 strains in HCV replicon cell culture assays were 7.7 nM and 1.8 nM, respectively.\\r\\n\\r\\n By binding to NS5b outside of the active site of the enzyme, dasabuvir induces a conformational change thereby preventing further elongation of the nascent viral genome [A19593, FDA Label]. A limitation of binding outside of the active site is that these binding sites are poorly preserved across the viral genotypes. This results in a limited potential for cross-genotypic activity and increased potential for development of resistance. Dasabuvir is therefore limited to treating genotypes 1a and 1b, and must be used in combination with other antiviral products. \", \"neighbor_flag\": \"N\", \"pubmed_ids\": [27179126], \"resource_name\": \"DrugBank\", \"resource_version\": \"5.1\", \"target_resource_id\": \"P10635\"}, {\"cofactor_in_ch_ikey\": \"YWPHCCPCQOJSGZ-UHFFFAOYSA-N\", \"cofactor_smiles\": \"CCOC1=CC=CC=C1OCC1CNCCO1\", \"cofactor_name\": \"Viloxazine\", \"cofactor_resource_id\": \"DB09185\", \"mechanism_of_action\": \"Attention Deficit Hyperactivity Disorder (ADHD) is a common neurodevelopmental disorder in children characterized by inattention and hyperactivity. In current literature, the pathophysiology of ADHD is understood to involve the imbalance of neurotransmitters, especially dopamine (DA) and norepinephrine (NE).[A247115] The mechanism of action of viloxazine has not been fully elucidated; however, viloxazine is believed to work by modulating the monoaminergic neurotransmitter systems. Viloxazine is a selective and moderate norepinephrine reuptake inhibitor that binds to the norepinephrine transporter and inhibits the reuptake of norepinephrine.[A247985,L41685] It thereby increases extracellular norepinephrine levels across several brain regions.[A247985]\\r\\n\\r\\nViloxazine potentiates serotonergic effects: it was shown to enhance neuronal sensitivity to serotonin and increase serotonin levels in the brain.[A247645,A247985] _In vitro_, viloxazine is an antagonist at 5-HT<sub>2B</sub> receptors and an agonist 5-HT<sub>2C</sub> receptors.[A247115,A247645] 5-HT<sub>2B</sub> receptors expressed on GABAergic interneurons are involved in tonic inhibitory control of serotonin neurons that innervate the medial prefrontal context; thus, antagonism of 5-HT<sub>2B</sub> receptors may result in disinhibition and enhanced serotonin release in the brain region.[A247985] \\r\\n\\r\\nThere is conflicting evidence in the literature that viloxazine increases dopamine levels in the brain via direct or indirect effects. For example, the norepinephrine transporter is also involved in the reuptake of dopamine in the prefrontal cortex [A247985] and stimulation of 5-HT<sub>2C</sub> receptors facilitates DA release and enhances dopaminergic transmission in the brain.[A247645] As dopamine dysregulation in the prefrontal cortex and amygdala is implicated in ADHD pathophysiology, the impact of viloxazine on dopamine levels may contribute to its mechanism of action. However, there is insufficient evidence to conclude this. Viloxazine has a negligible impact on dopamine in the nucleus accumbens and is not associated with an abuse risk.[A247985]\", \"neighbor_flag\": \"N\", \"pubmed_ids\": [32394778], \"resource_name\": \"DrugBank\", \"resource_version\": \"5.1\", \"target_resource_id\": \"P10635\"}, {\"cofactor_in_ch_ikey\": \"BNRMWKUVWLKDQJ-YJBOKZPZSA-N\", \"cofactor_smiles\": \"[H][C@@]12CCC[C@]1([H])C1=NN=C(CCN3CCN(CC3)C3=CC=CC(=C3)C(F)(F)F)N1C2\", \"cofactor_name\": \"Lorpiprazole\", \"cofactor_resource_id\": \"DB09195\", \"mechanism_of_action\": \"Lorpiprazole is a serotonin antagonist and reuptake inhibitor thus, its activity is performed by antagonizing the 5-HT2A and the 5-HT2C serotoninergic receptors as well as the alpha1 and alpha2 adrenergic receptors, H1 histaminergic receptors and at high doses, inhibiting the SERT serotonin transporter.[A31635]\", \"neighbor_flag\": \"N\", \"pubmed_ids\": [22232986], \"resource_name\": \"DrugBank\", \"resource_version\": \"5.1\", \"target_resource_id\": \"P10635\"}, {\"cofactor_in_ch_ikey\": \"BHIAIPWSVYSKJS-UHFFFAOYSA-N\", \"cofactor_smiles\": \"CC(C)(C)NCC(O)CSC1=NC(=CS1)C1=CC=C(S1)C(N)=O\", \"cofactor_name\": \"Arotinolol\", \"cofactor_resource_id\": \"DB09204\", \"mechanism_of_action\": \"Arotinolol binds to the \\u03b21-, \\u03b22- and \\u03b11- adrenergic receptor sites with a very high affinity. Radioligand studies have shown that arotinolol presents a higher affinity to the \\u03b2-receptor compared to the \\u03b1-receptor. The elucidated mechanism of action seems to be the result of a reduction in the cardiac output via the \\u03b2-blockade and an additional inhibition of the counter-regulatory increase in peripheral resistance mediated by the \\u03b1-blockade.[T87]\", \"neighbor_flag\": \"N\", \"pubmed_ids\": [27836712, 14732961, 17125412], \"resource_name\": \"DrugBank\", \"resource_version\": \"5.1\", \"target_resource_id\": \"P10635\"}, {\"cofactor_in_ch_ikey\": \"DKMFBWQBDIGMHM-UHFFFAOYSA-N\", \"cofactor_smiles\": \"CC1CCN(CCCC(=O)C2=CC=C(F)C=C2)CC1\", \"cofactor_name\": \"Melperone\", \"cofactor_resource_id\": \"DB09224\", \"mechanism_of_action\": \"Melperone demonstrates antagonist activity at D2 dopaminergic and 5HT2A serotonergic receptors [L1319]. It has a weak affinity to D2 receptors and possesses less risk of inducing dopamine receptor supersensitivity after both acute and chronic administration [L1346].  In addition, the ratio of dopamine D4/D2 occupancy for melperone has been shown to resemble the binding profile of clozapine [L1321].\", \"neighbor_flag\": \"N\", \"pubmed_ids\": [12649767], \"resource_name\": \"DrugBank\", \"resource_version\": \"5.1\", \"target_resource_id\": \"P10635\"}, {\"cofactor_in_ch_ikey\": \"ANEBWFXPVPTEET-UHFFFAOYSA-N\", \"cofactor_smiles\": \"COC(=O)C1=C(C)NC(C)=C(C1C1=CC(=CC=C1)N(=O)=O)C(=O)OCCN1CCN(CC1)C(C1=CC=CC=C1)C1=CC=CC=C1\", \"cofactor_name\": \"Manidipine\", \"cofactor_resource_id\": \"DB09238\", \"mechanism_of_action\": \"Contraction of vascular smooth muscle is stimulated by Gq coupled receptors which produce calcium release from the sarcoplasmic reticulum. This is followed by opening of voltage dependent calcium channels and an influx of calcium into the cell ultimately producing contraction. Manidipine binds to and dissociates slowly from L- and T-type voltage dependent calcium channels on smooth muscle cells, blocking the entrance of extracellular calcium into the cell and preventing this contraction [A7845, A20295]. This produces vasodilation which decreases blood pressure. Manidipine produces renal vasodilation and an increase in natriuresis. This likely contributes to the antihypertensive effect by reducing blood volume. Manidipine is selective for the vasculature and does not produce significant effects on the heart or central nervous system at clinically relevant dosages.\", \"neighbor_flag\": \"N\", \"pubmed_ids\": [15329044], \"resource_name\": \"DrugBank\", \"resource_version\": \"5.1\", \"target_resource_id\": \"P10635\"}, {\"cofactor_in_ch_ikey\": \"CXKWCBBOMKCUKX-UHFFFAOYSA-M\", \"cofactor_smiles\": \"[Cl-].CN(C)C1=CC2=[S+]C3=C(C=CC(=C3)N(C)C)N=C2C=C1\", \"cofactor_name\": \"Methylene blue\", \"cofactor_resource_id\": \"DB09241\", \"mechanism_of_action\": \"* Main mechanism of action involves  inhibition of nitric oxide synthase and guanylate cyclase. \\r\\n* In Alzheimers Disease: a mechanistic study found that methylene blue oxidizes cysteine sulfhydryl groups on tau to keep tau monomeric. One preclinical treatment study in tauopathy mice reported anti-inflammatory or neuroprotective effects mediated by the Nrf2/antioxidant response element (ARE); another reported insoluble tau reduction and a learning and memory benefit when given early. \\r\\n* In Methemoglobinemia: Methylene Blue acts by reacting within RBC to form leukomethylene blue, which is a reducing agent of oxidized hemoglobin converting the ferric ion (fe+++) back to its oxygen-carrying ferrous state(fe++). \\r\\n* As antimalarial agent: Methylene Blue, a specific inhibitor of P.falciparum glutathione reductase has the potential to reverse CQ resistance and it prevents the polymerization of haem into haemozoin similar to 4-amino-quinoline antimalarials. \\r\\n* For ifosfamide induced neurotoxicity: Methylene blue functions as an alternate electron acceptor. It acts to reverse the NADH inhibition caused by gluconeogenesis in the liver while blocking the transformation of chloroethylamine into chloroacetaldehyde. In addition, it inhibits various amine oxidase activities, which also prevents the formation of chloroacetaldehyde. \\r\\n\", \"neighbor_flag\": \"N\", \"resource_name\": \"DrugBank\", \"resource_version\": \"5.1\", \"target_resource_id\": \"P10635\"}, {\"cofactor_in_ch_ikey\": \"QTGAJCQTLIRCFL-UHFFFAOYSA-N\", \"cofactor_smiles\": \"CCN(CC)CC(=O)OC1=CC=C(NC(C)=O)C=C1\", \"cofactor_name\": \"Propacetamol\", \"cofactor_resource_id\": \"DB09288\", \"mechanism_of_action\": \"As propacetamol is a prodrug, its mechanism of action is directly linked to the activity of paracetamol. The mechanism of action of paracetamol is described by the inhibition of prostaglandin synthesis.[L1511] This inhibition is attained by inhibition of COX-1 and COX-2 in an environment where arachidonic acid and peroxides are kept low.[L1519] It is considered that paracetamol presents a very complex mechanism of action involving effects in the peripheral system, described by direct COX inhibition; the central system, characterized by inhibition of COX, serotonergic descending neuronal pathway, L-arginine/NO pathway and cannabinoid system; and a redox mechanism.[A32056] In the brain and spinal cord, paracetamol can combine with arachidonic acid to form N-arachidonoylphenolamine. This metabolite is an activator of capsaicin receptor (TRPV1) and cannabinoid CB1.[L1519]\", \"neighbor_flag\": \"N\", \"pubmed_ids\": [11095574], \"resource_name\": \"DrugBank\", \"resource_version\": \"5.1\", \"target_resource_id\": \"P10635\"}, {\"cofactor_in_ch_ikey\": \"FIVSJYGQAIEMOC-ZGNKEGEESA-N\", \"cofactor_smiles\": \"C[C@@H](OC[C@]1(CC[C@]2(CCC(=O)N2)CN1)C1=CC=CC=C1)C1=CC(=CC(=C1)C(F)(F)F)C(F)(F)F\", \"cofactor_name\": \"Rolapitant\", \"cofactor_resource_id\": \"DB09291\", \"mechanism_of_action\": \"Rolapitant is an orally active, highly selective Neurokinin-1 Receptor (NK1R) antagonist. NK1 receptors are located primarily in the gut and central nervous system and are activated by Substance P following chemotherapy administration. By binding to the NK1 receptor, rolapitant prevents binding of its ligand Substance P, which is released in the gut following chemotherapy administration. \", \"neighbor_flag\": \"N\", \"resource_name\": \"DrugBank\", \"resource_version\": \"5.1\", \"target_resource_id\": \"P10635\"}, {\"cofactor_in_ch_ikey\": \"NWIUTZDMDHAVTP-KRWDZBQOSA-N\", \"cofactor_smiles\": \"CC(C)NC[C@H](O)COC1=CC=C(CCOCC2CC2)C=C1\", \"cofactor_name\": \"Levobetaxolol\", \"cofactor_resource_id\": \"DB09351\", \"mechanism_of_action\": \"The exact mechanism by which levobetaxolol lowers intraocular pressure is not known. It it thought that antagonism of \\u03b2-adrenergic receptors may reduce the production of aqueous humour stimulated via the cyclic adenosine monophosphate-protein kinase A pathway [T29]. It is also thought that the vasoconstriction produced by antagonism of \\u03b2 adrenergic receptors reduces blood flow to the eye and therefore the ultrafiltration responsible for aqueous humour production. \\u03b21 selective antagonists are less effective than non-selective \\u03b2 adrenergic receptor antagonists because \\u03b22 receptors make up the bulk of the population in the eye. They do, however, come with the benefit of reduced respiratory complications.\", \"neighbor_flag\": \"N\", \"pubmed_ids\": [27836712, 14732961, 17125412], \"resource_name\": \"DrugBank\", \"resource_version\": \"5.1\", \"target_resource_id\": \"P10635\"}, {\"cofactor_in_ch_ikey\": \"DBAKFASWICGISY-DASCVMRKSA-N\", \"cofactor_smiles\": \"OC(=O)\\\\C=C/C(O)=O.CN(C)CC[C@@H](C1=CC=C(Cl)C=C1)C1=CC=CC=N1\", \"cofactor_name\": \"Dexchlorpheniramine maleate\", \"cofactor_resource_id\": \"DB09555\", \"mechanism_of_action\": \"Competes with histamine for H1-receptor sites on effector cells in the gastrointestinal tract, blood vessels, and respiratory tract. Dexchlorpheniramine is the predominant active isomer of chlorpheniramine and is approximately twice as active as the racemic compound. \", \"neighbor_flag\": \"N\", \"pubmed_ids\": [11994058, 11936702], \"resource_name\": \"DrugBank\", \"resource_version\": \"5.1\", \"target_resource_id\": \"P10635\"}, {\"cofactor_in_ch_ikey\": \"MXAYKZJJDUDWDS-LBPRGKRZSA-N\", \"cofactor_smiles\": \"CC(C)C[C@H](NC(=O)CNC(=O)C1=CC(Cl)=CC=C1Cl)B(O)O\", \"cofactor_chem_comp_id\": \"6V8\", \"cofactor_name\": \"Ixazomib\", \"cofactor_resource_id\": \"DB09570\", \"mechanism_of_action\": \"The ubiquitin-proteasome signalling pathway regulates cellular homeostasis and survival: It promotes protein degradation, activates the transcriptional factor nuclear factor (NF)-\\u03baB to upregulate the expression of growth and angiogenic factors, and blocks apoptosis. Made up of identical alpha (\\u03b1)- and beta (\\u03b2)-rings, the 20S proteasome catalytic core is part of the proteasome.[A7948]\\r\\n\\r\\nIxazomib is a selective, potent, and reversible inhibitor of the 20S proteasome. It preferentially binds to the \\u03b25 chymotrypsin-like proteolytic site with a half-maximal inhibitory concentration (IC50) value of 3.4 nmol/L.[A264329, L51234] At higher concentrations, ixazomib may inhibit the caspase-like (\\u03b21) and trypsin-like (\\u03b22) proteolytic sites.[A7948] \", \"neighbor_flag\": \"N\", \"resource_name\": \"DrugBank\", \"resource_version\": \"5.1\", \"target_resource_id\": \"P10635\"}, {\"cofactor_name\": \"Opium\", \"cofactor_resource_id\": \"DB11130\", \"mechanism_of_action\": \"Opium produces its effects by activating specific G protein-coupled receptors in the brain, spinal cord, and peripheral nervous system. There are three major classes of opioid receptors being \\u03b4-opioid, \\u03ba-opioid and \\u03bc-opioid. Opium will generate an agonist activity which will later open the potassium channels and prevent the opening of voltage-gated calcium channels. This activity causes a reduction in neuronal excitability and inhibits the release of pain neurotransmitters.[T136]\\r\\n\\r\\nThe addictive character of opium is related to the binding to the \\u03bc-opioid receptors, which will activate dopaminergic neurons in the ventral tegmental area of the midbrain and thus, enhance the dopamine release in the nucleus accumbens. This mechanism involves the reward activity of the mesolimbic dopaminergic pathway.[T137]\", \"neighbor_flag\": \"N\", \"resource_name\": \"DrugBank\", \"resource_version\": \"5.1\", \"target_resource_id\": \"P10635\"}, {\"cofactor_in_ch_ikey\": \"XRWSZZJLZRKHHD-WVWIJVSJSA-N\", \"cofactor_smiles\": \"COC1=CN=C(O[C@@H]2C[C@H](N(C2)C(=O)[C@@H](NC(=O)OC(C)(C)C)C(C)(C)C)C(=O)N[C@@]2(C[C@H]2C=C)C(=O)NS(=O)(=O)C2CC2)C2=C1C=CC(Cl)=C2\", \"cofactor_chem_comp_id\": \"2R9\", \"cofactor_name\": \"Asunaprevir\", \"cofactor_resource_id\": \"DB11586\", \"mechanism_of_action\": \"Asunaprevir is a highly active HCV NS3 protease inhibitor.[A32527] The genome of HCV has a positive polarity which allows it to be translated into a protein in the host cell without further transformation steps. However, the resultant protein needs to be divided by the enzyme NS3 protease into single proteins in order to be able to exert its enzymatic activity or structural role. Therefore, due to NS3 vital importance for viral replication, the inhibiting action of asunaprevir causes a robust antiviral activity.[A18434]\", \"neighbor_flag\": \"N\", \"pubmed_ids\": [26177803], \"resource_name\": \"DrugBank\", \"resource_version\": \"5.1\", \"target_resource_id\": \"P10635\"}, {\"cofactor_in_ch_ikey\": \"WUZYKBABMWJHDL-UHFFFAOYSA-N\", \"cofactor_smiles\": \"CC1=CC(CN2CCC(CC2)=C2C3=CC=C(Cl)C=C3CCC3=C2N=CC=C3)=CN=C1\", \"cofactor_name\": \"Rupatadine\", \"cofactor_resource_id\": \"DB11614\", \"mechanism_of_action\": \"Rupatadine is a dual histamine H1 receptor and platelet activating (PAF) receptor antagonist [A19779] [FDA Label]. During allergic response mast cells undergo degranulation, releasing histamine and other substances [A19780]. Histamine acts on H1 receptors to produce symptoms of nasal blockage, rhinorhea, itching, and swelling. PAF is produced from phospholipids cleaved by phospholipase A2. It acts to produce vascular leakage which contributes to rhinorhea and nasal blockage. By blocking both the H1 receptor and PAF receptor, rupatidine prevents these mediators from exerting their effects and so reduces the severity of allergic symptoms.\", \"neighbor_flag\": \"N\", \"resource_name\": \"DrugBank\", \"resource_version\": \"5.1\", \"target_resource_id\": \"P10635\"}, {\"cofactor_in_ch_ikey\": \"DDFOUSQFMYRUQK-RCDICMHDSA-N\", \"cofactor_smiles\": \"C[C@@H](C1=NC(=CS1)C1=CC=C(C=C1)C#N)[C@](O)(CN1C=NC=N1)C1=C(F)C=CC(F)=C1\", \"cofactor_chem_comp_id\": \"QKM\", \"cofactor_name\": \"Isavuconazole\", \"cofactor_resource_id\": \"DB11633\", \"mechanism_of_action\": \"Isavuconazole displays fungicidal actions by disrupting the biosynthesis of ergosterol, which is a key component of fungal cell membrane. It inhibits cytochrome P-450 dependent enzyme lanosterol 14-alpha-demethylase that mediates the conversion of lanosterol to ergosterol. The side arm of of the active isavuconazole molecule allows for greater affinity for the binding pocket in the fungal CYP51 protein by orienting the triazole ring of the molecule to engage with the heme moiety at the bottom of the binding pocket [A32026, A32029]. This explains the wide antifungal spectrum of isavuconazole and possible cross-resistance to other triazoles [A32026, A32029]. As a result of lanosterol 14-alpha-demethylase inhibition, toxic methylated sterol precursors such as 14-\\u03b1-methylated lanosterol, 4,14-dimethylzymosterol, and 24-methylenedihydrolanosterol alter the function of fungal membrane and accumulate within the fungal cytoplasm [A32029]. Depletion of ergosterol within the fungal cell membrane leads to decreased structural integrity and function of the cell membrane, inhibited fungal cell growth and replication [A32026], and ultimately cell death. Mammalian cell demethylation is less sensitive to isavuconazole inhibition [FDA Label].\\r\\n\\r\\nMechanism of resistance and reduced susceptibility to isavuconazole arises from mutations in the fungal cyp51A and cyp51B genes coding for the target protein lanosterol 14-alpha-demethylase [L1482]. Other multiple mechanisms leading to resistance, including changes in sterol profile and elevated efflux pump activity of fungal species, cannot be excluded [FDA Label].\", \"neighbor_flag\": \"N\", \"resource_name\": \"DrugBank\", \"resource_version\": \"5.1\", \"target_resource_id\": \"P10635\"}, {\"cofactor_in_ch_ikey\": \"BJDCWCLMFKKGEE-ISOSDAIHSA-N\", \"cofactor_smiles\": \"[H][C@@]12CC[C@@H](C)[C@]3([H])CC[C@@]4(C)OO[C@@]13[C@]([H])(O[C@H](O)[C@@H]2C)O4\", \"cofactor_name\": \"Artenimol\", \"cofactor_resource_id\": \"DB11638\", \"mechanism_of_action\": \"Artemisinins, including Artenimol which is a major active metabolite of many artemisinins, are thought to act via a common mechanism [A31589]. While the exact mechanism of action is not certain, theories exist as to how artemisinins produce their antimalarial effect.\\r\\n\\r\\nArtemisinins are believed to bind to haem within the *P. falciparum* parasite [A31564, A31588]. The source of this haem varies with the life stage of the parasite. When the parasite is in the early ring stage artemisinins are believed to bind haem produced by the parasite's haem biosynthesis pathway. In later stages artemisinins likely bind to haem released by haemoglobin digestion. Once bound to haem, artemisinins are thought to undergo activation involving ferrous iron via reductive scission which splits the endoperoxide bridge to produce a reactive oxygen [A31587, A31596]. This reactive oxygen is thought to undergo a subsequent intramolecular hydrogen abstraction to produce a reactive carbon radical [A31596]. The carbon radical is believed to be the source of the drugs potent activity against *P. falciparum* by alkylating a wide array of protein targets [A20257, A31564, A31596]. The nature and magnitude of the effect on specific protein function as a result of this alkylation is unknown.\\r\\n\\r\\nOne target which has been the focus of research is the sarco/endoplasmic reticulum Ca2+ ATPase pump of *P. falciparum* [A31594]. Artemisinins have been found to irreversably bind to and inhibit this protein at a binding site similar to that of Thapsigargin. The mechanism is likely the same as for other proteins, namely alkylation via the carbon radical intermediate.\\r\\n\\r\\nArtemisinins appear to preferentially collect in infected erythrocytes, concentrating the drug by several hundred-fold compared to uninfected cells [A31597]. This may play a role in why little alkylation is seen in uninfected erythrocytes [A31595].\", \"neighbor_flag\": \"N\", \"resource_name\": \"DrugBank\", \"resource_version\": \"5.1\", \"target_resource_id\": \"P10635\"}, {\"cofactor_in_ch_ikey\": \"NNACHAUCXXVJSP-UHFFFAOYSA-N\", \"cofactor_smiles\": \"ClC1=CC=C(CCCOCCCN2CCCCC2)C=C1\", \"cofactor_name\": \"Pitolisant\", \"cofactor_resource_id\": \"DB11642\", \"mechanism_of_action\": \"Signalling of histaminergic neurons plays a key role in activating the arousal system with widespread projections to the whole brain [L1471] via activating orexin receptors.[A32022] Narcolepsy is characterized by insufficient neurotransmission by orexins, or hypocretins, which are excitatory peptides released by neurons located from the lateral hypothalamus. These neurons project to aminergic neurons, such as histaminergic or noradrenergic neurons, that are responsible for the effects of orexin and control of wakefulness.[A32025] Histamine H3 receptors are presynaptic inhibitory autoreceptors [A183077] that are located in the cerebral cortex, hypothalamus, hippocampus, and basal ganglia.[A39822] H3 receptors promote the re-uptake of histamine at synaptic terminals and attenuate further histamine release into the synapse.[A32025] By blocking H3 autoreceptors and increasing the levels of histamine transmitters at the synapse, pitolisant enhances the activity of histaminergic neurons and promotes wakefulness.[L1471] Inverse agonism of pitolisant at H3 receptors also leads to enhanced synthesis and release of endogenous histamine over the basal level.[A32025]\\r\\n\\r\\nPitolisant acts as a high-affinity competitive antagonist (Ki 0.16 nM) and as an inverse agonist (EC50 1.5 nM) at the human H3 receptor [A32022] and mediates its pharmacological action at the presynaptic level.[A39822] It is thought to bind to the antagonist binding site of the H3 receptor, which is located within the transmembrane core just below the extracellular loops. Piperidines form a salt bridge with Glu206 in the membrane-spanning segment, and the hydroxyl of Tyr374 is H-bonded with the central oxygen of piperidine.[A32025] Pitolisant displays high selectivity for H3 receptors compared to other histamine receptor subtypes. Pitolisant also modulates acetylcholine, noradrenaline and dopamine release in the brain by increasing the levels of neurotransmitters but does not increase dopamine release in the stratal complex, including the nucleus accumbens.[L1471] At lower nanomolar concentrations, pitolisant acts as an inverse agonist at H3 receptors and enhances the release of endogenous histamine over the basal level.[A32025]\", \"neighbor_flag\": \"N\", \"resource_name\": \"DrugBank\", \"resource_version\": \"5.1\", \"target_resource_id\": \"P10635\"}, {\"cofactor_in_ch_ikey\": \"VFLDPWHFBUODDF-FCXRPNKRSA-N\", \"cofactor_smiles\": \"COC1=CC(\\\\C=C\\\\C(=O)CC(=O)\\\\C=C\\\\C2=CC(OC)=C(O)C=C2)=CC=C1O\", \"cofactor_chem_comp_id\": \"CC9\", \"cofactor_name\": \"Curcumin\", \"cofactor_resource_id\": \"DB11672\", \"mechanism_of_action\": \"Curcumin acts as a scavenger of oxygen species, such as hydroxyl radical, superoxide anion, and singlet oxygen and inhibit lipid peroxidation as well as peroxide-induced DNA damage [F114]. Curcumin mediates potent anti-inflammatory agent and anti-carcinogenic actions via modulating various signalling molecules. It suppresses a number of key elements in cellular signal transduction pathways pertinent to growth, differentiation, and malignant transformation; it was demonstrated _in vitro_ that curcumin inhibits protein kinases, c-Jun/AP-1 activation, prostaglandin biosynthesis, and the activity and expression of the enzyme cyclooxygenase (COX)-2 [F114].\", \"neighbor_flag\": \"N\", \"resource_name\": \"DrugBank\", \"resource_version\": \"5.1\", \"target_resource_id\": \"P10635\"}, {\"cofactor_in_ch_ikey\": \"MJUVRTYWUMPBTR-MRXNPFEDSA-N\", \"cofactor_smiles\": \"CC(C)(CO)C1=CC2=CC(NC(=O)C3(CC3)C3=CC=C4OC(F)(F)OC4=C3)=C(F)C=C2N1C[C@@H](O)CO\", \"cofactor_chem_comp_id\": \"CV6\", \"cofactor_name\": \"Tezacaftor\", \"cofactor_resource_id\": \"DB11712\", \"mechanism_of_action\": \"The transport of charged ions across cell membranes is normally achieved through the actions of the cystic fibrosis transmembrane regulator (CFTR) protein. This protein acts as a channel and allows for the passage of chloride and sodium. This process affects the movement of water in and out of the tissues and impacts the production of mucus that lubricates and protects certain organs and body tissues, including the lungs. In the _F508del_ mutation of the CFTR gene, one amino acid is deleted at the position 508, therefore, the CFTR channel function is compromised, resulting in thickened mucus secretions.[L1595]  CFTR correctors such as tezacaftor aim to repair F508del cellular misprocessing.[A179677] This is done by modulating the position of the CFTR protein on the cell surface to the correct position, allowing for adequate ion channel formation and increased in water and salt movement through the cell membrane.[L1595] The concomitant use of ivacaftor is intended to maintain an open channel, increasing the transport of chloride, reducing thick mucus production.[L1599]\", \"neighbor_flag\": \"N\", \"resource_name\": \"DrugBank\", \"resource_version\": \"5.1\", \"target_resource_id\": \"P10635\"}, {\"cofactor_in_ch_ikey\": \"CMJCXYNUCSMDBY-ZDUSSCGKSA-N\", \"cofactor_smiles\": \"COC(=O)N[C@@H](C)CNC1=NC=CC(=N1)C1=CN(N=C1C1=CC(Cl)=CC(NS(C)(=O)=O)=C1F)C(C)C\", \"cofactor_name\": \"Encorafenib\", \"cofactor_resource_id\": \"DB11718\", \"mechanism_of_action\": \"Encorafenib is a kinase inhibitor that targets BRAF V600E, as well as wild-type BRAF and CRAF in in vitro cell-free assays with IC50 values of 0.35, 0.47, and 0.3 nM, respectively. Mutations in the BRAF gene, such as BRAF V600E, can result in constitutively activated BRAF kinases that may stimulate tumor cell growth. Encorafenib was also able to bind to other kinases in vitro including JNK1, JNK2, JNK3, LIMK1, LIMK2, MEK4, and STK36, and reduce ligand binding to these kinases at clinically achievable concentrations (\\u22640.9 \\u00b5M).[L48581]\\r\\n\\r\\n\\r\\n\", \"neighbor_flag\": \"N\", \"resource_name\": \"DrugBank\", \"resource_version\": \"5.1\", \"target_resource_id\": \"P10635\"}, {\"cofactor_in_ch_ikey\": \"XEDHVZKDSYZQBF-UHFFFAOYSA-N\", \"cofactor_smiles\": \"CN1CCC(CC1)C(=O)C1=CC=CC(NC(=O)C2=C(F)C=C(F)C=C2F)=N1\", \"cofactor_chem_comp_id\": \"05X\", \"cofactor_name\": \"Lasmiditan\", \"cofactor_resource_id\": \"DB11732\", \"mechanism_of_action\": \"The acute treatment of migraine headaches has, in the past, been achieved via constriction of cerebral blood vessels, as the acute dilation of these vessels observed during migraines was thought to be the cause of the associated pain.[A187244] The neurogenic hypothesis of migraine pathophysiology, an alternative to the vascular hypothesis, suggests that cerebral vasodilation is a secondary mechanism in migraine pathogenesis, and that the main contributor to migraine headache pain is the increased pathogenic firing of trigeminal nerve pathways.[A187244,A187322] \\r\\n\\r\\nWhile the precise mechanism of action of lasmiditan is unclear, it likely supports this neurogenic hypothesis by exerting its therapeutic effects through potent and selective agonism of the 5-HT<sub>1F</sub> receptor.[L9338] 5-HT<sub>1F</sub> receptors are found in both the central and peripheral nervous system (on the central and peripheral ends of trigeminal neurons) and appear to contribute to hyperpolarization of nerve terminals and inhibition of trigeminal neuronal activity.[A187307,A187316] Lasmiditan's agonism at these receptors may, therefore, inhibit the firing of trigeminal nerves responsible for migraine headache pain.\\r\\n\\r\\nLasmiditan has virtually no affinity for other 5-HT receptor subtypes or monoamine receptors (e.g. adrenergic, dopaminergic).[A187307,A187244,A187322]\", \"neighbor_flag\": \"N\", \"resource_name\": \"DrugBank\", \"resource_version\": \"5.1\", \"target_resource_id\": \"P10635\"}, {\"cofactor_in_ch_ikey\": \"BFDBKMOZYNOTPK-UHFFFAOYSA-N\", \"cofactor_smiles\": \"CNCC1=CN(C(=C1)C1=CC=CC=C1F)S(=O)(=O)C1=CC=CN=C1\", \"cofactor_chem_comp_id\": \"HKT\", \"cofactor_name\": \"Vonoprazan\", \"cofactor_resource_id\": \"DB11739\", \"mechanism_of_action\": \"Vonoprazan is a potassium-competitive acid blocker (PCAB) that inhibits the H<sup>+</sup>, K<sup>+</sup>-ATPase enzyme system in a potassium-competitive manner. Through this mechanism, vonoprazan suppresses basal and stimulated gastric acid secretion at the secretory surface of gastric parietal cells.[L41695] \\r\\n\\r\\nAlthough both classes of drugs inhibit the H<sup>+</sup>, K<sup>+</sup>-ATPase, the mechanism of action of PCABs differs from that of proton-pump inhibitors (PPIs). PPIs form a covalent disulphide bond with a cysteine residue on the H<sup>+</sup>, K<sup>+</sup>-ATPase, which leads to the inactivation of the enzyme, while PCABs interfere with the binding of K<sup>+</sup> to the H<sup>+</sup>, K<sup>+</sup>-ATPase.[A253702]\", \"neighbor_flag\": \"N\", \"resource_name\": \"DrugBank\", \"resource_version\": \"5.1\", \"target_resource_id\": \"P10635\"}, {\"cofactor_in_ch_ikey\": \"HJYYPODYNSCCOU-ODRIEIDWSA-N\", \"cofactor_smiles\": \"CO[C@H]1\\\\C=C\\\\O[C@@]2(C)OC3=C(C)C(O)=C4C(O)=C(NC(=O)\\\\C(C)=C/C=C/[C@H](C)[C@H](O)[C@@H](C)[C@@H](O)[C@@H](C)[C@H](OC(C)=O)[C@@H]1C)C=C(O)C4=C3C2=O\", \"cofactor_name\": \"Rifamycin\", \"cofactor_resource_id\": \"DB11753\", \"mechanism_of_action\": \"Rifamycins, as well as all the other members of this group, present an antibacterial mechanism of action related to the inhibition of RNA synthesis. This mechanism of action is done by the strong binding to the DNA-dependent RNA polymerase of prokaryotes. The inhibition of the RNA synthesis is thought to be related with the initiation phase of the process and to involve stacking interactions between the naphthalene ring and the aromatic moiety in the polymerase. As well, it has been suggested that the presence of zinc atoms in the polymerase allows for the binding of phenolic -OH groups of the naphthalene ring.[T366] \\r\\n\\r\\nIn eukaryotic cells, the binding is significantly reduced making them at least 100 to 10,000 times less sensitive to the action of rifamycins. The members of the rifamycin family present the same mechanism of action and the structural modifications are usually related to pharmacokinetic properties as well as to the interaction with eukaryotic cells.[A40003]\", \"neighbor_flag\": \"N\", \"resource_name\": \"DrugBank\", \"resource_version\": \"5.1\", \"target_resource_id\": \"P10635\"}, {\"cofactor_in_ch_ikey\": \"IQVRBWUUXZMOPW-PKNBQFBNSA-N\", \"cofactor_smiles\": \"[H]\\\\C(=C(\\\\[H])C1=CC(OC)=C(OC)C=C1)C1=NC2=C(N1C)C(=O)N(CC)C(=O)N2CC\", \"cofactor_chem_comp_id\": \"JQ9\", \"cofactor_name\": \"Istradefylline\", \"cofactor_resource_id\": \"DB11757\", \"mechanism_of_action\": \"Istradefylline is a selective adenosine A<sub>2A</sub> receptor inhibitor.[A184064,A184067] These receptors are found in the basal ganglia, a region of the brain that suffers degeneration in Parkinson's disease, and is also significantly involved in motor control.[A184067] A<sub>2A</sub> receptors are also expressed on GABAergic medium spiny neurons within the indirect striato-pallidal pathway.[L8225] The GABAergic action of this pathway is thereby reduced.[L8225] Istradefylline has 56 times the affinity for A<sub>2A</sub> receptors than A<sub>1</sub> receptors.[A184067]\", \"neighbor_flag\": \"N\", \"pubmed_ids\": [28881378], \"resource_name\": \"DrugBank\", \"resource_version\": \"5.1\", \"target_resource_id\": \"P10635\"}, {\"cofactor_in_ch_ikey\": \"MXFWWQICDIZSOA-UHFFFAOYSA-N\", \"cofactor_smiles\": \"CC(C)(C)NCC(O)COC1=CC=C(NC(=O)NC2CCCCC2)C=C1\", \"cofactor_name\": \"Talinolol\", \"cofactor_resource_id\": \"DB11770\", \"neighbor_flag\": \"N\", \"pubmed_ids\": [17125412, 14732961, 27836712], \"resource_name\": \"DrugBank\", \"resource_version\": \"5.1\", \"target_resource_id\": \"P10635\"}, {\"cofactor_in_ch_ikey\": \"WTQYWNWRJNXDEG-RBZJEDDUSA-N\", \"cofactor_smiles\": \"CN1[C@@H]2C[C@H](O)[C@H]1C[C@H](C2)OC(=O)[C@H](CO)C1=CC=CC=C1\", \"cofactor_chem_comp_id\": \"OVR\", \"cofactor_name\": \"Anisodamine\", \"cofactor_resource_id\": \"DB11785\", \"neighbor_flag\": \"N\", \"pubmed_ids\": [17125412, 14732961, 27836712], \"resource_name\": \"DrugBank\", \"resource_version\": \"5.1\", \"target_resource_id\": \"P10635\"}, {\"cofactor_in_ch_ikey\": \"USUZGMWDZDXMDG-CYBMUJFWSA-N\", \"cofactor_smiles\": \"FC1=C(C=CC(=C1)C#N)[C@H]1CCC2=CN=CN12\", \"cofactor_chem_comp_id\": \"YSY\", \"cofactor_name\": \"Osilodrostat\", \"cofactor_resource_id\": \"DB11837\", \"mechanism_of_action\": \"Cushing\\u2019s syndrome is an endocrine disorder resulting from chronic and excessive exposure to glucocorticoids, the symptoms of which may include thinning of the skin and hair, weight gain, muscle weakness, and osteoporosis, as well a constellation of psychiatric, cardiovascular, and immunological deficiencies.[A191910] Cushing\\u2019s syndrome is most commonly precipitated by exogenous treatment with supraphysiological doses of glucocorticoids such as those found in nasal sprays, skin creams, and inhalers. Cushing\\u2019s disease - another less common cause of Cushing\\u2019s syndrome - is generally the result of increased endogenous cortisol exposure due to excessive secretion of adrenocroticotrophic hormone (ACTH) from a pituitary adenoma.[A191910]\\r\\n\\r\\nOsilodrostat is an inhibitor of 11\\u03b2-hydroxylase (CYP11B1) and, to a lesser extent, aldosterone synthase (CYP11B2).[L12123] The CYP11B1 enzyme is responsible for catalyzing the final step of cortisol synthesis - by inhibiting this enzyme, osilodrostat helps to normalize endogenous cortisol levels and alleviate symptoms of Cushing\\u2019s disease.[L12123]\", \"neighbor_flag\": \"N\", \"pubmed_ids\": [32141023], \"resource_name\": \"DrugBank\", \"resource_version\": \"5.1\", \"target_resource_id\": \"P10635\"}, {\"cofactor_in_ch_ikey\": \"FYDWDCIFZSGNBU-UHFFFAOYSA-N\", \"cofactor_smiles\": \"CN(CCN1CCC(CC1)OC(=O)NC1=CC=CC=C1C1=CC=CC=C1)C(=O)C1=CC=C(CN2CCC(CC2)C(N)=O)C=C1\", \"cofactor_name\": \"Revefenacin\", \"cofactor_resource_id\": \"DB11855\", \"mechanism_of_action\": \"Revefenacin is an inhaled bronchodilator muscarinic antagonist with a long-acting bronchodilation activity.[A40028] It has been shown to present a high affinity and behaved as a competitive antagonist of the five muscarinic cholinergic receptors. Studies have indicated that revefenacin dissociates significantly slower from the muscarinic receptor M3 (hM3) when compared to the receptor M2 (hM2) which indicates a kinetic selectivity for this subtype. This competitive antagonism produces a suppressive action of the acetylcholine-evoked calcium mobilization and contractile responses in the airway tissue.[A40029] Lastly, due to the duration of the bronchodilation, revefenacin is considered a long-acting muscarinic antagonist which allows it to be dosed once daily.[A40031]\\r\\n\\r\\nThis response is very important for the therapy of COPD as the main goal is the reduce the frequency and severity of exacerbations which are normally driven by the presence of elevated cholinergic bronchoconstrictor tone mediated by muscarinic receptors on parasympathetic ganglia and airway smooth muscle.[A40030] Hence, the activity of revefenacin produces a potent and long-lasting protection against the bronchoconstrictor response to acetylcholine or methacholine.[A40029]\", \"neighbor_flag\": \"N\", \"pubmed_ids\": [29096627], \"resource_name\": \"DrugBank\", \"resource_version\": \"5.1\", \"target_resource_id\": \"P10635\"}, {\"cofactor_in_ch_ikey\": \"GEJDGVNQKABXKG-CFKGEZKQSA-N\", \"cofactor_smiles\": \"COC1=C(OC)C=C2[C@H]3C[C@@H](OC(=O)[C@@H](N)C(C)C)[C@H](CC(C)C)CN3CCC2=C1\", \"cofactor_chem_comp_id\": \"XW7\", \"cofactor_name\": \"Valbenazine\", \"cofactor_resource_id\": \"DB11915\", \"mechanism_of_action\": \"Although the exact mechanism of action of valbenzine is still unknown, it is thought be mediated through the reversible inhibition of vesicular monoamine transporter 2 (VMAT2), a transporter that regulates monoamine uptake from the cytoplasm to the synaptic vesicle for storage and release.[L47885]\\r\\n\", \"neighbor_flag\": \"N\", \"resource_name\": \"DrugBank\", \"resource_version\": \"5.1\", \"target_resource_id\": \"P10635\"}, {\"cofactor_in_ch_ikey\": \"LVXJQMNHJWSHET-AATRIKPKSA-N\", \"cofactor_smiles\": \"COC1=C(NC(=O)\\\\C=C\\\\CN2CCCCC2)C=C2C(NC3=CC(Cl)=C(F)C=C3)=NC=NC2=C1\", \"cofactor_chem_comp_id\": \"1C9\", \"cofactor_name\": \"Dacomitinib\", \"cofactor_resource_id\": \"DB11963\", \"mechanism_of_action\": \"Dacomitinib is an irreversible small molecule inhibitor of the activity of the human epidermal growth factor receptor (EGFR) family (EGFR/HER1, HER2, and HER4) tyrosine kinases. It achieves irreversible inhibition via covalent bonding to the cysteine residues in the catalytic domains of the HER receptors.[A40011] The affinity of dacomitinib has been shown to have an IC50 of 6 nmol/L.[A40009]\\r\\n\\r\\nThe ErbB or epidermal growth factor (EGF) family plays a role in tumor growth, metastasis, and treatment resistance by activating downstream signal transduction pathways such as such as Ras-Raf-MAPK, PLCgamma-PKC-NFkB and PI3K/AKT through the tyrosine kinase-driven phosphorylation at the carboxy-terminus.[A39624] Around 40% of cases show amplification of EGFR gene and 50% of the cases present the _EGFRvIII_ mutation which represents a deletion that produces a continuous activation of the tyrosine kinase domain of the receptor.[A40016]\", \"neighbor_flag\": \"N\", \"pubmed_ids\": [22147075, 28648122], \"resource_name\": \"DrugBank\", \"resource_version\": \"5.1\", \"target_resource_id\": \"P10635\"}, {\"cofactor_in_ch_ikey\": \"HEAUOKZIVMZVQL-VWLOTQADSA-N\", \"cofactor_smiles\": \"COC1=CC=CC(=C1F)C1=C(C)N(CC2=C(C=CC=C2F)C(F)(F)F)C(=O)N(C[C@H](NCCCC(O)=O)C2=CC=CC=C2)C1=O\", \"cofactor_chem_comp_id\": \"F5O\", \"cofactor_name\": \"Elagolix\", \"cofactor_resource_id\": \"DB11979\", \"mechanism_of_action\": \"Endometriosis develops when tissue that is similar to the kind that is normally located in the uterus starts to grow outside of the uterus [A35868, F801]. Such growth leads to various symptoms like pain during periods, pelvic pain between periods, and pain during sexual intercourse [A35868, F801]. The growths themselves are referred to as lesions and frequently develop on the ovaries, fallopian tubes, and other areas around the uterus, including the bowel or bladder [A35868, F801]. The growth of these lesions is dependent upon the estrogen hormone [A35868].\\r\\n\\r\\nElagolix is an orally-administered, nonpeptide small molecule gonadotropin-releasing hormone (GnRH) receptor antagonist that inhibits endogenous GnRH signaling by binding competitively to GnRH receptors in the pituitary gland [FDA Label, A35855, A35856, A35857]. Administration of elagolix results in dose-dependent suppression of luteinizing hormone (LH) and follicle-stimulating hormone (FSH), leading to decreased blood concentrations of the ovarian sex hormones, estradiol and progesterone. \", \"neighbor_flag\": \"N\", \"resource_name\": \"DrugBank\", \"resource_version\": \"5.1\", \"target_resource_id\": \"P10635\"}, {\"cofactor_in_ch_ikey\": \"TYNLGDBUJLVSMA-UHFFFAOYSA-N\", \"cofactor_smiles\": \"CC(=O)OC1=CC=CC2=C1C(=O)C1=C(OC(C)=O)C=C(C=C1C2=O)C(O)=O\", \"cofactor_name\": \"Diacerein\", \"cofactor_resource_id\": \"DB11994\", \"mechanism_of_action\": \"Diacerein's active metabolite rhein [DB13174] reduces cartilage destruction by decreasing expression of matrix metalloproteinase (MMP)-1 and -3 as well as upregulating tissue inhibitor of matrix metalloproteinases which serve to reduce the activity of several MMPs [A19339]. The anti-inflammatory action of rhein reduces the level of interleukin-1beta activity which plays a large role in reduction of extracellular matrix production, MMP activity, and continued inflammation [A19338]. Rhein reduces abnormal osteoblast synthetic activity through an unknown mechanism [A19337].\", \"neighbor_flag\": \"N\", \"pubmed_ids\": [18814214], \"resource_name\": \"DrugBank\", \"resource_version\": \"5.1\", \"target_resource_id\": \"P10635\"}, {\"cofactor_in_ch_ikey\": \"UZWDCWONPYILKI-UHFFFAOYSA-N\", \"cofactor_smiles\": \"CCN1CCN(CC2=CC=C(NC3=NC=C(F)C(=N3)C3=CC(F)=C4N=C(C)N(C(C)C)C4=C3)N=C2)CC1\", \"cofactor_chem_comp_id\": \"6ZV\", \"cofactor_name\": \"Abemaciclib\", \"cofactor_resource_id\": \"DB12001\", \"mechanism_of_action\": \"Regulation of cell cycle is crucial in maintaining proper cell growth; dysregulated cell cycle signalling pathway is a key component in inducing hyperproliferation of cells and tumor formation in various cancers. G1 to S phase cell cycle progression, or transition through the G1 restriction point (R), is promoted by the retinoblastoma tumor suppressor protein (Rb)-mediated pathway. Activation of Rb-mediated pathway requires the interaction of Cyclin-dependent kinases (CDK) 4 and 6 with D-type cyclins, which drives the formation of active CDK4/CDK6 and subsequent phosphorylation of Rb [A27281, A27282]. \\r\\n\\r\\nRb is a tumor suppressant protein that inhibits proliferation through binding to and suppressing the activity of the E2F family of transcription factors [A27281]. However, phosphorylation of Rb relieves suppression of E2F to allow expression of genes required for passage through the restriction point [A27281]. This leads to increased expression of downstream signalling molecules and activity of protein kinases that promote the cell cycle progression and initiation of DNA replication. Phosphorylation of Rb and other proteins by CDK4/6 additionally leads to transcription of genes involved in cell cycle-independent activities including signal transduction, DNA repair transcriptional control, and mRNA processing [A27281]. \\r\\n\\r\\nAbemaciclib selectively inhibits CDK4 and CDK6 with low nanomolar potency, inhibits Rb phosphorylation resulting in a G1 arrest and inhibition of proliferation, and its activity is specific for Rb-proficient cells [A27281]. Unlike other CDK inhibitors such as [DB09073] and [DB11730], abemaciclib exhibits greater selectivity for CDK4 compared to CDK6 [A27282]. \", \"neighbor_flag\": \"N\", \"resource_name\": \"DrugBank\", \"resource_version\": \"5.1\", \"target_resource_id\": \"P10635\"}, {\"cofactor_in_ch_ikey\": \"VFCRKLWBYMDAED-REWPJTCUSA-N\", \"cofactor_smiles\": \"CCC[C@H](N[C@H]1CCC2=CC(F)=CC(F)=C2C1)C(=O)NC1=CN(C=N1)C(C)(C)CNCC(C)(C)C\", \"cofactor_chem_comp_id\": \"O6U\", \"cofactor_name\": \"Nirogacestat\", \"cofactor_resource_id\": \"DB12005\", \"mechanism_of_action\": \"Nirogacestat is a gamma secretase inhibitor that blocks proteolytic activation of the Notch receptor. When dysregulated, Notch can activate pathways that contribute to tumor growth.[L48857]\", \"neighbor_flag\": \"N\", \"resource_name\": \"DrugBank\", \"resource_version\": \"5.1\", \"target_resource_id\": \"P10635\"}, {\"cofactor_in_ch_ikey\": \"FWYSMLBETOMXAG-QHCPKHFHSA-N\", \"cofactor_smiles\": \"COC1=CC=CC(=C1)N1CCN(CC1)C1=NC2=C(C=CC=C2F)[C@H](CC(O)=O)N1C1=CC(=CC=C1OC)C(F)(F)F\", \"cofactor_name\": \"Letermovir\", \"cofactor_resource_id\": \"DB12070\", \"mechanism_of_action\": \"CMV relies on a DNA terminase complex consisting of multiple subunits (pUL51, pUL56, and pUL89) for processing of viral DNA. Viral DNA is produced in a single repeating strand which is then cut by the DNA terminase complex into individual viral genomes which can then be packaged into mature viral particles.[A31289] Letemovir inhibits the activity of this complex to prevent production of mature viral genomes and the production of viable viral particles. The exact nature of Letemovir's binding to this complex is not currently known. Initially, the observation of resistance-causing mutations in pUL56 suggested this subunit was the location of Letemovir binding.[A31290] However, resistance mutations have now been observed in pUL51, pUL56, and pUL89.[A31291] It is possible that changes in amino acid sequence in one subunit could result in conformational changes to interacting subunits affecting Letemovir binding or that Letemovir interacts with multiple subunits of the complex but evidence towards either of these distinctions has not yet been seen. pUL89 is known to contain the endonuclease activity of the complex but because all members of the complex are necessary for targeting as well as protection from proteosomal degradation, it is difficult to discern if Letemovir inhibits pUL89's activity directly.[A31292]\", \"neighbor_flag\": \"N\", \"resource_name\": \"DrugBank\", \"resource_version\": \"5.1\", \"target_resource_id\": \"P10635\"}, {\"cofactor_in_ch_ikey\": \"MDSQOJYHHZBZKA-GBXCKJPGSA-N\", \"cofactor_smiles\": \"CCOC(=O)[C@@H](N)CC1=CC=C(C=C1)C1=NC(N)=NC(O[C@H](C2=CC=C(Cl)C=C2N2C=CC(C)=N2)C(F)(F)F)=C1\", \"cofactor_name\": \"Telotristat ethyl\", \"cofactor_resource_id\": \"DB12095\", \"mechanism_of_action\": \"Telotristat, the active metabolite of telotristat ethyl, is an inhibitor of tryptophan hydroxylase, which mediates the rate-limiting step in serotonin biosynthesis. The in vitro inhibitory potency of telotristat towards tryptophan hydroxylase is 29 times higher than that of telotristat ethyl. Serotonin plays a role in mediating secretion, motility, inflammation, and sensation of the\\r\\ngastrointestinal tract, and is over-produced in patients with carcinoid syndrome. Through inhibition of tryptophan hydroxylase, telotristat and telotristat ethyl reduce the production of peripheral serotonin, and the frequency of carcinoid syndrome diarrhea.[L43342] \", \"neighbor_flag\": \"N\", \"resource_name\": \"DrugBank\", \"resource_version\": \"5.1\", \"target_resource_id\": \"P10635\"}, {\"cofactor_in_ch_ikey\": \"WXJFKKQWPMNTIM-VWLOTQADSA-N\", \"cofactor_smiles\": \"CCCCCCCCCCCCCCCCOCCCOP(O)(=O)CO[C@H](CO)CN1C=CC(N)=NC1=O\", \"cofactor_name\": \"Brincidofovir\", \"cofactor_resource_id\": \"DB12151\", \"mechanism_of_action\": \"Brincidofovir is a pro-drug comprising [cidofovir] conjugated to a lipid molecule - the lipid component mimics an endogenous lipid, lysophosphatidylcholine, which allows the molecule to hijack endogenous lipid uptake pathways to enter infected cells.[L34404,A235735] Following uptake, the lipid molecule is cleaved to generate cidofovir, which is then phosphorylated to generate the active antiviral compound, cidofovir disphosphate.[L34404]\\r\\n\\r\\nThe antiviral effects of cidofovir diphosphate appear to be the result of two distinct mechanisms. Mechanistic studies using recombinant vaccinia DNA polymerase suggest that it inhibits orthopoxvirus DNA polymerase-mediated DNA synthesis. In addition, cidofovir is an acyclic nucleotide analogue of deoxycytidine monophosphate - cidofovir diphosphate can therefore be incorporated into the growing viral DNA chain and consequently slow the rate of viral DNA synthesis.[L34404,A235725]\", \"neighbor_flag\": \"N\", \"resource_name\": \"DrugBank\", \"resource_version\": \"5.1\", \"target_resource_id\": \"P10635\"}, {\"cofactor_in_ch_ikey\": \"MKJIEFSOBYUXJB-WEZHFFAMSA-N\", \"cofactor_smiles\": \"[2H]C([2H])([2H])OC1=CC2=C(C=C1OC([2H])([2H])[2H])[C@@H]1CC(=O)[C@@H](CC(C)C)CN1CC2\", \"cofactor_name\": \"Deutetrabenazine\", \"cofactor_resource_id\": \"DB12161\", \"mechanism_of_action\": \"The precise mechanism of action of deutetrabenazine in mediating its anti-chorea effects is not fully elucidated. Deutetrabenazine reversibly depletes the levels of monoamines, such as dopamine, serotonin, norepinephrine, and histamine, from nerve terminals via its active metabolites. The major circulating metabolites are \\u03b1-dihydrotetrabenazine [HTBZ] and \\u03b2-HTBZ that act as reversible inhibitors of VMAT2. Inhibition of VMAT2 results in decreased uptake of monoamines into synaptic terminal and depletion of monoamine stores from nerve terminals [FDA Label]. \\r\\n\\r\\nDeutetrabenazine contains the molecule deuterium, which is a naturally-occurring, nontoxic hydrogen isotope but with an increased mass relative to hydrogen [A32046]. Placed at key positions, deuterium forms a stronger hydrogen bond with carbon that requires more energy for cleavage, thus attenuating CYP2D6-mediated metabolism without having any effect on the therapeutic target [A32046]. \", \"neighbor_flag\": \"N\", \"resource_name\": \"DrugBank\", \"resource_version\": \"5.1\", \"target_resource_id\": \"P10635\"}, {\"cofactor_in_ch_ikey\": \"WMDSZGFJQKSLLH-RBBKRZOGSA-N\", \"cofactor_smiles\": \"CC1(C)OC[C@@H](COC(=O)CCC2=CC=C(OC[C@@H](O)CNCCNC(=O)N3CCOCC3)C=C2)O1\", \"cofactor_name\": \"Landiolol\", \"cofactor_resource_id\": \"DB12212\", \"neighbor_flag\": \"N\", \"pubmed_ids\": [17125412, 14732961, 27836712], \"resource_name\": \"DrugBank\", \"resource_version\": \"5.1\", \"target_resource_id\": \"P10635\"}, {\"cofactor_in_ch_ikey\": \"BTCRKOKVYTVOLU-SJSRKZJXSA-N\", \"cofactor_smiles\": \"OC[C@H]1O[C@H]([C@H](O)[C@@H](O)[C@@H]1O)C1=CC=C(Cl)C(CC2=CC=C(OCCOC3CC3)C=C2)=C1\", \"cofactor_name\": \"Bexagliflozin\", \"cofactor_resource_id\": \"DB12236\", \"mechanism_of_action\": \"Bexagliflozin is a highly selective sodium\\u2013glucose co-transporter 2 (SGLT2) inhibitor. SGLT2 is located in the proximal renal tubule, a part of the kidney where most reabsorption takes place, and they transport glucose and sodium from the tubular lumen to the epithelium. By inhibiting SGLT2, bexagliflozin reduces glucose reabsorption in the kidney and promotes its excretion in urine. Therefore, in patients with type 2 diabetes mellitus (T2DM), bexagliflozin reduces blood glucose levels independently of insulin sensitivity.[A256423,L44758]\\r\\n\\r\\nAside from improving glycemic control, bexagliflozin may also reduce body weight, systolic blood pressure, and albuminuria.[A256433] The mechanism of action for these other effects have not been fully elucidated, but it is possible that they depend on the initial natriuresis caused by bexagliflozin, followed by a change in tissue sodium handling.[A256423]\", \"neighbor_flag\": \"N\", \"pubmed_ids\": [31432741], \"resource_name\": \"DrugBank\", \"resource_version\": \"5.1\", \"target_resource_id\": \"P10635\"}, {\"cofactor_in_ch_ikey\": \"NQPDXQQQCQDHHW-UHFFFAOYSA-N\", \"cofactor_smiles\": \"CSC1=NC2=C(N1)C=C(Cl)C(OC1=CC=CC(Cl)=C1Cl)=C2\", \"cofactor_chem_comp_id\": \"JA9\", \"cofactor_name\": \"Triclabendazole\", \"cofactor_resource_id\": \"DB12245\", \"mechanism_of_action\": \"Triclabendazole is an anthelmintic agent against _Fasciola_ species.[FDA label]\\r\\n\\r\\nThe mechanism of action against Fasciola species is not fully understood at this time. In vitro studies and animal studies suggest that triclabendazole and its active metabolites (_sulfoxide_ and _sulfone_) are absorbed by the outer body covering of the immature and mature worms, causing a reduction in the resting membrane potential, the inhibition of tubulin function as well as protein and enzyme synthesis necessary for survival. These metabolic disturbances lead to an inhibition of motility, disruption of the worm outer surface, in addition to the inhibition of spermatogenesis and egg/embryonic cells.[FDA label]\\r\\n\\r\\n**A note on resistance**\\r\\n\\r\\nIn vitro studies, in vivo studies, as well as case reports suggest a possibility for the development of resistance to triclabendazole.\\r\\nThe mechanism of resistance may be multifactorial and include changes in drug uptake/efflux mechanisms, target molecules, and changes in drug metabolism. The clinical significance of triclabendazole resistance in humans is not yet elucidated.[FDA label]\", \"neighbor_flag\": \"N\", \"resource_name\": \"DrugBank\", \"resource_version\": \"5.1\", \"target_resource_id\": \"P10635\"}, {\"cofactor_in_ch_ikey\": \"MIWWSGDADVMLTG-UHFFFAOYSA-N\", \"cofactor_smiles\": \"CSC1=CC=C(OCC2=NC=C(N2C)[N+]([O-])=O)C=C1\", \"cofactor_name\": \"Fexinidazole\", \"cofactor_resource_id\": \"DB12265\", \"mechanism_of_action\": \"Human African trypanosomiasis (HAT) is caused by two subspecies of _Trypanosoma brucei_, _T. brucei gambiense_ and _T. brucei rhodesiense_, with _T. brucei gambiense_ HAT accounting for ~97% of the total disease burden. Transmitted by the bite of an infected tsetse fly, HAT begins as a local infection at the bite site before disseminating throughout the blood and reticuloendothelial system (first or hemolymphatic stage) and eventually crossing the blood-brain barrier (second or meningoencephalitic stage). First stage _T. brucei gambiense_ HAT is characterized by fever, headache, swollen lymph nodes, pruritus, and other non-specific symptoms. Progression to the second stage results in progressive deterioration of neurological function, including sleep disturbances (HAT is also referred to as sleeping sickness), tremors, ataxia, abnormal behaviour, confusion, and coma; myocarditis and endocrine hypothalamic-hypophyseal dysfunction may also be present. If left untreated, HAT is fatal.[A237550]\\r\\n\\r\\nFexinidazole is the first all-oral treatment for _T. brucei gambiense_ HAT.[A237555] Both fexinidazole and its two main metabolites, a sulfoxide (M1) and sulfone (M2) metabolite, possess _in vitro_ activity against _T. brucei gambiense_, _T. brucei rhodesiense_, and _T. brucei brucei_ in the 0.2-0.9 \\u03bcg/mL range.[A237560, A237565] Further studies revealed _in vivo_ efficacy in HAT animal models and acceptable toxicity profiles, both in animal and human subjects.[A237560, A237565, A237570] Crucially, fexinidazole was shown to be non-inferior to existing [nifurtimox]/[eflornithine] combination therapy (NECT) in late-stage _T. brucei gambiense_ infection.[A237575]\\r\\n\\r\\nThe precise mechanism of action of fexinidazole remains unknown. However, it is suggested that bacterial-like nitroreductases encoded by trypanosomes activate fexinidazole and its M1/M2 metabolites through reduction to form reactive intermediates capable of damaging DNA and proteins.[A237555, A237560, L35940] Whole-body autoradiography of [14C]-labelled fexinidazole in rats revealed broad distribution into all tissues, including an observed brain-to-blood concentration ratio of 0.4-0.6.[A237560] Therefore, fexinidazole is capable of direct toxicity against trypanosomes throughout the body and in the brain, which is consistent with its efficacy against both early and late-stage infections.[A237560, A237565, A237575]\", \"neighbor_flag\": \"N\", \"pubmed_ids\": [21200426], \"resource_name\": \"DrugBank\", \"resource_version\": \"5.1\", \"target_resource_id\": \"P10635\"}, {\"cofactor_in_ch_ikey\": \"HMABYWSNWIZPAG-UHFFFAOYSA-N\", \"cofactor_smiles\": \"CNCC1=CC=C(C=C1)C1=C2CCNC(=O)C3=C2C(N1)=CC(F)=C3\", \"cofactor_chem_comp_id\": \"RPB\", \"cofactor_name\": \"Rucaparib\", \"cofactor_resource_id\": \"DB12332\", \"mechanism_of_action\": \"PARPs play a role in DNA repair by activating DNA damage response pathways, such as base excision repair, and facilitating DNA repair. PARPs were evaluated as novel anticancer therapeutic targets after discovering that PARP-1 inhibitors reduce tumour growth in BRCA-deficient cancers.[A18745] BRCA1 and BRCA2 are tumour suppressor genes involved in various cellular processes related to cell growth and death, including DNA repair.[A249195] More specifically, BRCA1 and BRCA2 are involved in homologous recombination (HR) DNA repair. Cancer cells with a deleterious BRCA mutation are HR-deficient, resulting in unregulated and aberrant cell repair and growth.[A18745]\\r\\n\\r\\nRucaparib inhibits PARP1, PARP2, and PARP3.[L42155] Inhibiting PARP traps the enzyme on damaged DNA, halting the repair process and forming toxic PARP\\u2013DNA complexes. Alternatively, other DNA repair processes such as error-prone nonhomologous end joining (NHEJ) or alternative end-joining pathways can be initiated, leading to mutations or chromosomal change.[A31354] Further DNA damage can trigger cancer cell apoptosis and cell death.[L42155] \\r\\n\\r\\nTypically, inhibition of PARP converts single-strand breaks in DNA to double-strand breaks at replication forks. HR DNA repair pathways repair double-strand breaks; however, HR-deficient cancer cells lack this repair mechanism. Because HR-deficient cancer cells are more vulnerable to unsalvageable DNA damage, rucaparib-induced PARP inhibition leads to synthetic lethality. In this phenomenon, two non-lethal defects (HR deficiency and PARP inhibition) combine and cause cell death.[A18745,A31354]\", \"neighbor_flag\": \"N\", \"resource_name\": \"DrugBank\", \"resource_version\": \"5.1\", \"target_resource_id\": \"P10635\"}, {\"cofactor_in_ch_ikey\": \"GPNHMOZDMYNCPO-PDUMRIMRSA-N\", \"cofactor_smiles\": \"[H][C@@]12CC[C@](OC(=O)CC)(C(=O)CO)[C@@]1(C)CC[C@@]1([H])[C@@]2([H])CCC2=CC(=O)CC[C@]12C\", \"cofactor_name\": \"Clascoterone\", \"cofactor_resource_id\": \"DB12499\", \"mechanism_of_action\": \"Acne is a multifactorial skin condition characterized by excess sebum production, epithelial hyperkeratinization, proliferation of the skin commensal bacteria, and inflammation.[A218761,A218771] Circulating and locally synthesized natural ligands, testosterone and dihydrotestosterone (DHT), serve as causative factors in both males and females. Upon binding of DHT, the DHT-androgen receptor complex dimerizes and translocates to the nucleus where it promotes the transcription of genes involved in acne pathogenesis, including proliferation and differentiation of sebocytes, excess sebum production, and inflammatory cytokine production.[A218771] Clascoterone is a potent antagonist at ARs and competes for androgens in binding to the receptor, thereby inhibiting downstream signalling of ARs that promote acne.[A218761]\\r\\n\\r\\nAndrogenetic alopecia is also an androgen-dependent and highly genetic condition. Dihydrotestosterone (DHT) binds to ARs expressed on dermal papilla cells (DPC) in the scalp to induce AR-mediated transcription of genes that contribute to androgenic alopecia. By blocking the interaction between DHT and aARs, clascoterone inhibits AR-regulated transcription and DHT-induced IL-6 synthesis.[A218766] \", \"neighbor_flag\": \"N\", \"resource_name\": \"DrugBank\", \"resource_version\": \"5.1\", \"target_resource_id\": \"P10635\"}, {\"cofactor_in_ch_ikey\": \"JOOXLOJCABQBSG-UHFFFAOYSA-N\", \"cofactor_smiles\": \"CC1=CN=C(NC2=CC=C(OCCN3CCCC3)C=C2)N=C1NC1=CC=CC(=C1)S(=O)(=O)NC(C)(C)C\", \"cofactor_chem_comp_id\": \"2TA\", \"cofactor_name\": \"Fedratinib\", \"cofactor_resource_id\": \"DB12500\", \"mechanism_of_action\": \"Fedratinib is an inhibitor of Janus Activated Kinase 2 (JAK2) and FMS-like tyrosine kinase 3.[A183173,L8090] JAK2 is highly active in myeloproliferative neoplasms like myelofibrosis.[L8090] Fedratinib's inhibition of JAK2 inhibits phosphorylation of signal transducer and activator of transcription (STAT) 3 and 5, which prevents cell division and induces apoptosis.[A183182,L8090]\", \"neighbor_flag\": \"N\", \"resource_name\": \"DrugBank\", \"resource_version\": \"5.1\", \"target_resource_id\": \"P10635\"}, {\"cofactor_in_ch_ikey\": \"PVLJETXTTWAYEW-UHFFFAOYSA-N\", \"cofactor_smiles\": \"CN(C1CCN(CC1)C1=NC2=C(C=CC=C2)N1CC1=CC=C(F)C=C1)C1=NC=CC(=O)N1\", \"cofactor_name\": \"Mizolastine\", \"cofactor_resource_id\": \"DB12523\", \"neighbor_flag\": \"N\", \"pubmed_ids\": [10597902], \"resource_name\": \"DrugBank\", \"resource_version\": \"5.1\", \"target_resource_id\": \"P10635\"}, {\"cofactor_in_ch_ikey\": \"JUQLTPCYUFPYKE-UHFFFAOYSA-N\", \"cofactor_smiles\": \"CC1=C(CCN2CCC(CC2)=C(C2=CC=C(F)C=C2)C2=CC=C(F)C=C2)C(=O)N2C=CSC2=N1\", \"cofactor_chem_comp_id\": \"E2J\", \"cofactor_name\": \"Ritanserin\", \"cofactor_resource_id\": \"DB12693\", \"neighbor_flag\": \"N\", \"pubmed_ids\": [8477556], \"resource_name\": \"DrugBank\", \"resource_version\": \"5.1\", \"target_resource_id\": \"P10635\"}, {\"cofactor_in_ch_ikey\": \"QKDRXGFQVGOQKS-CRSSMBPESA-N\", \"cofactor_smiles\": \"CCOC1=CC=C(CC2=CC(=CC=C2Cl)[C@@H]2O[C@H](SC)[C@@H](O)[C@H](O)[C@H]2O)C=C1\", \"cofactor_chem_comp_id\": \"LFL\", \"cofactor_name\": \"Sotagliflozin\", \"cofactor_resource_id\": \"DB12713\", \"mechanism_of_action\": \"Sodium-glucose co-transporter types 1 and 2 (SGLT1 and SGLT2) are integral in the transport of glucose in the body. SGLT1 is the major transporter for glucose absorption in the gastrointestinal tract,[A244470] while SGLT2 is the predominant transporter responsible for reabsorption of glucose in the glomerulus.[L39705]\\r\\n\\r\\nSotagliflozin is a dual inhibitor of both SGLT1 and SGLT2.[L39705] Inhibition of SGLT1 results in a delay in glucose absorption and a blunting of postprandial hyperglycemia, while inhibition of SGLT2 reduces renal reabsorption of filtered glucose, thereby increasing urinary glucose excretion.\", \"neighbor_flag\": \"N\", \"resource_name\": \"DrugBank\", \"resource_version\": \"5.1\", \"target_resource_id\": \"P10635\"}, {\"cofactor_in_ch_ikey\": \"FBMYKMYQHCBIGU-UHFFFAOYSA-N\", \"cofactor_smiles\": \"CC(C)(CC1=CNC2=CC=CC=C12)NCC(O)COC1=CC=CC=C1C#N\", \"cofactor_name\": \"Bucindolol\", \"cofactor_resource_id\": \"DB12752\", \"neighbor_flag\": \"N\", \"pubmed_ids\": [17125412, 14732961, 27836712], \"resource_name\": \"DrugBank\", \"resource_version\": \"5.1\", \"target_resource_id\": \"P10635\"}, {\"cofactor_in_ch_ikey\": \"FCDLCPWAQCPTKC-UHFFFAOYSA-N\", \"cofactor_smiles\": \"OC(=O)C1=CC2=C(C(O)=C1)C(=O)C1=C(C=CC=C1O)C2=O\", \"cofactor_chem_comp_id\": \"RHN\", \"cofactor_name\": \"Rhein\", \"cofactor_resource_id\": \"DB13174\", \"mechanism_of_action\": \"**Liver: **The reversal of non-alcoholic fatty liver disease stems from rhien's lipid lowering and anti-obesity actions which result in an overall decrease in body weight, high density lipoprotein, and low density lipoprotein as well as its anti-inflammatory action [A19303]. The reversal of hepatic fibrosis is thought to be due to rhien's anti-inflammatory and anti-oxidant action which suppresses the pro-fibrotic signalling from macrophages and further damage from reactive oxygen species respectively [A19304]. Ultimately this results in reduced expression of alpha-smooth muscle actin (Alpha-SMA) which is indicative of decreased hepatic stellate cell and myofibroblast activation. Rhein also appears to suppress the expression of transforming growth factor-Beta (TGF-Beta) \\r\\n\\r\\n**Kidney: **The protection from fibrosis in the kidney also appears to stem from rhien's anti-inflammatory action resulting in less inflammatory cell infiltration along with suppression of alpha-SMA and fibronectin expression [A19307]. These indicate a reduction in the activation of interstitial fibroblasts which are responsible for excess production of extracellular matrix components. Rhien may also suppress TGF-beta expression in the kidney. The anti-fibrotic mechanism of rhien may involve the upregulation of bone morphogenetic protein 7 and hepatic growth factor [A19308]. In diabetic nephropathy rhein appears to suppress the expression of integrin-linked kinase leading to a reduction in the matrix metalloproteinase-9/tissue inhibitor of matrix metalloproteinase-1 ratio [A19311]. The improvement of epithelial tight junction function seems to involve upregulation of zona occludins protein-1 and occludin expression [A19310].\\r\\n\\r\\n**Bone and joint:**Rhein reduces cartilage destruction by decreasing expression of matrix metalloproteinase (MMP)-1 and -3 as well as upregulating tissue inhibitor of matrix metalloproteinases which serve to reduce the activity of several MMPs [A19339]. The anti-inflammatory action of rhein reduces the level of interleukin-1beta activity which plays a large role in reduction of extracellular matrix production, MMP activity, and continued inflammation [A19338]. Rhein reduces abnormal osteoblast synthetic activity through an unknown mechanism [A19337].\\r\\n\\r\\n**Lipid lowering and anti-obesity: **Rhein is known to bind and inhibit liver X receptor alpha and beta with Kd values of 46.7 microM and 31.97 microM respectively [A19315]. This decreases the expression of genes such as that of sterol regulatory element binding transcription factor 1 (SREBP1c) and its downstream genes for fatty acid synthase (FAS), steroyl-coenzyme A desaturase 1 (SCD1), and acetyl CoA carboxylase 1 (ACC1). SREBP1c, FAS, SCD1, and ACC1 are all involved in adipogenesis and their suppression results in less fat content. The genes for ABCA1 and ABCG1 are also suppressed. These correspond to cholesterol efflux trasporters and likely explain the reductiion in HDL and LDL seen with rhein. The inhibition of LXR by rhien relieves the inhibition on uncoupling protein 1 expression in brown adipose tissue. The result of this is increased thermogenesis which likely plays a role in the reduction of body weight produced by rhien. Additionally, rhein may downregulate peroxisome proliferator-receptor gamma and its downstream genes to inhibit adipocyte differentiation [A19314].\\r\\n\\r\\n**Anti-oxidant/Pro-oxidant:** The antoxidant mechanism is unknown. The pro-oxidant action of rhien may involve the inhibition of mitochondrial respiratory complex 1 and subsequent facilitation of NADH and NADPH dependent lipid peroxidation [A19323].\\r\\n\\r\\n**Anti-cancer:** The exact mechanism of rhein's ability to damage DNA and supress the expression of DNA repair enzymes ADR and MGMT is unknown [A19340]. The mechanism through which rhien induces ER stress is unknown but likely involves its pro-oxidant properties [A19341]. Rhein has been observed to produce increases in cytosolic calcium, reductions in mitochondrial membrane potential, and upregulation of pro-apoptotic proteins as well as leakage of cytochrome C which would induce apoptosis via the intrinsic pathway. The reduction of matrix metalloproteinase-9 serves to prevent extra cellular matrix breakdown by cancer cells and hinders their invasion into surrounding tissue [A19342]. Rhein also decreases vascular endothelial growth factor expression through an unknown mechanism to prevent cancer cells from stimulating agiogenesis. Rhein reduces the activity of the nuclear factor kappa (NFkappaB) pathway by preventing the destruction of IKBalpha [A19342] [A19345]. The activity of the phosphoinositol 3-kinase/Akt pathway is also reduced by rhien [A19343]. Rhein's inhibition of the mitogen-activated protein kinase pathways (particularly those involving extracellular signal regulated kinase) appears to follow a U-shaped dose response curve. ERK phosphorylation is inhibited at low concentrations of around 3microM but activated at higher concentrations of around 30microM [A19344]. Furthermore, ERK phosporylation is again inhibited at extremely high concentrations in excess of 100 microM [A19342]. The suppression of these three pathways is likely involved in the anti-proliferative effects of rhein.\\r\\n\\r\\n**Anti-inflammatory:** The mechanism of rhein's anti-inflammatory effect likely involves its inhibition of the NFkappa B pathway which plays a role in the production of many pro-inflammatory cytokines [A19342] [A19345]. Rhein's anti-oxidant activity may also play a role in preventing damage during inflammation.\\r\\n\\r\\n**Anti-diabetic:** Rhein is thought to increase islet beta cell survival by suppressing the expression of dynamin-related protein 1 and thereby preventing mitochondrial fission [A19288]. Rhein's anti-oxidant properties are also thought to play a role in protecting islet beta cells. The reduction in plasma glucose is likely due to increased survival of islet beta cells and subsequent increases in insulin secretion. Rhein's anti-inflammatory action may also serve to reduce insulin resistance.\\r\\n\\r\\n**Anti-microbial:** Rhien inhibits H. pylori arylamine N-acetyltransferase in a dose dependent manner [A19312]. The mechanism of rhein's anti-microbial effect on H. pylori and S. aureus are unknown.\\r\\n\\r\\n**Anti-allergenic:** Rhien inhibits 5-lipoxygenase with an IC50 of 13.7microM [A19329]. Rhien also inhibits mast cell degranulation although the specific mechanism is unknown.\", \"neighbor_flag\": \"N\", \"pubmed_ids\": [18814214], \"resource_name\": \"DrugBank\", \"resource_version\": \"5.1\", \"target_resource_id\": \"P10635\"}, {\"cofactor_name\": \"Ipecac\", \"cofactor_resource_id\": \"DB13293\", \"mechanism_of_action\": \"The emetic components of ipecac, emetine and cephaeline, act centrally and locally in the gastrointestinal tract to cause vomiting.[L2753] The mechanism by which ipecac performs his effect is by irritating the stomach lining and chemically stimulating the chemoreceptor trigger zone.[T202]\", \"neighbor_flag\": \"N\", \"resource_name\": \"DrugBank\", \"resource_version\": \"5.1\", \"target_resource_id\": \"P10635\"}, {\"cofactor_in_ch_ikey\": \"METKIMKYRPQLGS-LBPRGKRZSA-N\", \"cofactor_smiles\": \"CC(C)NC[C@H](O)COC1=CC=C(CC(N)=O)C=C1\", \"cofactor_name\": \"Esatenolol\", \"cofactor_resource_id\": \"DB13443\", \"neighbor_flag\": \"N\", \"pubmed_ids\": [27836712, 14732961, 17125412], \"resource_name\": \"DrugBank\", \"resource_version\": \"5.1\", \"target_resource_id\": \"P10635\"}, {\"cofactor_in_ch_ikey\": \"XYCMOTOFHFTUIU-UHFFFAOYSA-N\", \"cofactor_smiles\": \"CC(C)(C)NCC(O)COC1=CC(Cl)=CC=C1Cl\", \"cofactor_name\": \"Cloranolol\", \"cofactor_resource_id\": \"DB13508\", \"neighbor_flag\": \"N\", \"pubmed_ids\": [27836712, 14732961, 17125412], \"resource_name\": \"DrugBank\", \"resource_version\": \"5.1\", \"target_resource_id\": \"P10635\"}, {\"cofactor_in_ch_ikey\": \"NXWGWUVGUSFQJC-UHFFFAOYSA-N\", \"cofactor_smiles\": \"CC(C)NCC(O)COC1=CC=CC2=C1C=C(C)N2\", \"cofactor_name\": \"Mepindolol\", \"cofactor_resource_id\": \"DB13530\", \"neighbor_flag\": \"N\", \"pubmed_ids\": [27836712, 14732961, 17125412], \"resource_name\": \"DrugBank\", \"resource_version\": \"5.1\", \"target_resource_id\": \"P10635\"}, {\"cofactor_in_ch_ikey\": \"KCFYEAOKVJSACF-UHFFFAOYSA-N\", \"cofactor_smiles\": \"CCOC(=O)C1=C(CSC2=CC=CC=C2)N(C)C2=CC(Br)=C(O)C(CN(C)C)=C12\", \"cofactor_chem_comp_id\": \"75U\", \"cofactor_name\": \"Umifenovir\", \"cofactor_resource_id\": \"DB13609\", \"mechanism_of_action\": \"Umifenovir is considered both a direct-acting antiviral (DAA) due to direct virucidal effects and a host-targeting agent (HTA) due to effects on one or multiple stages of viral life cycle (e.g. attachment, internalization), and its broad-spectrum antiviral activity is thought to be due to this dual activity.[A191475] It is a hydrophobic molecule capable of forming aromatic stacking interactions with certain amino acid residues (e.g. tyrosine, tryptophan), which contributes to its ability to directly act against viruses. Antiviral activity may also be due to interactions with aromatic residues within the viral glycoproteins involved in fusion and cellular recognition,[A191397,A191406] with the plasma membrane to interfere with clathrin-mediated exocytosis and intracellular trafficking,[A191433] or directly with the viral lipid envelope itself (in enveloped viruses).[A191475,A191469] Interactions at the plasma membrane may also serve to stabilize it and prevent viral entry (e.g. stabilizing influenza hemagglutinin inhibits the fusion step necessary for viral entry).[A191475]\\r\\n\\r\\nDue to umifenovir\\u2019s ability to interact with both viral proteins and lipids, it may also interfere with later stages of the viral life cycle. Some virus families, such as _Flaviviridae_, replicate in a subcellular compartment called the membranous web - this web requires lipid-protein interactions that may be hindered by umifenovir. Similarly, viral assembly of hepatitis C viruses is contingent upon the assembly of lipoproteins, presenting another potential target.[A191475]\", \"neighbor_flag\": \"N\", \"pubmed_ids\": [23357765], \"resource_name\": \"DrugBank\", \"resource_version\": \"5.1\", \"target_resource_id\": \"P10635\"}, {\"cofactor_in_ch_ikey\": \"SOYKEARSMXGVTM-HNNXBMFYSA-N\", \"cofactor_smiles\": \"CN(C)CC[C@@H](C1=CC=C(Cl)C=C1)C1=CC=CC=N1\", \"cofactor_name\": \"Dexchlorpheniramine\", \"cofactor_resource_id\": \"DB13679\", \"neighbor_flag\": \"N\", \"pubmed_ids\": [11936702, 11994058], \"resource_name\": \"DrugBank\", \"resource_version\": \"5.1\", \"target_resource_id\": \"P10635\"}, {\"cofactor_in_ch_ikey\": \"YARKMNAWFIMDKV-UHFFFAOYSA-N\", \"cofactor_smiles\": \"OC(CNCCNC(=O)CC1=CC=C(O)C=C1)COC1=CC=CC=C1C#N\", \"cofactor_name\": \"Epanolol\", \"cofactor_resource_id\": \"DB13757\", \"neighbor_flag\": \"N\", \"pubmed_ids\": [17125412, 14732961, 27836712], \"resource_name\": \"DrugBank\", \"resource_version\": \"5.1\", \"target_resource_id\": \"P10635\"}, {\"cofactor_in_ch_ikey\": \"HTWFXPCUFWKXOP-UHFFFAOYSA-N\", \"cofactor_smiles\": \"CC(C)(C)NCC(O)COC1=CC=CC2=C1SCCC2\", \"cofactor_name\": \"Tertatolol\", \"cofactor_resource_id\": \"DB13775\", \"neighbor_flag\": \"N\", \"pubmed_ids\": [27836712, 14732961, 17125412], \"resource_name\": \"DrugBank\", \"resource_version\": \"5.1\", \"target_resource_id\": \"P10635\"}, {\"cofactor_in_ch_ikey\": \"DYLUUSLLRIQKOE-UHFFFAOYSA-N\", \"cofactor_smiles\": \"CC(C)(O)CNC1=NC(=NC(NC2=CC(=NC=C2)C(F)(F)F)=N1)C1=NC(=CC=C1)C(F)(F)F\", \"cofactor_chem_comp_id\": \"69Q\", \"cofactor_name\": \"Enasidenib\", \"cofactor_resource_id\": \"DB13874\", \"mechanism_of_action\": \"Enasidenib is a selective inhibitor of IDH2, a mitochondria-localized enzyme involved in diverse cellular processes, including adaptation to hypoxia, histone demethylation and DNA modification [A20344]. Wild-type IDH proteins play a cruicial role in the Krebs/citric acid cycle where it catalyzes the oxidative decarboxylation of isocitrate to \\u03b1-ketoglutarate. In comparison, mutant forms of IDH2 enzyme mediates a neomorphic activity and catalyze reduction of \\u03b1-KG to the (R) enantiomer of 2-hydroxyglutarate, which is associated with DNA and histone hypermethylation, altered gene expression and blocked cellular differentiation of hematopoietic progenitor cells [A20344]. Enasidenib primarily targets the mutant IDH2 variants R140Q, R172S, and R172K with higher potency than the wild type enzyme form [FDA Label]. Inhibition of the enzyme leads to decreased levels of 2-hydroxyglutarate (2-HG) and promotion of proper differentiation and clonal proliferation of cells of the myeloid lineage [A20345]. \", \"neighbor_flag\": \"N\", \"resource_name\": \"DrugBank\", \"resource_version\": \"5.1\", \"target_resource_id\": \"P10635\"}, {\"cofactor_name\": \"Black cohosh\", \"cofactor_resource_id\": \"DB13975\", \"mechanism_of_action\": \"Although the mechanism by which black cohosh relieves menopausal symptoms is unknown, several hypotheses have been made. It is believed to act through the following mechanisms/effects:[L2302]\\r\\n\\r\\n 1) as a selective estrogen receptor modulator\\r\\n 2) through serotonergic pathways\\r\\n 3) as an antioxidant\\r\\n 4) on inflammatory pathways\\r\\n\\r\\nThe primary active component of the black cohosh root is believed to be the _terpene glycoside_ fraction, including _actein_ and _cimifugoside_.[L2302] The triterpenes are one of the most ubiquitous and diverse groups of plant natural products.[L2308] They are classified as complex molecules that are beyond the reach of chemical synthesis in the laboratory. Simple triterpenes are constituents of surface waxes and specialized plant membranes and may possibly serve as signaling molecules. More complex glycosylated triterpenes (also known as saponins) provide protection against pathogens and pests.[L2308] The rhizome (stem portion of the plant) also contains other potentially biologically active substances, including alkaloids, flavonoids, and tannins. The therapeutic activity of black cohosh was initially believed to be the activation of estrogen receptors; however, more recent studies show that although some components of the extract bind to at least one subtype of estrogen receptor, the receptor binding produces very little (if any) estrogenic effect, and may selectively block some of the effects.[L2302]\\r\\n\\r\\nAn early study reported that treatment with black cohosh leads to a decrease in luteinizing hormone (LH) levels consistent with its purported estrogenic effect. Despite this, more recent studies have shown no effect on levels of LH, follicle-stimulating hormone (FSH), or prolactin. To this day it is unclear whether black cohosh exerts its effect via estrogen receptors or through another mechanism.[L2307]\\r\\n\\r\\nOne study observed that while the most prominent _triterpene_ in black cohosh, known as _23-epi-26-deoxyactein_, inhibits cytokine-induced nitric oxide production in brain microglial cells, the complete black cohosh extract demonstrated to enhance this pathway.[L2302] A variety of activities have been reported for black cohosh and its compounds, however, the absorption and tissue distribution of these compounds is not known.[L2302]\\r\\n\\r\\n_Cimicifuga racemosa_ (black cohosh) is used most often to treat symptoms occurring during menopause. However, in recent years, several concerns regarding its safety have been voiced.[A32542]\", \"neighbor_flag\": \"N\", \"resource_name\": \"DrugBank\", \"resource_version\": \"5.1\", \"target_resource_id\": \"P10635\"}, {\"cofactor_name\": \"Medical Cannabis\", \"cofactor_resource_id\": \"DB14009\", \"neighbor_flag\": \"N\", \"pubmed_ids\": [26264914, 34493602, 30583596, 24160757, 31433338], \"resource_name\": \"DrugBank\", \"resource_version\": \"5.1\", \"target_resource_id\": \"P10635\"}, {\"cofactor_in_ch_ikey\": \"ZSTKHSQDNIGFLM-UHFFFAOYSA-N\", \"cofactor_smiles\": \"COC1=CC=C2NC=C(CCN(C)C)C2=C1\", \"cofactor_chem_comp_id\": \"YFW\", \"cofactor_name\": \"5-methoxy-N,N-dimethyltryptamine\", \"cofactor_resource_id\": \"DB14010\", \"neighbor_flag\": \"N\", \"pubmed_ids\": [20942780], \"resource_name\": \"DrugBank\", \"resource_version\": \"5.1\", \"target_resource_id\": \"P10635\"}, {\"cofactor_in_ch_ikey\": \"SSNHGLKFJISNTR-DYSNNVSPSA-N\", \"cofactor_smiles\": \"[H][C@]1(CCC(C)=C[C@@]1([H])C1=C(O)C=C(CCCCC)C=C1O)C(C)=C.[H][C@@]12CCC(C)=C[C@@]1([H])C1=C(O)C=C(CCCCC)C=C1OC2(C)C\", \"cofactor_name\": \"Nabiximols\", \"cofactor_resource_id\": \"DB14011\", \"mechanism_of_action\": \"The primary psychoactive component of Cannabis, delta 9-tetrahydrocannabinol (\\u03949-THC), demonstrates its effects through weak partial agonist activity at Cannabinoid-1 (CB1R) and Cannabinoid-2 (CB2R) receptors. This activity results in the well-known effects of smoking cannabis such as increased appetite, reduced pain, and changes in emotional and cognitive processes. In contrast to THC's weak agonist activity, CBD has been shown to act as a negative allosteric modulator of the cannabinoid CB1 receptor, the most abundant G-Protein Coupled Receptor (GPCR) in the body [A32469]. Allosteric regulation is achieved through the modulation of receptor activity on a functionally distinct site from the agonist or antagonist binding site. The negative allosteric modulatory effects of CBD are therapeutically important as direct agonists are limited by their psychomimetic effects while direct antagonists are limited by their depressant effects [A32469]. \\r\\n\\r\\nThere is further evidence that CBD also activates 5-HT1A serotonergic and TRPV1\\u20132 vanilloid receptors, antagonizes alpha-1 adrenergic and \\u00b5-opioid receptors, inhibits synaptosomal uptake of noradrenaline, dopamine, serotonin and gaminobutyric acid and cellular uptake of anandamide, acts on mitochondria Ca2 stores, blocks low-voltage-activated (T-type) Ca2 channels, stimulates activity of the inhibitory glycine-receptor, and inhibits activity of fatty amide hydrolase (FAAH) [A31555, A31574].\", \"neighbor_flag\": \"N\", \"pubmed_ids\": [26264914], \"resource_name\": \"DrugBank\", \"resource_version\": \"5.1\", \"target_resource_id\": \"P10635\"}, {\"cofactor_in_ch_ikey\": \"QGPKADBNRMWEQR-UHFFFAOYSA-N\", \"cofactor_smiles\": \"NC1CCN(C1)C1=C(F)C=C2C(=O)C(=CN(C3CC3)C2=C1Cl)C(O)=O\", \"cofactor_name\": \"Clinafloxacin\", \"cofactor_resource_id\": \"DB14025\", \"neighbor_flag\": \"N\", \"pubmed_ids\": [11502527], \"resource_name\": \"DrugBank\", \"resource_version\": \"5.1\", \"target_resource_id\": \"P10635\"}, {\"cofactor_in_ch_ikey\": \"DDINXHAORAAYAD-UHFFFAOYSA-N\", \"cofactor_smiles\": \"CCCCCCCCCCCC(=O)OCN1C(=O)CCC2=CC=C(OCCCCN3CCN(CC3)C3=C(Cl)C(Cl)=CC=C3)C=C12\", \"cofactor_name\": \"Aripiprazole lauroxil\", \"cofactor_resource_id\": \"DB14185\", \"mechanism_of_action\": \"The pharmacological activity of aripiprazole lauroxil is thought to be mainly mediated by its metabolite aripiprazole, and to a lesser extent, dehydro-aripiprazole. Aripiprazole functions as a partial agonist at the dopamine D2 and the serotonin 5-HT1A receptors, and as an antagonist at the serotonin 5-HT2A receptor [FDA Label]. The desired outcome of antipsuchotic agents in schizophrenia is to inhibit dopaminergic transmission in the limbic system and enhance dopaminergic transmission in the prefrontal cortex. As a partial agonist at D2 receptors in the mesolimbic dopaminergic pathway, aripiprazole acts as a functional antagonist in the mesolimbic dopamine pathway and reduces the extent of dopaminergic pathway activity. This results in reduced positive symptoms in schizophrenia and extrapyramidal motor side effects [A34403]. In contrast, aripiprazole is thought to act as a functional agonist in the mesocortical pathway, where reduced dopamine activity is seen in association with negative symptoms and cognitive impairment [A34403]. Antagonism at 5-HT2A receptors by aripiprazole alleviates the negative symptoms and cognitive impairment of schizophrenia [T28]. 5-HT2A receptors are Gi/Go-coupled that upon activation, produce neuronal inhibition via decreased neuronal excitability and decreased transmitter release at the nerve terminals. In the nigrostriatal pathway, 5-HT2A regulates the release of dopamine. Through antagonism of 5-HT2A receptors, aripiprazole disinhibits the release of dopamine in the striatum and enhance the levels of the transmitters at the nerve terminals [T28]. The combined effects of D2 and 5-HT2A antagonism are thought to counteract the increased dopamine function causing increased extrapyramidal side effects [T28]. Blocking 5-HT2A receptors may also lead to the modulation of glutamate release in the mesocortical circuit, which is a transmitter that plays a role in schizophrenia [A34403]. 5-HT1A receptors are autoreceptors that inhibit 5-HT release upon activation. Aripiprazole is a partial agonist at theses receptors and reduces 5-HT release; this results in potentiated dopamine release in the striatum and prefrontal cortex [T28]. It is reported that therapeutic doses of aripiprazole occupies up to 90% of brain D2 receptors in a dose-dependent manner [A4965]. \\r\\n\\r\\nApripiprazole targets different receptors that lead to drug-related adverse reactions; for example, the antagonist activity at the alpha-1 adrenergic receptors results in orthostatic hypotension [A34289]. Aripiprazole's antagonism of histamine H1 receptors may explain the somnolence observed with this drug [A34289].\", \"neighbor_flag\": \"N\", \"pubmed_ids\": [15257633], \"resource_name\": \"DrugBank\", \"resource_version\": \"5.1\", \"target_resource_id\": \"P10635\"}, {\"cofactor_in_ch_ikey\": \"NEJVQQBBTRFOHB-FCXRPNKRSA-N\", \"cofactor_smiles\": \"COC1=CC(\\\\C=C\\\\C(=O)CC(=O)\\\\C=C\\\\C2=CC=C(OS(O)(=O)=O)C(OC)=C2)=CC=C1O\", \"cofactor_name\": \"Curcumin sulfate\", \"cofactor_resource_id\": \"DB14635\", \"mechanism_of_action\": \"Curcumin acts as a scavenger of oxygen species, such as hydroxyl radical, superoxide anion, and singlet oxygen and inhibit lipid peroxidation as well as peroxide-induced DNA damage [L34044]. Curcumin mediates potent anti-inflammatory agent and anti-carcinogenic actions via modulating various signalling molecules. It suppresses a number of key elements in cellular signal transduction pathways pertinent to growth, differentiation, and malignant transformation; it was demonstrated _in vitro_ that curcumin inhibits protein kinases, c-Jun/AP-1 activation, prostaglandin biosynthesis, and the activity and expression of the enzyme cyclooxygenase (COX)-2 [L34044].\", \"neighbor_flag\": \"N\", \"pubmed_ids\": [18480186, 24510399], \"resource_name\": \"DrugBank\", \"resource_version\": \"5.1\", \"target_resource_id\": \"P10635\"}, {\"cofactor_in_ch_ikey\": \"VBGLYOIFKLUMQG-UHFFFAOYSA-N\", \"cofactor_smiles\": \"CCCCCC1=CC2=C(C(O)=C1)C1=C(C=CC(C)=C1)C(C)(C)O2\", \"cofactor_name\": \"Cannabinol\", \"cofactor_resource_id\": \"DB14737\", \"neighbor_flag\": \"N\", \"pubmed_ids\": [30583596, 24160757, 31433338], \"resource_name\": \"DrugBank\", \"resource_version\": \"5.1\", \"target_resource_id\": \"P10635\"}, {\"cofactor_in_ch_ikey\": \"RWWYLEGWBNMMLJ-YSOARWBDSA-N\", \"cofactor_smiles\": \"CCC(CC)COC(=O)[C@H](C)N[P@](=O)(OC[C@H]1O[C@](C#N)([C@H](O)[C@@H]1O)C1=CC=C2N1N=CN=C2N)OC1=CC=CC=C1\", \"cofactor_name\": \"Remdesivir\", \"cofactor_resource_id\": \"DB14761\", \"mechanism_of_action\": \"COVID-19 is caused by the positive-sense RNA virus severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). Replication of the viral genome is a key step in the infectious cycle of RNA viruses, including those of the _Filoviridae_, _Paramyxoviridae_, _Pneumoviridae_, and _Coronaviridae_ families, and is carried out by viral RNA-dependent RNA polymerase (RdRp) enzymes or enzyme complexes.[A222393, A222398] For both SARS-CoV and SARS-CoV-2, the RdRp comprises nsp7, nsp8, and nsp12 subunits under physiological conditions, although functional RdRp complexes can be reassembled _in vitro_ that incorporate only the nsp8 and nsp12 subunits, similar to the Middle East respiratory syndrome coronavirus (MERS-CoV).[A222398]\\r\\n\\r\\nRemdesivir is a phosphoramidite prodrug of a 1'-cyano-substituted adenosine nucleotide analogue that competes with ATP for incorporation into newly synthesized viral RNA by the corresponding RdRp complex.[A222398] Remdesivir enters cells before being cleaved to its monophosphate form through the action of either carboxylesterase 1 or cathepsin A; it is subsequently phosphorylated by undescribed kinases to yield its active triphosphate form remdesivir triphosphate (RDV-TP or GS-443902).[A222393, L18438] RDV-TP is efficiently incorporated by the SARS-CoV-2 RdRp complex, with a 3.65-fold selectivity for RDV-TP over endogenous ATP.[A222398, L18438] Unlike some nucleoside analogues, remdesivir provides a free 3'-hydroxyl group that allows for continued chain elongation.[A222398, L18438] However, modelling and _in vitro_ experiments suggest that at _i_ + 4 (corresponding to the position for the incorporation of the fourth nucleotide following RDV-TP incorporation), the 1'-cyano group of remdesivir sterically clashes with Ser-861 of the RdRp, preventing further enzyme translocation and terminating replication at position _i_ + 3. This mechanism was essentially identical between SARS-CoV, SARS-CoV-2, and MERS-CoV, and genomic comparisons reveal that Ser-861 is conserved across alpha-, beta-, and deltacoronaviruses, suggesting remdesivir may possess broad antiviral activity.[A222398]\\r\\n\\r\\nConsiderations for the use of nucleotide analogues like remdesivir include the possible accumulation of resistance mutations. Excision of analogues through the 3'-5' exonuclease (ExoN) activity of replication complexes, mediated in SARS-CoV by the nsp14 subunit, is of possible concern.[A222398] Murine hepatitis viruses (MHVs) engineered to lack ExoN activity are approximately 4-fold more susceptible to remdesivir, supporting the proposed mechanism of action.[A191400] However, the relatively mild benefit of ExoN activity to remdesivir resistance is proposed to involve its delayed chain termination mechanism, whereby additional endogenous nucleotides are incorporated following RDV-TP.[A222398] In addition, serial passage of MHV in increasing concentrations of the remdesivir parent molecule [GS-441524] led to the development of resistance mutations F476L and V553L, which maintain activity when transferred to SARS-CoV. However, these mutant viruses are less fit than wild-type in both competition assays and _in vivo_ in the absence of selective pressure.[A191400] To date, no clinical data on SARS-CoV-2 resistance to remdesivir have been described.[L18438]\", \"neighbor_flag\": \"N\", \"pubmed_ids\": [32402130], \"resource_name\": \"DrugBank\", \"resource_version\": \"5.1\", \"target_resource_id\": \"P10635\"}, {\"cofactor_in_ch_ikey\": \"CEFJVGZHQAGLHS-UHFFFAOYSA-N\", \"cofactor_smiles\": \"CCN1C(=O)C(=CC2=C1C=C(NC)N=C2)C1=C(Br)C=C(F)C(NC(=O)NC2=CC=CC=C2)=C1\", \"cofactor_name\": \"Ripretinib\", \"cofactor_resource_id\": \"DB14840\", \"mechanism_of_action\": \"Protein kinases play important roles in cellular function, and their dysregulation can lead to carcinogenesis.[A203114] Ripretinib inhibits protein kinases including wild type and mutant platelet-derived growth factor receptor A (PDGFRA) and KIT that cause the majority of gastrointestinal stromal tumor (GIST).[A203096] In vitro, ripretinib has been shown to inhibit PDGFRB, BRAF, VEGF, and TIE2 genes.[A189339,A203063,L13769] \\r\\n\\r\\nRipretinib binds to KIT and PDGFRA receptors with mutations on the exons 9, 11, 13, 14, 17 and 18 (for KIT mutations), and exons 12, 14 and 18 (for PDGFRA mutations).[A203060] The \\u201cswitch pocket\\u201d of a protein kinase is normally bound to the activation loop, acting as an \\u201con-off switch\\u201d of a kinase.   Ripretinib boasts a unique dual mechanism of action of binding to the kinase switch pocket as well as the activation loop, thereby turning off the kinase and its ability to cause dysregulated cell growth.[A203060,L13811]\\r\\n\\r\\n\", \"neighbor_flag\": \"N\", \"resource_name\": \"DrugBank\", \"resource_version\": \"5.1\", \"target_resource_id\": \"P10635\"}, {\"cofactor_in_ch_ikey\": \"DMNOVGJWPASQDL-OAQYLSRUSA-N\", \"cofactor_smiles\": \"COC1=C(CNCC[C@]2(CCOC3(CCCC3)C2)C2=NC=CC=C2)SC=C1\", \"cofactor_chem_comp_id\": \"WH2\", \"cofactor_name\": \"Oliceridine\", \"cofactor_resource_id\": \"DB14881\", \"mechanism_of_action\": \"Pain perception follows a complex pathway initiated in primary sensory neurons, subsequently transmitted to the spinal cord dorsal horn and through ascending axons to multiple regions within the thalamus, brainstem, and midbrain, and finally relayed through descending signals that either inhibit or facilitate the nociceptive signalling.[A218041, A218046] Opioid receptors are seven-transmembrane G-protein-coupled receptors (GPCRs) that can be divided into \\u03bc, \\u03ba, \\u03b4, and opioid-like-1 (ORL1) subtypes,[A218031, A218046]. However, the \\u03bc-opioid receptor is predominantly targeted by and is responsible for the effects of traditional opioids.[A218046] GPCRs in the inactive state are bound intracellularly by a complex consisting of a G<sub>\\u03b1</sub>, \\u03b2, and \\u03b3 subunit together with guanosine diphosphate (GDP). Activation of the GPCR through extracellular agonist binding catalyzes the replacement of GDP with guanosine triphosphate (GTP), dissociation of both G<sub>\\u03b1</sub>-GTP and a \\u03b2\\u03b3 heterodimer, and subsequent downstream effects.[A218046]\\r\\n\\r\\nIn the case of the \\u03bc-opioid receptor, the G<sub>\\u03b1</sub>-GTP directly interacts with the potassium channel K<sub>ir</sub>3 while the dissociated G\\u03b2\\u03b3 subunit directly binds to and occludes the pore of P/Q-, N-, and L-type Ca<sup>2+</sup> channels. Furthermore, opioid receptor activation inhibits adenylyl cyclase, which in turn reduces cAMP-dependent Ca<sup>2+</sup> influx. By altering membrane ion conductivity, these effects modulate nociceptive signalling and produce an analgesic effect.[A218036, A218041, A218046] In addition to the G-protein pathway, \\u03bc-opioid receptor activation can also result in downstream signalling through \\u03b2-arrestin, which results in receptor internalization and is associated with negative effects of opioid use including respiratory depression, gastrointestinal effects, and desensitization/tolerance.[A218026, A218031, A218036, A218041, A218046]\\r\\n\\r\\nOliceridine acts as a \\\"biased agonist\\\" at the \\u03bc-opioid receptor by preferentially activating the G-protein pathway with minimal receptor phosphorylation and recruitment of \\u03b2-arrestin.[A218026, A218031] Competetive binding assays and structural modelling suggest that the binding site for oliceridine on the \\u03bc-opioid receptor is the same as for classical opioids.[A218026, A216961] However, molecular modelling supports a model whereby oliceridine binding induces a different intracellular conformation of the \\u03bc-opioid receptor, specifically due to a lack of coupling with transmembrane helix six, which confers the specificity for G-protein over \\u03b2-arrestin interaction.[A216961] Numerous _in vitro_, _in vivo_, and clinical studies support the view that this biased agonism results in comparable analgesia compared with traditional opioids at a comparable or decreased risk of opioid-related adverse effects such as constipation and respiratory depression.[A218026, A218031, A218051, A218056, A218061, A218066, A218071, L15516]\", \"neighbor_flag\": \"N\", \"resource_name\": \"DrugBank\", \"resource_version\": \"5.1\", \"target_resource_id\": \"P10635\"}, {\"cofactor_in_ch_ikey\": \"RLCLASQCAPXVLM-NSHDSACASA-N\", \"cofactor_smiles\": \"CC(C)N1C(=O)NC(N[C@@H](C)C2=CC=CC=C2)=CC1=O\", \"cofactor_chem_comp_id\": \"XB2\", \"cofactor_name\": \"Mavacamten\", \"cofactor_resource_id\": \"DB14921\", \"mechanism_of_action\": \"Myosin is a family of enzymes that can produce mechanical output by an ATP-mediated cyclic interaction with actin. When ATP is bound to the myosin head, it is hydrolyzed into ADP and organophosphate by myosin ATPase activity, and the energy produced from the reaction is stored in the myosin head. As the organophosphate dissociates from myosin, it shifts myosin into a strong binding state to actin, thus creating a myosin-actin complex otherwise known as \\\"cross-bridging\\\".[A248280, A247120, A248290]Dissociation of the organophosphate also causes a conformation change in myosin that creates strain in the actin-myosin bridge that can only be released once the actin and myosin filaments slide past each other, thus shortening the sarcomere and create a muscle contraction.[A248290,A248425] Once the sliding is completed, ADP is released to create further movement of the myosin head.[A248425] Although this ADP release-induced movement is minor and unlikely to contribute to the sarcomere movement, researchers have hypothesized that this movement is likely essential in limiting the sliding velocity of actin.[A248410,A248415,A248420,A248425]Finally, myosin then bind to a new ATP molecule to initiate the chemomechanical cycle again. \\r\\n\\r\\n\\r\\nMavacamten reduces sarcomere hypercontractility by acting as an allosteric and reversible modulator of the beta-cardiac isoform of myosin to reduce its ATPase activity, thus reducing actin-myosin cross bridging.[A248285] Specifically, mavacamten inhibits the phosphate release, the cycle's rate-limiting step, without affecting the ADP release rate in actin-bound myosin.[A247155]Also, mavacamten inhibits binding of ADP-bound myosin to actin as well as ADP release to prime the myosin head to initiate turnover.[A247120]Recently, it was also discovered when myosin is not in its active state to interact with actin, it exists in equilibrium between 2 energy sparing states: a disordered relaxed state, where interaction between actin and myosin by the thin filament regulatory proteins, and a super relaxed state, where significant myosin head-to-head interaction lengthen ATP turnover rate.[A248430,A248435]. Mavacamten's binding to myosin can shift the equilibrium toward the super relaxed state, effectively exerting both a basal and actin-activated ATP inhibition.[A248430,L41680]\\r\\n\", \"neighbor_flag\": \"N\", \"pubmed_ids\": [30044681], \"resource_name\": \"DrugBank\", \"resource_version\": \"5.1\", \"target_resource_id\": \"P10635\"}, {\"cofactor_in_ch_ikey\": \"WYQFJHHDOKWSHR-MNOVXSKESA-N\", \"cofactor_smiles\": \"CC[C@@H]1CN(C[C@@H]1C1=CN=C2C=NC3=C(C=CN3)N12)C(=O)NCC(F)(F)F\", \"cofactor_name\": \"Upadacitinib\", \"cofactor_resource_id\": \"DB15091\", \"mechanism_of_action\": \"Rheumatoid arthritis (RA) is a chronic autoimmune inflammatory disease that involves the interplay of several mediators, including the immune cells (mainly T- and B-lymphocytes) and pro-inflammatory cytokines, such as the tumour necrosis factor (TNF), transforming growth factor (TGF), and interleukin 6 (IL-6).[A189165] The Janus Kinase (JAK) family plays an essential role in the normal physiological functions (such as erythropoiesis), but also the signalling of pro-inflammatory cytokines that are implicated in many immune-mediated diseases.[A189168] The JAK family consists of four isoforms (JAK1, JAK2, JAK3, and Tyrosine Kinase 2) that each interacts with different cytokine receptors and uniquely associates with the intracellular domains of Type I/II cytokine receptors.[A189168] JAK1 is primarily involved in the signalling transduction pathways of IL-6, IFN and the common \\u03b3 -chain cytokines, including IL-2 and IL-15.[A189180] IL-6 has been closely studied in particular, as it is a major cytokine involved in B- and T-cell differentiation and the acute phase response in inflammation.[A189177]\\r\\n\\r\\nUpon interaction of cytokines with their cytokine receptors, the JAKs mediate the JAK-STAT signal transduction pathway in response to receptor activation. JAKs are tyrosine kinases that cause phosphorylation of several proteins, including cytokine receptors and JAKs themselves. Phosphorylation of JAKs promotes the phosphorylation and activation of the signalling molecules called STATs, leading to their nuclear translocation, binding to DNA promoters, and target gene transcription. JAK1-mediated signalling pathways ultimately promote pro-inflammatory events, such as increased proliferation and survival of immune cells, T cell differentiation, and macrophage activation.[A189168] Upadacitinib is a selective JAK1 inhibitor that has a negligible effect on JAK3, leading to an improved drug safety profile.[A189165] Upadacitinib blocks the cellular processes that contribute to the inflammatory conditions in rheumatoid arthritis. In human leukocytes cellular assays, upadacitinib inhibited JAK1/3-induced phosphorylation of STAT3/5 mediated by IL-6/7.[L10896]\", \"neighbor_flag\": \"N\", \"pubmed_ids\": [30945116, 29688617], \"resource_name\": \"DrugBank\", \"resource_version\": \"5.1\", \"target_resource_id\": \"P10635\"}, {\"cofactor_name\": \"Ropeginterferon alfa-2b\", \"cofactor_resource_id\": \"DB15119\", \"mechanism_of_action\": \"Polycythemia vera (PV) is the most common Philadelphia chromosome-negative myeloproliferative neoplasm (MPN), which also includes essential thrombocytopenia and myelofibrosis.[A242000, A242005] PV is characterized by increased hematocrit and platelet/leukocyte counts, an increased risk for hemorrhage and thromboembolic events, and a long-term propensity for myelofibrosis and leukemia. The main driver mutation, _JAK2_ V617F, is present in >95% of PV patients and results in constitutive JAK/STAT signalling; other exon 12 mutations in _JAK2_ may also result in PV. PV results in clonal hematopoietic stem cells, such that they form endogenous erythroid colonies (EECs) _in vitro_.[A242000]\\r\\n\\r\\nInterferon alfa-2b has been used for decades in PV despite the lack of formal approval.[A242005] Although the mechanism of action is unclear, interferon alfa-2b is known to bind the interferon-alpha/beta receptor (IFNAR) and activate downstream JAK/STAT signalling.[A242005, L39170] The overall result is a series of anti-proliferative, anti-angiogenic, pro-apoptotic, and immunomodulatory effects, including augmenting T-cell, macrophage, and natural killer cells.[A242005] Interestingly, _in vitro_ studies have revealed that ropeginterferon alfa-2b is specific to some extent for _JAK2_-mutant EECs, a result that is in line with the reduced allelic burden observed in clinical trials.[A242010, A242015] Partial and complete molecular and hematological responses have been achieved with ropeginterferon alfa-2b.[A242015]\", \"neighbor_flag\": \"N\", \"resource_name\": \"DrugBank\", \"resource_version\": \"5.1\", \"target_resource_id\": \"P10635\"}, {\"cofactor_in_ch_ikey\": \"KEIPNCCJPRMIAX-HNNXBMFYSA-N\", \"cofactor_smiles\": \"COC1=CC(=CC(OC)=C1)C#CC1=NN([C@H]2CCN(C2)C(=O)C=C)C2=C1C(N)=NC=N2\", \"cofactor_chem_comp_id\": \"TZ0\", \"cofactor_name\": \"Futibatinib\", \"cofactor_resource_id\": \"DB15149\", \"mechanism_of_action\": \"Fibroblast Growth Factor receptor (FGFR) pathway play a key role in cell proliferation, differentiation, migration, and survival. Notably, FGFR genomic aberrations and aberrant FGFR signalling pathways are observed in some cancers,[A253193,A253198] as constitutive FGFR signalling can support the proliferation and survival of malignant cells.[L43347]\\r\\n\\r\\nFutibatinib is a selective, irreversible inhibitor of FGFR 1, 2, 3, and 4 with IC<sub>50</sub> values of less than 4 nM.[A253198,L43347] It binds to the FGFR kinase domain by forming a covalent bond with cysteine in the ATP-binding pocket.[A253198] Upon binding to FGFR, futibatinib blocks FGFR phosphorylation and downstream signalling pathways,[L43347] such as the RAS-dependent mitogen-activated protein kinase (MAPK), phosphatidylinositol 3-kinase (PI3KCA)/Akt/mTOR, phospholipase C\\u03b3 (PLC\\u03b3), and JAK/STAT.[A253223] Futibatinib ultimately decreases cell viability in cancer cell lines with FGFR alterations, including FGFR fusions or rearrangements, amplifications, and mutations.[L43347]\", \"neighbor_flag\": \"N\", \"resource_name\": \"DrugBank\", \"resource_version\": \"5.1\", \"target_resource_id\": \"P10635\"}, {\"cofactor_in_ch_ikey\": \"DDOOFTLHJSMHLN-ZQHRPCGSSA-N\", \"cofactor_smiles\": \"C[C@@H]1[C@@H](C[C@H](NC(=O)C2=CN=C3C[C@]4(CC3=C2)C(=O)NC2=NC=CC=C42)C(=O)N1CC(F)(F)F)C1=CC=CC=C1\", \"cofactor_name\": \"Ubrogepant\", \"cofactor_resource_id\": \"DB15328\", \"mechanism_of_action\": \"The currently accepted theory of migraine pathophysiology considers dysfunction of the central nervous system, in particular the trigeminal ganglion, to be the root cause behind the condition.[A189207] Activation of the trigeminal ganglion triggers the stimulation of trigeminal afferents that project to the spinal cord and synapse on various pain-sensing intra- and extracranial structures, such as the dura mater. Pain signals are then further transmitted via second-order ascending neurons to the brainstem, hypothalamus, and thalamic nuclei, and from there to several cortical regions (e.g. auditory, visual, motor cortices).[A189207] The trigeminal ganglion appears to amplify and perpetuate the migraine headache pain through the activation of perivascular fibers and the release of molecules involved in pain generation, such as calcitonin gene-related peptide (CGRP).[A189207]\\r\\n\\r\\nThe \\u03b1-isoform of CGRP, expressed in primary sensory neurons, is a potent vasodilator and has been implicated in migraine pathogenesis - CGRP levels are acutely elevated during migraine attacks, return to normal following treatment with triptan medications, and intravenous infusions of CGRP have been shown to trigger migraine-like headaches in migraine patients. In addition to its vasodilatory properties, CGRP appears to be a pronociceptive factor that modulates neuronal excitability to facilitate pain responses.[A189213]\\r\\n\\r\\nUbrogepant is a potent antagonist of the calcitonin gene-related peptide receptor[L10926] - it competes with CGRP for occupancy at these receptors, preventing the actions of CGRP and its ability to amplify and perpetuate migraine headache pain, ultimately terminating the headache.[A189213]\", \"neighbor_flag\": \"N\", \"resource_name\": \"DrugBank\", \"resource_version\": \"5.1\", \"target_resource_id\": \"P10635\"}, {\"cofactor_in_ch_ikey\": \"JOLJIIDDOBNFHW-UHFFFAOYSA-N\", \"cofactor_smiles\": \"CCCCCCOC1=NSN=C1C1=CCCN(C)C1\", \"cofactor_chem_comp_id\": \"XNO\", \"cofactor_name\": \"Xanomeline\", \"cofactor_resource_id\": \"DB15357\", \"mechanism_of_action\": \"The efficacy of xanomeline in the treatment of schizophrenia is thought to be due to its agonist activity at muscarinic acetylcholine receptors M1 and M4 in the central nervous system.[L51629] It binds to muscarinic receptors M1 to M5 with comparable affinity and exhibits relatively higher agonist activity at the M1 and M4 receptors.[L51629]\", \"neighbor_flag\": \"N\", \"resource_name\": \"DrugBank\", \"resource_version\": \"5.1\", \"target_resource_id\": \"P10635\"}, {\"cofactor_in_ch_ikey\": \"MVRHVFSOIWFBTE-INIZCTEOSA-N\", \"cofactor_smiles\": \"C[C@@H]1CN(C2=NC(=CC=C2C(=O)NS(=O)(=O)C2=CN(C)N=C2C)N2C=CC(OCC(C)(C)C(F)(F)F)=N2)C(C)(C)C1\", \"cofactor_chem_comp_id\": \"WJX\", \"cofactor_name\": \"Elexacaftor\", \"cofactor_resource_id\": \"DB15444\", \"mechanism_of_action\": \"Cystic fibrosis (CF) is the result of a mutation in the cystic fibrosis transmembrane conductance regulator (CFTR) gene.[A187373] The CFTR proteins produced by this gene are transmembrane ion channels that move sodium and chloride across cell membranes - water follows the flow of chloride ions to the cell surface, which consequently helps to hydrate the surface of the cell and thin the secretions (i.e. mucous) around the cell.[A187373] Mutations in the CFTR gene produce CFTR proteins of insufficient quantity and/or function, leading to defective ion transport and a build-up of thick mucous throughout the body that causes multi-organ disease involving the pulmonary, gastrointestinal, and pancreatic systems (amongst others). The most common CFTR mutation, the _F508del_ mutation, is estimated to account for 70[A187373] to 90%[A187361,A187355] of all CFTR mutations and results in severe processing and trafficking defects of the CFTR protein.[A187358]\\r\\n\\r\\nElexacaftor is a CFTR corrector that modulates CFTR proteins to facilitate trafficking to the cell surface for incorporation into the cell membrane.[L9395] The end result is an increase in the number of mature CFTR proteins present at the cell surface and, therefore, improved ion transport and CF symptomatology. Elexacaftor is used in combination with tezacaftor, another CFTR corrector with a different mechanism of action, and ivacaftor, a CFTR potentiator that improves the function of CFTR proteins on the cell surface - this multi-faceted, triple-drug approach confers a synergistic effect beyond that seen in typical corrector/potentiator dual therapy regimens.[L9395,A187361]\", \"neighbor_flag\": \"N\", \"resource_name\": \"DrugBank\", \"resource_version\": \"5.1\", \"target_resource_id\": \"P10635\"}, {\"cofactor_in_ch_ikey\": \"PEMUGDMSUDYLHU-ZEQRLZLVSA-N\", \"cofactor_smiles\": \"[H][C@@]1(COC2=NC3=C(CCN(C3)C3=CC=CC4=C3C(Cl)=CC=C4)C(=N2)N2CCN(C(=O)C(F)=C)[C@@]([H])(CC#N)C2)CCCN1C\", \"cofactor_chem_comp_id\": \"A1B7W\", \"cofactor_name\": \"Adagrasib\", \"cofactor_resource_id\": \"DB15568\", \"mechanism_of_action\": \"In normal cells, KRAS is activated by binding to guanosine triphosphate (GTP), and this promotes the activation of the MAP kinase pathway and intracellular signal transduction. When GTP is hydrolyzed to guanosine diphosphate (GDP), KRAS is inactivated. This mechanism works as an \\\"on\\\"/\\\"off\\\" system that regulates cell growth. The substitution of Gly12 by cysteine in KRAS (KRAS<sup>G12C</sup>) impairs GTP hydrolysis, and maintains KRAS in its active form. Therefore, the presence of this mutation leads to uncontrolled cellular proliferation and growth, as well as malignant transformation.[A187559] Adagrasib is a covalent inhibitor of KRAS<sup>G12C</sup> that irreversibly and selectively binds and locks KRAS<sup>G12C</sup> in its inactive, guanosine diphosphate\\u2013bound state.[A254052] Therefore, the use of adagrasib inhibits tumor cell growth and viability in cancers with  KRAS<sup>G12C</sup> mutations with minimal off-target activity.[L44361]\", \"neighbor_flag\": \"N\", \"resource_name\": \"DrugBank\", \"resource_version\": \"5.1\", \"target_resource_id\": \"P10635\"}, {\"cofactor_in_ch_ikey\": \"JJVAPHYEOZSKJZ-JGCGQSQUSA-N\", \"cofactor_smiles\": \"CN1CCC(CC1)N1CCN(CC1)C(=O)[C@@H](CC1=CC2=C(NN=C2)C(C)=C1)NC(=O)N1CCC(CC1)C1=CC2=C(NC1=O)C=CC=C2\", \"cofactor_name\": \"Zavegepant\", \"cofactor_resource_id\": \"DB15688\", \"mechanism_of_action\": \"Zavegepant is a calcitonin gene-related peptide (CGRP) receptor antagonist used for the acute treatment of migraine.[L45505] The pathophysiology of migraine has not been fully elucidated; however, specific vasoactive substances and neurotransmitters such as CGRP, neurokinin A, nitric oxide, and substance P may participate in the neurovascular and cortical spreading depression mechanisms.[A258190] In acute migraine, the release of CGRP increases vasodilation and modulates neuronal excitability, which facilitates pain responses in structures for migraine pain transmission, such as the trigeminal system.[A189213] Therefore, CGRP receptor antagonists such as zavegepant inhibit vasodilation mechanisms and desensitize neuronal circuits.[A258195]\", \"neighbor_flag\": \"N\", \"resource_name\": \"DrugBank\", \"resource_version\": \"5.1\", \"target_resource_id\": \"P10635\"}, {\"cofactor_in_ch_ikey\": \"GBLBJPZSROAGMF-RWYJCYHVSA-N\", \"cofactor_smiles\": \"CO[C@@]1(CC[C@@H](CC1)C1=NC(NC2=NNC(C)=C2)=CC(C)=N1)C(=O)N[C@@H](C)C1=CC=C(N=C1)N1C=C(F)C=N1\", \"cofactor_chem_comp_id\": \"Q4J\", \"cofactor_name\": \"Pralsetinib\", \"cofactor_resource_id\": \"DB15822\", \"mechanism_of_action\": \"Rearranged during transfection (RET) is a transmembrane receptor tyrosine kinase containing extracellular, transmembrane, and intracellular domains whose activity is required for normal kidney and nervous system development.[A202061, A202055] Constitutive RET activation is achieved through chromosomal rearrangements producing 5' fusions of dimerizable domains to the 3' _RET_ tyrosine kinase domain leading to constitutive dimerization and subsequent autophosphorylation; the most common fusions are _KIF5B-RET_ and _CCDC6-RET_, although more than 35 genes have been reported to fuse with _RET_.[A202055, A202049, A202073] Constitutive activation leads to increased downstream signalling and is associated with tumour invasion, migration, and proliferation.[A202046]\\r\\n\\r\\nPralsetinib (formerly referred to as BLU-667) was developed through screening more than 10,000 agnostically designed kinase inhibitors followed by extensive chemical modification to improve its properties. Pralsetinib displays _in vitro_ IC<sub>50</sub> values for both WT RET as well as several mutant forms, including CCDC6-RET, in the range of 0.3-0.4 nmol/L, and is 100-fold more selective for RET kinase over 96% of 371 kinases tested.[A219751] It is this specific inhibition of RET kinase that is associated with anti-tumour activity and clinical benefit in patients.[A219751, A219756, L15986]\\r\\n\\r\\nDespite increased selectivity for RET over other kinases, pralsetinib has been reported to inhibit DDR1, TRKC, FLT3, JAK1-2, TRKA, VEGFR2, PDGFRb, and FGFR1-2 at clinically relevant concentrations. The significance of these findings remains uncertain.[L15986]\", \"neighbor_flag\": \"N\", \"resource_name\": \"DrugBank\", \"resource_version\": \"5.1\", \"target_resource_id\": \"P10635\"}, {\"cofactor_in_ch_ikey\": \"UXNXMBYCBRBRFD-MUUNZHRXSA-N\", \"cofactor_smiles\": \"NCC1=CC(=CC=C1)N1N=C(C=C1C(=O)NC1=CC(=CC=C1F)[C@H](NCC1CC1)C1=CC=CC(=C1)C#N)C(F)(F)F\", \"cofactor_chem_comp_id\": \"0RI\", \"cofactor_name\": \"Berotralstat\", \"cofactor_resource_id\": \"DB15982\", \"mechanism_of_action\": \"Hereditary angioedema (HAE) is a rare genetic disorder associated with severe swelling of the skin and upper airway.[A225106] It is caused by mutations in the regulatory or coding regions of the gene that encodes C1 inhibitor (SERPING1), which result in either a deficiency (type I) or dysfunction (type II) of C1 inhibitor (C1 esterase inhibitor, C1-INH). C1 inhibitor is a serine protease inhibitor that normally regulates bradykinin production by covalently binding to and inactivating plasma kallikrein.[A225121] \\r\\n\\r\\nPlasma kallikrein is a protease that cleaves high-molecular-weight-kininogen (HMWK) to generate cleaved HMWK (cHMWK).[L26661] During HAE attacks, the levels of plasma kallikrein fall, leading to the cleavage of high-molecular-weight-kininogen and the release of bradykinin, a potent vasodilator that increases vascular permeability. Bradykinin plays a major role in promoting edema and pain associated with HAE.[A225166,L26661] Patients with HAE cannot properly regulate plasma kallikrein activity due to the deficiency or dysfunction of a serum inhibitor of C1 inhibitor, leading to uncontrolled increases in plasma kallikrein activity and recurrent angioedema attacks.[L26661] Berotralstat is a potent inhibitor of plasma kallikrein that works by binding to plasma kallikrein and blocking its proteolytic activity, thereby controlling excess bradykinin generation.[A225121,L26661]\", \"neighbor_flag\": \"N\", \"resource_name\": \"DrugBank\", \"resource_version\": \"5.1\", \"target_resource_id\": \"P10635\"}, {\"cofactor_in_ch_ikey\": \"CSOBIBXVIYAXFM-BYNJWEBRSA-N\", \"cofactor_smiles\": \"COC1=C(OC)C=C2C(CCN3C(=O)N(CCNC(N)=O)\\\\C(C=C23)=N\\\\C2=C(C)C=C(C)C=C2C)=C1\", \"cofactor_name\": \"Ensifentrine\", \"cofactor_resource_id\": \"DB16157\", \"mechanism_of_action\": \"COPD is characterized by progressive airflow obstruction and chronic inflammation of the respiratory tract. Because PDE3 and PDE4 are expressed in airway smooth muscle, inflammatory cells, and bronchial epithelial cells to drive inflammation and bronchial muscle tone, these two PDE isoforms have been identified as therapeutic targets in the treatment of COPD.[A263913] PDE3 primarily hydrolyzes the second-messenger molecule cyclic adenosine monophosphate (cAMP) in airway smooth muscle, mediating muscle tone.[A263903, A263913] PDE3 can also hydrolyze cyclic guanosine monophosphate (cGMP).[A263903] PDE4 regulates cAMP only and is involved in inflammatory cell activation and migration, as well as Cystic Fibrosis Transmembrane Conductance Regulator (CFTR) stimulation in bronchial epithelial cells.[A263903, A263913, A263918] \\r\\n\\r\\nEnsifentrine is a drug that selectively inhibits the PDE3 and PDE4 enzymes.[L50893] Dual inhibition of PDE3 and PDE4 results in the accumulation of intracellular levels of cAMP and/or cGMP, causing a synergistic effect in contracting airway smooth muscle and suppressing inflammatory response.[A263903, L50893]\", \"neighbor_flag\": \"N\", \"resource_name\": \"DrugBank\", \"resource_version\": \"5.1\", \"target_resource_id\": \"P10635\"}, {\"cofactor_in_ch_ikey\": \"RENRQMCACQEWFC-UGKGYDQZSA-N\", \"cofactor_smiles\": \"CCO[C@H]1CCN(CC2=C(OC)C=C(C)C3=C2C=CN3)[C@@H](C1)C1=CC=C(C=C1)C(O)=O\", \"cofactor_chem_comp_id\": \"JGQ\", \"cofactor_name\": \"Iptacopan\", \"cofactor_resource_id\": \"DB16200\", \"mechanism_of_action\": \"Iptacopan binds to Factor B of the alternative complement pathway and regulates the cleavage of C3, the generation of downstream effectors, and the amplification of the terminal pathway. In paroxysmal nocturnal hemoglobinuria, intravascular hemolysis (IVH) is mediated by the downstream membrane attack complex (MAC), while extravascular hemolysis (EVH) is facilitated by C3b opsonization. Iptacopan acts proximally in the alternative pathway of the complement cascade to control both C3b-mediated EVH and terminal complement-mediated IVH.[L49066] \", \"neighbor_flag\": \"N\", \"resource_name\": \"DrugBank\", \"resource_version\": \"5.1\", \"target_resource_id\": \"P10635\"}, {\"cofactor_in_ch_ikey\": \"MWKYMZXCGYXLPL-ZDUSSCGKSA-N\", \"cofactor_smiles\": \"CCC(=O)N1CC[C@@H](C1)NC1=C2CN(CCC2=NC=N1)C1=CN=C(OC)C(=C1)C(F)(F)F\", \"cofactor_chem_comp_id\": \"9NQ\", \"cofactor_name\": \"Leniolisib\", \"cofactor_resource_id\": \"DB16217\", \"mechanism_of_action\": \"Phosphoinositide-3-kinase \\u03b4 (PI3K\\u03b4) is a lipid kinase activated downstream of tyrosine kinase receptors and G-protein\\u2013coupled receptors in immune cells.[A258473,A258468,A258518] It mediates the PI3K/AKT pathway, which is involved in cell proliferation, growth, and survival.[A258508,A258513] A heterodimer made up of a regulatory subunit (p85\\u03b1) and a catalytic subunit (p110\\u03b4), PI3K\\u03b4 is primarily expressed on hematopoietic cells such as lymphocytes and myeloid cells. It converts phosphatidylinositol-4,5-bisphosphate (PIP2) to phosphatidylinositol-3,4,5-trisphosphate (PIP3), a signalling molecule that downstream proteins like the AKT kinase, which activate mammalian target of rapamycin (mTOR) complex I and inhibit FOXO family of transcription factors.[A258473,A258463] APDS is associated with gain-of-function variants in the gene encoding p110\\u03b4 or loss of function variants in the gene encoding p85\\u03b1, each causing hyperactivity of PI3K-delta, reduced T cell function, lymphadenopathy, and immunodeficiency.[A258473,L45753]\\r\\n\\r\\nLeniolisib inhibits PI3K\\u03b4 by blocking the active binding site in the p110\\u03b4 subunit.[A258463] In cell-free isolated enzyme assays, the selectivity was higher for PI3K-delta over PI3K-alpha (28-fold), PI3K-beta (43-fold), and PI3K-gamma (257-fold), as well as the broader kinome. In cell-based assays, leniolisib reduced pAKT pathway activity and inhibited proliferation and activation of B and T cell subsets. Leniolisib inhibits the signalling pathways that lead to increased production of PIP3, hyperactivity of the downstream mTOR/AKT pathway, and the dysregulation of B and T cells.[L45753]\", \"neighbor_flag\": \"N\", \"resource_name\": \"DrugBank\", \"resource_version\": \"5.1\", \"target_resource_id\": \"P10635\"}, {\"cofactor_in_ch_ikey\": \"BZZKEPGENYLQSC-FIBGUPNXSA-N\", \"cofactor_smiles\": \"[2H]C([2H])([2H])NC(=O)C1=C(NC2=CC=CC(C3=NN(C)C=N3)=C2OC)C=C(NC(=O)C2CC2)N=N1\", \"cofactor_name\": \"Deucravacitinib\", \"cofactor_resource_id\": \"DB16650\", \"mechanism_of_action\": \"Tyrosine kinase 2 (TYK2) is a member of the Janus kinase (JAK) family of kinases, which are intracellular tyrosine kinases that activate the JAK\\u2013signal transducer and activator of the transcription pathway. Unlike other members of the JAK family that promote broader immune and extra-immune pathways, such as lipid metabolism, the TYK2 signalling pathway is responsible for selected immune pathways.[A246938] TYK2 mediates the signalling of inflammatory cytokines of both adaptive (e.g., interleukin (IL) 12 and IL-23) and innate (e.g., type I interferons) immune responses.[A246948] IL-23 has been implicated in the pathogenesis of immune-mediated disorders such as psoriasis and psoriatic arthritis.[A246938] It activates and promotes the proliferation of Th17 cells: subsequently, Th17 cells secrete inflammatory mediators, such as IL-17 and tumour necrosis factor-alpha, that stimulate epidermal cells to produce cytokines and chemokines that attract and activate innate immune system cells.[A246938, A246943] Enhanced activity of Th17 cells leads to sustained inflammatory responses in the skin and joints as manifested in psoriatic arthritis.[A246938]\\r\\n\\r\\nDeucravacitinib inhibits TYK2 via an allosteric mechanism: it binds to the enzyme's regulatory domain - also known as the pseudokinase (JH2) domain - instead of the catalytic domain. This binding activity allows high selectivity towards TYK2 over other tyrosine kinase enzymes. In _in vitro_ cellular assays, deucravacitinib showed a 100-fold to 2000-fold selectivity for TYK2 over JAK 1/2/3 and demonstrated minimal or no activity against JAK 1/2/3. Upon binding to TYK2, deucravacitinib induces a conformational change and locks the regulatory domain of TYK2 into an inhibitory confirmation with the catalytic domain, trapping TYK2 in an inactive state.[A246938, A246943] Inhibiting TYK2 leads to the downregulation of the IL-23/TH17 pathway, IL-12 signalling, type 1 interferon pathway, and keratinocyte activation.[A246948]\", \"neighbor_flag\": \"N\", \"resource_name\": \"DrugBank\", \"resource_version\": \"5.1\", \"target_resource_id\": \"P10635\"}, {\"cofactor_in_ch_ikey\": \"GKHIVNAUVKXIIY-UHFFFAOYSA-N\", \"cofactor_smiles\": \"CC(C)NC(=O)COC1=CC=CC(=C1)C1=NC2=C(C=CC=C2)C(NC2=CC=C3NN=CC3=C2)=N1\", \"cofactor_chem_comp_id\": \"ICQ\", \"cofactor_name\": \"Belumosudil\", \"cofactor_resource_id\": \"DB16703\", \"mechanism_of_action\": \"Chronic graft-versus-host disease (GVHD) is a life-threatening complication of allogeneic hematopoietic stem cell transplantation in which the transplanted donor T-cells recognize the recipient's tissues as foreign and mount an immune response.[A236639] During the conditioning regimen prior to stem cell transplantation (e.g. involving irradiation or chemotherapy) the host tissues can become damaged which results in downstream inflammatory responses and the generation of inflammatory mediators like TNF-alpha and IL-1. These cytokines increase the expression of host major histocompatibility (MHC) antigens and adhesion molecules which enhances the ability of mature donor T-cells to recognize these molecules. The activation of these donor T-cells results in the activation of mononuclear phagocytes, whose effector functions are triggered by stimulatory molecules generated by the damage incurred during the conditioning phase of treatment. Activated macrophages and cytotoxic T-lymphocytes begin to directly lyse target cells and/or cause their apoptosis, which eventually leads to local tissue damage and further inflammatory responses.[A236644]\\r\\n\\r\\nBelumosudil is an inhibitor of Rho-associated coiled-coil kinase 2 (ROCK2), a protein that plays a vital role in the pathogenesis of immune and fibrotic diseases. The inhibition of ROCK2 has been shown to resolve immune dysregulation by down-regulating pro-inflammatory Th17 cells and up-regulating regulatory T-cells by manipulating the phosphorylation of STAT3 and STAT5.[L34749,L34759]\", \"neighbor_flag\": \"N\", \"resource_name\": \"DrugBank\", \"resource_version\": \"5.1\", \"target_resource_id\": \"P10635\"}, {\"cofactor_in_ch_ikey\": \"QCZAWDGAVJMPTA-RNFRBKRXSA-N\", \"cofactor_smiles\": \"C[C@@H](NC1=NC(=NC(N[C@H](C)C(F)(F)F)=N1)C1=CC=CC(Cl)=N1)C(F)(F)F\", \"cofactor_chem_comp_id\": \"9UO\", \"cofactor_name\": \"Vorasidenib\", \"cofactor_resource_id\": \"DB17097\", \"mechanism_of_action\": \"Mutations in the isocitrate dehydrogenase 1 and 2 (IDH1/2) enzymes can be identified in various malignancies, including acute myeloid leukemia (AML) and gliomas.[A264209, A264214] Mutant enzymes produce an oncometabolite D-2-hydroxyglutarate (2-HG), which contributes to oncogenesis and tumour growth [A264209, A264214, A264219] by blocking the activity of \\u03b1-ketoglutarate\\u2013dependent enzymes and causing epigenetic dysregulation, such as global DNA hypermethylation, and interfering with immunity.[A264214, A264219]\\r\\n\\r\\nVorasidenib is a small molecule inhibitor that targets isocitrate dehydrogenase-1 and 2 (IDH1 and IDH2) enzymes. In vitro, vorasidenib inhibited the IDH1 wild-type and mutant variants, including R132H and the IDH2 wild-type and mutant variants. In cell-based and in vivo tumour models expressing IDH1 or IDH2 mutated proteins, vorasidenib decreased the production of 2-2-HG and partially restored cellular differentiation.[L51139]\", \"neighbor_flag\": \"N\", \"resource_name\": \"DrugBank\", \"resource_version\": \"5.1\", \"target_resource_id\": \"P10635\"}, {\"cofactor_in_ch_ikey\": \"FWZAWAUZXYCBKZ-NSHDSACASA-N\", \"cofactor_smiles\": \"COC1=C(C=C(F)C=C1)C(=O)NCC1=CC=C(C=C1)C1=NN([C@@H](C)C(F)(F)F)C(N)=C1C(N)=O\", \"cofactor_chem_comp_id\": \"Y7W\", \"cofactor_name\": \"Pirtobrutinib\", \"cofactor_resource_id\": \"DB17472\", \"mechanism_of_action\": \"Bruton\\u2019s tyrosine kinase (BTK) is a tyrosine kinase located in the cytoplasm that is recruited to the cytoplasm upon activation. In B-cells, BTK participates in the activation of B-cell antigen receptor (BCR) signaling and cytokine receptor pathways, both critical for B-cell development, function, adhesion and migration. Therefore, the inhibition of BTK is a valuable target for the treatment of B-cell cancers.[A256768,L44863] Pirtobrutinib binds to Bruton\\u2019s tyrosine kinase (BTK) in a non-covalent manner and inhibits its activity. Unlike other BTK inhibitors that bind covalently to the active site of BTK, the inhibitory activity of pirtobrutinib is maintained even in the presence of mutations in this region, such as the presence of Cys481.[A256758,L44863] In nonclinical studies, pirtobrutinib inhibited BTK-mediated B-cell CD69 expression and inhibited malignant B-cell proliferation.[L44863]\", \"neighbor_flag\": \"N\", \"resource_name\": \"DrugBank\", \"resource_version\": \"5.1\", \"target_resource_id\": \"P10635\"}, {\"cofactor_in_ch_ikey\": \"SEVCTUCCZYBJER-BSJAROSPSA-N\", \"cofactor_smiles\": \"CCOC(=O)C[N+]1(C)CC[C@H](C1)OC(=O)[C@@](O)(C1CCCC1)C1=CC=CC=C1\", \"cofactor_name\": \"Sofpironium\", \"cofactor_resource_id\": \"DB19325\", \"mechanism_of_action\": \"Sofpironium is a competitive inhibitor of muscarinic acetylcholine receptors are located on certain peripheral tissues, including eccrine sweat glands.[L51108] By inhibiting the activity of these receptors, sofpironium indirectly reduces the rate of sweating in patients with axillary hyperhidrosis.\", \"neighbor_flag\": \"N\", \"resource_name\": \"DrugBank\", \"resource_version\": \"5.1\", \"target_resource_id\": \"P10635\"}, {\"cofactor_in_ch_ikey\": \"JKVNJTYHRABHIY-WXVUKLJWSA-N\", \"cofactor_smiles\": \"[H][C@]12C[C@@H](OC(=O)C3=CC=CC=C3)C=C[C@]11CCN(C)CC3=CC=C(OC)C(O2)=C13\", \"cofactor_name\": \"Benzgalantamine\", \"cofactor_resource_id\": \"DB19353\", \"mechanism_of_action\": \"[Galantamine], the active moiety of benzgalantamine, is a reversible and competitive inhibitor of acetylcholinesterase.[L51534] It inhibits the hydrolysis of acetylcholine by acetylcholinesterase, thereby increasing the concentration of available acetylcholine. \\r\\n\\r\\nAlthough the underlying etiology of Alzheimer's disease is largely unclear, it appears that acetylcholine-producing neurons degenerate in the brains of patients with Alzheimer's disease and that the degree of this degeneration correlates with the degree of cognitive impairment and density of amyloid plaques.[L51534] By increasing the concentration of available acetylcholine, galantamine may enhance cholinergic function and improve dementia symptoms.\", \"neighbor_flag\": \"N\", \"pubmed_ids\": [12162759, 14674789, 12177686, 12751272], \"resource_name\": \"DrugBank\", \"resource_version\": \"5.1\", \"target_resource_id\": \"P10635\"}, {\"binding_assay_value\": 8.7, \"binding_assay_value_type\": \"pAC50\", \"cofactor_smiles\": \"COC(=O)C1=CO[C@@H](C)[C@H]2CN3CCc4c([nH]c5ccccc45)[C@@H]3C[C@H]12\", \"cofactor_chem_comp_id\": \"AJN\", \"cofactor_resource_id\": \"CHEMBL123325\", \"neighbor_flag\": \"Y\", \"resource_name\": \"Pharos\", \"resource_version\": \"6.13.4\", \"target_resource_id\": \"58\"}, {\"binding_assay_value\": 8.7, \"binding_assay_value_type\": \"pIC50\", \"cofactor_smiles\": \"C[C@@H](c1cccnc1)c1c(CCN(C)C)sc2ccccc12\", \"cofactor_resource_id\": \"CHEMBL1091778\", \"neighbor_flag\": \"N\", \"pubmed_ids\": [20188547], \"resource_name\": \"Pharos\", \"resource_version\": \"6.13.4\", \"target_resource_id\": \"58\"}, {\"binding_assay_value\": 8.6, \"binding_assay_value_type\": \"pAC50\", \"cofactor_smiles\": \"O=C(Nc1cccc2ccccc12)c1ccccc1\", \"cofactor_resource_id\": \"CHEMBL1330614\", \"neighbor_flag\": \"N\", \"resource_name\": \"Pharos\", \"resource_version\": \"6.13.4\", \"target_resource_id\": \"58\"}, {\"binding_assay_value\": 8.5, \"binding_assay_value_type\": \"pAC50\", \"cofactor_smiles\": \"Cc1cccc(C(=O)N2CCC(c3nc(-c4ccc(S(=O)(=O)N5CCOCC5)cc4)no3)CC2)c1\", \"cofactor_resource_id\": \"CHEMBL1611066\", \"neighbor_flag\": \"N\", \"resource_name\": \"Pharos\", \"resource_version\": \"6.13.4\", \"target_resource_id\": \"58\"}, {\"binding_assay_value\": 8.32, \"binding_assay_value_type\": \"pKi\", \"cofactor_smiles\": \"CC(C)N1CCC(c2ccccc2)(c2ccccc2)CC1\", \"cofactor_resource_id\": \"CHEMBL277382\", \"neighbor_flag\": \"N\", \"pubmed_ids\": [8487254], \"resource_name\": \"Pharos\", \"resource_version\": \"6.13.4\", \"target_resource_id\": \"58\"}, {\"binding_assay_value\": 8.3, \"binding_assay_value_type\": \"pAC50\", \"cofactor_smiles\": \"c1ccc2c(c1)ncn2-c1ncnc2sc3c(c12)CCCC3\", \"cofactor_resource_id\": \"CHEMBL1598281\", \"neighbor_flag\": \"N\", \"resource_name\": \"Pharos\", \"resource_version\": \"6.13.4\", \"target_resource_id\": \"58\"}, {\"binding_assay_value\": 8.3, \"binding_assay_value_type\": \"pAC50\", \"cofactor_smiles\": \"CC(=O)c1c(O)cc(=O)n(-c2ccccc2)c1-c1ccc(C)cc1\", \"cofactor_resource_id\": \"CHEMBL1543028\", \"neighbor_flag\": \"N\", \"resource_name\": \"Pharos\", \"resource_version\": \"6.13.4\", \"target_resource_id\": \"58\"}, {\"binding_assay_value\": 8.25, \"binding_assay_value_type\": \"pAC50\", \"cofactor_smiles\": \"CCCN1C(=O)C(NC(C)=O)c2cc(OC)ccc21\", \"cofactor_resource_id\": \"CHEMBL1301946\", \"neighbor_flag\": \"N\", \"resource_name\": \"Pharos\", \"resource_version\": \"6.13.4\", \"target_resource_id\": \"58\"}, {\"binding_assay_value\": 8.0, \"binding_assay_value_type\": \"pIC50\", \"cofactor_smiles\": \"C=C[C@H]1CN2CC[C@H]1C[C@H]2[C@H](O)c1ccnc2ccc(OC)cc12\", \"cofactor_chem_comp_id\": \"QI9\", \"cofactor_resource_id\": \"CHEMBL170\", \"neighbor_flag\": \"Y\", \"pubmed_ids\": [31734022], \"resource_name\": \"Pharos\", \"resource_version\": \"6.13.4\", \"target_resource_id\": \"58\"}, {\"binding_assay_value\": 6.8, \"binding_assay_value_type\": \"pAC50\", \"cofactor_smiles\": \"CSc1ccc2c(c1)N(CC[C@H]1CCCCN1C)c1ccccc1S2\", \"cofactor_chem_comp_id\": \"RTZ\", \"cofactor_resource_id\": \"CHEMBL1357558\", \"neighbor_flag\": \"Y\", \"resource_name\": \"Pharos\", \"resource_version\": \"6.13.4\", \"target_resource_id\": \"58\"}], \"rcsb_id\": \"2F9Q_1\"}}, \"interface_chains\": {\"chain1\": \"A\", \"chain2\": \"D\", \"assembly_chain1\": \"A\", \"assembly_chain2\": \"B\"}, \"enrichment_timestamp\": \"2025-12-24T06:15:02.591182\", \"interface_sequence_analysis\": {\"chain1_sequence_length\": 479, \"chain2_sequence_length\": 479, \"sequences_identical\": true, \"sequence_identity\": 100.0}}",
        "valueReference": {
          "@type": "PropertyValue",
          "name": "ParsedPDBMetadata",
          "value": {
            "resolution": 3.002,
            "experimentalMethod": null,
            "depositionDate": "2005-12-06T00:00:00+0000",
            "releaseDate": "2005-12-20T00:00:00+0000",
            "sourceOrganism": [
              "Homo sapiens"
            ],
            "spaceGroup": null,
            "rFactor": null,
            "entityCount": 4,
            "chainCount": 4,
            "uniqueSequences": 1,
            "isHomomer": true,
            "homomerType": "monomer",
            "taxonomyIds": [
              9606
            ],
            "primaryTaxonomyId": 9606
          }
        }
      },
      {
        "@type": "PropertyValue",
        "name": "PDBMetadataStatus",
        "value": "Complete metadata available",
        "description": "This PDB entry is current and all metadata has been fetched successfully"
      },
      {
        "@type": "PropertyValue",
        "name": "Resolution",
        "value": 3.002,
        "unitCode": "",
        "description": "X-ray crystallography resolution"
      },
      {
        "@type": "PropertyValue",
        "name": "SourceOrganism",
        "value": "Homo sapiens",
        "description": "Homo sapiens (taxonomy ID: 9606)",
        "taxonomyId": 9606,
        "taxonomyUrl": "https://www.ncbi.nlm.nih.gov/Taxonomy/Browser/wwwtax.cgi?id=9606"
      },
      {
        "@type": "PropertyValue",
        "name": "HomomericStructure",
        "value": true,
        "description": "This is a homomeric monomer"
      },
      {
        "@type": "PropertyValue",
        "name": "HomomerType",
        "value": "monomer",
        "description": "Type of homomeric assembly"
      },
      {
        "@type": "PropertyValue",
        "name": "ChainCount",
        "value": 4,
        "description": "Number of chains in the structure (from RCSB API)"
      },
      {
        "@type": "PropertyValue",
        "name": "UniqueSequenceCount",
        "value": 1,
        "description": "Number of unique amino acid sequences (from RCSB API)"
      },
      {
        "@type": "PropertyValue",
        "name": "Chain_A_Sequence",
        "value": "MAKKTSSKGKLPPGPLPLPGLGNLLHVDFQNTPYCFDQLRRRFGDVFSLQLAWTPVVVLNGLAAVREALVTHGEDTADRPPVPITQILGFGPRSQGVFLARYGPAWREQRRFSVSTLRNLGLGKKSLEQWVTEEAACLCAAFANHSGRPFRPNGLLDKAVSNVIASLTCGRRFEYDDPRFLRLLDLAQEGLKEESGFLREVLNAVPVDRHIPALAGKVLRFQKAFLTQLDELLTEHRMTWDPAQPPRDLTEAFLAEMEKAKGNPESSFNDENLRIVVADLFSAGMVTTSTTLAWGLLLMILHPDVQRRVQQEIDDVIGQVRRPEMGDQAHMPYTTAVIHEVQRFGDIVPLGMTHMTSRDIEVQGFRIPKGTTLITNLSSVLKDEAVWEKPFRFHPEHFLDAQGHFVKPEAFLPFSAGRRACLGEPLARMELFLFFTSLLQHFSFSVPTGQPRPSHHGVFAFLVSPSPYELCAVPRHHHH",
        "description": "Amino acid sequence for chain A (length: 479) from RCSB API",
        "chainId": "A",
        "entityId": "1",
        "sequenceLength": 479,
        "sequenceSource": "RCSB API",
        "sourceUrl": "https://www.rcsb.org/structure/2F9Q"
      },
      {
        "@type": "PropertyValue",
        "name": "Chain_B_Sequence",
        "value": "MAKKTSSKGKLPPGPLPLPGLGNLLHVDFQNTPYCFDQLRRRFGDVFSLQLAWTPVVVLNGLAAVREALVTHGEDTADRPPVPITQILGFGPRSQGVFLARYGPAWREQRRFSVSTLRNLGLGKKSLEQWVTEEAACLCAAFANHSGRPFRPNGLLDKAVSNVIASLTCGRRFEYDDPRFLRLLDLAQEGLKEESGFLREVLNAVPVDRHIPALAGKVLRFQKAFLTQLDELLTEHRMTWDPAQPPRDLTEAFLAEMEKAKGNPESSFNDENLRIVVADLFSAGMVTTSTTLAWGLLLMILHPDVQRRVQQEIDDVIGQVRRPEMGDQAHMPYTTAVIHEVQRFGDIVPLGMTHMTSRDIEVQGFRIPKGTTLITNLSSVLKDEAVWEKPFRFHPEHFLDAQGHFVKPEAFLPFSAGRRACLGEPLARMELFLFFTSLLQHFSFSVPTGQPRPSHHGVFAFLVSPSPYELCAVPRHHHH",
        "description": "Amino acid sequence for chain B (length: 479) from RCSB API",
        "chainId": "B",
        "entityId": "1",
        "sequenceLength": 479,
        "sequenceSource": "RCSB API",
        "sourceUrl": "https://www.rcsb.org/structure/2F9Q"
      },
      {
        "@type": "PropertyValue",
        "name": "Chain_C_Sequence",
        "value": "MAKKTSSKGKLPPGPLPLPGLGNLLHVDFQNTPYCFDQLRRRFGDVFSLQLAWTPVVVLNGLAAVREALVTHGEDTADRPPVPITQILGFGPRSQGVFLARYGPAWREQRRFSVSTLRNLGLGKKSLEQWVTEEAACLCAAFANHSGRPFRPNGLLDKAVSNVIASLTCGRRFEYDDPRFLRLLDLAQEGLKEESGFLREVLNAVPVDRHIPALAGKVLRFQKAFLTQLDELLTEHRMTWDPAQPPRDLTEAFLAEMEKAKGNPESSFNDENLRIVVADLFSAGMVTTSTTLAWGLLLMILHPDVQRRVQQEIDDVIGQVRRPEMGDQAHMPYTTAVIHEVQRFGDIVPLGMTHMTSRDIEVQGFRIPKGTTLITNLSSVLKDEAVWEKPFRFHPEHFLDAQGHFVKPEAFLPFSAGRRACLGEPLARMELFLFFTSLLQHFSFSVPTGQPRPSHHGVFAFLVSPSPYELCAVPRHHHH",
        "description": "Amino acid sequence for chain C (length: 479) from RCSB API",
        "chainId": "C",
        "entityId": "1",
        "sequenceLength": 479,
        "sequenceSource": "RCSB API",
        "sourceUrl": "https://www.rcsb.org/structure/2F9Q"
      },
      {
        "@type": "PropertyValue",
        "name": "Chain_D_Sequence",
        "value": "MAKKTSSKGKLPPGPLPLPGLGNLLHVDFQNTPYCFDQLRRRFGDVFSLQLAWTPVVVLNGLAAVREALVTHGEDTADRPPVPITQILGFGPRSQGVFLARYGPAWREQRRFSVSTLRNLGLGKKSLEQWVTEEAACLCAAFANHSGRPFRPNGLLDKAVSNVIASLTCGRRFEYDDPRFLRLLDLAQEGLKEESGFLREVLNAVPVDRHIPALAGKVLRFQKAFLTQLDELLTEHRMTWDPAQPPRDLTEAFLAEMEKAKGNPESSFNDENLRIVVADLFSAGMVTTSTTLAWGLLLMILHPDVQRRVQQEIDDVIGQVRRPEMGDQAHMPYTTAVIHEVQRFGDIVPLGMTHMTSRDIEVQGFRIPKGTTLITNLSSVLKDEAVWEKPFRFHPEHFLDAQGHFVKPEAFLPFSAGRRACLGEPLARMELFLFFTSLLQHFSFSVPTGQPRPSHHGVFAFLVSPSPYELCAVPRHHHH",
        "description": "Amino acid sequence for chain D (length: 479) from RCSB API",
        "chainId": "D",
        "entityId": "1",
        "sequenceLength": 479,
        "sequenceSource": "RCSB API",
        "sourceUrl": "https://www.rcsb.org/structure/2F9Q"
      },
      {
        "@type": "PropertyValue",
        "name": "PrimaryCitation",
        "value": "Crystal Structure of Human Cytochrome P450 2D6",
        "description": "Primary publication for this structure"
      },
      {
        "@type": "PropertyValue",
        "name": "PublicationDOI",
        "value": "10.1074/jbc.M511232200",
        "description": "DOI of the primary publication"
      },
      {
        "@type": "PropertyValue",
        "name": "Entity_1",
        "value": "Chains: A, B, C, D, Length: 479",
        "description": "Entity 1 information",
        "organism": "Homo sapiens",
        "taxonomyId": 9606,
        "taxonomyUrl": "https://www.ncbi.nlm.nih.gov/Taxonomy/Browser/wwwtax.cgi?id=9606"
      },
      {
        "@type": "PropertyValue",
        "name": "NCBI_Taxonomy_ID",
        "value": "9606",
        "description": "NCBI Taxonomy ID for Homo sapiens",
        "url": "https://www.ncbi.nlm.nih.gov/Taxonomy/Browser/wwwtax.cgi?id=9606"
      },
      {
        "@type": "PropertyValue",
        "name": "ClusterID",
        "value": "2F9Q_2",
        "description": "Sequence cluster ID from BLASTClust analysis"
      },
      {
        "@type": "PropertyValue",
        "name": "ClusterSize",
        "value": 3,
        "description": "Number of interfaces in this cluster"
      },
      {
        "@type": "PropertyValue",
        "name": "ClusterMembers",
        "value": [
          "2F9Q_2",
          "2BDM_2"
        ],
        "description": "List of other interfaces in the same cluster (excluding current interface)"
      },
      {
        "@type": "PropertyValue",
        "name": "ClusterMethod",
        "value": "BLASTClust sequence clustering",
        "description": "Method used for sequence-based clustering"
      },
      {
        "@type": "PropertyValue",
        "name": "ClusterMethodOptions",
        "value": "-S 25 -L 0.5 -b F",
        "description": "BLASTClust parameters used for sequence clustering"
      }
    ],
    "hasMolecularFunction": {
      "@type": "DefinedTerm",
      "name": "protein binding",
      "inDefinedTermSet": "http://purl.obolibrary.org/obo/GO_0005515"
    },
    "bioChemInteraction": {
      "@type": "Protein",
      "name": "Homodimer partner for interface 2F9Q_3",
      "description": "Homodimer interaction partner in chain D"
    }
  },
  "additionalProperty": [
    {
      "@type": "PropertyValue",
      "name": "InterfaceSource",
      "value": "ProtCID",
      "description": "Source of interface ID: ProtCID"
    },
    {
      "@type": "PropertyValue",
      "name": "physio",
      "value": false,
      "description": "Physiological (TRUE) or non-physiological (FALSE)"
    },
    {
      "@type": "PropertyValue",
      "name": "label",
      "value": 0,
      "description": "Numeric label (1=physio, 0=non-physio)"
    },
    {
      "@type": "PropertyValue",
      "name": "PDB_ID",
      "value": "2F9Q",
      "description": "Protein Data Bank identifier"
    },
    {
      "@type": "PropertyValue",
      "name": "AuthChain1",
      "value": "A",
      "description": "First chain in interface"
    },
    {
      "@type": "PropertyValue",
      "name": "AuthChain2",
      "value": "D",
      "description": "Second chain in interface"
    },
    {
      "@type": "PropertyValue",
      "name": "AuthChain1",
      "value": "A",
      "description": "First chain in the interface (may be updated from assembly)"
    },
    {
      "@type": "PropertyValue",
      "name": "AuthChain2",
      "value": "D",
      "description": "Second chain in the interface (may be updated from assembly)"
    },
    {
      "@type": "PropertyValue",
      "name": "SymmetryOp1",
      "value": "1_555",
      "description": "Symmetry operation for chain 1"
    },
    {
      "@type": "PropertyValue",
      "name": "SymmetryOp2",
      "value": "1_555",
      "description": "Symmetry operation for chain 2"
    },
    {
      "@type": "PropertyValue",
      "name": "LabelChain1",
      "value": "A",
      "description": "First chain in the assembly interface"
    },
    {
      "@type": "PropertyValue",
      "name": "LabelChain2",
      "value": "B",
      "description": "Second chain in the assembly interface"
    },
    {
      "@type": "PropertyValue",
      "name": "Buried Surface Area (BSA)",
      "value": 2376.28000000001,
      "unitCode": "",
      "description": "Total buried surface area at the interface"
    },
    {
      "@type": "PropertyValue",
      "name": "Atomic Contacts",
      "value": 74,
      "description": "Number of atomic contacts at the interface"
    },
    {
      "@type": "PropertyValue",
      "name": "Gene",
      "value": "CYP2D6",
      "description": "Gene name associated with the protein"
    },
    {
      "@type": "PropertyValue",
      "name": "Superfamily",
      "value": "1.10.630.10",
      "description": "Protein superfamily classification"
    },
    {
      "@type": "PropertyValue",
      "name": "Pfam",
      "value": "PF00067",
      "description": "Pfam domain classification"
    },
    {
      "@type": "PropertyValue",
      "name": "BSA Polar",
      "value": 436.339999999997,
      "unitCode": "",
      "description": "Polar component of buried surface area"
    },
    {
      "@type": "PropertyValue",
      "name": "BSA Apolar",
      "value": 1939.94,
      "unitCode": "",
      "description": "Apolar component of buried surface area"
    },
    {
      "@type": "PropertyValue",
      "name": "Fraction Polar",
      "value": 0.183623142053965,
      "description": "Fraction of polar contacts at the interface"
    },
    {
      "@type": "PropertyValue",
      "name": "Fraction Apolar",
      "value": 0.816376857946031,
      "description": "Fraction of apolar contacts at the interface"
    },
    {
      "@type": "PropertyValue",
      "name": "ClusterID",
      "value": "2F9Q_2",
      "description": "Sequence cluster ID from BLASTClust analysis"
    },
    {
      "@type": "PropertyValue",
      "name": "ClusterSize",
      "value": 3,
      "description": "Number of interfaces in this cluster"
    },
    {
      "@type": "PropertyValue",
      "name": "ClusterMembers",
      "value": [
        "2F9Q_2",
        "2BDM_2"
      ],
      "description": "List of other interfaces in the same cluster (excluding current interface)"
    },
    {
      "@type": "PropertyValue",
      "name": "ClusterMethod",
      "value": "BLASTClust sequence clustering",
      "description": "Method used for sequence-based clustering"
    },
    {
      "@type": "PropertyValue",
      "name": "ClusterMethodOptions",
      "value": "-S 25 -L 0.5 -b F",
      "description": "BLASTClust parameters used for sequence clustering"
    }
  ]
}